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One fundamental aim of drug discovery is the development of new molecular entities 
that have a considerably advantage over already existing therapies. Urinary tract 
infections (UTIs) urgently require an alternative to the conventional antibiotic therapy 
as resistance rates for antibiotics are increasing. The development of an anti-adhesive 
UTI treatment strategy with the bacterial lectin FimH as target is a promising approach 
to remedy such alarming tendencies. FimH is presented by uropathogenic E. coli 
(UPEC) strains on the tip of type 1 pili and mediates adhesion to mannosylated residues 
on the urothelium. This interaction prevents the clearance of UPECs during micturition 
and enables internalization of the pathogens by urothelial cells. Mannoside-derived 
FimH antagonists are under development and are considered as promising treatment 
option for UTIs. In contrast to antibiotics, FimH antagonists do not necessarily exert 
resistance mechanisms against drugs because they block the adhesion of bacteria to the 
urothelium without killing them or inhibiting their growth.  
 
In the present thesis, FimH and its interaction with mannose-based antagonists were 
biophysically characterized. Additionally, new methodical approaches are introduced, 
which are relevant not only for a strategic development of FimH antagonists but also 
for drugs of other therapeutic areas. The following aspects were investigated: 
 
 Publication 2: The publication “KinITC – One method supports both thermo-
dynamic and kinetic SARs” (Chemistry, 2018, 24(49), 13049-13057) comments on 
kinITC-ETC, a new method based on ITC data to reveal the kinetic fingerprint of 
a drug–target interaction. In this study, kinITC-ETC was independently validated 
for the first time. Moreover, structural properties of FimH antagonists could be 
correlated with kinetic parameters of FimH–antagonist interactions. 
 
 Manuscript 1: The development of an off-rate screening approach is presented 
in the study “Off-rate screening by surface plasmon resonance – The search for 
promising lead structures targeting low-affinity FimH”. The method is subse-
quently applied to screen a mannose-based compound library against full-length 
FimH. The assay allows classification of structurally diverse FimH antagonist in 
order to spot chemical classes exhibiting long dissociative half-lives. 
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 Publication 3: The lectin domain is conformationally rigid and needs the pilin 
domain for allosteric propagation. However, the crosstalk between allosteric sites 
within the lectin domain takes also place in the absence of the pilin domain as 
demonstrated in the publication “Conformational switch of the bacterial adhesin 
FimH in the absence of the regulatory domain – Engineering a minimalistic 
allosteric system” (J. Biol. Chem., 2018, 293(5), 1835-1849). Mutants of the isolated 
lectin domain, FimHLD R60P and V27C/L34C, exhibited a low-affinity state and 
mimic full-length FimH regarding its conformational transition upon mannoside 
binding. 
 
 Publication 4: The publication “Target-directed dynamic combinatorial 
chemistry: A study on potentials and pitfalls as exemplified on a bacterial target” 
(Chemistry, 2017, 23, 11570-11577) illustrates a target-directed dynamic 
combinatorial chemistry (tdDCC) approach employing reversible acylhydrazone 
formation with FimH full-length as target. Optimal sample preparation and data 
procession are discussed in detail. Finally, the results of the tdDCC assay were 
subsequently compared with the affinity of library constituents by SPR. 
 
 Publication 5: In the publication “Comparison of affinity ranking by target-
directed dynamic combinatorial chemistry and surface plasmon resonance” 
larger FimH antagonist libraries were screened using the tdDCC method 
established in publication 3. The comparison of amplification rates of library 
substituents with respective binding affinities determined by SPR revealed a 
linear association. Furthermore, the hazardous acylhydrazone moiety could be 
replaced by various bioisosteres without changing the affinity of the parent 
compound.  
 
 Manuscript 2: The hydrogen bond network formed between mannose derivates 
and the CRD of FimH is extensively elucidated in the manuscript ”High-affinity 
carbohydrate–lectin interaction: How nature makes it possible”. Computational 
methods and structural prediction in combination with binding data revealed that 
the hydrogen bond network forms a unified whole. The removal of only a single 
hydroxyl group leads to a disruption of the cooperative interplay within the 





 Manuscript 3: In the study “The tyrosine gate of the bacterial adhesion FimH – 
An evolutionary remnant paves the way for drug discovery”, ITC measurements 
demonstrated the influence of the tyrosine gate on binding affinity between FimH 
and natural ligands. While the tyrosine gate is exploited to form optimal 
hydrophobic interactions with aryl aglycones of synthetic FimH antagonists in 
order to increase their binding affinity, the tyrosine gate has only a marginal 
impact on the KD of natural ligands. In contrast to wild-type FimH, mutants that 
partially or completely lack the tyrosine gate exhibited a comparable binding 
affinity to dimannoside.  
 
 Publication 6: The publication “Improvement of aglycone π-stacking yields 
nanomolar to sub-nanomolar FimH antagonists” displays that fluorination of 
biphenyl mannosides further improved π-π stacking with the tyrosine gate, 
reaching nanomolar affinities with FimHFL and even picomolar affinities with 
FimHLD. It also could be shown that ligand binding to FimHFL occurs with a 
highly favorable enthalpic and a considerably unfavorable entropic contribution. 
 
Publication 7: In the publication “Enhancing the enthalpic contribution of 
hydrogen bonds by solvent shielding” microcalorimetric studies of FimH could 
reveal that conformational adaptions of the binding site can establish a solvent-
free cavity. Shielding the solvent results in a lower dielectric environment, in 
which the formation of hydrogen bonds has a considerable enthalpic contribution 






























∆Cp change in heat capacity  
ΔG  change in Gibbs free energy  
ΔG° standard Gibbs free energy change 
ΔH enthalpy change  
ΔH° standard enthalpy change 
ΔT temperature difference  
ΔS entropy change 
ΔS° standard entropy change 
ε0 vacuum permittivity 
εr dielectric constant 
τ residence time 
A acceptor 
ADME absorption, distribution, metabolism, and excretion 
atm standard atmosphere (1 atm = 101.325 kPa) 
AUC analytical ultracentrifugation  
BIA-MS biomolecular interaction analysis mass spectrometry  
CD circular dichroism  
CRD carbohydrate recognition domain 
D donor 
Da dalton 
DP differential power 
DsG donor strand FimG 
DsF donor strand FimF 
DSF differential scanning fluorimetry  
E electrostatic energy 
E. coli Escherichia coli 
EDC 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
ESI electrospray ionization 
ETC equilibration time curve 
Fc  Fragment, crystallizable 
FimHLD FimH lectin domain 
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FimHPD FimH pilin domain  
FDA Food and Drug Administration 
GCPR G-protein-coupled receptor 
H–S enthalpy–entropy  
HBD hydrogen bond donor 
HBA hydrogen bond acceptor 
High high-affinity state 
HM n-heptyl α-D- mannopyranoside  
HSQC heteronuclear single quantum correlation  
HTS high-throughput screening 
IBC intracellular bacterial communities  
IFC integrated µ-fluidic cartridge 
ITC isothermal titration calorimetry 
Ig immunoglobulin 
IUPAC International Union of Pure and Applied Chemistry 
KD equilibrium dissociation constant 
Keq equilibrium constant  
KinITC kinetic ITC  
kinITC-ETC kinetic ITC - Equilibration Time Curve 
kon association rate constant 
koff dissociation rate constant 
L ligand 
log P partition coefficient 
Low low-affinity state  
MALDI-MS  matrix-assisted laser desorption/ionization mass spectrometry 
Medium medium-affinity  
mRNA messenger ribonucleic acid 
MCK multi-cycle kinetics 
MW molecular weight 
MS mass spectrometry  
MST microscale thermophoresis  
MW molecular weight 
n binding stoichiometry 




NHS N-hydroxysuccinimide  
NMR nuclear magnetic resonance 
P20 polysorbate 20 
PCR polymerase chain reaction 
PDB Protein Data Bank 
PID proportional-integral-derivative  
q1 quantity of charge on object 1  
q2 quantity of charge on object 2 
QIR quiescent intracellular reservoirs 
r distance 
R gas constant 
R&D research and development 
RI refractive index 
Ro5 Lipinski`s ‘rule of five’ 
RU  response units 
rUTI recurrent UTI 
SAR structure–activity relationship  
SCK single-cycle kinetics  
SEC-MS size-exclusion chromatography mass spectroscopy 
SPR surface plasmon resonance 
TIR total internal reflection 
TM melting temperature 
TSA thermal shift analysis  
uHTS ultra-high-throughput screening 
UPEC uropathogenic Escherichia coli 
UPIa uroplakin Ia 
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Introduction Drug Discovery 
1. Drug Discovery
1.1 The drug development process 
When drug discovery was still in its infancy, drugs were discovered by a serendipity 
or identified based on ancient traditions or on their phenotypic effects.[1,2] Nowadays, 
de novo drug discovery mostly starts with the identification and validation of 
promising therapeutic targets. Target-based drug discovery has its origin in 1894 
when Emil Fischer proposed his lock-and-key concept to explain enzyme specificity. 
In the early 1990s, the implementation of high-throughput screening (HTS) in 
research and development (R&D) revolutionized the search for active compounds. 
Henceforth, combinatorial chemistry libraries were subjected to automated screening 
against target proteins.[3] Because in general the overall screening attrition rate is 
usually extremely high, on average, one million compounds have to be screened for 
one licensed drug.[4] If the three-dimensional structure of the ligand binding site is 
available, virtual screening is an alternative approach to find promising drug-like 
molecules by docking ligands into the target binding site.[5] Primary screening hits are 
confirmed and characterized in secondary assays afterwards. In parallel, structure-
activity relationship (SAR) analyses are performed to further optimize target 
selectivity and potency by chemical modifications. Before entering the clinical phase, 
candidate molecules have to survive preclinical in vitro and in vivo ADME 
(absorption, distribution, metabolism and excretion) and toxicology studies. Once a 
selected candidate enters clinical development the probability to reach the market is 
below 10% (Figure 1).[6,7] A failure at this stage has the highest financial 
consequence, especially in phase III confirmatory efficacy and safety trials, which 
recruit the largest number of participants and are often logistically complex.[8]  
Figure 1: De novo drug discovery and development. The overall process usually amounts between 
10-17 years. The figure is adapted from Reference [9]. ADME-T; absorption, distribution, metabolism,
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A better assessment of pharmacological and toxicological properties earlier in the 
drug development process enables an earlier rejection of inadequate compounds and 
thus an improvement in cost efficiency. 
1.2 The drug-like chemical space 
HTS is able to test between 10,000 to 100,000 compounds per day while ultra-high-
throughput screening (uHTS) methods can even handle more than 100,000 small 
molecules per day.[10] These screening numbers seem negligible when compared to 
the drug-like chemical space, which has been estimated to be in the order of 1023 to 
1060 organic molecules following Lipinski`s ‘rule of five’ (Ro5) for oral 
bioavailability.[11,12,13] Molecules complying with the Ro5 commonly exhibit 
favorable pharmacokinetic properties, like suitable solubility and permeability, which 
enable oral absorption and distribution.[14] The Ro5 proposes that at least two of the 
four following criteria have to be fulfilled:[15]  
(1) number of hydrogen bond donor (HBD) atoms ≤ 5
(2) number of hydrogen bond acceptor (HBA) atoms ≤ 10
(3) partition coefficient (log P) ≤ 5
(4) molecular weight (MW) ≤ 500 Da
The partition coefficient (log P) is a logarithmic value of the distribution between 
water and an organic solvent. It is utilized to predict the lipophilicity/hydrophilicity of 
small molecules and defined	  as	  a	  ratio	  of	  concentrations	  of	  a	  unionized	  compound	  
in	  the	  water	  and	  the	  n-­‐octanol	  phase	  at	  equilibrium	  (Equation	  1).[16,17]	  
𝑙𝑜𝑔  𝑃 = 𝑙𝑜𝑔   [!"#$"#%&'  !"#$"%&']!"#$%!&
[!"#$"#%&'  !"#$"%&']!"#$%
	   (Equation	  1)	  
Medicinal chemists are constantly designing new structural classes of molecules to 
feed the drug development pipeline. Since only about 100 million drug-like 
compounds have been synthesized yet, a huge treasure of potential drug candidates is 
still available.[18]	  
4
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1.3 Potential drug targets and their druggability 
Most small molecule drugs currently on the market interact with protein targets to 
exert the desired pharmacological effect. However, for numerous protein targets the 
search for small molecule ligands is heavily complex or even failed. They are 
therefore named undruggable targets characterized by a strong hydrophilicity, a small 
or shallow binding shape, and/or the requirement of covalent binding.[19,20] In 2002, 
Hopkins and Groom introduced the concept of druggability that includes all proteins 
that bind Ro5 molecules with a KD below 10 µM. At that time, the druggable genome 
was estimated to consist of more or less 3,000 genes of which about 600-1,500 were 
considered as potential drug targets.[21] However, over the time the condition of target 
druggability blurred and became more a contemporary assessment adapting to 
scientific knowledge and technical progress. Targets initially appearing to be 
undruggable became druggable with time, as for instance carbohydrate-binding 
lectins, e.g. involved in essential cellular recognition mechanisms. There original 
classification as undruggable targets is related to their shallow binding sites and 
pronounced polarity.[21] Nowadays, several promising lectin antagonists for the 
treatment of different disorders are in preclinical and clinical development. One of 
them is the pan-selectin antagonist rivipansel for the treatment of vaso-occlusive crisis 
in patients with sickle cell disease. It was developed in the group of Beat Ernst in 
collaboration with the company GlycoMimitics, licensed to Pfizer in 2011, and is 
currently in clinical trial phase 3.[22,23,24]  
Recently, it was also assumed that not only as originally assumed 3,000 [21] but up to 
10,000 [25] of the 20,000-25,000 protein-coding genes [26] in the human genome are 
related to diseases rendering them interesting for the pharmaceutical industry. 
However, this number is likely still a vast underestimation, as the number of disease-
relevant proteins greatly excel the number of genes due to alternative splicing of 
precursor mRNAs, post-translational modifications, and the formation of heteromeric 
protein complexes, increasing the number of possible targets.[27]  
In 2017, the overall number of FDA-approved protein targets of small molecule drugs 
amounted to 549.[28] Protein targets mainly belong to the families of GCPRs, kinases, 
ion channels, nuclear receptors, or transporters.[28,29] Further target families are 
proteases, epigenetic drugs, and proton pump inhibitors that are highlighted in the 
5
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following conference report of the 11th Swiss Course on Medicinal Chemistry in 
Leysin that took place in 2014 (Publication 1). The Swiss Course on Medicinal 
Chemistry provided an insight in the manifold aspects of medical chemistry and 
clarified the current status of research progress. In this context, approaches to increase 
the number of drug-like molecules are elucidated. Moreover, current tactical aspects 
and technologies in the drug development process are discussed. 
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Drug Discovery Summit: 11th Swiss Course on Medicinal
Chemistry
Priska Frei,[a] Giulio Navarra,[a] Christoph P. Sager,*[a] Marleen Silbermann,[a] Norbert Varga,[a]
and Eike-Christian Wamhoff[b]
Introduction
In the beautiful surroundings of the Swiss mountains and vine-
yards, more than 100 young scientists assembled with 33
speakers and instructors to attend the 11th Swiss Course on Me-
dicinal Chemistry (SCMC, October 12–17, Leysin, Switzerland).[1]
The aim of the course is to attract and train young scientists
working in the field of medicinal chemistry by expert speakers
coming from both industry and academia, while providing
a state-of-the-art scientific program focused on some of the
hottest topics in life science research. The program highlighted
various target families that were introduced by general over-
view talks, followed by well-selected case studies of recent and
successful drug discovery projects that have led to develop-
ment candidates or even marketed drugs. Furthermore, various
tactical aspects and technologies, applied in modern drug dis-
covery, were covered in several presentations and tutorials.
Demonstrations of case studies offered detailed insight into
the drug discovery and development process, all the way from
target identification through the lead-finding and optimization
phase into clinical trials. This report gives a comprehensive ac-
count of the topics covered at this year’s conference and high-
lights transformative contributions and approaches.
Chemical Space
Several talks addressed strategies to access new chemotypes
for drug discovery. Natural products are a particularly intrigu-
ing class of compounds, as they are evolutionarily optimized
to interact with a number of biological targets. It has been
shown that a wide range of biological effects might be ach-
ieved by only small changes to their structure. Inspired by this
concept, Karl-Heinz Altmann (ETH Zrich, Switzerland) and Bart
DeCorte (Entura, Johnson & Johnson, USA) presented ap-
proaches to exploit the chemical space of natural products for
the discovery of new drugs. Other contributions focused on
peptidomimetics as highly selective and active candidates.
Norbert Sewald (Bielefeld University, Germany) presented strat-
egies to overcome metabolic stability issues and highlighted
their potential to target protein–protein interactions (PPI). A
lecture about macrocyclic peptidomimetics (D. Obrecht, Poly-
phor, Switzerland) further underscored the versatility of this
class of molecule (see Target Families below). The use of glyco-
mimetics as inhibitors of lectins was addressed by Beat Ernst
(University of Basel), who demonstrated the potential of carbo-
hydrate-derived selectin antagonists for the treatment of vaso-
occlusive crisis patients of sickle cell anemia (Figure 1).
Target Families
This year’s discussion focused on six major target families of
considerable pharmaceutical interest : ion channels (R. Owen,
Pfizer Neusentis, UK), proteases (R. Sedrani, Novartis Pharma
AG, Switzerland), kinases (G. Mller, Mercachem, Netherlands),
epigenetic drug targets (P. Brennan, University of Oxford, UK),
PPIs (D. Obrecht, Polyphor, Switzerland), and G-protein-coupled
receptors (GPCRs; J. Mason, Heptares Therapeutics, UK).
Moving from broad concepts to specific in-depth observations,
a series of case studies was also presented (Figure 2). Ivacaftor,
a new treatment for cystic fibrosis (see Highlights below), was
introduced by Peter Grootenhuis (Vertex Pharmaceuticals,
USA). As an important example of protease drug discovery,
Sven Ruf (Sanofi-Aventis, Germany) presented the case of cath-
epsin A inhibitors as a novel treatment for cardiovascular dis-
eases. Ray Finlay (AstraZeneca, UK) briefly introduced non-
small-cell lung cancer and the challenges associated with re-
sistance (kinase mutants), before he presented AZD9291 as
a new mutant-selective inhibitor of the epidermal growth
factor receptor (EGFR). DNA deregulation is emerging as an im-
portant causative agent for cancer and a wide variety of other
diseases, which does not necessarily involve mutations in the
DNA sequence. It is the epigenetic control that governs gene
expression, which is regulated by post-translational modifica-
tions of histone proteins. The development of the methyltrans-
ferase inhibitor EPZ-6438 as an epigenetic drug against the
EZH2 enzyme was extensively described by Richard Chesworth
(Epizyme, USA). Among the several projects in Polyphor’s pipe-
line, Daniel Obrecht presented the PPI inhibitor POL7080 as an
innovative drug against Pseudomonas spp.
Tactical Aspects
Another thematic priority was set on strategies and ap-
proaches for efficient drug discovery. In this context, the po-
[a] P. Frei,+ G. Navarra,+ C. P. Sager,+ M. Silbermann,+ Dr. N. Varga+
University of Basel, Klingelbergstrasse 50, 4056 Basel (Switzerland)
E-mail : christoph.sager@unibas.ch
[b] E.-C. Wamhoff+
Max Planck Institute of Colloids and Interfaces
Wissenschaftspark Potsdam-Golm
Am Mhleberg 1 OT Golm, 14476 Potsdam (Germany)
[+] These authors contributed equally to this work.
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tential of the bioisostere concept (N. Meanwell, Bristol-Myers
Squibb, USA) was discussed as well as the influence of binding
kinetics on the pharmacological properties of a candidate (D.
Swinney, iRND3, USA). Additionally, the audience was intro-
duced to ADME determinants and their crucial role during the
optimization of drug candidates (C. Funk, Roche, Switzerland).
Subsequently, the impact of metabolic processes on drugs was
elucidated in detail (H. Kubinyi, University of Heidelberg, Ger-
many). Polypharmacological (J.-U. Peters, Roche, Switzerland)
and covalent drugs (J. Singh, Celgene Avilomics Research, USA;
see Highlights) were illustrated by various examples as an alter-
native to conventional agents. Furthermore, Richard Morphy
(Lilly Research Centre, UK) elaborated on the challenges and
opportunities in targeting the central nervous system (CNS),
which comes with specific restrictions on the molecular prop-
erty space. Emphasis was also placed on tactical aspects in
lead finding and optimization (A. Mortlock, AstraZeneca, UK),
which was deepened further into two interactive tutorials (A.
Mortlock, AstraZeneca, UK; L. van Berkom and S. Gremmen,
both Mercachem, Netherlands). In this way, participants were
able to apply their newly acquired knowledge and had the op-
portunity to discuss specific issues extensively with experts in
the field. Hands-on practice was offered for fragment-based
lead generation (S. Courtney and M. Mazanetz, both Evotec,
UK) and patents in drug discovery (F. Schager, Actelion, Swit-
zerland).
Technologies
In the field of screening technologies, focus was laid on recent
developments in hit series generation and toward the applica-
tion of novel phenotypic screening methods, which were also
widely applied in the presented case studies.
The development of DNA-encoded libraries, even for hard-
to-drug targets such as PPIs, was addressed by Nils Hansen (Vi-
pergen, Denmark). He showed that the virtues of this combina-
torial method are its high success rates and general applicabili-
ty to soluble proteins. Dirk Ullmann (Evotec AG, Germany)
commented on the importance of phenotypic screening for
first-in-class small-molecule drugs over the last decade and
gave an outlook on complex cellular models that can only be
accessed by high-content screening. A three-dimensional in-
Figure 1. Schematic overview of the main groups of topics covered. Top left : chemical space (natural products, peptidomimetics, glycomimetics) ; right: tech-
nical aspects (phenotypic screening, NMR techniques, DNA-encoded libraries, water networks) ; bottom left : tactical aspects (fragment-based lead generation,
binding kinetics, ADME).
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sight into the fundamental role of water molecules in protein–
ligand interactions was given by Jonathan Mason (Heptares
Therapeutics, UK). In various examples of stabilized GPCRs
(StaRs), he showed how elucidation of water molecules
during the binding process improves the quality of structure-
based drug design. Mark Murcko (Disruptive Biomedical, USA)
presented recent advancements in force fields and free-energy
perturbation (FEP; see Highlights). Participants could also take
part in an interactive NMR tutorial lead by Christoph Rade-
macher (Max Planck Institute of Colloids and Interfaces, Berlin)
and Anders Friberg (Bayer Healthcare Pharmaceuticals, Germa-
ny).
Highlights
A small panel of presentations was selected for more detailed
accounts. This subjective selection reflects the particular scien-
tific background and preferences of the authors.
Discovery of the CF drug ivacaftor
On the first day of the SCMC, Peter Grootenhuis (Vertex Phar-
maceuticals, USA) presented the decade-spanning story of the
recently approved cystic fibrosis (CF) drug, ivacaftor. CF pa-
tients suffer from decreased lung function, frequent lung infec-
tions, and pancreatic dysfunction among other symptoms.
These symptoms are caused by defects in the CF transmem-
brane conductance regulator (CFTR) gene responsible for chlo-
ride transport. Various mechanisms of CFTR dysfunction have
been proposed, and different modes of action are pursued by
Vertex Pharmaceuticals accordingly. The discovery process for
ivacaftor started from a high-throughput screen followed by
extensive medicinal chemistry and structure–activity relation-
ship studies to advance the initial hit into a clinical candidate.
The talk emphasized the in vitro model developed in-house,
which is based on cultured human bronchial epithelial cells,
and was employed to monitor the activity of potential drug
candidates. Ivacaftor works as a potentiator of CFTR function
and was approved for the treatment of patients with gene de-
fects leading to defective CFTR gating at the cell surface
(Figure 3). At the end of his lecture, Grootenhuis left the audi-
ence with an inspiring success story demonstrating the impact
of medicinal chemistry efforts on challenging targets. This
stimulated many fruitful discussions in the further course of
the conference.
Pushing the limits of FEP calculations
Another highlight of this year’s program was Mark Murcko’s
(Disruptive Biomedical, USA) presentation on selected aspects
Figure 2. Examples from the target families mentioned in the lectures, and corresponding inhibitors of (left to right): sodium ion channel Nav, EGFR, EZH2,
A2A GPCR, cathepsin A, and two proteins involved in a PPI.
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of computational chemistry. Starting from case studies, Murcko
went on to discuss the opportunities structure-based drug
design (SBDD) can offer, while also mentioning its shortcom-
ings. He highlighted recent work aimed at overcoming some
of the limitations of SBDD by advancing the free-energy per-
turbation (FEP) method. FEP pro-
vides a means to accurately pre-
dict affinity, selectivity, and phar-
macokinetic properties based on
structural data (Figure 4).
First proposed by Robert
Zwanzig in 1954, the applicabili-
ty of FEP to SBDD has been lim-
ited by issues with usability, ac-
curacy, and throughput. Recent
technological progress in the
areas of graphic processors, sam-
pling algorithms, and force-field
parameterization has significant-
ly pushed the boundaries in this
field. Consequently, the latest
developments have been able to
show great predictive power for
their FEP implementation in
both retrospective and predic-
tive settings. The implementa-
tion comprises a substantial set
of ligand structure perturbations and is accessible for non-ex-
perts. Therefore, FEP can be envisioned to accelerate SBDD in
the near future.
Resurgence of covalent drugs
Irreversible binders (i.e. , covalent inhibitors) are generally con-
sidered harmful, as they can form covalent bonds with several
biological molecules in vivo, thus leading to all kinds of un-
wanted side effects. Yet, in many cases reactive drug metabo-
lites, rather than the original drug, are responsible for such
bonds. Moreover, targeted covalent inhibitors with exceptional
potency and selectivity as well as prolonged pharmacokinetic
profiles have been discovered. Juswinder Singh (formerly with
Celgene Avilomics Research, USA) presented an elegant tech-
nological platform for the rational design of covalent drugs.
The approach uses structural data of known reversible inhibi-
Figure 3. Closed (left) and open (right) CFTR chloride channels at the cell
surface.
Figure 4. The principle of free-energy perturbation (FEP). Left : scheme of FEP calculations; right: examples of chemotype perturbations.
Figure 5. Schematic representation of the Avilomics approach. Structural information of the protein and its
known binder (CNX512) is used to selectively introduce a reactive moiety on the latter, producing a new covalent
drug (CNX277) that can form an irreversible bond to its target.
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tors to install low-reactive functional groups, such as hindered
Michael acceptors, on high-affinity molecules (Figure 5). Avilo-
mics’ approach has been applied to various target classes, in-
cluding hepatitis C virus protease and EGFR and has produced
several clinical candidates. Notably, targeted covalent inhibitors
display sustained efficacy in cases of mutational resistance as
observed for antiviral therapy, further validating their therapeu-
tic potential.
Concluding Remarks
Besides the excellent talks and tutorials, the 11th SCMC provid-
ed a good opportunity for young scientists to approach the
speakers and instructors during the breaks and social events.
The course was filled with fruitful discussions as well as active
networking between the participants. The presence of numer-
ous trendsetters and opinion leaders in the field created
a truly inspiring atmosphere and set the quality of the event at
a high level. As young medicinal chemists from academia, we
emphasize the uniqueness of this opportunity that allowed us
to directly interact with world-class experts in biomedical re-
search and to gain authentic insight into industrial drug dis-
covery and development.
Outlook 2016
As we learned from the organizers, Gerhard Mller (Merca-
chem, Netherlands) and Beat Ernst (University of Basel), the tra-
dition of organizing this Medicinal Chemistry Academy will be
extended beyond this year’s event, which marked a 20-year an-
niversary; the first SCMC was held in 1994 in Leysin. As this
conference has developed its own distinct trademark over the
last 20 years as “the Leysin course”, it will be held again in this
scenic setting in October 2016. Over the past two decades,
this event has covered many technological and thematic
changes in our industry at the highest possible level, and
hence we can be confident that the 12th Swiss Course on Me-
dicinal Chemistry will live up to the highest expectations. The
international medicinal chemistry community can confidently
look forward to learning more about the next event.
At this point, we cordially thank this year’s organizing com-
mittee: first of all, Yvonne Baggerman (Mercachem, Nether-
lands), who did a marvelous job as the event assistant, finding
a solution for each and every problem that surfaced during
the conference; also Beat Ernst and Gerhard Mller, who once
again put together a program based on state-of-the-art expert
talks from leading trendsetters, all the while accounting for the
requisite educational effort for young colleagues in the field.
[1] 11th Swiss Course on Medicinal Chemistry, Swiss Chemical Society, Division
of Medicinal Chemistry & Chemical Biology: scg.ch/leysin2014.
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3. The Bacterial Lectin FimH 
 
 
3.1 Urinary tract infection 
 
Urinary tract infections (UTIs) are the second most often diagnosed type of infection 
worldwide that affects any part of the urinary tract.[1] A distinction is made between 
uncomplicated and complicated UTIs: Uncomplicated UTIs are predominant and 
typically occur in otherwise healthy individuals, while complicated UTIs are often 
related to functionally or structurally abnormal urinary tracts, including pregnant 
women, patients with kidney transplantations, catheters, or metabolic diseases.[2,3,4] 
Uncomplicated UTIs are characterized by episodes of acute cystitis and 
pyelonephritis and in approximately 80% of the cases are caused by a heterogeneous 
group of uropathogenic E. coli (UPEC) strains.[4,5,6] The infection rate is significantly 
higher in women than in men. Around 50-60% of women experience at least one 
symptomatic UTI during their lifetime.[7,8] The health condition of these affected 
women is further aggravated due to a high incidence of recurrent UTIs (rUTIs).[9] 
Besides their effects on health issues, UTIs additionally impose a great economic 
burden, also due to the high recurrence rate.[10] The standard therapy for UTI is a 
short-term administration of antibiotics to treat symptoms and to prevent the infection 
from ascending to the upper urinary tract, where it can progress to a life threatening 
pyelonephritis or urosepsis.[5] Unfortunately, frequent antimicrobial treatment is 
followed by an increased resistance rate of uropathogens to antibiotics. Further risk 
factors that additionally promote antimicrobial resistances include rUTIs, 
hospitalization, and renal transplantation.[11] In order to prevent the development of 
bacterial resistance, alternative therapies are required.[12,13]  
 
 
3.2 Acute infection cycle of uropathogenic Escherichia coli  
 
The gram-negative and facultative anaerobic bacterium E. coli primarily inhabits the 
gastrointestinal tract where it lives in symbiosis with its host.[14] Although UPEC 
strains are commensals in the gut, they exhibit a pathogenic behavior once they reach 
the urinary tract. In order to invade and colonize the urothelium, UPECs use a set of 
virulence factors such as adhesins.[15,16]  
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In the first step of the acute infection cycle (Figure 1) UPECs adhere to the 
urothelium. This step prevents the clearance of UPECs during micturition and enables 
internalization of the pathogens by urothelial cells.[17] It is mediated by the mannose-
specific bacterial lectin FimH localized at the tip of type 1 pili. FimH binds to 
mannose residues of high-mannose N-linked glycans of the transmembrane 
glycoprotein uroplakin Ia (UPIa) that is expressed on urothelial facet cells.[17,18] Upon 
FimH-mediated internalization, UPECs replicate and are able to form biofilm-like 
intracellular bacterial communities (IBCs). IBCs are enclosed by a proteinaceous 
polysaccharide matrix that protects the bacteria from antibiotics and the host's innate 
immune response.[19,20] At the early stage of IBC formation, UPECs are rod-shaped 
cells in loosely organized colonies that mature into a tightly packed cluster of coccoid 
cells.[20] In the matured IBC, UPECs revert into their rod-like morphology or 
transition into long filaments. Both subpopulations flux from infected cells into the 
bladder lumen and may re-infect adjacent differentiated superficial facet cells.[21] An 
UPEC infection can also lead to an activation of the apoptotic machinery resulting in 
cell exfoliation. This leads to a clearance of adherent and intracellular bacteria, but 
also enables the bacteria to establish quiescent intracellular reservoirs (QIRs) in 
underlying cell layers.[22]  
Figure 1: Acute infection cycle of uropathogenic E. coli (UPEC). Adhesion and internalization is 
achieved by FimH on the tip of type I pili interacting with oligomannosides presented on urothelial 
cells. UPECs replicate and form intracellular bacterial communities (IBCs). After IBCs are matured, 
the infected urothelial cell may exfoliate and UPECs flux into the bladder infecting other cells or 
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Upon epithelial turnover, latent bacteria can provoke relapse.[25] Besides FimH-
mediated adhesion and host defense avoidance mechanisms, toxins, and iron 
acquisition systems are further virulence factors of UPECs.[26]  
 
 
3.3 Structure of type I pili and FimH 
 
A single E. coli cell expresses between 100-500 peritrichously arranged type 1 pili, 
which enable the attachment to UPIa (Figure 2-A & 2-B). Type 1 pili are hetero-
oligomeric mannose-binding fibers of about 7 nm in diameter, up to 2 µm in 
length,[27,28] and are assembled via the chaperone-usher pathway.[29] They are made of 
homologous proteins encoded by a set of fim genes located in the fim operon.[30] The 
pilus is divided into a fibrillar tip element (FimF, FimG, and FimH) and a rod-shaped 
main element (FimA subunits) (Figure 2-B). All proteins possess an incomplete, 
immunoglobulin (Ig)-like fold and interact via donor strand complementation, i.e. an 
N-terminal donor strand of each protein completes the β-sandwich structure of the 
following subunit.[31] The helical pilus rod is formed by 500 to 3000 copies of FimA 
and is anchored to the assembly platform FimD in the outer E.	  coli membrane. The 
fibrillar tip is composed of a single or multiple copies of FimF and FimG, which are 





Figure 2: Structural elements of UPECs. A) Electron micrograph of a type I-fimbriated uropatho-
genic E. coli (UPEC) cell.[33] B) Schematic representation (modified from[34,35]) of an UPEC binding to 
oligomannosylated UPIa. C) Illustration of a type I pilus consisting of a helical rod (FimA subunits) 
and a fibrillar tip (FimF, FimG, and FimH). D) Crystal structure of full-length FimH consisting of a 
lectin domain (FimHLD) and a pilin domain (FimHPD), which is complemented with the N-terminal 
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FimH is a 29 kDa protein consisting of 279 amino acids consisting of two domains; 
the N-terminal FimH lectin domain (FimLD, residues 1-156) containing the mannose- 
binding site, and the C-terminal FimH pilin domain (FimHPD, residues 159-279) 
connected by a three-amino acid linker (Figure 2-C).[31] FimHPD anchors the protein 
to FimG whereas FimHLD acts as a mannose-specific carbohydrate recognition 
domain (CRD). Both domains predominately comprise β-sheets forming β-sandwich 
folds. Isolated FimH is unstable and requires a 14-amino acid donor strand from 
FimG for stabilization (ADVTITVNGKVVAK).[31,36] In experimental studies, a 15-
amino acid synthetic peptide donor strand derived from FimG with an additional 
arginine at the C-terminus to improve solubility (DsG) is used to stabilize 
recombinant FimH (FimH*DsG or full-length FimH, FimHFL).[36,37,38] FimH is also 
stable when isolated in complex with the donor strand-donating chaperone FimC.[39] 
In its isolated form, the lectin domain FimHLD can be stably expressed as well.[40]  
 
 
3.4 Conformations and binding behavior of FimH 
 
FimHFL exhibits a sophisticated allosteric mechanism to modulate its affinity for 
mannosides by conformational regulation. Recent work of Sauer et al. demonstrated 
that FimH*DsG mainly adopts three distinct conformational states: the low-affinity 
state (unbound FimHFL, Low), the medium-affinity state (mannoside-bound FimHFL 
under static conditions, Medium), and the high-affinity state (mannoside-bound 
FimHFL under shear force, High) (Figure 3-A).[36] Through the conformational 
flexibility of FimHFL, UPECs are able to regulate their binding affinity to mannose as 
an evolutionary adaption. A weak interaction with host cells is advantageous for 
bacterial motility to colonize the urinary tract for nutrient acquisition whereas strong 
adherence avoids clearance from the bladder by urination.[38]  
 
The crystal structure of a ligand-unbound fimbrial tip (PDB: 3JWN) revealed a 
compressed FimH lectin domain that harbors a shallow binding site.[41] The same 
structure was observed for ligand-free FimHFL (Figure 3-A, Low).[36] In this 
conformation, FimHLD and FimHPD form a hook-shaped structure.[41,42] The lectin 
domain interacts with the pilin domain with three loop segments: the swing loop 
(residues 27-33), the linker loop (residues 154-160), and the insertion loop (residues 
112-118).  
Introduction  The Bacterial Lectin FimH 
	  
	   19	  
Upon ligand binding and under static conditions, the clamp loop moves towards the 
ligand resulting in a deep and well-defined binding pocket (Figure 3-A, Medium). 
Apart from the change in the CRD, the overall conformation of the medium-affinity 
state is very similar to the unbound low-affinity conformation, maintaining the 
interaction between the two domains. Dissociation of FimHLD from UPIa is promoted 
via dynamic allostery by FimHPD, which functions as a negative allosteric 
regulator.[36] In the medium-affinity state, the binding affinity of FimHFL to mannose 
is low. In the absence of urine flow, fast binding and release from UPIa enables fast 
reversible attachment and bacterial expansion in the urinary tract.[36,41,43] However, 
under shear stress, the binding affinity for mannose is dramatically increased due to 
the catch bond behavior of FimH, first discovered in 2002 (Figure 3-B).[44] In general, 
many adhesive proteins form catch bonds that are induced by mechanical force.[45,46] 
In case of FimH, the separation of FimHLD and FimHPD is induced by tensil forces 
during micturition. Nowadays, it is known that the consequent disruption of the 
allosteric interplay between the domains results in an up to 300-fold increase of the 





Nevertheless, in our study “Conformational switch of the bacterial adhesin FimH in 






















Figure 3: Binding mechanism of FimHFL and its confor-
mations. A) Under static conditions, the transition between the 
low- (Low) and medium-affinity (Medium) state is highly 
dynamic. Unbound FimHFL is in the low-affinity conformation 
and adopts a medium-affinity conformation upon binding to 
uroplakin 1a (UPIa), presumably via a transient encounter 
complex (in square brackets). An increase of the mechanical 
force induces a separation of FimHLD and FimHPD resulting in a 
reduced dissociation rate compared to the medium-affinity 
state. FimHLD is shown in yellow, FimHPD in purple, and DsG 
in green. Figure 3-A is modified from [36,38]. B) Schematic plot 
displaying the lifetime of a formed FimH-mannoside 
interaction with increasing tensile mechanical force. Catch 
bonds gain strength with increasing shear force until being 
overpowered.[48]	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(publication 3) we could demonstrate that in absence of the pilin domain, the 
crosstalk of allosteric sites within the lectin domain is also present in FimHLD variants 
harboring specific site mutations. In the flow-induced conformation, the shape of the 
binding pocket is similar to the medium-affinity state, though the overall shape of the 
lectin domain is narrower and more elongated in comparison to the low- and medium-
affinity states.[41,47,48] Flow experiments with bacterial cells have shown that the FimH 
high-affinity state is nearly incapable to initiate bacterial adhesion at high shear 
stresses while FimH in the low-affinity state exhibits shear-enhanced attachment to 
urothelial cells and is thus fundamental for adhesion under flow conditions.[49]  
 
Crystal structures are available for both the apoprotein in the low-affinity 
conformation (PDB: 4XOD) and the ligand-bound medium-affinity conformation 
(PDB: 4XOE). A high-affinity conformation of FimHFL can be experimentally 
induced in certain FimHFL crystals, in which the peptide DsG is replaced with the 
non-native donor strand of FimF (DsF). DsF stabilizes the pilin domain less well 
facilitating the domain separation even under crystal growing conditions 




Figure 4: Crystal structures of FimH conformational states. A) Unbound FimHFL is present in the 
low-affinity conformation (PDB: 4XOD) and consists of the lectin domain (FimHLD, golden) and the 
DsG-stabilized (green) pilin domain (FimHPD, purple) interacting with each other. The lectin domain 
has a compressed shape with an open clamp loop (red) forming a shallow binding site. B) Binding of a 
ligand (n-heptyl α-D-mannopyranoside, blue) under static conditions leads to the medium-affinity state 
(PDB: 4XOE) with a closed clamp loop building a well-defined binding pocket. C) Under shear stress, 
both domains separate leading to an elongation of FimHLD by 11 Å in the high-affinity conformation. 
Domain separation of FimHFL under crystallization conditions was achieved by replacing DsG with the 
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The high-affinity conformation has also been observed in a crystal structure of FimH 
in complex with pilus assembly chaperone FimC, where FimC is wedged between 
FimHLD and FimHPD (PDB: 1QUN).[31] Crystal structures of the isolated FimHLD, 
both in the free (PDB: 4AUU) and ligand-bound (PDB: 4AV4) state, always show the 
extended high-affinity conformation.[50] In contrast to FimHLD within full-length 
FimH, the isolated lectin domain does not undergo significant conformational changes 
upon ligand binding.[51] Binding affinities of FimHFL for mannose-based antagonists 
are reduced by a factor of about 100 compared to isolated FimHLD.[38] In 
manuscript 5 “The Different Affinity Stages of FimH and Their Thermodynamics of 
Binding” a difference of two orders of magnitude in affinity was also discovered 
between the low-affinity and the high-affinity state. Isothermal titration calorimetry 
(ITC; method described in chapter I.5) demonstrated that ligand binding to FimHFL 
occurs with a highly favorable enthalpic and a considerably unfavorable entropic 
contribution. A considerable influence on the thermodynamics can be attributed to the 
dielectric constant of the binding pocket. 
 
 
3.5 Molecular insight into the FimH binding site 
 
In comparison to other lectin–monosaccharide interactions, the CRD of FimH has not 
only a remarkable binding specificity but also an unusually high-affinity with a KD 
value of 2.3 µM for its ligand mannose.[52] This is due to a well-defined and charged 
binding pocket that envelops the sugar monomer and forms an extended network of 
12 direct and indirect hydrogen bonds with the pyranose ring (Figure 5-A). Apart 
from the α-anomeric position, all hydroxyl groups of mannose form direct hydrogen 
bonds with the protein (Asp47, Asp54, Asn135, Asp140, and Phe1). Indirect 
hydrogen bonds with Gln133 and Gly14 are established via a water molecule, which 
is well-resolved in crystal structures of the high-affinity conformation. In total, the 
nine direct and the three indirect hydrogen bonds are formed with an appropriate 
hydrogen-bonding geometry.[52,53] Any modification on the hydroxyl groups of 
mannose considerably diminishes its binding affinity to FimH.[52,53,54]  
 
The entrance of the mannose-binding site consists of a hydrophobic ridge (Ile13, 
Phe1, and Phe142) and the tyrosine gate motif (Tyr48, Ile52, and Tyr137) at the 
opposite side (Figure 5-B).[39,52] The X-ray crystal structure of the isolated FimHLD 
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with oligomannose-3 (PDB: 2VCO) provided evidence that the tyrosine gate is 
involved in hydrophobic interactions with oligomannosides.[55] Thereupon, many 
studies focused on the development of mannoside derivatives with hydrophobic 
aglycones for anti-adhesive therapy of UTI. Favorable stacking and van der Waals 
interactions of the aglycone with aromatic side chains of the tyrosine gate lead to 
continuously improved affinities of synthetic FimH antagonists.[50,56,57] However, in 
contrast to synthetic FimH ligands, our study “The tyrosine gate of the bacterial 
adhesion FimH – An evolutionary remnant paves the way for drug discovery” 
(manuscript 4) on natural ligands of FimH has shown that a partial or complete 
removal of the tyrosine gate had no impact on the binding affinity of dimannosides in 
comparison with wild-type FimH. Furthermore, the binding affinity of 
oligomannoside–FimH complexes was not significantly affected by different 
glycosidic linkage types or a varying number of mannose residues. 
 
 
Figure 5: The carbohydrate recognition domain of the isolated FimH lectin domain in complex 
with n-heptyl α-D- mannopyranoside (HM). A) Schematic illustration of the hydrogen bond network 
with its ligand-accepted (red) and -donated (blue) hydrogen bonds. The structural water W1 is 
highlighted in blue. For clarity reasons, Gln133 is displayed twice. The figure is adapted from 
manuscript 3. B) Co-crystal structure of the FimHLD-HM complex (PDB: 4BUQ)[58] displaying the 
hydrogen bond network (dashed lines) and the tyrosine gate. 
 
The binding pocket is discussed in manuscript 3 ”High-affinity carbohydrate-lectin 
interaction: How nature makes it possible”. In this study, the hydrogen bond network 
between FimH and mannose is elucidated at high detail by a systematic analysis of 
mannose derivatives by several biophysical methods. Deoxy- and deoxy-halogeno 
derivates of HM displayed a dramatic loss in binding affinity by the removal of only a 
single hydroxyl group. The reason for this is the disruption of the cooperative 
interplay of all hydrogen bonds in the network. 
B"A"
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3.6 FimH antagonists 
 
To date, antibiotics are still the first line treatment for UTIs,[59] although they may 
induce selection pressure on UPECs.[60] As a result, antibiotic-resistant organisms 
might emerge more often and are an expanding health problem worldwide.[61] In order 
to remedy such alarming tendencies, an alternative to the conventional antibiotic 
therapy is the development of an anti-adhesive UTI treatment strategy with FimH as 
promising target. In contrast to antibiotics, FimH antagonists do not necessarily exert 
resistance mechanisms against drugs because they block the adhesion of bacteria to 
the urothelium without killing them or inhibiting their growth.[62,63]  
 
The development of high-affinity FimH antagonists with a therapeutic profile is still 
an ongoing challenge. As early as in the late 1960s, researchers discovered that type 1 
pili enable E. coli to adhere to several cell types including erythrocytes and epithelial 
cells.[64] A few years later, it was observed that D-mannose and methyl α-D-
mannopyranoside (1) prevented the attachment of type 1-pili-presenting E. coli strains 
to epithelial cells, and the type 1-pili-mediated agglutination of mannan-containing 
yeast.[65,66] In the 1980s, linear and branched oligosaccharides were studied and over 
the years several multivalent antagonists with nanomolar affinities were 
developed.[67,68,69] However, due to physicochemical and pharmacokinetic drawbacks, 
these large molecules are not suited for oral application, a prerequisite for the 
treatment of UTIs.  
 
For the identification of orally available FimH antagonists, the development of 
monovalent ligands is the most promising approach. The first monovalent binders 
with reasonably high affinities to FimHLD were mannosides bearing an aromatic 
aglycone. One of them, p-nitrophenyl α-D-mannopyranoside (2a), inhibited the 
adherence of E. coli to epithelial cells 70 times more effective than methyl α-D-
mannopyranoside. The introduction of a chloro substituent (2b) in ortho position 
further improved the inhibition by a factor of 7.[70] From 1999 on, crystal structures 
were used to rationally design high-affinity antagonists. Only since the first crystal 
structure of FimHLD in complex with a mannoside ligand was solved, detailed 
information was available regarding the tyrosine gate as a potential contact area for 
antagonists.[52] Long-chain alkyl aglycones turned out to provide hydrophobic 
contacts with the tyrosine gate allowing a drastic affinity increase. Among the studied 
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alkyl mannosides, n-heptyl α-D-mannopyranoside (HM; 3) was the best FimHLD 
antagonist with a KD of 5 nM in surface plasmon resonance assays (SPR; method 
described in chapter I.4).[52] The interaction of anti-adhesives with the tyrosine gate 
could be further enhanced by π-π stacking of several aryl aglycones with Tyr48. 
Substitution of the phenyl ring in para position resulted in squaric acid monoamide 
derivatives (4),[71,72] indolinyl phenyl mannosides (5),[73] and biphenyl α-D-manno-
pyranosides with distinct ring substitutions (6a and 6b).[63,74,75] All previously 




Figure 6: Chemical structures of selected FimH antagonists. Monovalent alkyl (1 and 3) and aryl 
(2a, 2b and 4-7) α-D-mannopyranosides that represent milestones in the development of high-affinity 
FimH antagonists.  
 
Although a therapeutically effective FimH antagonist should as well exhibit a high 
affinity for FimH in the low-affinity conformation, previous drug development efforts 
mostly based on the high-affinity conformation by using isolated FimHLD as target 
protein. Only recently, FimHFL was included in the search of an appropriate FimH 
antagonist for a successful anti-adhesive UTI therapy. SPR and ITC measurements 
have shown that binding affinities of mannose-based antagonists are about 100 times 
lower for FimHFL compared to FimHLD.[38,76] This two orders of magnitude difference 
in affinity was also confirmed in manuscript 5 “The Different Affinity Stages of 
FimH and Their Thermodynamics of Binding”. In this study, it was demonstrated that 
fluorination of biphenyl mannosides further improved π-π stacking with the tyrosine 
gate, reaching nanomolar affinities with FimHFL and even picomolar affinities with 
FimHLD. Perfluorination of the terminal phenyl ring in combination with a cyano 
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for FimHFL, currently representing the highest published affinity for a FimHFL 
antagonist.  
 
To develop successful FimH anti-adhesives, medicinal chemists not only focus on 
optimized affinities and long residence times. Target selectivity as an indicator for 
toxicity and unwanted side effects is also an essential component of drug 
development and should be carefully investigated early on.[77] FimH antagonists based 
on α-D-mannopyranose may produce adverse side effects due to non-specific binding 
to mannose receptors of the human host system. As a promising result, competitive 
binding assays demonstrated a 105 lower affinity of antagonists 3, 4, 5, 6a, and 6b to 
eight human mannose receptors compared to the isolated lectin domain, likely due to 
less optimal hydrophobic interactions and the fundamental design of human mannose 
receptors for multivalent interactions.[78] Furthermore, physicochemical and 
pharmacokinetic properties including solubility, lipophilicity, and membrane 
permeability have to be optimized to ensure oral bioavailability. Prodrug approaches 
can be taken into consideration to balance between solubility and lipophilicity for 
effective dosage and membrane permeation. For instance, insufficient solubility of 
FimH antagonists, which otherwise show high passive permeability, has been 
overcome by a phosphate prodrug strategy.[79] In another study, a series of ester 
prodrugs of biphenyl α-D-mannopyranosides with linear short-chain acyl promoieties 
at the C-6 position showed not only good permeability but also adequate solubility for 
intestinal absorption.[80]  
 
 
3.7 Kinetics of FimH 
 
Typically, carbohydrate–lectin interactions display fast binding kinetics that 
complicate the development of successful carbohydrate-based drugs.[81] Of particular 
interest is the dissociation rate constant (koff), because it determines the half-life (t1/2 = 
ln2/koff) of a drug–target complex, i.e. the time a target is occupied by a drug. Since 
target occupancy is directly related to in vivo drug efficacy considering 
pharmacokinetic effects such as metabolism and elimination from the body, an 
extended t1/2 is very often required to obtain a therapeutically potent antagonist.[82,83] 
In the case of E-, L- and P-selectins, SPR experiments unveiled fast off-rates that 
resulted in half-lives of less than a second.[84,85,86] Other carbohydrate–lectin 
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interactions showed similar kinetic properties with t1/2 values in the second range. The 
longest half-lives were observed for concanavalin A[87] and mannose-binding 
protein[88] that exhibited half-lives of 1.2 min and 4.4 min in complex with a 
D-mannose derivate and D-Man16-BSA, respectively. All the more surprising was the 
discovery of FimHLD–antagonist complexes exhibiting half-lives of above 3.6 h.[81] In 
contrast to the other investigated lectins, which possess shallow and water-accessible 
CRDs,[89,90,91] the deep and polar binding pocket of FimHLD an extended hydrogen 
bond network can be established being responsible for slow dissociation rates and 
thus for the observed long complex half-lives. 
 
Yakovenko et al. performed SPR measurements of isolated fimbriae to investigate the 
kinetic difference between the low-affinity state in wild-type K12 FimH and the 
engineered FocH variant[76] that is locked in the high-affinity state.[49] In this study, 
the low-affinity conformation exhibited a 23-fold faster association rate and a 600-fold 




Figure 7: Kinetic fingerprints of fimbriae presenting FimH in the high- and low-affinity 
conformations. Binding behavior of fimbriae from the strains FocH (high-affinity conformation, A) 
and wild type K12 (low-affinity conformation, B) to immobilized man-BSA. Measurements were 
performed with the indicated fimbriae concentrations using a Biacore 2000. Sensorgrams were fitted 
with a one-state (FocH, A) and a two-state model (K12, B), respectively. Results were taken from 
Yakovenko et al., 2015.[49] 
 
Fast association and dissociation rates of HM (3) binding to FimH in the low affinity 
conformation were also demonstrated by Sauer et al. for the full-length FimH 
construct stabilized by DsG. A kon of 5.0*106 M-1s-1 and a koff of 22 s-1 were measured, 
resulting in a complex half-life of 32 ms.[36] Apart from these studies, kinetic 
information about the low-affinity state is still rare, despite the fact that a 
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half-life. A stable antagonist–FimHFL complex should prevent the adhesion of UPEC 
to the bladder epithelium under static conditions and consequently promotes bacterial 
clearance from the urinary tract. In order to find chemical structures with optimized 
half-lives, we designed a SPR method to screen a compound library against low-
affinity FimHFL. Assay development and screening of structurally diverse FimH 
antagonist classes is highlighted in manuscript 1 “Off-rate screening by surface 
plasmon resonance - The search for promising lead structures targeting low-affinity 
FimH”. 
 
Considering the emerging importance of binding kinetics in drug discovery, efforts 
have also been made to develop new methods for determination of association and 
dissociation rates. Publication 2 “KinITC – One method supports both thermo-
dynamic and kinetic SARs” elaborates on kinetic ITC based	  upon	  the	  determination	  
of	  an	  "Equilibration	  Time	  Curve"	  (kinITC-­‐ETC), a novel technique that extracts the 
kinetic fingerprint of a drug–target complex from ITC data. In this context, structural 
properties of FimH antagonists could be correlated with kinetic parameters of 
FimHLD–antagonist interactions. In case of the isolated FimH lectin domain, it was 
shown that the rate constant koff is mainly influenced by formation of the hydrogen 
bond network, whereas electrostatic interactions and conformational restrictions 
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4. Biophysical Methods in Drug Discovery
Modern drug discovery heavily relies on biophysical techniques and quite a number 
of these have matured into key technologies for the drug development process. In the 
present studies, a number of them have been applied.  
For structure elucidation and structure-based rational drug design, X-ray 
crystallography is usually the method of choice. Based on X-ray diffraction patterns 
three-dimensional structures of macromolecules are unveiled at an atomic level.[1,2] 
Up until the beginning of 2018, more than 120.000 structures of apoproteins and 
protein–ligand complexes in the Protein Data Bank (PDB) were determined using 
X-ray crystallography.[3]
Additional 12.000 structures were solved by nuclear magnetic resonance (NMR),[3] a 
versatile method to study protein structure, dynamics, and protein–ligand interactions 
including the identification of binding partners, determination of the binding mode, 
and affinity measurements.[4] In ligand-observed NMR experiments, the resonances of 
small molecules are observed in the presence of a target protein to screen for ligand 
binding and to further characterize the complex in terms of affinity and kinetics. 
Isotopic labeling of the interaction partners is not necessary. The pharmaceutical 
industry not only applies ligand-based NMR as a primary screening tool but also for 
the validation of hits from various screening techniques and for the optimization of 
leads.[5] Protein-based NMR measurements are often indispensable for structure-based 
drug discovery that demands information of the binding pocket. However, these 
techniques usually require isotopic labeling of the target protein. The single most-
widely used protein-based NMR approach for analyses of drug-target interactions is 
2D 1H–15N heteronuclear single quantum correlation (HSQC) of 15N-labelled protein 
samples.[6]  
The secondary structural elements of proteins, such as helices, sheets, turns, and coils 
can be investigated by circular dichroism (CD) spectroscopy. CD determines the 
protein conformation in solution by detecting the difference in absorption of left- and 
right-circularly polarized light over a range of wavelengths.[7] CD can be combined 
with stopped-flow instruments to measure protein-folding kinetics or ligand-binding 
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kinetics if the binding event involves a change in chirality of the protein.[8] The 
stopped-flow device enables a simultaneous pressure-injection of solution in different 
syringes into a mixing chamber. Thereupon, the flow is then promptly stopped and the 
reaction is measured at different time points.[9] Stopped-flow kinetic measurements 
can also be performed in combination with a UV/Vis or fluorescence spectrometer if a 
change in absorbance or fluorescence takes place during the binding event.[10] 
The gold standard to obtain kinetic parameters of bimolecular interactions is surface 
plasmon resonance (SPR). In addition, kinetic structure–activity relationship (SAR) 
studies can also be performed with the recently introduced analytical tool kinetic ITC 
(kinITC) that extracts kinetic information from isothermal titration calorimetry (ITC) 
data. In publication 2 “KinITC – One method supports both thermodynamic and 
kinetic SARs” kinITC was independently validated for the first time and applied to 
deduce the kinetic parameters from existing ITC data. ITC is the standard technique 
to obtain thermodynamic parameters of a binding event. Both methods, SPR and ITC 
(including kinITC), are described in detail in Section 4 and 5, respectively.  
Mass spectroscopy (MS) is a powerful tool for the determination of concentration, 
purity, and molecular mass of molecules, but also for the identification of unknown 
samples, and revelation of protein structure and dynamics.[11,12] For protein–ligand or 
protein–protein interaction studies, size-exclusion chromatography in combination 
with MS (SEC-MS) is a suitable technique.[13] An MS analysis requires the 
conversion of the sample molecule into gaseous ions, e.g. by using electrospray 
ionization (ESI). Subsequently, the ionized fragments are assessed and recorded by 
their mass to charge ratios (m/z).[14] Frequently, gas or liquid chromatography is used 
as pre-MS separation technique especially for analysis of complex samples.[15] MS 
can also be combined with SPR devices for ligand-fishing experiments. A target 
immobilized on a SPR chip captures unknown ligands, which can be eluted and 
analyzed by ESI-MS or identified by matrix-assisted laser desorption/ionization mass 
spectroscopy (MALDI-MS) directly from the chip.[16]  
Ligands with low affinity can be identified by differential scanning fluorimetry 
(DSF), also known as thermal shift analysis (TSA). DSF determines the melting 
temperature (Tm) of a protein by monitoring its thermal denaturation in the presence 
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of a fluorescent dye that binds to exposed hydrophobic residues.[17,18] Binding of a 
ligand typically stabilizes but sometimes also destabilizes the protein resulting in a Tm 
shift in each case. DSF is a robust and inexpensive method that makes use of a real-
time quantitative PCR cycler, and therefore is often applied for primary fragment-
based library screenings.[19,20] 
With the rather new technique microscale thermophoresis (MST) biomolecular 
interactions with pico- to millimolar affinities can be studied based on the movement 
of fluorescent molecules in a temperature gradient.[21,22] The fluorescence is either an 
intrinsic property of the molecule of interest or can be generated by attaching a 
fluorescent protein or dye.[23] The method is highly sensitive and detects changes in 
the hydration shell of biomolecules as well as size- and charge-alterations, which have 
an impact on the thermophoretic mobility of proteins.[24] Thus, the affinity of protein–
protein as well as of protein–small molecule interactions can be determined.[22] 
The multifaceted method analytical ultracentrifugation (AUC) quantitatively analyzes 
the influence of a gravitational field generated by a centrifuge on macromolecules in 
solution. The technique allows the study of biomolecules over a broad concentration 
range and tolerates numerous solvent additives.[25] The two main AUC application 
methods are sedimentation velocity and sedimentation equilibrium. Sedimentation 
velocity experiments assess the movement rate of macromolecules in a strong 
centrifugal field. Based on the sedimentation rate the shape and the size of 
macromolecules can be ascertained. In sedimentation equilibrium experiments a 
comparatively lower centrifugal force acts on the protein in such a way that 
sedimentation and diffusion are exactly balanced resulting in a concentration 
distribution at equilibrium. Studying the sedimentation equilibrium of macro-
molecules in a centrifugal field provides information about molecular masses, binding 
stoichiometry, and affinities as well as the protein quaternary structure.[26,27] 
In Table 1 the main application areas of the previously mentioned biophysical 
methods are summarized. In addition, advantages and limitations are listed. 
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+ Highly accurate structure determination
+ Suitable for large complexes
− Need of high-quality homogeneous crystals
− Examination of static structures









+ Measurement in solution
+ No crystal packing artifacts
+ Determination of affinity and dynamics
− Large consumption of isotopically labeled protein
− High expenditure of time






+ Does not require isotopic labeling
+ Suitable for high-throughput studies
+ Can detect low affinity interactions






+ Highly sensitive and label-free
+ Low protein consumption
− Desalting of sample required
− Buffer limitations
− No detergents tolerated
− No 3D information






+ Fast measurements and data acquisition
+ Non-destructive method
− Careful sample preparation (exact protein concentration)
− Protein sequence information is needed
− No residue-specific information




+ In solution measurements
+ Can examine slow and relatively fast kinetics
− Dead time of instrument
− Need of optical signals to monitor changes
− Interpretation of data
[35,36]
SPR Kinetics Affinity 
+ Label-free real-time detection
+ Low sample consumption
+ High sensitivity
− Immobilization of one interaction partner
− High stability of immobilized sample required






+ Direct determination of thermodynamic parameters
+ Both interaction partners are free in solution
+ Recently applicable for kinetic analysis (see 5.5)
− High protein consumption
[40]
MST Affinity 
+ Both interaction partners are free in solution
+ Low sample consumption
− If no intrinsic fluorescence, labeling required
[22,23,41]
AUC 




+Versatile and non-destructive method
+ In solution measurement
+ No solvent and pH limitations




+ Low protein consumption
− Requirement of a fluorescent dye
− Unsuitable for hydrophobic proteins
− Artifacts due to fluorescence quenching & aggregation
− No quantitative affinity information
[17,43]
Table 1. Important biophysical techniques in drug discovery. 
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5. Surface Plasmon Resonance (SPR) 
 
 
5.1 SPR – A short historical overview 
 
Surface plasmon resonance (SPR) is a optical sensing technique that involves a 
collective charge-density oscillation at a metal-dielectric interface.[1] In 1902, Wood 
initially observed the effect of SPR while allowing polarized light to be incident on a 
metallic diffraction grating. He noticed some puzzling dark bands in the reflected 
light but did not associate this optical phenomenon with surface plasmons.[2] It was 
the work of Otto,[3] Kretschmann, and Raether [4] that completely described SPR in 
1968. They also established the instrumental basis - the Otto configuration and the 
Kretschmann-Raether configuration - for the investigation of surface plasmons. In 
1983, Liedberg and coworkers applied an SPR-based biosensor for the first time to 
detect antibody–antigen interactions [1] and seven years later Pharmacia Biosensor AB 
(today GE Healthcare Life Science) launched the first SPR instrument (BIACORE 
1000).[5,6] Thereupon, SPR rapidly developed to become a powerful label-free method 
for real-time monitoring of biomolecular interactions in liquids.[7] For many years, 
Biacore was undisputed market leader for SPR devices. Nowadays, other suppliers 
(e.g. Bio-Rad, ForteBio, Horbia Scientific, Reichert Analytical Instruments) also 
brought SPR instruments on the market.[8] 
 
 
5.2 Principles of SPR 
 
SPR is based on total internal reflection (TIR) a physical effect that occurs in non-
absorbing media when light travels from a medium with a higher refractive index 
(e.g. glass, n1) to a medium with a lower refractive index (e.g. air, buffer, n2). A light 
beam that hits a half circular prism with an incident light angle of 0 (Θ = 0) exits the 
flat prism site straight into the air. Increasing Θ gives rise to refracted beams until the 
critical angle of incidence is reached. This occurs when the refracted beam travels 
between the two media. Above the critical incidence angle the beam fully reflects 
within the prism without any light passing through (Figure 1-A).[9] In case of TIR, an 
electromagnetic field emerges in the medium of lower refractive index without a loss 
in net energy of the reflected beam. This phenomenon is called an evanescent field 
wave that has the same wavelength as the incident light. The amplitude of the wave 
exponentially decreases with increasing distance from the media boundary.[10,11]  



























Nowadays, the most prevalent operation mode in SPR devices, including Biacore 
instruments, is still the Kretschmann-Raether configuration. In this configuration, the 
reflection site of a prism is coated with a non-magnetic metal like gold. Under TIR, 
the p-polarized component of the evanescent field wave (the electrical field 
component lying in the plane of incidence) penetrates the thin metal layer and SPR 
can occur.[11] In the resonance event, free electrons at the gold surface completely 
absorb the light photon energy and convert it into collective oscillating metal 
electrons (also referred to as surface plasmons, surface plasmon polaritons or surface 
plasma waves), a form of electromagnetic energy.[12,13,14] This requires that the wave 
vector of the photons equals the wave vector of surface plasmons that is dependent on 
the refractive index of the metal and the adjacent lower refractive index medium.[15] 
Surface plasmons propagate on the surface of the metal layer and create an enhanced 
evanescent wave. Simultaneously a sharp decrease in reflection intensity is observed 
(Figure 1-B, right).[16,17,18] The angle at which the greatest loss in intensity of the 
reflected light emerges is defined as the SPR angle (Θ = SPR angle).[19] The shape 
and location of the SPR dip can be used to convey information about the sensor 
surface. In comparison to the evanescent wave field generated by TIR at a non-
coating interface, the SPR-generated evanescent wave field is enhanced. It is still 














Figure 1: Principles of SPR. A) A light beam that travels from a dense to a less dense medium is 
refracted (green line). When the refracted light travels along the boundary of the two media, the 
corresponding incidental angle is referred to as the critical angle (dashed red line). An incident angle 
greater than the critical angle results in total internal reflection (TIR, yellow line). B) Prism coated with 
a gold layer (Kretschmann-Raether configuration) visualizing surface plasmon resonance (left); SPs, 
surface plasmons. An intensity decrease of reflected light is observed at the SPR angle (right). Pictures 
modified from References [11,20].  
 
The resonance event is dependent on the incidence angle, the wavelength of light and 
the refractive index close to the gold surface. SPR can be received by variation of the 
incident light angle and the refractive index of the medium adjacent to the gold layer 
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while keeping the metal and its thickness constant. Consequently, changes in the 
adjacent medium can be monitored by adjusting the incident light angle until the 
occurrence of SPR.[22,23] 
 
 
5.3 Biacore T200 
 
The Biacore (Bia standing for biomelecular / biospecific interaction analysis) 
technology exploits SPR for the detection of differences of the refractive index caused 
by a change in mass concentration close to a surface of a sensor chip.[24] The key 
components of all Biacore instruments are a SPR optical detection unit, a sensor chip, 
and a microfluidic handling system. All SPR experiments in this thesis were 
performed with a Biacore T200.  
 
The Biacore T200 is a highly automated instrument with an exceptional sensitivity 
and was designed for high-quality characterization of molecular interactions. The 
sensor chip together with its protective cassette is introduced into the T200 via the 
sensor chip port and is placed between the prism and the integrated µ-fluidic cartridge 
(IFC) within the instrument. Samples and reagents are hold in removable racks that 
are placed in a temperature-controlled compartment that occupies an autosampler and 
a sample injection needle. The injection needle is part of the liquid handling system 
that delivers samples and buffers to the flow cells. Bottles containing the running 
buffer are placed on the left tray whereas a waste bottle and a bottle containing water 







Figure 2: The Biacore T200 device. Prior to a SPR measurement the sample rack is placed in the 
temperature-controlled sample compartment and the sensor chip is inserted into the instrument over the 
sensor chip. Within the T200 the sensor chip is pressed against the integrated µ-fluidic cartridge (IFC). 
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The water bottle is supposed to rinse the injection needle between sample injections. 
Operation of the instrument, data collection and evaluation is handled from a PC 
running Biacore T200 Control Software and Biacore T200 Evaluation Software 
(Figure 2). 
 
The Biacore optical unit is composed of a diode emitting polarized light at 760 nm [25] 
that passes through a semi-cylindrical prism and hits a sensor chip, a glass surface 
coated with a thin gold layer (50 nm). The glass side of the sensor chip is in optical 
contact with the prism, while its gold layer is facing the flow cells, which are formed 
by the IFC on the chip surface (Figure 3). In case of the T200, the IFC creates 










Figure 3: Simplified illustration of a Biacore setup. The prism is a curial component of the optical 
unit. It directs the incident light onto the sensor chip that consists of a glass layer (detector side) and a 
gold layer (sample side). The IFC forms the flow cell and is in direct contact with the sensor chip. The 
figure is modified from Reference [21]. 
 
The IFC consist of several micro channels that can be opened and closed through 
computer-controlled pneumatic microvalves. It is the heart of the microfluidic 
handling system that controls the delivery of samples and buffers to the sensor chip 
surface and allows the analyte to pass over the chip surface in a pulse-free, 
continuous, and automated flow. A regular maintenance of the instrument retards the 
attrition of liquid handling components, especially of the IFC, and supports the 
generation of precise and high quality data.[26]  
 
 
5.4 A typical SPR biosensor experiment and underlying principles 
 
In a biosensor experiment, one binding partner (the ligand) is immobilized on the 
sensor chip surface whereas the other binding partner (the analyte) is free in 
solution.[27] A beam of incident light is focused on the ligand-immobilized gold layer 
and is totally reflected at the glass-gold interface. The generated evanescent wave 
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penetrates into the flow cell and enables the detection of refractive index properties 
near the gold layer. During the measurement, a diode array detector [25] continuously 
records the position of reduced intensity of reflected light and thus is able to calculate 
the SPR angle (Figure 4-A). Once the analyte is injected into the flow cell, it binds to 
the immobilized ligand, with the consequence that in turn the refractive index changes 
close to the sensor chip surface. Since surface plasmon waves are very sensitive to a 
change in the refractive index, the SPR angle alters and hence the position of the dark 


















Figure 4: Biacore experiment. The SPR angle shifts from position I (A) to position II (B) when 
analyte bind to the immobilized ligand. The figure is modified from Reference [21]. 
 
The change in SPR angle is proportional to the mass of material bound and is reported 
as response units (RU), where 1000 RU corresponds to an SPR angle shift of 
~ 0,0001° or a change in the refractive index of 10-3.[28] In the case of proteins, 
1000 RU represents the binding of 1 ng protein per square nm to the sensor chip 
surface (Equation 1).[29] 
 
1 RU = 1 pg/mm2    (Equation 1) 
 
A binding curve of a small molecule–protein interaction can be visualized in a 
sensorgram, a plot of resonance units (RU) against time. A typical sensorgram 
comprises four phases: an association phase, an equilibrium phase, a dissociation 
phase, and a regeneration phase. In order to generate high quality data, it is also 
important to mention that at the beginning of each experiment the system should be 
primed with running buffer to obtain a stable baseline. The injection of analyte allows 
the formation of analyte–ligand complexes. In the association phase, analyte binding 
to the surface-immobilized ligand dominates, resulting in an increase of response 
units until association balances dissociation. At the end of analyte injection, only 
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running buffer flows over the surface with the consequence that dissociation of the 
analyte outweighs, accompanied by a decrease in response units. A regeneration step 
is indispensable if the analyte is not completely removed from the chip surface 
(Figure 5).[27,30,31] Regeneration is performed with high ionic strength buffers, 
detergents, and mild basic (NaOH) or acidic (glycine-HCl) solutions.[32] It is also 
noteworthy that the ligand solution not only flows over the sample chip surface, but 
also over a reference cell surface, which is either blank or immobilized with an 
inactive ligand. Additionally, buffer blanks are included prior to and throughout the 
































Figure 5: Schematic representation of a typical SPR sensorgram. In the association phase, analyte 
binds to the immobilized ligand until an equilibrium state is reached. A formed ligand–analyte complex 
dissociates when analyte injected is completed and only running buffer is in the mobile phase. 
Regeneration of the chip surface is often applied to restore a stable baseline. 
 
Subsequent to a kinetic run, all sensorgrams are processed using the double 
referencing procedure that has a favorable impact on the quality of the data.[33] In a 
first step the reference response is subtracted from the response of the sample cell to 
compensate for matrix effects, refractive index effects, and non-specific binding of 
the analyte. In a second data processing step, the response from the average of the 
blank sensorgrams is subtracted from the already referenced sensorgrams.  
 
The association rate constant (kon, the rate of complex formation) and the dissociation 
rate constants (koff, the rate of complex decay) can be obtained from a sensorgram by 
applying suitable curve fitting procedures in the BIAevaluation software.[34]  
 
Introduction   Surface Plasmon Resonance (SPR) 
 45 
5.5 Kinetic measurements 
 
In order to obtain a complete kinetic profile of a biomolecular interaction, different 
analyte concentrations have to be injected in a single experiment due to kon, which is 
concentration dependent (see also Section 1.6). In order to receive reliable data, 
analyte concentrations should cover a range between 0.1 to 10 times the KD, which 
roughly corresponds to about 10% to 90% of ligand saturation. Prior to a 
measurement the single concentrations are manually prepared by diluting the analyte 
in running buffer.[35] A conventional Biacore running buffer consists of 10 mM 
HEPES at pH 7.4, 150 mM NaCl and 0.005% P20 (polysorbate 20). The purpose of 
the salt is to suppress electrostatic effects on the carboxylated sensor chip matrix 
while the surfactant P20 should reduce adsorption of hydrophobic molecules to flow 
system surfaces. Depending on the assay EDTA is also added to chelate divalent 
metal ions that might be present in the running buffer.[36]  
 
The kinetics can be determined by multi-cycle kinetics (MCK), the standard kinetic 
assay comprising several cycles, where each analyte concentration is injected in a 
separate cycle (Figure 6-A). If the analyte is not completely detached after the 
dissociation phase, a regeneration step needs to be included to ensure equal starting 
conditions for the next cycle. To avoid multiple regeneration steps, which sometimes 
harm or even irreversibly inactivate the immobilized ligand (especially proteins),[37,38] 
a single-cycle kinetics (SCK) can be performed. During a SCK measurement the 
analyte is injected with increasing concentrations and short dissociation times in 
between. A long dissociation period takes place after the last analyte injection.   
 
 
Figure 6. Kinetic SPR measurements. The sensorgrams display a multi-cycle kinetics (MCK) (A) 
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In the end of the measurement, the surface can be regenerated. During the SCK there 
are no buffer injections or regeneration steps (Figure 6-B).[39] 
 
Compared to MCK, it could be affirmed that SCK provides kinetic results with the 
same precision.[40] The SCK approach requires less time for a complete analysis, and 
benefits from the lack of multiple regeneration steps during the measurement. 
However, SCK is more sensitive to baseline drifts, which are for instance caused by 
the dissociation of ligand in a capture assay, due to its comparatively long cycle time.  
 
 
5.6 Interaction mechanisms and kinetic models 
 
There are various kinetic models that operators can apply to calculate kon and koff. The 
most commonly used model is the Langmuir binding model that describes a 
1:1 interaction of an analyte (Y) with a ligand (Z) to form a complex (YZ) 
(Equation 2). In the Langmuir binding model, all binding sites are considered to be 
independent and equivalent.[41,42]  
 
Y + Z  
 kon 
koff 
  YZ    (Equation 2) 
 
The on-rate kon is a second-order rate constant in units of per molar per second 
(M-1s-1). Generally, the formation of a protein–small molecule complex is rapid. 
Though, considering that two binding partners need to collide before binding, kon is 
diffusion-limited and possesses about 5x109 M-1s-1 as maximum value for two 
molecules in solution.[43] Due to favorable electrostatic forces the diffusion limit can 
also be exceeded.[44] The association of the complex is concentration dependent, while 
koff does not depend on concentrations of the interaction partners. The off-rate is a 
first-order rate constant measured in per second (s-1).[45] Based on koff, the dissociative 
half-life t1/2 (time required for 50% of the initially present analyte–ligand complexes 
to dissociate, Equation 3) or residence time τ (average time an analyte stays bound to 
its ligand, Equation 4) of a ligand–analyte complex can be calculated.[45,46]  
 
t1/2 = ln2/koff    (Equation 3) 
 
τ = 1/koff     (Equation 4) 
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In a kinetic Langmuir analysis, koff can be obtained by exponential curve fitting of the 
dissociation phase. Fast-on and slow-off kinetics are indicative for strong affinities. In 
a simple bimolecular 1:1 interaction, the equilibrium dissociation constant (KD) can 
be directly calculated from the ratio of koff and kon (Equation 5).  
 
KD = koff/kon    (Equation 5) 
 
Additionally, the KD can be indirectly determined by an equilibrium analysis, 
providing that the steady state of association and dissociation is reached. If so, the 
theoretical binding capacity Rmax is detected at various concentrations.[31,47]  
 
For more complex binding reactions the two-state reaction model is often 
applied.[48,49,50] This model represents 1:1 binding of analyte to the sensor chip-
immobilized ligand with a binding-induced conformational change of one or both 
reaction partners, where complex YZ undergoes transition into complex YZ* 
(Equation 6).  
 






 YZ*         (Equation 6)  
 
The on and off rate constants of the complex YZ formation and dissociation are kon,1 
and koff,1, whereas kon,2 and koff,2 describe the conformational change. For reasons of 
simplification, the model assumes that complex YZ* solely emerges from and 
dissociates to complex YZ.[51] 
 
It should be noted that conformational changes usually do not cause a response signal 
change in Biacore. However, a very pronounced conformational change, e.g. spherical 
protein adopts an elongated conformation, might imply a refractive index shift 
pretending a mass concentration alteration on the sensor surface.  
 
In the two-state reaction model, the overall KD is determined according to 
equation 7.[51] 
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5.7 Immobilization strategies 
 
Depending on its nature, the ligand is attached to the sensor surface by either covalent 



















Figure 7: Methods for ligand attachment to the sensor chip surface. The ligand can be covalently 
immobilized to the sensor chip surface (A) or is captured by a molecule that is immobilized to the 
surface (B). A ligand and/or a hydrophobic carrier (lipid monolayer or bilayer) are/is attached by 
hydrophobic adsorption (C). The illustration is modified from Reference [52]. 
 
The first two approaches are used in several studies of this thesis and are explained in 
more details below (Section 1.7.1 & 1.7.2). Especially for covalent immobilization 
and capturing approaches, sensor chips covered by a 30-100 nm thick and flexible 
carboxymethyl dextran matrix are used (Figure 8).[53,54] This three-dimensional layer 
increases the possible immobilization level of ligands and exploits SPR to the greatest 
feasible extent. Biacore sensor chips possessing only the dextran matrix belong to the 




























Figure 8: Schematic representation of a carboxymetylated dextran matrix. The matrix covers the 
surface of a number of Biacore sensor chips (Section 1.7.3). 
 
 
5.7.1 Covalent immobilization approaches 
 
Covalent immobilization involves irreversible attachment of the ligand to the sensor 
surface by a covalent chemical link. It is a conventional method used to immobilize 
ligands and molecules for capturing approaches. The covalent attachment of ligands 
results in stable surfaces without any detachment of ligands during interaction 
analysis. This has also the advantage that only bound analyte molecules are removed 
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during a regeneration cycle. If small molecules are covalently coupled, harsh 
regeneration solutions are usually unproblematic. The carboxymethylated dextran 
matrix provides a foundation for numerous covalent immobilization chemistries. 
 
Amine coupling: The most commonly used covalent immobilization method is amine 
coupling. After the surface is activated with 1-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) and N-hydroxysuccinimide (NHS) the formed NHS-esters react 
with primary amine groups of the ligand (Figure 9). 
 
In case of protein ligands, amine groups being part of the protein-binding site often 
have a negative impact on the activity of the immobilized interaction partner. To 
avoid this problem, either the binding site can be protected during the immobilization 
process or another immobilization should be applied. Moreover, amine coupling often 
gives rise to heterogeneous immobilization results because most proteins have several 































Figure 9. Amine coupling. The dextran surface (1) is activated with EDC/NHS. NHS-esters (2) 
covalently couple to primary amine groups of a protein (3). Finally, the cell surface is blocked with 
ethanolamine (4). 
 
Thiol coupling: To obtain a homogenous orientation of the immobilized interaction 
partner, thiol coupling could be the method of choice. In contrast to amines, thiol 
groups are usually less common in proteins. Immobilization of thiol-containing 
ligands can be conducted by the formation of disulfide bridges either with a ligand or 
a surface thiol coupling approach. In case of ligand thiol coupling, the ligand harbors 
free thiol groups while the sensor surface has active disulfide groups. In contrast, the 
chemical conditions for surface thiol coupling are vice versa (Figure 10-A). The 
formed disulfide bridges are stable under physiological conditions but can be reduced 
by ß-mercaptoethanol or dithiothreitol as well as by a high pH. In this way, a 
complete regeneration of the chip surface is possible. However, the unstable 
characteristic under these reducing conditions might negatively influence the 
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measurements. In such circumstances, operators can make use of maleimide coupling. 
Maleimides form covalent non-reducible thioester bonds with free thiol groups of the 





























Figure 10. Covalent coupling methods for thiol containing ligands. Ligand and surface thiol 
coupling (A) and covalent ligand immobilization by maleimide coupling. 
 
Aldehyde coupling: This method is suitable for ligands having aldehyde groups or 
ligands containing cis-diols and sialic acids residues (e.g. polysaccharides, 
glycoproteins, and glycoconjugates) that can be easily oxidized to aldehydes.[55] The 
aldehyde residues are able to couple to a hydrazine-activated surface. To obtain a 
stable surface, a reduction step with cyanoborohydride is performed at the end of the 
immobilization procedure (Figure 11). However, ligands might suffer from oxidation 




















Figure 11. Aldehyde coupling of aldehyde containing ligands. 
 
One should be aware that covalent coupling approaches chemically modify ligands. 
The modification may influence ligand activity and can result in a decrease or even an 
affinity loss of the studied interaction. This should be taken into account, especially if 
small molecules are immobilized. In these unpleasant cases, capturing approaches 
provide an alternative strategy (Section 1.7.2). 
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5.7.2 Capturing approaches 
 
Capturing approaches enable that ligands are captured by non-covalent interaction 
with a capturing molecule. In the majority of cases, the capturing molecule is 
covalently attached to the sensor surface and mostly ensures that ligands are bound in 
an orientation-specific manner with the result of a homogeneous chip surface. 
Additionally, a damage of the ligand is unlikely because the capture can be performed 
under physiological conditions. 
 
Streptavidin-Biotin Capture: One of the strongest known biological interactions is the 
non-covalent binding of biotin to streptavidin (KD about 10-15).[56] The high affinity 
streptavidin-biotin interaction is rather resistant to extreme pH and temperature 
conditions, denaturing and detergent agents, and organic solvents.[57] Biacore utilizes 
this strong interaction to capture biotinylated ligands to a sensor chip surface with 
covalently attached streptavidin (Figure 12-A). Ready-made streptavidin chips 
(Sensor Chip SA) can be ordered or streptavidin is covalently immobilized to the 
sensor chip surface by the operator. The dissociation of streptavidin–biotin caught 
ligands is usually negligible during a measurement. Biotin can be introduced into a 
molecule by several methods. One method is the insertion of a unique 15 amino acid 
peptide taq (AviTaq peptide) into the ligand. Subsequently, the AviTaq peptide can be 
covalently biotinylated by the biotin ligase (BirA) from E.coli.[58] 
 
Antibody-based capture: An antibody based capture uses a specific antibody as 
capturing molecule. High affinity antibodies against a variety of antigens are 
commercially available. They can be easily immobilized by amine coupling and their 
regeneration with low pH containing buffers (e.g. glycine-HCl) is usually 
unproblematic. After a regeneration cycle ligands and ligand–analyte complexes are 
not longer available and the capturing molecule needs to bind new ligand for the next 
cycle. Thus an increased amount of ligand is needed, but one can be sure that the 
ligand is not damaged by regeneration solutions. Due to the high selectivity for their 
antigen, antibodies are suitable for the capture of ligands from impure samples or 
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Instead of covalent immobilization, antibodies from several mammalian species 
(including human IgG1, IgG2, and IgG4) can be captured by pre-immobilized 
Protein A. After the antibody (capturing molecule) is bound with its Fc-region to 
Protein A, the antigen (ligand) can be injected and captured by the antibody 
(Figure 12-B). Regeneration of the protein A surface is performed using low pH 
buffers that completely remove the capturing molecule-ligand-analyte complex.[59,60] 
 
Capturing tagged proteins: For purification purposes, proteins are often tagged with 
poly-histidine that enables binding to Ni2+-nitrilotriacetic acid (NTA) complexes. This 
principle can also be exploited for capturing His-tagged ligands on a NTA chip 
surface (Figure 12-C). According to the manufacturer, optimal binding can be 
obtained by using tags with at least 6 histidine residues. However, the KD for a single 
His6-tagged protein with Ni2+-NTA is only about 10-6 M at neutral pH and usually 
proteins with one His-tag rapidly dissociate from the Ni2+-NTA surface.[61] A more 
stable surface can be prepared using proteins with a double-His6 tag (two His6 
separated a short peptide sequence).[61,62] An advantage Ni2+-NTA is the possibility to 
remove the captured ligands with the chelating agent EDTA. Alternatively, anti-His 
antibodies can be used to capture His-tagged proteins. 
 
Other prominent protein tags for ligand capturing are FLAG[63] and glutathione-S-
transferase (GST) [64] that can be captured by an anti-FLAG mAb and anti-GST 





























Figure 12. High affinity capturing methods. An SPR method to capture ligands is streptavidin-biotin 
capturing (A). Protein A binds IgG (capturing molecule) that in turn captures the ligand (B). The right 
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5.7.3 Biacore sensor chip surfaces 
 
The following table gives an overview of the different Biacore sensor chips.[52] 
 
Chip  Surface  Application 
AU plain gold surface  custom design 
CM3 short dextran matrix  immobilization of large ligands 
CM4 standard dextran matrix with  
a low degree of carboxylation 
 immobilization of small ligands 
CM5 standard dextran matrix  general approach 
CM7 standard dextran matrix with  
a high degree of carboxylation 
 reaching high immobilization levels  
C1 no matrix, low capacity  prevention of dextran interactions 
SA streptavidin immobilized  capture of biotinylated analytes 
L1 
 
lipid capturing surface  capture of vesicles and liposomes 
while maintaining the lipid bilayer 
NTA NTA  capture of His-tagged ligands 
HPA octadecanethiol   hydrophobic adsorption of a  
polar lipid monolayer 
Protein A Protein A immobilized  capture of IgG1, IgG2, and IgG4 
 
Table 1: Overview of Biacore sensor chips. The table lists chip surfaces and their basic 
application.[52] 
 
In addition, Xantec bioanalytics also offers a wide range of SPR sensor chips 
including various polymers, densities, thicknesses, and capture molecules.[65] 
 
 
5.8 Assay design  
 
The examination of small molecule–protein interactions raises the question whether 
the small molecule or the protein should be immobilized. According to the scientific 
issue and properties of the interaction partners, it is an individual decision. In drug 
discovery, a small molecule has an organic origin and an upper molecular weight of 
around 900 Da.[66] Proteins are macromolecules that most commonly have molecular 
weights in the range of 5.5 kDa to 220 kDa.[67] Therefore, higher signal responses are 
achieved when the small molecule is immobilized.  
 
However, small molecule analytes and high response signals are simultaneously 
possible by using a sandwich assay. Solution competitive or surface competitive 
assays can be performed as well. A sandwich assay works with an enhancement 
molecule (a macromolecule) that specifically binds to the ligand-bound analyte and 
thus increases the SPR signal (Figure 13-B).[68,69] In a solution competitive assay a 
macromolecule (detecting molecule) binds to both the analyte and the ligand (the 
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ligand is equal to the analyte) (Figure 13-C) whereas in a surface competitive assay 
the macromolecular competitor (detecting molecule) only interacts with the ligand 
(the ligand is unequal to the analyte) (Figure 13-D). The injection of different analyte 
concentrations over the ligand, while keeping the concentration of the detecting 
molecule constant, yields various SPR signals. A higher analyte concentration results 
in lower changes of response units. In this way, the SPR response can be inversely set 
in relation to individual analyte concentrations.[36,69,70] 
 
 
Figure 13: Various SPR assay principles. The schematic illustrations display a direct assay (A), a 
sandwich assay (B), a solution competitive assay (C), and a surface competitive assay (D). The figure 
is modified from Reference [69]. 
 
In order to estimate eventual experimental signal responses, a pivotal variable is the 
theoretical analyte binding capacity Rmax. It can be calculated as follows: 
 
Rmax = (MWanalyte/MWLigand) x RL x Sm (Equation 8)  
 
where Rmax is the theoretical analyte binding capacity (RU), MWanalyte and MWligand is 
the molecular weight of the analyte and the ligand, respectively, RL is the 
immobilized level of the ligand (RU), and Sm the stoichiometric ratio.[71] 
 
 
5.9 Bioanalytical and biophysical applications of SPR 
 
Apart from affinity and kinetic information, the Biacore instrument can also indirectly 
determine thermodynamic parameters of a molecular interaction. SPR is also a helpful 













Introduction   Surface Plasmon Resonance (SPR) 
 55 
structural integrity and activity. Generally, the active concentration of the 
biotherapeutic protein is tested by calibration-free concentration analysis. In addition, 
its binding activity to antigens and Fc receptors is verified. When comparing 
sensorgrams of the latest protein batch with reference sensorgrams, information about 
drug stability and potency can be obtained.[36]  
 
The application of SPR in protenomics aims for investigations of protein–protein 
interactions in complex biomolecular networks. In this field, SPR devices are often 
coupled with MALDI-MS and LC-MS/MS to gain qualitative information about the 
assayed proteins. In this manner, intramolecular interactions and structure–activity 
relationships can be ascertained. The newly acquired knowledge may have an 
important impact on further proteomic research or might facilitate the breakthrough of 
drug discovery studies.[72] 
 
A newer application area of SPR biosensors is the direct examination of specific 
ligands in blood plasma. This is a challenging issue due to the high number of 
biomolecules that might compete with the analyte for binding to the ligand or could 
unspecifically interact with the sensor chip matrix. Positive experiences have been 
made with some surface coatings like polymers and peptides that decrease artifactic 
absorption of unspecific blood plasma proteins and simultaneously function as anchor 
for the ligand. The usage of metallic nanoparticles as plasmonic materials instead of 
gold surfaces has enabled a resolution increase and sensitivity gain of SPR 
measurements. In contrast to the gold layer that induces propagating SPR, 
nanoparticles are based on localized surface plasmon resonance (LSPR).[73] 
 
In addition, studies exist describing SPR as an effective tool for medical diagnostic 
analysis in order to verify biological markers. Validated biomarkers for the detection 
of cancer are for example interleukin-8,[74] the protein vascular endothelial growth 
factor,[75] and the carcinoembryonic antigen.[76] Moreover, pathogen specific 
antibodies can be detected and the conduction of both vitamin and hormone analyses 
are also possible with SPR biosensors.[15] The vision of the future is the usage of 
miniaturized SPR devices that can be applied for rapid examination of a patient`s 
blood sample in healthcare facilities.[77] 
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6. Isothermal Titration Calorimetry (ITC)
6.1 ITC - A short historical overview 
Calorimetry is defined as the measurement of heat at constant pressure.[1] All 
physical, chemical, and biological processes that either release (exothermic reaction) 
or absorb (endothermic reaction) heat are amenable to a calorimetric 
characterization.[2] A calorimeter is used to detect quantities of heat transferred to or 
from an investigational sample. The first reported calorimeter, an ice calorimeter, 
dated back to 1783 and was designed by Lavoisier and Laplace. The ice calorimeter 
measured the heat given off by a guinea pig as the amount of water originating from 
an ice jacket surrounding the measurement chamber. To prevent an influence from the 
ambient temperature, an ice-water chamber shielded the ice jacket (Figure 1).[3]  
Figure 1: The ice calorimeter. The ice calorimeter is the first reported calorimeter and was developed 
by Lavoisier and Laplace, who published their invention in 1783. The picture is taken from 
Reference [4].  
Titration calorimetry had its beginnings about 50 years ago when Christensen and 
Izatt simultaneously determined the equilibrium dissociation constant (KD) and 
enthalpy change (ΔH) of metal–cyanide complexation reactions by titrating one 
component into the other.[5,6] At the same time, titration calorimeters that run under 
constant temperature were developed.[7,8] Sensitivity improvements of the instruments 
enabled the study of biological systems in the 1980s.[9,10,11] The first commercially 
available isothermal titration calorimeter was released by Microcal in 1989. It was 
called a device for ”determining Keq in minutes”, where Keq is the equilibrium binding 
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constant. It was specifically designed for the study of biological systems.[12] From this 
date onward, ITC developed from a specialist technique into a standard tool to 
directly characterize thermodynamic parameters.[13] Nowadays, high-sensitive 
isothermal titration calorimeters (VP-ITC and Microcal iTC200 from Malvern as well 
as Nano ITC Standard Volume and Nano ITC Low Volume from TA Instruments) are 
routinely used in drug discovery. Recently launched devices (PEAQ ITC from
Malvern, and Affinity ITC by TA Instruments) feature even better sensitivity and 
volume requirements.[14] 
6.2 Binding Thermodynamics 
ITC is a versatile technique to analyze the physical basis of molecular binding 
interactions under constant temperature (isothermal conditions). During a 
measurement, heat generation or absorption is measured, which is equivalent to the 
change in enthalpy.[15] In addition to ΔH, the equilibrium dissociation constant KD, 
and the binding stoichiometry n can be directly determined.[16] KD (KD =1/KA) is 
related to the change in free energy of binding that is also known as the change in 
Gibbs free energy (ΔG), which can be calculated by the Gibbs` equation 
(Equation 1):[17]  
Δ𝐺 =   Δ𝐺! −   𝑅 · 𝑇 · ln𝐾! (Equation 1) 
where R is the gas constant (8.314 JK-1mol-1), T the absolute temperature in Kelvin, 
and ΔG° the free energy change under standard conditions. Standard conditions are a 
concentration of 1.0 M for each reactant, a temperature of 25°C, and a pressure of 
1 atm.[18] The binding reaction is in equilibrium if ΔG = 0.
0 =   Δ𝐺! −   𝑅 · 𝑇 · ln𝐾! (Equation 2) 
Δ𝐺! = 𝑅 · T · ln𝐾! = −  𝑅 · 𝑇 · ln𝐾! (Equation 3) 
Under standard conditions the change of entropy ΔS° can be readily deduced from
ΔH° and ΔG° (Equation 4) without being dependent on van’t Hoff approximations.
Δ𝑆! = (Δ𝐻! − Δ𝐺!)/𝑇 (Equation 4) 
 
Δ𝐺! = Δ𝐻! − TΔS! (Equation 5) 
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Changes in both enthalpy and entropy determine whether a non-covalent molecular 
interaction is spontaneous (thermodynamically favorable). This is the case when ΔG° 
is negative (ΔG° < 0). Many different combinations of ΔH and ΔS can result in
identical Gibbs free energy and consequently the same binding affinity.[19] 
Since enthalpy is commonly dependent on temperature, the change in heat capacity 
(∆Cp) of a binding interaction can be determined as well. This is done by repeating a 
titration at different temperatures under otherwise identical reaction conditions 
(Equation 8).[20] 
∆𝐶! = (𝜕∆𝐻°)/𝜕𝑇 (Equation 8) 
6.2.1 Enthalpic components
Enthalpically driven forces of a bimolecular interaction involve heat release or 
consumption. Enthalpic contributions are electrostatic interactions, such as hydrogen 
bonds, salt bridges, halogen bonds, stacking with π-systems, and van der Waals 
interactions.[21] The energy of an electrostatic interaction can be approximated using 




where E is the electrostatic energy, q1 and q2 are changes of two interacting atoms, 
r is the distance between q1 and q2, ε0 is the vacuum permittivity, and εr is the 
dielectric constant of the surrounding medium.[22] 
Electrostatic interactions involving permanent or induced dipoles are known as van
der Waals forces. A single van der Waals interaction typically ranges from 
−2 kJ mol−1 to −4 kJ mol−1. However, van der Waals forces are omnipresent and the
impact of several van der Waals bonds can significantly contribute to the stabilization 
of protein–ligand interactions.[23] Hydrogen bonds are dipole-dipole interactions that
are typically stronger than van der Waals forces. They are formed between a
hydrogen donor group Xδ−−Hδ+ and an electronegative hydrogen bond acceptor
Aδ−.[24] The free energy for hydrogen bonding is in the range between –6.5 kJ mol−1 to 
−19.5 kJ mol−1.[25] Hydrogen bonds are directional and their strength is dependent on
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bond length and bond angle. As defined by the IUPAC recommendations of 2011, the
strength of the hydrogen bond increases with decreasing distance between the binding 
partners and an approximation of the donor angle to 180°.[26] Prevalent hydrogen 
bonds formed in protein–ligand complexes are N-H⋯O, O−H⋯O, and N−H⋯N and 
feature a median bond length of about 2.8 Å between donor and acceptor heavy
atoms.[27] A salt bridge is a hydrogen bond that involves an oppositely and 
permanently charged ion pair that is within 5 Å. Its strength heavily depends on the 
environment and particularly buried salt bridges can even exceed an enthalpy
contribution of −40 kJ mol−1.[27,28] Halogen bonds can be formed between an 
electrophilic region of a halogen, the donor (D), and a nucleophile, the acceptor (A), 
yielding a R−D⋯A non-covalent contact. The acceptor is commonly a lone pair 
possessing atom, an anion, or a π-system.[29] In a π-system, π-electrons generate a 
negatively charged periphery that surrounds a positively charged core 
(σ-framework).[30] This electrostatic distribution enables aromatic-aromatic 
interactions of the π-system-containing amino acids phenylalanine, tyrosine, 
tryptophan and histidine. These interactions can provide a substantial amount of 
binding enthalpy. As an example, π-π stacking between neutral histidine and the other 
aromatic amino acids gives rise to an enthalpy change between -13.0 kJ mol−1 
to -17.0 kJ mol−1.[31] Furthermore, π-systems of aromatic acids are able to attract 
cations (cation–π-interaction)[32], halogens, and molecules with permanent dipoles 
such as water. The (water) OH⋯π interaction is considered to be a non-conventional 
hydrogen bond.[33] In addition to their contribution to the binding free energy, 
interactions involving aromatic rings are also of importance for protein–ligand 
recognition.[34] 
6.2.2 Entropic components
Entropy describes the flexibility of a system and is either favorable or 
unfavorable.[35,36] The change in entropy related to a small molecule–protein 
interaction is expressed as the sum of various entropic contributions, as demonstrated 
in Equation 10.  
Δ𝑆 =   Δ𝑆!"#$%&'"( + Δ𝑆!"#$"%&'()"# + Δ𝑆!"#$#%"&$'/!"#$%&#!'($#&  (Equation 10) 
Thereby, ΔSsolvation reflects the solvation entropy that usually favorably contributes to 
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the binding entropy because it represents the solvent release to bulk upon binding of 
two interaction partners. The component ΔSconformation describes the change in 
conformational entropy and constitutes the alteration of conformational freedom of 
both binding partners in comparison to their unbound state, which may be a favorable 
or an unfavorable binding entropy contribution.[19,37] In some cases favorable 
conformational entropy may decrease the entropic cost of binding. The confinement 
in translational and rotational freedom is expressed by ΔSrotational/translational. It describes 
the reduction of free particles in solution and consequently is unfavorable.[19] 
6.2.3 Enthalpy-entropy compensation 
In the drug development process, a frequent occurrence is enthalpy–entropy (H–S) 
compensation in aqueous solutions. It describes a linear correlation between enthalpy 
and entropy changes of interactions between proteins and small molecules.[38,39]  
A molecular change in the ligand leading to an additional and/or tighter contact 
between the interaction partners results in an enthalpic improvement. However, newly 
formed non-covalent interactions can concurrently lead to a decrease in flexibility in 
either or both interaction partners. As a consequence, the loss in the overall 
conformational entropy compensates the gain in enthalpy giving rise to similar values 
for ΔG°.[40]  
Frequently, solvent water molecules are responsible for H–S compensation effects. 
The hydration shell of both protein and ligand has to be partially desolvated, a 
enthalpically unfavorable process, to enable direct interactions between the binding 
partners.[41] In this process, the penalty for desolvation enthalpies is more pronounced 
for polar groups than for nonpolar groups. However, an associated water-entropy gain 
(ΔSsolvation) due to the release of tightly water molecules into bulk water can 
compensate the loss of enthalpy.[21] 
6.3 Isothermal titration calorimeters 
An isothermal calorimeter is equipped with a sample cell containing one binding 
partner (titrate) and a motor-driven syringe that provides the other binding partner 
(titrant). The syringe is provided with a rotating paddle that serves as a titrant delivery 
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and stirring device. In addition to the sample cell, the microcalorimeter possesses a 
reference cell filled with water. Both cells are identical and made of chemically inert 
and thermally conducting material.[42] They are surrounded by a thermostated 
adiabatic jacket and are equilibrated to the same temperature before a measurement. 
During a run the titrant is injected into the sample cell and heat is released or 
absorbed in case of complex formation between titrant and titrate. The temperature 
change in the sample cell is recognized by a heat-sensing component (thermocouple) 
that determines the temperature differences (ΔT) between the two cells. In order to 
consistently maintain the sample and reference cell at exactly the same temperature, a 
proportional-integral-derivative (PID) translates ΔT to the power that should be 
supplied to a feedback heater located on the sample cell to compensate for this 
difference [43] while the requirement of cooling occurs passively by heat exchange 
with the adiabatic jacket (Figure 2-A).[44,45]  
Figure 2: Setup of an isothermal titration calorimeter. The calorimeter is based on the heat-
conduction principle, i.e. the power change is directly recorded upon titration of one binding partner 
into the other. The illustration is modified from Reference [43]. 
The calorimeters MicroCal iTC200 and MicroCal VP-ITC used in our studies are 
both from Malvern and execute titrations with the heat-conduction principle as 
described above. They operate with nanowatt sensitivity.[45] MicroCal iTC200 is a 
small volume isothermal calorimeter with low sample consumption. The calorimeter 
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Figure 3: ITC instruments from Malvern. The pictures display a MicroCal iTC200 (left) and a 
MicroCal VP-ITC (right) isothermal titration calorimeter.  
6.4 ITC binding assays  
6.4.1 A typical ITC experiment 
A careful preparation of samples is a prerequisite to receive reliable thermodynamic 
parameters that accurately reflect the binding interaction. Prior to every measurement, 
a soluble titrant aliquot (usually a small molecule if a small molecule–protein 
interaction is studied) is drawn up into the syringe that is subsequently inserted into 
the sample cell containing a soluble sample of the other binding partner (commonly a 
macromolecule). In the course of an experiment, known amounts of the titrant are 
repetitively injected at isothermal conditions into the sample cell. The formation of a 
complex gives rise to the release (in case of an exothermic reaction) or the absorption 
(in the event of an endothermic reaction) of heat.[43,46] Heat alterations are universal 
and in the most cases they amount to submillions of a degree.[20] The change in the 
cell feedback power, used to keep a constant temperature, is referred as differential 
power (DP, with units of µcal sec−1) that is recorded as output signal as a function of 
time displaying spikes at each titrant injection. (Figure 4-A).[47] To evaluate the 
measurement, the heat per injection is determined by integrating the DP from the 
respective spike over time. Afterwards, the single injection heats are normalized by 
the amount of titrant injected. The integrated and normalized heats per injection are 
used to fit the binding isotherm as a function of molar ratio [Titrant]/[Titrate] in the 
sample cell. Based on the binding isotherm, the thermodynamic parameters n, KD, and 
ΔH of a binding process can be derived (Figure 4-B).[15]  
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Figure 4: ITC raw data and its analysis. (A) ITC raw data. (B) The blue curve displays the binding 
isotherm as function of the molar ligand–protein ratio. A simple bimolecular interaction (A + B ⇔	  AB) 
uses a 1:1 binding model to fit the normalized heats per injection. The illustration and plots are 
modified from References [43,48]. 
6.4.2 Displacement titration - An assay for tight & very low interactions 
ITC can be applied to a wide variety of binding systems were a heat change occurs 
including protein–protein [49,50] and protein–small molecule [51,52] interactions. 
However, the dissociation constant of high-affinity interactions (KD < 10−8 M) cannot 
be determined directly by a single experiment. Due to a very steep slope of the 
binding isotherm, the direct determination of KD is unreliable and requires a more 
complex approach.  In this case, a displacement titration experiment is performed, in 
which a competing weaker ligand artificially reduces the binding affinity of the tight-
binding ligand. Thereby, three different titrations have to be conducted (i) a direct 
titration of the high-affinity ligand (investigational ligand) to the target protein, (ii) a 
direct titration of the weaker ligand (competing ligand) to the target protein, and (iii) a 
displacement titration of the high-affinity ligand to the titrate mixture consisting of 
competing ligand and target protein.[53,54] All three titrations are conducted under the 
same experimental conditions.[54] The same procedure can be performed with very 
low-affinity bimolecular interactions, for which the transition of the binding isotherm 
in a direct titration is ill-defined.[55,56]  
6.4.3 Possible emerging undesirable heat effects 
The assessed enthalpy in an ITC run not only comprises the binding heat, but also 
heats arising due to molecular reorganization and conformational changes of one or 
both interaction partners.[57] Thus, the calculated change in entropy is also incorrect 




























Introduction Isothermal Titration Calorimetry (ITC) 
In some cases, heat effects not involved in the binding interaction itself can also 
occur. These adverse heats can result from friction and turbulence due to the injection 
of ligand, the mixing procedure per se, or is depended on the dilution of both samples. 
Unfavorable heats of dilution can either arise when the titrant solution is much higher 
concentrated than titrate solution or when the pH or ionic strength of titrant and titrate 
buffer solutions are mismatched. A water into water titration can unveil heat effects 
due to friction and turbulence and also helps to recognize impurities, for instance due 
to precipitated protein samples.[54]  
6.5 A further ITC application – KinITC 
KinITC is a new method developed by Prof. Philippe Dumas to gain not only 
thermodynamic parameters but also kinetic information, i.e. the association rate 
constant (kon) and the dissociation constant (koff) of a binding reaction.[58] The 
implementation of kinITC-ETC (equilibration time curve) into the software 
Affinimeter made the method commercially accessible. Affinimeter deduces koff from 
the equilibrium time of each individual peak while classical processing of the 
corresponding ITC raw data and fitting of the isotherm provides the KD. Finally, kon 
can be calculated as the quotient of koff/KD.[59] 
In publication 1, “KinITC – One method supports both thermodynamic and kinetic 
SARs as exemplified on FimH antagonists” the method was independently validated 
for the first time. The publication also describes the methodical basis of kinITC-ETC 
and encourages scientists to analyze their ITC raw data with Affinimeter. One 
interesting aspect of kinITC is the fact that already thermodynamically analyzed and 
stored ITC data can be reinvestigated to ascertain the kinetic knowledge about the 
binding process as well. 
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Abstract: Affinity data, such as dissociation constants (KD) or
inhibitory concentrations (IC50), are widely used in drug dis-
covery. However, these parameters describe an equilibrium
state, which is often not established in vivo due to pharma-
cokinetic effects and they are therefore not necessarily suffi-
cient for evaluating drug efficacy. More accurate indicators
for pharmacological activity are the kinetics of binding pro-
cesses, as they shed light on the rate of formation of pro-
tein–ligand complexes and their half-life. Nonetheless, al-
though highly desirable for medicinal chemistry programs,
studies on structure–kinetic relationships (SKR) are still rare.
With the recently introduced analytical tool kinITC this situa-
tion may change, since not only thermodynamic but also ki-
netic information of the binding process can be deduced
from isothermal titration calorimetry (ITC) experiments.
Using kinITC, ITC data of 29 mannosides binding to the bac-
terial adhesin FimH were re-analyzed to make their binding
kinetics accessible. To validate these kinetic data, surface
plasmon resonance (SPR) experiments were conducted. The
kinetic analysis by kinITC revealed that the nanomolar affini-
ties of the FimH antagonists arise from both (i) an optimized
interaction between protein and ligand in the bound state
(reduced off-rate constant koff) and (ii) a stabilization of the
transition state or a destabilization of the unbound state (in-
creased on-rate constant kon). Based on congeneric ligand
modifications and structural input from co-crystal structures,
a strong relationship between the formed hydrogen-bond
network and koff could be concluded, whereas electrostatic
interactions and conformational restrictions upon binding
were found to have mainly an impact on kon.
Introduction
Although the theoretical foundation of binding kinetics in
drug–target interactions was set by Paul Ehrlich more than a
century ago (“corpora non agunt nisi fixata”),[1] little attention
has been paid to kinetic aspects until recently. Only after Cope-
land introduced the drug–target residence time concept in
2006, kinetic considerations gained increasing interest.[2] The
key message of this model is that residence time (t= 1/koff)
[3]
or half-life (t1/2 = ln2/koff)
[2, 4] of a binary drug–target complex,
and not the binding affinity (e.g. expressed by the dissociation
constant KD), controls the in vivo pharmacological activity.
The launch of a new drug is associated not only with high fi-
nancial costs but also with a substantial risk of failure, mainly
due to insufficient efficacy and unwanted side effects.[5] Several
studies have shown that kinetic information is more reliable
than affinity data to predict in vivo potency as well as the re-
sistance potential of a drug candidate.[6] One of many exam-
ples is the HIV reverse transcriptase inhibitor efavirenz that ex-
hibits only a low affinity for its target (5 mm) but a long dissoci-
ation half-life (t1/2 = 2.8 h).
[7] Furthermore, kinetic studies by Ma-
schera et al. on HIV-1 protease mutants revealed a correlation
between drug resistance to the HIV protease inhibitor saquina-
vir and an increased dissociation rate of the drug–target com-
plex.[8] Nevertheless, early-phase drug discovery still focuses
mainly on the optimization of KDs, although it has been recog-
nized that kinetic rate constants for association (kon) and disso-
ciation (koff) are a necessary precondition for a comprehensive
description of the binding process.[9]
Long dissociation half-lives are a crucial feature of many
small molecule drugs on the market, for example, for the neu-
raminidase inhibitor oseltamivir (47 min),[10] the selective COX-2
inhibitor rofecoxib (9 h)[11] or the HIV-1 protease inhibitor daru-
navir (>240 h).[12] Generally, a drug–target complex with a long
dissociation half-life can compensate for unfavorable pharma-
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cokinetics, that is, a bimolecular complex can still exist while
the unbound drug molecule is already cleared from the
body.[13] This is of particular importance for substances with
short plasma half-lives.[4] In contrast, in the case of drug toxici-
ty, fast off-rates are favored as it is the case for antipsychotics
that occupy D2 receptors (t1/2<1 min).
[14] In vivo, fast on-rates
play a central role in drug rebinding, which can be influenced
for example by the local accumulation of the target and spatial
characteristics of the binding site.[15] In opposition to off-rates,
which are independent of free ligand concentration, on-rates
can be increased by the administration of higher doses. How-
ever, this requires sufficient oral bioavailability and increases
the risk of undesired side effects based on the elevated
amount of drug in circulation.[16]
It is surprising that studies on the correlation of molecular
structures and their binding kinetics, so-called structure–kinetic
relationships (SKRs), are rare.[17] In a rough approximation,
more rotatable bonds and higher molecular weights correlate
with long complex half-lives.[18] Moreover, water-shielded hy-
drogen bonds also tend to improve the lifetime of protein–
ligand complexes.[19] On the other hand, the on-rate is limited
by diffusion and can be influenced by steric and electrostatic
factors as well as conformational dynamics.[9]
Surface plasmon resonance (SPR) spectroscopy has evolved
into the method of choice for measuring binding kinetics in
drug discovery.[20] It monitors non-covalent interactions in real-
time by detecting a mass-dependent change in the refractive
index close to the sensor surface.[21] SPR is also applied to
obtain thermodynamic information from affinity data as a func-
tion of temperature by van’t Hoff analysis. However, since the
heat capacity change (DCp) of macromolecular interactions
with small molecules is mostly different from zero, enthalpy
and entropy changes for binding are usually temperature de-
pendent. This introduces curvatures in van’t Hoff plots and can
limit the accuracy of linear approximations compared to direct
measurements.[22]
Therefore, the method of choice to directly determine the
thermodynamics of a molecular binding event is isothermal ti-
tration calorimetry (ITC). In contrast to SPR, where one interac-
tion partner has to be immobilized on the sensor chip surface,
ITC measures the heat change of a binding interaction in solu-
tion. This heat change can be converted into a binding iso-
therm that allows the direct measurement of KD and the
change in enthalpy (DH8), whereas the change in free energy
(DG8= RTlnKD, with R being the universal gas constant and T
the absolute temperature) and the change in entropy (DS8,
DG8=DH8@TDS8) are calculated.[23] Both techniques are the
gold-standard in their field of application, SPR for the determi-
nation of kinetic and ITC for thermodynamic parameters.[24]
Recent publications from Dumas and co-workers have the
potential to transform the role of ITC in drug discovery, since it
describes an approach to derive binding kinetics from ITC data
(kinITC).[25]
In an ITC experiment, after each injection and mixing of ti-
trant, an association reaction in the calorimeter cell relaxes to
the equilibrium position dictated by the new total concentra-
tions of reactants. This relaxation to equilibrium occurs at a
rate that is determined by the association and dissociation rate
constants for the reaction, together with the concentrations of
free and complexed species. This relaxation process gives rise
to a peak of heat release or uptake that is measured in the cal-
orimeter. As the concentration of species changes throughout
the titration, the relaxation kinetics changes, and so the shape
(width) of the peak changes, with narrower peaks at the begin-
ning of the titration and wider peaks nearer the point of stoi-
chiometric equivalence. Since the observed shape of the peak
actually depends on both the rate of relaxation to equilibrium
and the intrinsic rate constant of the power compensation
electronics of the calorimeter, it is necessary to deconvolute
these contributions.
KinITC extracts the underlying kinetic information from the
ITC thermogram by analysing the shape of each injection
peak, and has been described by Dumas.[25] Here we have em-
ployed a simplified version of this analysis, kinITC-ETC (Equili-
bration Time Curve), implemented in the commercially avail-
able ITC analysis software AFFINI-meter.[25a] This method calcu-
lates the time necessary for the differential power curve to
return to the baseline after an injection using the baseline-cor-
rected thermogram, yielding a bell-shaped ETC curve. This
curve is fitted as a function of koff and the intrinsic rate con-
stant for the instrument electronics. The enthalpy changes for
association and the association constant, derived from fitting
of the integrated binding isotherm (or determined in other ex-
periments), are used to constrain this fit, so the kinetic and
equilibrium parameters determined by this analysis are neces-
sarily correlated and a reliable fitted value of the equilibrium
constant is essential (Figure 1).
Clearly, kinITC-ETC greatly increases the value of ITC data, al-
lowing the direct determination of all relevant biophysical con-
stants describing a binding event within one experiment. Al-
though bearing a great potential to expand the positive
impact of kinetic investigations in drug discovery, kinITC has
only hesitantly found its way into SKR studies yet.[26] To reduce
the initial reservation for the application of kinITC, kinetic pa-
rameters derived from ITC experiments are independently vali-
dated for the first time in the present study. In addition, we
demonstrate that kinITC is a powerful tool for “data mining”.
Therefore, the binding kinetics of a series of congeneric
mannosides binding to the lectin domain of FimH (FimHLD)
were determined. FimH is a virulence factor located at the tip
of type 1 pili of uropathogenic E. coli (UPEC) strains.[27] It inter-
acts with the highly mannosylated glycoprotein uroplakin Ia,
which is part of the urothelial mucosa and thereby mediates
bacterial adhesion to the bladder epithelium as the initial step
of urinary tract infections (UTI).[28] An anti-adhesion therapy
with FimH antagonists, which block the adhesion and thereby
prevent the infection, could therefore be beneficial for patients
suffering from recurrent UTI.[29] Re-analyzing data from numer-
ous ITC[30] and SPR[31] studies we published in the last 5 years,
enabled the validation of the kinITC-ETC approach and the cor-
relation of kinetic parameters with structural properties of a
large ligand dataset. The kinetic fingerprints of FimH antago-
nists offer the opportunity to further improve the binding
characteristics essential for a clinical application.




The publication on kinITC by Burnouf et al. in 2012 gained
wide interest, but the complexity of the analysis hampered a
broader application.[25b] However, with kinITC-ETC integrated
into the commercially available ITC analysis software AFFINIme-
ter (Version 1.0415–1.1510) this hurdle could be overcome. It
uses fully automated data processing to derive kinetic and
thermodynamic parameters from ITC raw data avoiding the
risk of user bias as can arise through manual evaluation of
thermograms. We applied kinITC-ETC to deduce binding kinet-
ics from ITC data of a large set of structurally diverse FimH an-
tagonists (compounds 1–29, see Tables 1, 2, and S1). This kinet-
ic information proved to be extremely valuable as it provided
a more detailed insight into the binding process of carbohy-
drate-based antagonists to the adhesin FimHLD.
Validation of kinITC-ETC by SPR
Although Dumas et al. proved the potential of kinITC with the
evaluation of multistep kinetic RNA folding,[25b] there is, to the
best of our knowledge, no independent comparison of data
Figure 1. Illustrative representation of the kinITC-ETC obtained from the thermogram of a 1:1 interaction. The peak broadening observed at mid-titration (in-
jection 8) as compared to the initial peaks (injection 2) is an indicative that the thermogram contains kinetic information that can be determined with kinITC.
The equilibration time for each peak is plotted against titrant/titrate molar ratio to yield the ETC. Curve fitting of ETC according to the simplified kinITC
method yields the values of the off-rate constant (koff) and the response time.
Table 1. Comparison of kinetic data obtained by kinITC-ETC and SPR for the interaction of FimHLD with the mannose-derived antagonists 1–4.
[a]







@1s@1] rkon kon [M
@1s@1] rkon Absolute Relative
1 3.32 V 104 1.00 2.45 V 104 1.00 1.35 1.00
2 9.71 V 103 0.29 5.57 V 103 0.23 1.74 1.29
3 2.31 V 103 0.07 2.45 V 103 0.10 0.94 0.70
4 2.00 V 103 0.06 2.67 V 103 0.11 0.75 0.55







@1] rkoff t1/2 [min] koff [s
@1] rkoff t1/2 [min] Absolute Relative
1 7.27 V 10@4 1.00 15.9 1.54 V 10@4 1.00 75.0 4.72 1.00
2 1.15 V 10@3 1.58 10.1 1.89 V 10@4 1.23 61.1 6.07 1.29
3 2.86 V 10@3 3.93 4.1 1.11 V 10@3 7.21 10.4 2.57 0.54
4 1.82 V 10@3 2.50 6.3 6.51 V 10@4 4.23 17.7 2.80 0.59
[a] Absolute (kon and koff) and relative (rkon and rkoff) kinetic parameters are reported for both methods (Table 1 A for on-rates and Table 1 B for off-rates). Rel-
ative values are normalized to n-heptyl a-d-mannopyranoside (1), which is set to 1. The discrepancies between kinITC-ETC and SPR for kon (Table 1 A) and
koff (Table 1 B) values are displayed in the rightmost columns. KD values (Table S2) as well as confidence intervals for kon and koff (ITC, Table S4 and SPR,
Table S5) are part of the Supporting Information.
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obtained by kinITC-ETC and those derived from alternative bio-
physical methods available to date. For this purpose, a subset
of four mannose-based FimH antagonists (compounds 1–4)
was investigated by SPR. For the on-rate constants kon, the
comparison revealed an excellent correlation with absolute
values differing by less than a factor of two (Table 1 A), whereas
up to 6-fold deviation was observed for koff values (Table 1 B).
These differences might be a consequence of ligand rebinding
on the SPR chip surface.[32] However, when we normalized the
koff values obtained by SPR and kinITC-ETC to that of n-heptyl
a-d-mannopyranoside (1) (giving relative koff, rkoff) differences
of less than a factor of 2 arose (Table 1 B). In their comparison
of SPR and kinITC, Burnouf et al. reported a similar difference
for thiamine pyrophosphate interacting with mRNA.[25b]
Kinetics of FimHLD binding
Only recently, when correlations between prolonged drug–
target half-lives and clinical efficacy of drugs were reported,
binding kinetics attracted the interest of the drug discovery
community.[14a, 33] The initial assumption that association rate
constants are only diffusion controlled and rather constant
within a congeneric set of ligands for a specific target had to
be revised.[17, 18, 34] Indeed, our test subset clearly indicates that
the variations of the on-rate constants within the series of con-
generic FimH antagonists 1–4 are more pronounced (for kinITC
&1:16, Table 1 A) than of the off-rate constants (for kinITC
&1:4, Table 1 B).
To exclude that the length of the aliphatic aglycone affects
the extended hydrogen bond network formed by the mannose
moieties of compounds 1–4, co-crystal structures of com-
pound 3 (PDB-code: 5JCR) and 4 (PDB-code: 5MUC) were
solved and compared with published structures of com-
pound 1 (PDB-code: 4XO8)[35] and 2 (PDB-code: 1UWF)[36]
(Table S3). For all four ligands, both protein structure and bind-
ing mode were found to be identical (Figure 2). Hence, the
higher on-rate constants of antagonist 1 and 2 must be a
result of their elongated aglycones. This finding is unexpected
since the favorable interactions of the elongated aglycones of
compound 1 and 2 with Tyr48 and Tyr137 (called tyrosine
gate) were presumed to primarily lower the off-rate resulting
in a prolonged complex half-life.
A one-step model with ligand and protein in the unbound
state (U), in the transition state (TS*), and in the bound state
(B) characterized by the kinetic rate constants kon and koff is the
simplest way to describe a protein–ligand interaction (Fig-
ure 3 A). However, more common is a multistep binding mech-
anism with apparent rate constants composed of multiple ele-
mentary rate constants.[9] Rate constants depend upon the free
Table 2. Kinetic binding parameters for the interaction of FimHLD with mannose derivatives of n-heptyl a-d-mannopyranoside (1).
[a]
Compound kon [m
@1s@1] 1/rkon koff [s
@1] rkoff t1/2 [min]
1 3.32 V 104 1.0 7.27 V 10@4 1.0 15.9
5 (2-F) 2.04 V 104 1.6 1.02 V 10@2 14.0 1.1
6 (2-Cl) 8.90 V 103 3.7 1.19 V 10@2 16.4 1.0
7 (2-Br) 7.90 V 103 4.2 1.45 V 10@2 19.9 0.8
8 (2-H) 5.35 V 103 6.2 4.13 V 10@2 56.8 0.3
9 (7-ring) 5.10 V 103 6.5 1.35 V 10@3 1.9 8.6
[a] Confidence intervals of the fitted parameters kon, koff, KD, and the response time of the calorimeter feedback circuit are part of the Supporting Informa-
tion (Table S4). Relative changes (rkon, rkoff) are compared to n-heptyl a-d-mannopyranoside (1).
Figure 2. Binding mode of compounds 1–4 to FimHLD. The co-crystal struc-
tures of 1 (red, PDB-code: 4XO8), 2 (yellow, PDB-code: 1UWF), 3 (green,
PDB-code: 5JCR), and 4 (blue, PDB-code: 5MUC) show coinciding binding
modes. Their mannose moieties form identical hydrogen bond networks
with FimHLD and a structural water molecule (W1), whereas only the agly-
cones of 1 and 2 interact with the two tyrosines 48 and 137.
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energy difference DGTS-U (between TS
* and U) for kon and the
free energy difference DGTS-B (between TS
* and B) for koff, re-
spectively (Figure 3 A). The energy difference between B and U
represents the equilibrium free energy of binding (DGB-U, or
DG8). Changes in the relative stability of these states due to
structural differences of the ligand (or the protein as a conse-
quence of mutations) provoke changes in one or both rate
constants. A stabilization of U and B relative to TS* (or destabi-
lization of TS* relative to U and B) decreases the on-rate and
the off-rate, respectively. Ligand modifications leading to im-
proved or worsened interaction with the target protein, affect
the stability of the various states. Thus, for example, an addi-
tional interaction predominantly formed in B and to a lesser
extent in TS* will increase DGTS-B (decrease koff) and to a lesser
extent decrease DGTS-U (increase kon). Concomitantly, the
change of DG8 leads to tighter binding. Furthermore, structural
modifications that affect long-range electrostatics of the ligand
and thus its proper orientation can affect the rate constants by
altered diffusion, significantly impeding an interpretation
based only on changes in the relative thermodynamic stability
of states.
The kinetic data of antagonists 1–4 obtained by both ITC
and SPR demonstrate that the improvements of on-rates go
hand in hand with the elongation of the aglycone, whereas
off-rates are decreased, however to a lesser extent, leading to
an overall improved KD value (Table S2). Hence, increased on-
rates are related to favorable interactions realized in TS* or a
destabilization of U relative to TS*, whereas decreased off-
rates imply an additional stabilization of B relative to TS*. Al-
though structural information regarding TS* is not available, it
seems plausible to speculate that a hydrophobic aglycone first
establishes a contact with the surface-exposed tyrosine gate of
FimHLD. Only then the protein–ligand complex relaxes from the
TS* to the bound state B by a successful completion of the hy-
drogen bond network within the binding site. A similar effect
was described for the human carbonic anhydrase II (hCAII),
where the on-rate increased in parallel with the chain length
of interacting alkyl benzenesulfonamides,[37] that is, in a pre-
binding state, an interaction with a hydrophobic patch of the
enzymatic cavity is formed.[38]
To investigate the kinetic behavior of FimHLD antagonists in
more detail, its binding interaction with 29 antagonists (for
structural details see Supporting Information, Table S1) cover-
ing a broad range of affinities (1 nm to 100 mm) were analyzed
by kinITC-ETC. Thermodynamic and kinetic fits (Table S1) and
binding parameters (Table S3 and S4) are listed in the Support-
ing Information.
Structure–kinetic relationship (SKR)
Influence of the site of ligand modification
With the set of 29 carbohydrate-based antagonists, we studied
how the site of the structural modification affects the correla-
tion between binding energies and kinetic binding rates. The
ligands were divided into two subsets ; one subset (n = 17)
containing all representatives with varied aglycones (com-
pounds 2–4 with alkyl chains of different length, 10–21 with
biphenyl aglycones, 22 with a squaric acid aglycone, and 23
with an indolinylphenyl aglycone) and a second subset (n = 11)
representing compounds with modified mannose moieties
(deoxy- and deoxy-halogeno derivatives 5–8 and 24–27, a sep-
tulose derivative 9 and two C-2 branched mannose deriva-
tives 28 and 29) (see Supporting Information, Table S1). For
the two subsets, significantly different correlations of DG8 with
kon (Figure 3 B, p<0.001) and koff values (Figure 3 C, p<0.001)
were obtained. Modifications of the mannose moiety, known
to form an extended hydrogen bond network in the deep
binding pocket of FimHLD, affect the koff values (slope = 0.268,
R2 = 0.906) to a greater extent than those of the aglycone
(slope = 0.133, R2 = 0.801). In contrast, modifications of the
aglycone, forming beneficial contacts with the tyrosine gate in
the bound state,[30c] influence kon values (slope =@0.270, R2 =
0.943) to a larger degree than those of the mannose moiety
(slope =@0.135, R2 = 0.710).
Thus, the mannose moiety establishes stronger interactions
in the bound state B than in the transition state TS*, resulting
Figure 3. A) The energy diagram illustrates a simple one-step binding process with the transition state (TS*) separating the unbound state (U) from the
bound state (B). DGTS@U is the activation free energy of association, DGTS-B the activation free energy of dissociation, DG8 the free energy of binding, and kon
and koff are the kinetic rate constants. B) The correlation of the kinetic parameters kon and C) koff with changes of DG8 depends on the site of a ligand’s modifi-
cation. Ligands with modified aglycones (2–4 and 10–23 ; for structures and binding parameters see Supporting Information, full symbols, solid regression
lines) are separated from ligands with modified mannose moieties (5–9 and 24–29 ; for structure and binding parameters see Supporting Information, hollow
symbols, dotted regression lines): A, aglycone; M, mannose moiety.
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in the observed stronger effect on the off-rate constant koff
(slope = 0.268) than on the on-rate constant kon (slope =
@0.135). For structural modifications of the aglycone, however,
the impact on kon values (slope =@0.270) is more pronounced
than on koff values (slope = 0.133). This suggests that either the
TS* is stabilized relative to the bound state B (e.g. when the
aglycone establishes stronger interactions with the receptor in
the TS* than in the bound state) or that the unbound state U
is destabilized relative to TS*.
The results observed for compounds 1–4 seamlessly fit into
the trend observed for all studied FimH antagonists. However,
these correlations are based on a rough ligand classification
(modifications of glycan or aglycone), neglecting various fac-
tors, for example, electrostatic interactions or flexibility of the
ligand. Contributions from these factors can only be revealed
by a closer look at individual structural details of the various li-
gands and at their interactions with the protein.
Hydrogen bonds, electrostatic interactions, and conforma-
tional changes
To rationalize the trend that mannose modifications have a
larger impact on off-rates than on on-rates (Figure 3 B and Fig-
ure 3 C), interactions of ligands 5–9 with FimHLD were analyzed
in more detail (Table 2). The 2-hydroxyl of n-heptyl a-d-manno-
pyranoside (1) forms two hydrogen bonds with FimHLD, once
as H-bond donor to a structural water molecule (W1) and once
as H-bond acceptor from the positively charged N-terminal
Phe (Figure 2). Substitution of the 2-hydroxy group with a fluo-
rine (1!5) leads to a loss of hydrogen bonds, while the elec-
trostatic interactions are largely preserved as oxygen and fluo-
rine share a comparable polarity and a close isosteric relation-
ship. Upon removal of the 2-hydroxy group (1!8) both the H-
bonds and the electrostatic interactions are lost. In terms of ki-
netics, the loss of H-bonds (1!5) mainly affects the off-rate. In
contrast, decreasing electronegativity reduces the electrostatic
interaction with the N-terminus from fluorine to chlorine to
bromine (5!6!7) and affects the kon value to a larger extent
than the koff value. This complex behavior results from differen-
tial contributions: (i) electrostatic guiding during the formation
of the TS*, which enhances on- and off-rates and (ii) the for-
mation of more specific interactions in the bound state, which
decreases off-rates. However, mannose modification may also
affect the on-rate constant, as observed for the ring extended
compound 9. As shown in the study of Sager et al. ,[30a] septu-
lose 9 (PDB-code: 5CGB) and pyranoside 1 (PDB-code: 4XO8)
establish an identical H-bond network with FimHLD. Upon bind-
ing to the lectin, the markedly increased flexibility of septu-
lose 9 in solution leads to an entropy penalty due to a loss of
conformational freedom upon binding. The present work dis-
plays that the increased flexibility in solution of ligand 9 stabil-
izes U relative to TS* and to a lesser extent to B where the
flexibility of all ligands is largely restricted by binding interac-
tions. This results in a considerably lowered on-rate and a rela-
tively small increase in the off-rate when compared to 1
(Table 2).
Conclusions
Based on ITC measurements, the new analytical tool kinITC-
ETC allowed the determination of kinetic data for 29 FimH an-
tagonists. To test the reliability of kinITC-ETC, the kinetic rate
constants for a subset of 4 ligands were compared with data
measured by SPR. The systematically lower dissociation rate
constant (koff) obtained by SPR may originate from a funda-
mental difference between the two approaches. ITC measures
molecular interactions in free solution, whereas SPR requires
the immobilization of one binding partner on a chip surface.
The reduction of the apparent koff in SPR measurements may
be due to the rebinding of the analyte to the immobilized
partner. However, our attempts to mitigate this effect by using
a low immobilization density had only a limited effect. Another
rationale for the observed difference in koff may arise from
errors associated with the kinITC-ETC method, that is, the ob-
served kinetics of heat evolution in ITC experiments includes a
contribution from the intrinsic instrumental response (tITC),
which can vary between instruments and for the same instru-
ment depending on cleanliness. Since we re-analyzed existing
data for this study, tITC was included as a fitting parameter in
the kinITC-ETC analysis and not measured for the instrument
at the time of the experiment. Nevertheless, it should be
noted that the systematic disagreement in off-rates between
SPR and ITC measurements is at most in the order of a factor
of 6 and therefore in an acceptable range and that the relative
rate constants obtained with kinITC-ETC and SPR are in good
agreement. Therefore, kinITC-ETC can be regarded as a reliable
method to derive kinetic information from ITC experiments.
The insight into the binding kinetics of the 29 mannose-
based antagonists strongly improved our understanding of
their binding characteristics. Their enhanced KD values not only
stand for prolonged complex half-lives, but also for increased
on-rates indicating a stabilization of the transition state and
destabilization of the unbound state. On a structural level, the
kinetic contribution of the carbohydrate moiety could be sepa-
rated from that of the aglycone. The structural variations of
the sugar moiety, which forms an extended hydrogen-bond
network in the deep binding pocket of FimHLD, mainly influ-
ence the off-rate constant koff, while modifications on the agly-
cone establishing hydrophobic interactions with the two tyro-
sines at the entrance to the mannose-binding pocket, predom-
inantly affect kon. The latter observation could be an indication
that the aglycone initially establishes a contact with the tyro-
sine gate to facilitate the mannose moiety to enter the carbo-
hydrate recognition domain. This finding is in excellent agree-
ment with previous observations from Gaspari et al. for the in-
teraction of hCAII with hydrophobic ligands.[38] In general, ini-
tial hydrophobic interactions to stabilize protein–ligand inter-
actions established before the final binding mode is reached
might facilitate ligand recruitment from solution. Furthermore,
electrostatic interactions may beneficially influence the on-rate
as exemplified by the replacement of the 2-hydroxy group of
the mannose moiety by fluorine, chlorine, bromine, or hydro-
gen. Finally, due to its flexibility in solution, the unbound state
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of septulose derivative 9 is stabilized relative to its transition
state, resulting in a reduced on-rate.
These kinetic considerations are essential for the success of
a therapeutic treatment of UTI, because the half-life of the
complex formed by a carbohydrate-based antagonist is a cardi-
nal parameter. Only an extended half-life of the antagonist–
FimH complex prevents bacteria from interacting with the uro-
thelial cells of the host for long enough to allow bacterial elim-
ination by urination. In contrast to our in vitro results, rebind-
ing of monovalent antagonists to the CRD of neighboring pili
may result in a longer FimH occupancy in vivo.
Our kinetic study with FimHLD is the first systematic analysis
of protein–ligand interactions using kinITC-ETC. Additional
studies will improve the insight into the effects originating
from ligand modifications upon binding kinetics and may lead
to generally applicable rules. For numerous projects over the
past 20 years ITC data had been acquired and the hidden ki-
netic treasures can now be raised by kinITC-ETC. We therefore
expect kinITC-ETC to become a popular instrument for “data
mining.”
Experimental Section
Protein cloning, expression, purification, and biotinylation. For
all ITC experiments, FimHLD of E.coli K-12 strain was expressed with
a C-terminal thrombin cleavage site and a 6His-tag (FimHLD-Th-
6His, 173 residues) following a previously published protocol.[39]
For SPR experiments FimHLD-AVITag-6His gene construct was
cloned by overlap extension PCR using the FimHLD-Th-6His
[39] gene
construct and an AVITag-6His gene sequence as templates and was
subsequently ligated into the plasmid pNT.[40] The histidine-tagged
recombinant protein was expressed in the protease-deficient E. coli
strain HM125 and purified with Ni-NTA affinity chromatography.[39]
AVITag is a specific 15-amino acid peptide sequence (GLNDIFEAQ-
KIEWHE) that can be biotinylated by the E. coli biotin ligase BirA.
To keep the BirA enzyme active, the protein was dialyzed with
Slide-A-Lyzer MINI Dialysis Units (3’500 MWCO, Thermo Scientific)
in 50 mm bicine, pH 8.3. Biotinylation was done according to the
manufacturer’s protocol (Avidity). In order to remove excessive
biotin the protein sample was dialyzed in HBS-EP, 7.4, overnight.
Surface plasmon resonance (SPR). Surface plasmon resonance-
based experiments were performed using a Biacore T200 instru-
ment (GE Healthcare). Biotinylated FimHLD (100 nm) was immobi-
lized on the surface of a streptavidin chip (sensor chip SA) using
the “aim for immobilized level wizard” (1’300 RU, 5 mL min@1). A ref-
erence surface with Amino PEG biotin (50 mm, Polypure) was pre-
pared (time and flow rate: 60 s and 10 mL min@1, respectively) to
correct for unspecific binding events of the glycomimetics with
streptavidin on the sample surface. Kinetic experiments were run
at 25 8C using HBS-EP (0.01 m HEPES pH 7.4, 0.15 m NaCl, 3 mm
EDTA, 0.005 % surfactant P20, from GE Healthcare) as running
buffer at a flow rate of 30 mL min@1. Since a convenient regenera-
tion condition, which keeps the protein active, was not found,
single-cycle kinetics (SCKs) without regeneration steps was used.
Instead of surface regeneration with chemical agents after each in-
jection, a complete dissociation of the respective compound from
the protein was allowed, before a new run was started. Blank injec-
tions (HBS-EP running buffer) were conducted under equal condi-
tions in order to apply double referencing. Binding data was evalu-
ated using Biacore T200 Evaluation software version 1 (GE Health-
care).
Isothermal titration calorimetry. Standard ITC experiments were
performed at 25 8C using a VP-ITC (Malvern Instruments, Worcester-
shire, UK) with an injection volume between 3 ml and 15 ml, a refer-
ence power of 10 mcal/sec, a stirring speed of 307 rpm, in high
feedback mode, and with a filter period of 2 sec. Preceding the
measurements, FimHLD-Th-His6 was dialyzed against a 10 mm
HEPES buffer adjusted to pH 7.4, containing 150 mm NaCl. Ligand
and protein were dissolved in the same buffer. Protein concentra-
tion was determined by NanoDrop ND-1000 Spectrophotometer
(Thermo Scientific, MA, USA) using an extinction coefficient of
24’180 m@1 cm@1. The active protein concentration was determined
by an ITC experiment with FimHLD binding to compound 1.
[41] The
thermodynamic parameters KA (association constant) and DH8
(change in enthalpy) and the kinetic parameter koff (dissociation
rate constant) were measured by ITC. All parameters were evaluat-
ed using the fully automated analysis software package from AF-
FINImeter (Version 1.0415–1.1510, Software for Science Develop-
ments, Santiago de Compostela, Spain).[25b] The parameters DG8
(free energy of binding) and DS8 (change in entropy) were calculat-
ed from [Eq. (1)] and kon (association rate constant) was calculated
according to [Eq. (2)]:
DG2 ¼ DH2@TDS2 ¼ @RT lnK A ð1Þ
KA¼kon=koff¼1=K D ð2Þ
with T being the absolute temperature and R the universal gas
constant (8.314 Jmol@1K@1). The thermodynamic and kinetic pa-
rameters of compounds 1–10 and 24–29 were calculated from
the average of two independent experiments. The c values of
compounds 15–21 and 23 were significantly above 1,000 for
the direct titrations, therefore additional competitive ITC ex-
periments were performed to achieve valid KD values.
[42] These
compounds were titrated into protein, which was preincubat-
ed with excess of the weak binding compound 8, resulting in
sigmoidal titration curves. The experimental conditions and
the analysis method with Origin 7.0 (OriginLab, Northampton,
MA, USA) and SEDPHAT version 10.4 (National Institute of
Health)[43] for the competitive experiments of compounds 19
and 23 are described in Fiege et al. 2015[30c] and for com-
pounds 15–18, 20, and 21 in Kleeb et al. 2015.[30d] These inde-
pendently derived KD values from competitive experiments of
compounds 15–21 and 23 were manually fixed for the kinetic
analysis with AFFINImeter. For the low-affinity compounds 26
and 27, the c value was below 1. To extract reliable thermody-
namic and kinetic data from low c value experiments the stoi-
chiometry was manually fixed to 1.[23] Correlations of the kinet-
ic parameters kon (B) and koff (C) with the change of free energy
of binding (DG8), as well as the F-test to check if the slopes of
the two subgroups (modified mannose moiety vs. modified
aglycone moiety) are identical or different, were calculated
with Prism version 5.0c from GraphPad, Inc. (La Jolla, CA, USA).
Crystallization and structure. FimHLD–3 and FimHLD–4 (com-
pound 3 and 4 in complex with FimHLD) were crystallized by sit-
ting-drop vapor diffusion at 4 8C. FimHLD (residues 1–158) was used
at a final concentration of 10 mg mL@1 (ca. 0.5 mm) with a 5-fold
molar ligand excess in HEPES buffer (pH 7.4, 20 mm). After several
months, plate like crystals appeared in 1.6 m (NH4)2SO4, 0.1 m
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HEPES pH 7.5, 1 % PEG 3350 (w/v) and were flash-cooled to 100 K
after a quick soak in 2.5 m Li2SO4.
[44] Data were collected at the PX
beamline (X06SA) of the Swiss Light Source (Paul Scherrer Institute,
Switzerland), indexed, integrated, and scaled with XDS.[45] The
structures were solved by molecular replacement with PHASER[46]
with 4X50.pdb[30c] as a search model. The models were built in
COOT[47] and refined with the PHENIX software.[48] Geometric ligand
restraints were generated with PRODRG.[49] The atomic coordinates
and structure factors are deposited in the Protein Data Bank with
PDB code 5JCR (3) and 5MUC (4).
Molecular Modeling. Protein–ligand complexes of the crystal
structures (PDB accession codes: 1UWF, 4XO8, 5JCR, 5MUC) were
processed with the Protein Preparation Wizard.[50] Figure 2 was pro-
duced using PyMOL (The PyMOL Molecular Graphics System, Ver-
sion 1.8 Schrçdinger, LLC).
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CRD - carbohydrate recognition domain 
Da - dalton 
DMSO - Dimethyl sulfoxide 
DsG - donor strand of FimG  
DsGbiotin - biotinylated donor strand of FimG 
EDTA - ethylenediaminetetraacetic acid  
ESI - electrospray ionization 
FimHFL - full-length FimH 
FimHFL-B - biotinylated full-length FimH  
FimHLD - FimH lectin domain 
FimHPD - FimH pilin domain 
FPA - flourescence polarization assay 
FPLC - fast protein liquid chromatography 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HM - n-heptyl α-D-mannopyranoside 
IPTG - isopropyl β-D-1-thiogalactopyranoside 
KD - equilibrium dissociation constant  
koff - dissociation rate constant  
kon - association rate constant  
LB - lysogeny broth 
MCKs - Multi-cycle kinetics  
MOPS - 3-(N-morpholino)propanesulfonic acid 
NaCl - sodium chloride 
NaH2PO4 - sodium dihydrogen phosphate 
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OD600 - optical density measured at a wavelength of 600 nm 
P20 - Polysorbate 20 
PEG - polyethylene glycol 
τ - residence time  
r = Pearson correlation coefficient 
R&D - research and development  
RI - refractive index 
RU - resonance units 
SA - streptavidin sensor chip  
SDS-PAGE - sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SPR - surface plasmon resonance 
UPECs - uropathogenic Escherichia coli strains 
UPIa - uroplakin Ia  
UTIs - urinary tract infections 
t1/2 – dissociative half-life 
Tris - tris(hydroxymethyl)aminomethane 
Ttds - trioxatridecan-succinamic acid 
X - time 
Y - response units  








The development of new medicines is a tedious business with high expenses and an 
enormous time exposure. Linked to this problem is an extremely high compound 
failure rate also after completion of the discovery research. Affinity-based methods 
are routinely employed to determine the binding affinity of a compound–target 
complex in vitro, which decides if the compound stays in the drug discovery pipeline. 
However, binding affinity frequently does not reflect in vivo efficacy of potential drug 
candidates. It has been shown that the dissociation half-life (t1/2) or the residence time 
(τ) of a bimolecular complex is a reliable measure to predict in vivo efficacy. Both 
rely on the dissociation rate constant (koff), which can be determined by surface 
plasmon resonance (SPR) experiments. On this account we developed an off-rate 
screen that can be easily implemented into early drug discovery to identify potential 
hits and leads. We used the bacterial lectin FimH as therapeutical target and tested a 
library consisting of various structural compound classes based on mannose with the 
intention to detect antagonists exhibiting long half-lives. FimH is under investigation 
as treatment option for urinary tract infections (UTIs) caused by uropathogenic E. coli 
(UPEC) strains. So far, the standard therapy is a short-term administration of 
antibiotics but due to the growing problem of antibiotic-resistance an alternative 
medication is required. We concentrated on the low-affinity state of FimH (FimHFL), 
which most probably is the therapeutically relevant conformation that needs to be 




The constant need for new drugs is a highly challenging task for the pharmaceutical 
industry. The overall research and development (R&D) process across all therapeutic 
areas on average amounts 14 years for new drugs [1] and is accompanied by a 
extremely high compound attrition rate.[2] A serious issue in this respect is the high 
probability to fail due to poor in vivo efficacy,[3] which is tested only after 4.5 years of 
discovery research.[4] In order to reduce R&D expenses, companies work on 
aproaches to avoid the high compound dropout caused by incomparable in vitro and 
in vivo results.  
 
Traditional de novo drug discovery mostly starts with the identification and the 
validation of a biological target for therapeutic intervention and is followed by the 
search for small molecules that bind to the target and elicit a pharmacological 
effect.[5] The formation of a binary complex of a drug and a protein is of primary 
importance for in vivo drug action because a drug only triggers a pharmacological 
effect when bound to the target.[6] For this reason, affinity-based techniques are 
routinely employed to identify active compounds by measuring the binding strength 
of small molecule–protein complexes in vitro.[7,8] Binding affinity is often quantified 
by measuring the equilibrium dissociation constant (KD), which is the ratio of koff/kon, 
where koff is the dissociation rate constant and kon the association rate constant.[9] The 
KD of a bimolecular interaction can be determined in vitro by several analytical 
methods as for example isothermal titration calorimetry (ITC),[10] surface plasmon 
resonance (SPR),[11] fluorescence polarization (FP),[12] fluorescence energy resonance 
transfer (FRET),[13] and affinity chromatography.[14]  
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However, it has been observed that binding affinity, measured in vitro, is not 
comparable with in vivo conditions, which are rather described by the lifetime of a 
binary complex.[15,16] The lifetime of a binary complex in vivo principally depends on 
koff and can be quantified either by the dissociative half-life (t1/2 = (ln2)/koff) or the 
residence time (τ = 1/koff).[15,17,18] A low koff is associated with an occupation of the 
binding site over an extended period of time. Kinetic in vitro studies exhibited that koff 
does not always correlate with KD [16,19] and contradict the general use of binding 
affinity as surrogate of in vivo efficacy.[20] A higher binding affinity does not 
necessarily yield a better drug. For instance, it could be shown that in vivo efficacy of 
a series of A2A adenosine receptor agonists correlated well with the residence time 
(r2 = 0.90), while a correlation with the binding affinity (r2 = 0.13) was not 
observed.[21] A study on epidermal growth factor (EGFR) tyrosine kinase inhibitors 
(TKIs) showed that lapatinib exhibited a prolonged downregulation of EGFR 
signaling compared to gefitinib despite a worse apparent inhibitory constant (Kiapp) of 
3 nM over 0.4 nM. By contrast, the inhibitory efficacy is better reflected by the off-
rate. Lapatinib featured a half-life of 300 min while the t1/2 of gefitinib was of less 
than 10 min.[22] Furthermore, the work of Seow and coworkers on antagonists 
targeting the inflammatory protein complement C5a could even demonstrate that 
amongst antagonists with comparable in vitro potency, the one with the longest 
residence time exhibited a better oral activity in comparison to more drug-like or 
orally better bioavailable drug candidates.[23] 
 
The off-rate can be determined by SPR, which is the method of choice to reveal the 
kinetic fingerprint of small molecule–protein interactions. The performance of an SPR 
experiment requires the immobilization of one interaction partner (the ligand). During 
a kinetic measurement, the other interaction partner (the analyte) is injected over the 
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chip-immobilized ligand. The investigation of both the on-rate and the off-rate is 
time-consuming and includes several measurement cycles with different 
concentrations of the analyte due to the concentration dependence of kon. In contrast, 
the determination of exclusively the off-rate only contains one cycle because koff is a 
first-order rate constant measured in per second (s-1) and consequently concentrations 
of the interaction partners do not matter.[24] A study of Murray and coworkers also 
shows that due to the concentration independence of koff it is also possible to perform 
an off-rate screen with unpurified compound reaction mixtures containing varying 
concentrations of the investigational compound. This approach additionally saves 
time that is usually required for compound separation and purification.[25] Despite the 
mentioned advantages, off-rate screens, are only hesitantly implemented in discovery 
research as practically non-existent published studies display. This is surprising, 
because an off-rate screen is a straightforward approach delivering an appropriate 
prediction of in vivo efficacy and a promising selection of successful lead candidates.  
 
In our study, we originated an SPR off-rate screening assay to spot small molecule 
antagonists that efficiently target the low-affinity state of the bacterial lectin FimH. 
The development of antagonists that bind to FimH is a new attempt to treat urinary 
tract infections (UTIs) that are triggered by a heterogeneous group of uropathogenic 
Escherichia coli (UPEC) strains. For women, the risk to develop at least one 
symptomatic UTI during life is around 50% to 60%.[26,27] Until now, the only 
treatment option is a short-term administration of antibiotics. The antibiotic therapy 
relieves affected patients from symptoms and prevents bacterial expansion to the 
upper urinary tract, where the infection can progress into a life-threatening 
pyelonephritis or urosepsis.[28] However, an increasing resistance formation among 
different bacterial strains against antibiotics requests an effective alternative 
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medication. FimH is the main virulence factor used by UPECs to provoke an infection 
by mediating mannose-specific adherence to uroplakin Ia (UPIa) that is expressed on 
human host cells. The protein is localized at the tip of type 1 pili, filamentous surface 
organelles of E. coli, and consists of a pilin domain (FimHPD) and a lectin domain 
(FimHLD). FimHLD acts as a mannose-specific carbohydrate recognition domain 
(CRD), while FimHPD anchors the protein to FimG, the preceding pilus subunit.  
 
However, the development of FimH antagonists is difficult, mainly due to the 
conformational nature of FimH. Recent work of Sauer et al. demonstrated that FimH 
mainly adopts three distinct conformational states: a low-affinity, a medium-affinity, 
and a high-affinity state.[29] Most of the studies performed so far have focused on the 
development of antagonists binding to high-affinity FimH that can be easily produced 
by expressing only the isolated lectin domain (FimHLD).[30] Cristal structures of 
FimHLD cocrystallized with diverse monovalent mannosides unveiled a hydrophobic 
entrance, the tyrosine gate, which is formed by two tyrosines (Tyr48 and Tyr137) and 
an isoleucine (Ile52). As a consequence several studies concentrated on the 
identification of high-affinity antagonists with lipophilic aglycones that efficiently 
interact with the tyrosine gate.[12,31,32,33,34,35,36,37,38,39,40,41,42] Modifications on the 
mannose moiety resulted in a drop in binding affinity due to an impairment of the 
sophisticated hydrogen bond network between mannose and amino acids buried in the 
mannose-binding pocket.[35,43,44] Apart from the α-anomeric position, all hydroxyl 
groups of mannose form direct hydrogen bonds with the protein (Asp47, Asp54, 
Asn135, Asp140, and Phe1).[45] However, high-affinity FimH exists in the urinary 
tract only when the protein is already bound to UPIa and in the presence of tensile 
forces, which are produced by the bulk flow of urine during micturition. 
Therapeutically successful FimH antagonists should, however, occupy the low-
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affinity state of FimH. When the binding site is blocked, the adhesion of UPECs to 
the bladder epithelium is prevented leading to bacterial clearance. Under static 
conditions, the transition between the low- and medium-affinity state is highly 
dynamic. Unbound full-length FimH (FimHFL) is in the low-affinity conformation and 
adopts a medium-affinity conformation upon binding to UPIa. In contrast to high-
affinity FimH, low-affinity FimH has a shallow binding site and displays much 
weaker affinities against antagonists that were on average 100-fold worse for n-heptyl 
α-D-mannopyranoside (HM) and series of biphenyl mannoside-based antago-
nists.[46,47]  
 
In order to spot promising small molecules for FimHFL with long half-lives, we 
designed an SPR assay to screen a mannoside-based compound library against 
FimHFL. The study describes both the development and the application of the SPR 
off-rate screening method. We used biotinylated low-affinity FimH for ligand capture 
on a streptavidin SPR sensor chip. A production of recombinant full-length FimH 
(FimHFL) is generally sophisticated. It requires a 14-amino acid synthetic peptide 
donor strand (ADVTITVNGKVVAKR) derived from FimG (DsG) otherwise it is 




Protein production and purification 
Biotinylated full-length FimH (FimHFL-B) was basically prepared according to Sauer 
and coworkers.[29] Initially, the plasmid encoding for FimHFimC was introduced into 
the E. coli K12 strain HM125 that lacks periplasmic proteases.[49] Bacterial cells 
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harboring the plasmid were grown at 30°C in LB (lysogeny broth) medium 
supplemented with 100 µg mL-1 ampicillin until the density of the bacterial culture 
reached an OD600 of 1.5. At this point, co-expression of FimH and FimC was induced 
by adding isopropyl β-D-1-thiogalactopyranoside (IPTG) to a final concentration of 
1 mM. The bacterial culture was incubated for another 12 to 16 h and subsequently 
harvested by centrifugation. Bacterial pellets were resuspended in extraction buffer 
containing 50 mM Tris (tris(hydroxymethyl)aminomethane), pH 7.5, 150 mM NaCl 
(sodium chloride), 5 mM EDTA (ethylenediaminetetraacetic acid), and 1 mg mL-1 
polymyxin B sulfate that lysed the bacterial membrane releasing periplasmic proteins. 
The suspension was prepared with 13 mL extraction buffer per liter of culture 
medium and stirred for 1.5 h at 4°C. Centrifugation allowed collection of the 
supernatant containing the released proteins, which are referred to as periplasmic 
extract. Purification of FimHFimC and later of FimHFL-B was performed using anion-
exchange or cation-exchange fast protein liquid chromatography (FPLC) at 4°C. 
Before protein mixtures were loaded on either an Uno Q column (anion exchange 
column from Bio-Rad) or a Mono S column (cation exchange column from GE 
Healthcare), the columns were equilibrated with the same buffer the protein mixtures 
were dialyzed against. During the first purification step, the supernatant was dialyzed 
against 20 mM Tris, pH 8.0 and loaded onto the Uno Q column. Subsequently, the 
flow-through containing the FimHFimC complex was collected and dialyzed against 
10 mM MOPS (3-(N-morpholino)propanesulfonic acid), pH 8.0. The second 
purification step comprised loading of the protein mixture onto the Mono S column. 
FimHFimC bound to the cation exchange column and was eluted with a linear 
gradient of increasing NaCl concentrations from 0 to 300 mM. Fractions were 
collected and those comprising the FimHFimC complex were pooled and dialyzed 
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against 20 mM NaH2PO4 (sodium dihydrogen phosphate), pH 7.4 and 50 mM NaCl. 
The FimHFimC eluate was concentrated to about 40 µM and incubated with a 3-fold 
molar excess of DsGbiotin under constant shaking (70 rpm) for 48 h at 37°C 
afterwards. The synthetic peptide DsGbiotin (purchased from JPT Peptide 
Technologies) consisted of the donor strand FimG sequence ADVTITVNGKVVAKR 
(DsG) that was C-terminal amended with a Ttds (trioxatridecan-succinamic acid) 
linker and a biotinylated lysine. During the incubation time, FimC was substituted by 
DsGbiotin resulting in the formation of FimHDsGbiotin complexes. The mixture was 
then dialyzed against 20 mM acetic acid, pH 4.5. To separate FimHDsGbiotin 
(FimHFL-B) from FimC, excess of DsGbiotin, and unreacted FimHFimC, a third 
purification step was performed. On that account, the mixture was loaded onto the 
Mono S column and FimHFL-B was eluated with a linear gradient of increasing NaCl 
concentrations from 0 to 400 mM. Fractions containing FimHFL-B were pooled and 
dialyzed against 50 mM NaH2PO4. The purity of FimHFL-B was verified by SDS-
PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and its mass 
(calculated mass: 31 291.2 Da) was checked by electrospray ionization (ESI)-mass 
spectrometry (measured mass: 31 291.0 Da, Functional Genomic Center Zürich; 
Supporting Information, S1). The yield of purified FimHFL-B was between 1-2 mg per 
liter culture medium. The activity of FimHFL-B was tested using a fluorescence 
polarization assay (FPA) (Supporting Information, S2). FimHFL-B was stored at -80°C.  
 
Surface plasmon resonance 
Capturing of FimHFL-B: 
FimHFL-B was captured on a streptavidin sensor chip (SA, from GE Healthcare) via its 
biotinylated peptide. The streptavidin–biotin system is one of the strongest 
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noncovalent biological interactions, having an exceptionally high affinity (KD of 
about 10-14), and is stable under a wide range of chemical conditions.[50,51]  
 
FimHFL-B (100 nM) was pulse-wise delivered to the chip surface by an immobilization 
wizard using a flow rate of 5 µL min-1. In order to minimize mass transfer during 
kinetic measurements, the capturing density of the protein was kept rather low (aimed 
immobilization level: 2.000 RU). Since FimHFL-B is solely biotinylated at the 
C-terminus of the peptide, the capturing of the protein on the chip is homogenous. 
The reference surface was blocked by injecting 100 nM biotin-PEG8-amine (8-units 
polyethylene glycol spacer) for 60 s at a flow rate of 10 µL min-1 since injection of 
mannosides over an unimmobilized streptavidin surface exhibited unspecific binding 
events. Unspecific binding of mannose to streptavidin was already observed by 
Houen and coworkers.[52]  
 
The production and the capturing protocol of FimHFL-B were also applied in another 
study about target-directed dynamic combinatorial chemistry (tdDCC).[11] 
 
Sample preparation: 
Stock compounds were stored at a concentration of 10 mM in 100% DMSO. HBS-EP 
running buffer (0.01 M HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
pH 7.4, 0.15 M NaCl, 3 mM EDTA, and 0.005% surfactant P20 from GE Healthcare) 
was used to dilute compounds to intermediate compound dilutions of 100 µM 
(1% DMSO) at first. These intermediate stocks were further diluted with HBS-EP to 





The off-rate screen was performed at 37°C using HBS-EP as running buffer. 
According to control measurements the remaining DMSO concentration (0.01%) in 
the 1 µM working solutions did not affect the refractive index. Thus, an 
implementation of DMSO solvent correction was not necessary. However, 
0.01% DMSO was mixed into the running buffer to keep sample and running buffer 
conditions as equal as possible. The multi-cycle wizard was used to perform single 
cycle measurements per mannoside ligand with an association time of 120 s and a 
dissociation time of 900 s. Positive controls were used to monitor and confirm 
consistent binding responses. Raw data was processed using Prism (GraphPad 
Software) by plotting the response units (Y) versus the time of the dissociation phase 
(X) (Figure 1A). The association phase was cut off and solely the dissociation phase 
was fitted using the Dissociation - One phase exponential decay model (Figure 
1B).[53]  
 
The determination of the off-rate with the Dissociation - One phase exponential decay 
model was calculated as follows:  
 
Y = (Y0 ˗ plateau) • exp(˗ koff • X) + plateau  (Equation 1) 
 
where Y0 is the binding in response units (RU) at time zero of the dissociation fit and 
consists of span + plateau. Y decreases to the baseline with the rate constant koff (in 
inverse units of seconds). The off-rate was used to determine the dissociation half-life 
(t1/2) as follows: 
 




Figure 1. Data processing and evaluation with Prism GraphPad. (A) Single-cycle measurements 
were performed per compound with an association time of 120 s and a dissociation time of 900 s. (B) 
The dissociation phase was fitted using the Dissociation - One phase exponential decay model.[53] 
 
 
Multi-cycle kinetics (MCKs) measurements: 
Multi-cycle kinetics (MCKs) assays were performed in order to investigate and 
confirm hits of the off-rate screen. The association and the dissociation phase were 
adjusted to 180 s (or 240 s) and 1200 s (or 2200 s), respectively. The Biacore T200 
Control Software and the Biacore T200 Evaluation Software (both Version 3.0) were 
applied for data processing and kinetic evaluation. Due to a biphasic behavior of 
antagonist–FimHFL interactions, which was also investigated in other studies,[54,55] a 
two-state binding model was applied using double referenced sensorgrams with RI 
(bulk refraction index) set to 0. Any change in the RI was subtracted out by using the 
information of the reference cell that lacked FimHFL-B.  
 
Results  
1. Off-rate screen 
The search for potent monovalent α-D-mannosides over the past decades gave rise to 
various promising candidates.[12,31,32,33,34,35,36,37,38,39,40,41,42] However, predominantly 
binding affinity was used as a measure for the identification of lead structures. In 





























isolated FimH lectin domain (FimHLD), which is locked in the high-affinity state. To 
counteract this drawback, a library of 177 α-D-mannosides belonging to 10 different 
structural aglycone classes (Figure 2A-J) was screened against the biotinylated low-
affinity state of FimH (FimHFL-B) to discover monovalent antagonists that bind to 
FimHFL-B with long half-lives. Additionally, compounds with an altered mannose 
moiety (Figure 2K-L) were screened to investigate the impact of an altered hydrogen 
bond network on the kinetic point of view.  
 
 
Figure 2. α-D-mannoside classes included in the FimHFL-B off-rate screen. Altogether 12 different 
compound classes were investigated: Biphenyl derivates (A), diphenylamine derivates (B), 
phenylbenzamide derivates (C), diphenylthiourea derivates (D), spaced bi/triphenyl derivates (E), 
squaric acid derivates (F), phenyl derivates (G), monocyclic hetroarylphenyl derivates (H), bicyclic 
hetroarylphenyl derivates (I), indolinphenyl and tetrahydroquinolonephenyl derivates (J), antagonists 
with modifications on the mannose ring (K), and branched mannosides (L). 
 
Library compounds were assigned to the following structural classes (class size in 
brackets): biphenyl derivates (42), diphenylamine derivates (16), phenylbenzamide 
derivates (15), diphenylthiourea derivates (2), spaced bi/triphenyl derivates (15), 
squaric acid derivates (9), phenyl derivates (5), monocyclic hetroarylphenyl derivates 
(23), bicyclic hetroarylphenyl derivates (17), indolylphenyl and tetrahydro-
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(12), and branched mannosides (1). The core structure of the single compound classes 
is illustrated in Figure 2. 
 
In the following, mannosides that exhibited half-lives longer than 1 min in the screen 
were defined as hits. In total, 37 mannosides fulfilled this criterion and exhibited t1/2s 
up to 3.3 min. The remaining compounds either displayed dissociation half-lives 
between 0.1 to 1 min (85 compounds) or did not bind at all (55 compounds). Hits 
were further assigned to low-response and high-response hits. High-response hit 
compounds had a response equal or greater than 2.5 RU at the beginning of the 
dissociation fit whereas low-response compounds displayed lower binding values. In 
Figure 3, high-response hit compounds are circled. 
 
 
Figure 3. Scatter plot displaying the half-lives of screened mannosides. Compounds were grouped 
according to their structural classes (Figure 2). Mannosides with a t1/2 longer than 1 min are colored 
according to their sensorgram shapes I-IV, which are described in Figure 4 (red = I, green = II, blue = 
III, and brown = IV). All hits that exhibited a RU equal or greater than 2.5 at the beginning of the 
dissociation fit are circled. 
 
Affinity studies of biphenyl derivates binding to FimHLD revealed high-affinity 
interactions.[34,35,39] This high-affinity antagonism was attributed to π-π staking and 
hydrophobic interactions between the aromatic phenyl rings and the tyrosine gate.[35] 
In our study, biphenyl mannosides (Figure 3A) represented the biggest compound 















biphenyl derivates displayed poor dissociation half-lives with the exception of 
2 biphenyls (one ester prodrug with a chloride group in ortho position of the first 
phenyl ring and one cyano-substituted in ortho and para position of the first and 
second phenyl ring, respectively) that exhibited t1/2s of more than 2.5 min. At the first 
glance, this result may seem surprising because a study of Sauer and coworkers had 
shown that upon ligand binding the shallow mannose-binding pocket of FimHFL 
adopts the same conformation (including the tyrosine gate) as FimHLD. However, it 
has also been observed that the pilin domain acts as negative allosteric regulator. 
Intramolecular conformational dynamics enhance the dissociation of antagonists by 
more than 100,000-fold and consequently accelerate the release of FimHFL.[29]  
 
Bicyclic heteroarylphenyl derivates (Figure 3I), mainly comprising indolylphenyls, 
and compounds with indolinylphenyl aglycones (Figure 3J) were also under 
investigation. In search of high-affinity FimHLD antagonists, docking studies 
predicted an improved fit of the indolyl and the indolinyl moiety with Tyr48 in 
comparison to the outer phenyl group of biphenyl mannosides.[38] As already 
observed for biphenyl derivates, the interaction with Tyr48 of FimHFL seems 
unimportant for long dissociation half-lives. Only 5 hits were detected out of both 
classes with a total of 37 compounds. Additionally, an ortho-chloro substituent on the 
phenyl ring adjacent to the aromatic oxygen did not improve t1/2 as it was the case for 
the binding affinity of mannoside–FimHLD interactions.[38] 
All mannosides with a phenyltriazole aglycone did not bind to FimHFL-B at all. They 
belonged to the structural class of monocyclic hetroarylphenyl derivates (Figure 3H) 
that altogether displayed few hits (3 hits out of 23 compounds). Aglycones of the 
spaced bi/triphenyl class (Figure 3E) were quite inhomogeneous due to different 
spacer moieties and the number of phenyl groups. The most promising hit candidate 
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in this class was a mannoside with a triphenyl aglycone. The class of biphenyls 
spaced by an amide moiety (Figure 3C) yielded 3 hits out of 15 compounds. All 
phenylbenzamide hits featured t1/2s above 2 min and a response above 2.5 at the 
beginning of the dissociation fit. 
 
Biphenyls spaced by an aniline moiety (Figure 3B) or a thiourea moiety (Figure 3D) 
exhibited a relatively high number of hits (6 out of 16 and 2 hits out of 2 compounds, 
respectively) with dissociation half-lives up to 3.3 min. Another promising 
monovalent mannoside class binding to FimHFL consisted of compounds with 
aglycones including a squaric acid moiety (Figure 3F). The screen revealed 7 out of 
9 squaric acid derivates that bound to FimHFL-B with a half-life above 1 min. In a cell-
free competitive binding assay, a squaric acid mannoside also showed a high binding 
affinity towards the mannose-binding site of FimHLD.[56] The development of FimH 
antagonists efficiently targeting the CRD of FimHFL and FimHLD might be beneficial 
for the treatment of urinary tract infections. A more precise investigation of 
diphenylamines, squaric acids, and diphenylthiourea derivates seems to be worth the 
effort in the search of antagonists blocking FimHFL as long as possible.  
 
Binding studies have shown that any modification on the hydroxyl moieties of the 
pyranose ring considerably diminishes the binding affinity of mannosides to 
FimHLD.[31,44,57] The hydrogen bond network between the mannose moiety and amino 
acids buried in the CRD seems to be already perfectly aligned. The off-rate screen 
underlines this assertion. All compounds that were modified on the mannose moiety 
(Figure 3K) did not bind to FimHFL-B at all. 
 
The only investigated branched antagonist, a 2-C-branched mannoside (Figure 3L), 
showed a t1/2 of 2.8 min but a low response of only 1.0 RU at the beginning of the 
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dissociation fit (low-response hit). The same 2-C branched mannoside was already 
examined in a binding study with FimHLD as target protein. The binding assay 
unveiled that functional groups in equatorial 2-position of the mannose were not able 
to occupy a vacant hydrophobic cavity in the binding pocket of FimHLD. On the 
contrary, steric hindrance even deteriorated the affinity compared to the mother 
compound n-heptyl α-D-mannoside (HM).[58] In the present screen, the 2-C-branched 
mannoside exhibited indeed a considerable half-life, however only a low amount of 
compound bound to FimHFL-B during association. The low binding response may 
probably be connected to the steric constraint.  
 
2. Sensorgram Shapes 
Among all antagonists displaying a t1/2 above 1 min, diverse sensorgram shapes 
became apparent indicating different modes of binding. The dissociation phase can be 
divided into 4 different unbinding mechanism: the off-rate is very slow and the 
sensorgram does not return to the initial baseline during the investigated dissociation 
phase (I), the off-rate is slow and the sensorgram returns to the initial baseline during 
the investigated dissociation phase (II), dissociation is biphasic (very fast dissociation 
at first and slow unbinding behavior afterwards) and hallmarked by a nonexistent 
return to the initial baseline during investigated dissociation (III), dissociation is 
biphasic (very fast dissociation at first and slow unbinding afterwards) and the 
sensorgram returns to the initial baseline (IV). Figure 4 illustrates the distinct 
sensorgram shapes, which are also assigned to the compounds in the scatter plot by 




Figure 4. Binding behavior of potential FimH antagonists. Hit compounds displayed 4 various 
kinetic fingerprints: the off-rate is very slow characterized by a nonexistent return to the initial baseline 
during the investigated dissociation phase (I), the off-rate is slow and dissociation returns to the initial 
baseline (II), dissociation is biphasic (very fast dissociation at first and slow unbinding behavior 
afterwards) and hallmarked by a nonexistent return to the initial baseline during investigated 
dissociation (III), dissociation is biphasic (very fast dissociation at first and slow unbinding afterwards) 































































































Table 1 lists the hits from the longest t1/2 of 3.3 min down to 1.1 min. In addition it 
shows the sensorgram shape of the respective hit and displays compounds with a 
response equal or larger than 2.5 at the beginning of the dissociation fit. High-
response compounds are indicated in bold. 
 
Table 1. Hit compounds of the FimHFL-B off-rate screen. All compounds with a dissociation half-
live above 1 min are ranked by t1/2 (t1/2 = (ln2/koff). Additionally, the shape of the dissociation phase is 
indicated. Hits with a response equal or larger than 2.5 at the beginning of the dissociation fit (high-
response hits) are highlighted in bold. 
 
Rank Class Shape  koff×10-3 t1/2 Rank Class Shape koff×10-3 t1/2 
   s-1 min    s-1 min 
1 squaric  acid III 3.46 3.3 20 phenylbenzamide IV 5.59 2.1 
2 diphenylamine IV 3.50 3.3 21 monocycl. HA IV 5.61 2.1 
3 phenylbenzamide IV 3.83 3.0 22 diphenylthiourea II 5.90 2.0 
4 squaric  acid III 3.92 3.0 23 diphenylamine IV 6.26 1.8 
5 diphenylamine IV 3.93 2.9 24 diphenylamine IV 6.49 1.8 
6 phenylbenzamide IV 3.95 2.9 25 phenyl I 6.87 1.7 
7 biphenyl I 4.00 2.9 26 monocycl. HA IV 7.53 1.5 
8 branched mannose II 4.14 2.8 27 squaric  acid IV 7.99 1.5 
8 squaric  acid III 4.14 2.8 28 spaced BiPh II 8.03 1.4 
10 phenyl IV 4.23 2.7 29 indolinphenyl IV 8.14 1.4 
11 diphenylamine I 4.38 2.6 30 squaric  acid IV 8.38 1.4 
12 biphenyl III 4.39 2.6 31 spaced BiPh  IV 8.53 1.4 
13 squaric  acid III 4.41 2.6 32 indolinphenyl IV 8.56 1.4 
14 diphenylamine III 4.51 2.6 33 spaced BiPh IV 10.1 1.1 
15 diphenylthiourea II 4.65 2.5 33 monocycl. HA III 10.1 1.1 
16 indolinphenyl I 5.21 2.2 35 squaric  acid IV 10.7 1.1 
17 bicyclic HA III 5.45 2.1 35 phenyl IV 10.7 1.1 
18 branched BiPh I 5.48 2.1 37 spaced BiPh IV 10.9 1.1 
19 indolinphenyl I 5.55 2.1      
 
The dissociation half-life of antagonists featuring a dissociation phase that does not 
return to the initial baseline (dissociation type I and III) is probably underestimated. 
This is due to the fact that the association phase was cut off before the off-rate was 
determined by the Dissociation - One phase exponential decay model.[53] The 
dissociation phase solely is taken into consideration for the determination of the off-
rate. Hence, the information loss can result in a shifted baseline and a 





Figure 5. Evaluation of mannosides with type I and II dissociation. A) During the investigated 
dissociation phase, sensorgrams are not returning to the initial baseline. B) Due to the information loss 
of the initial baseline, the binding model falsely interprets curve progression of compound dissociation. 
 
 
3. Multi-cycle kinetics (MCKs) 
Multi-cycle kinetics (MCKs) measurements were performed in order to prove the 
assumption that dissociation half-lives might be underestimated for compounds with 
type I and III sensorgrams. In addition, MCKs runs allowed a verification of the 
calculated t1/2 in general and an evaluation of the biphasic dissociation behavior in 
more detail. A detailed kinetic assessment was completed for 1 (type IV dissociation), 
2 (type I dissociation), and 3 (type II dissociation) (Figure 6) that displayed half-lives 
ranging from 2.5 to 3.3 min in the off-rate screen. 
 
 
Figure 6. Hit compounds evaluated with multi-cycle kinetics (MCKs). MCKs measurements were 
performed with phenylbenzamide derivate 1 (group IV, rank 3, OS540), diphenylamine derivate 2 
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As expected, the dissociation phase (type IV) of 1 was characterized by a biphasic 
behavior (Figure 7A). The same applied to the association phase, with the result that 
the kinetic data required fitting to a two-state binding model (Equation 3).[55] In this 
model, the analyte (FimH, A) binds to the ligand (mannoside, B) to form an initial 
complex (AB) and then undergoes subsequent binding or conformational change to 








A∗B                                                                                        (Equation 3)  
 
Against our expectations, it was not possible to fit MCKs measurements of 2 and 3 
with a simple Langmuir 1:1 binding model. Although both compounds did not exhibit 
a biphasic dissociation phase in the off-rate screen (2 = dissociation type I and 3 = 
dissociation type II), the kinetic data of 2 and 3 also had to be fitted using the two-
state binding model described above (Figure 7B-C). It might be that all FimH 
antagonists dissociate from the CRD of FimHFL in 2 phases with an initial fast 
dissociation phase and a slower unbinding phase afterwards resulting in a short t1/2,1 
and long t1/2,2, respectively. The ratio of fast and slow dissociation is variable and 
depends on the compound binding to FimHFL-B. The studies of Rabbani et al. and 
Yakovenko et al. also displayed a biphasic binding behavior of compounds targeting 
FimHFL and fimbrial tip FimH, respectively.[54,55] The on- and off-rates of 1, 2, and 3 
determined by MCKs measurements are listed in Table 2. 
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Figure 7. Multi-cycle kinetics (MCKs) measurements of mannosides binding to FimHFL-B. MCKs 
of 1 (A), 2 (B), and 3 (C) binding to FimHFL-B were performed with association times of 180 s or 240 s 
and a dissociation time of 1200 s or 2200 s using a flow rate of 30 µL min-1. Raw data was fitted using 
a two-state reaction model with RI (bulk refractive index) set to zero. 
 
 
Table 2. Kinetic parameters of FimHFL-B with mannosides 1-3 determined by MCKs. 
The table shows values of multi-cycle kinetics runs on a SA sensor chip with captured FimHFL-B. 
 
Comp. kon,1×104 koff,1 t1/2,1a  kon,2×10-4 koff,2×10-4 t1/2,2 KD, kineticb 
 M-1s-1 s-1 min M-1s-1 s-1 min nM 
1 159 0.932 0.01 57.6 6.7 1.7 314 
2 2.4 0.029 0.39 21.9 6.2 18.6 271 
3 5.5 0.039 0.29 43.9 50.3 2.3 384 
 
a Complex half-lives (t1⁄2) were calculated as follows: t1⁄2 = ln2/koff. 
b Kinetic KD value was determined according to the following equation:  
 KD = koff,1/kon,1×(koff,2/(koff,2 + kon,2)). 
 
The dissociation half-lives of 1 and 3 determined by the off-rate screen could be 
confirmed by the MCKs measurements (Table 3). As expected, the t1/2 of 2 was even 
underestimated in the screen due to an incorrect baseline interpretation (Figure 5). 
The determined dissociation half-life for 2 amounted 2.6 min in the off-rate screen 





















































Table 3. Comparison of t1/2 determined by the off-rate screen (left column) and MCKs measurement 
(right column). 
 
Compound t1/2  
off-rate screen  
t1/2,2  
MCKs  
 min min 
1 3.0 1.7 
2 2.6 18.6 
3 2.5 2.3 
 
 
4. Comparison off-rate versus affinity  
Relative affinities (FPsignal) of binding to FimHFL are available for all screened 
mannosides. They were determined by a fluorescence polarization assay (FPA) and 
were subsequently ranked. The off-rate rank and the relative affinity (FPsignal) rank of 
one compound were plotted to evaluate a potential relative correlation of koff and 
binding affinity (Figure 8A). The two data sets showed no correlation (Pearson 
correlation coefficient (r) = -0.43). Solely compounds that did not bind in the off-rate 
screen at all (not included in the plot, Figure 8A), most notably ligands with modified 
mannose moiety, had in the majority of cases (70 %) also poor affinities (above 
100 nM).  
 
Absolute affinities are available for the 34 best relative affinity-binders. It turned out 
that all of them had a KD value below 100 nM. The KD of these compounds was 
subsequently plotted versus its koff value (Figure 8B). Only 2 compounds that bound 
FimHFL with a KD below 100 nM displayed a half-live above 1 min in the off-rate 
screen. The most promising of these two compounds concerning its kinetics is a 
squaric acid derivate (OS420, rank 13, t1/2 = 2.6 min, sensorgram shape III, RU at the 





Figure 8. Correlation of affinity and kinetic data of mannosides binding to FimHFL. (A) The 
relative affinity (rank) of mannosides was plotted against its relative off-rate (rank). (B) The KD of the 
34 best relative affinity-binders was determined by fluorescence polarization and plotted against koff. 
Only 2 of these 34 compounds had a t1/2 above 1 min (OS420 (rank 13, type III dissociation, t1/2 = 




The determination of the dissociation half-life (t1/2), which is given as ln2/koff, has 
been proven as a successful method to predict in vivo efficacy at early stages of drug 
discovery.[21,22,59] For that reason, a surface plasmon resonance (SPR) assay with full-
length FimH (FimHFL) as target protein was developed to screen the off-rate of a 
library consisting of 177 α-D-mannosides with various aglycone classes and modified 
mannose moieties.  
 
The off-rate screen revealed that removal or replacement of individual hydroxyl 
groups resulted in an inability of all investigated compounds with modified mannose 
moieties to bind FimHFL. The determination of relative binding affinities between 
FimHFL and ligands with modified mannose moieties resulted in a similar 
observation. An altered hydrogen bond network implicated significant affinity losses. 
An inevitable importance of the hydrogen bond network also displayed both 
affinity [35,43,44] and kinetic [48] investigations of FimHLD interacting with compounds 
comprising a modified mannose moiety. The hydrogen bond network seems to be the 
basic condition of complex stability for both mannoside–FimHLD and mannoside–
FimHFL complexes. A change in the hydrogen bond network exerts a substantial 
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influence on both KD and koff. In the context of FimHLD, kinetic data has already been 
shown that the off-rate is more depended on the maintenance of the hydrogen bond 
network whereas higher on-rates resulted from a more pronounced interaction of the 
aglycone with the tyrosine gate.[48]  
 
Biphenyl, phenylindole, and phenylindoline derivates binding to FimHFL showed poor 
dissociation half-lives indicating a nonexistent or minor support of these aglycones in 
complex stabilization. In contrast, biphenyl derivates binding to FimHFL performed 
well in the relative affinity screen. A beneficial impact of aglycones with two 
aromatic rings was also observed in binding affinity studies with high-affinity FimH 
as target.[34,35,38,39] An ortho-chloro substituent on the first phenyl ring was not 
identified to prolong t1/2 as it contributed to an improvement in binding affinity for 
both mannoside–FimHFL and mannoside–FimHLD interactions.[38] In general, the 
performance of mannosides in the off-rate screen compared to relative affinity screen, 
both having FimHFL as target, revealed no correlation between long half-lives and 
strong affinities. Among the different aglycone classes, biphenyls spaced by an 
aniline or a thiourea moiety and mannosides with aglycones including a squaric acid 
moiety exhibited relatively high numbers of hits with dissociation half-lives up to 
3.3 min.  
 
The off-rate screening results also emphasized the importance of a thoroughly 
considered assay dissociation time. The longer the dissociation time, the longer the 
measurement time, but the more likely the sensorgram returns to baseline. A return to 
the initial baseline ensures a correct dissociation fit and thus a reliable estimate of the 
dissociation half-life. The determined t1/2s of compounds, which exhibited no baseline 
return during the investigated dissociation time, are likely always underestimated. 
 110
Especially for these compounds it is worthwhile to reassess t1/2 in secondary 
measurements such as a multi-cycle kinetics (MCKs) assay. For mannoside 2 a t1/2,2 
of 18.6 min was measured in a MCKs run.  
 
As MCKs measurements have shown, probably all mannosides interact with FimHFL 
in a biphasic manner. Unbinding of mannoside–FimHFL complexes involved a fast 
and a slow dissociation component that occurred in varying proportions. As a 
consequence, an evaluation of the off-rate screen was more complex than expected. 
Furthermore, the complex dissociation behavior of mannoside–FimHFL complexes 
presumably made it impossible to find molecular descriptors that correlated with long 
dissociation half-lives. The descriptor analysis was performed with PaDEL-
Descriptor, DRAGON, Schrödinger's QikProp, and CODESSA software and included 
the off-rates of the whole dataset (177 α-D-mannosides). Nevertheless, a new 
knowledge basis was generated, including structural elements and insights in the 
dissociation behavior of mannoside–FimHFL complexes, to develop potent FimHFL 
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S2 Activity of FimHFL-B
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S2.2 Activity of FimHFL-B after binding to streptavidin 
S3 Chemical Structures and koff/t1/2 
S4 Sensorgrams different shapes 
S.1 Molecular mass of FimHFL-B
In order to check the molecular mass of FimHFL-B, the molecular weight of the
purified protein was determined by electrospray ionisation mass spectrometry (ESI-
MS) analysis (Functional Genomics Center Zurich). The measured mass of FimHFL-B
amounted to 31 291.0 Da and is in accordance with the calculated mass of
31 291.2 Da.
Figure S1. Mass spectrum of the purified FimHFL-B revealed a peak (100%) at 31291 kDa. 
mass 
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S2 Activity of FimHFL-B  
S2.1 FimHFL-B activity compared to FimHFL using a FPA assay 
The activity of the protein was determined by a fluorescence polarization assay (FPA) 
first described for FimHLD (isolated lectin domain) [1] and later adapted for FimHFL 
(full-length FimH using a peptide without biotin).[2] The binding affinity of FimHFL-B 
was compared with FimHFL using a FITC-labeled tracer (constant concentration) as 
interaction partner. Therefore, dilution series of the proteins (final concentration: 
beginning with 10 µM and then decreasing with a dilution factor of 2) mixed with 
tracer (final concentration: 50 nM) were prepared. For this purpose, the protein 
batches and a tracer stock (10 mM in 100% DMSO) were diluted with assay buffer 
(20 mM HEPES, 150 mM NaCl, 50 µg/mL BSA, pH 7.4). Samples were incubated 
for 1 hour before fluorescence polarization was measured with the Synergy™ H1 
Multi-Mode microplate reader (BioTek Intruments). KD values of FimHFL-B and 
FimHFL-B were determined using Prism (GraphPad Software) and were comparable 
(KD of FimHFL-B: 129.4 nM versus KD of FimHFL: 111.0 nM). 


























S3 Chemical structures and general information 
Table S1. All compounds included in the off-rate screen are ranked according to their koff. In the table 
the chemical structure, the dissociation half-life (t1/2), and the binding response at the beginning (RUB) 
and the end (RUE) of the dissociation phase are indicated. In addition, the logD7.4 if available is listed 
and the fluorescence polarization (FP) value, which was determined in a FP assay that measured the 
relative affinity of mannosides. 





OS395 4.4 1.7 3.46E-03 3.3 1.0 1.1±0.0 82 
Rank: 2 
OS465.2 2.3 0.2 3.50E-03 3.3 1.0 < -1.5 163 
Rank: 3 
OS540 4.7 0.0 3.83E-03 3.0 1.0 0.4±0.1 80 
Rank: 4 
OS556 9.7 2.9 3.92E-03 3.0 1.0 -1.1±0.2 69 
Rank: 5 
OS550 2.2 0.1 3.93E-03 2.9 1.0 1.7±0.0 146 
Rank: 6 
OS494 2.7 0.4 3.95E-03 2.9 1.0 0.2±0.1 76 
Rank: 7 
WS176 6.5 2.5 4.00E-03 2.9 1.0 n.d. 86 
Rank: 8 
OS349 1.0 0.2 4.14E-03 2.8 1.0 3.0±0.0 189 
Rank: 8 
OS397 2.1 0.6 4.14E-03 2.8 0.9 1.1±0.0 68 
Rank: 10 
HS030 1.5 0.0 4.23E-03 2.7 1.0 0.3±0.2 140 
Rank: 11 
















































































































PF57 2.5 -0.2 4.39E-03 2.6 0.9 n.d. 84 
Rank: 13 
OS420 4.2 2.3 4.41E-03 2.6 0.9 -0.5±0.1 62 
Rank: 14 
PF18 13.2 4.6 4.51E-03 2.6 1.0 1.5±0.1 117 
Rank: 15 
OS472.2 3.0 0.0 4.65E-03 2.5 1.0 n.d. 158 
Rank: 16 
JXH-III-057 9.1 4.7 5.21E-03 2.2 1.0 1.2±0.0 102 
Rank: 17 
JXH-@090 3.8 1.7 5.45E-03 2.1 1.0 n.d. 90 
Rank: 18 
WS268 2.7 1.2 5.48E-03 2.1 1.0 n.d. 164 
Rank: 19 
JXH-III-0712 7.0 3.3 5.55E-03 2.1 1.0 1.1±0.1 106 
Rank: 20 
OS542 2.5 0.1 5.59E-03 2.1 1.0 0.6±0.1 71 
Rank: 21 
PLJ01068A 2.4 0.3 5.61E-03 2.1 1.0 n.d. 143 
Rank: 22 
OS470.2 3.1 0.4 5.90E-03 2.0 1.0 n.d. 159 
Rank: 23 
OS562 2.7 0.7 6.26E-03 1.8 0.9 0.1±0.1 133 
Rank: 24 





























































































































WS302A 4.3 1.4 6.87E-03 1.7 1.0 1.3±0.2 169 
Rank: 26 
WS320 1.4 0.4 7.53E-03 1.5 0.9 n.d. 64 
Rank: 27 
OS464 1.5 -0.1 7.99E-03 1.5 0.9 -1.1±0.1 77 
Rank: 28 
PLJ02174B 2.0 -0.7 8.03E-03 1.4 1.0 n.d 190 
Rank: 29 
JXH-IV-073 1.1 0.3 8.14E-03 1.4 0.9 1.4±0.1 123 
Rank: 30 
OS396 1.5 0.0 8.38E-03 1.4 0.9 0.8±0.1 71 
Rank: 31 
WS384 5.2 -0.2 8.53E-03 1.4 0.9 n.d. 8 
Rank: 32 
JXH-IV-090 1.1 0.1 8.56E-03 1.4 1.0 n.d. 157 
Rank: 33 
WS265A 1.3 0.6 1.01E-02 1.1 0.9 n.d. 171 
Rank: 33 
PL2238A 1.4 0.6 1.01E-02 1.1 0.9 2.1±0.0 110 
Rank: 35 
OS555 2.3 0.9 1.07E-02 1.1 0.9 -0.7±0.1 73 
Rank: 35 













































































































WS400 2.2 0.1 1.09E-02 1.1 1.0 n.d 93 
Rank: 38 
WS370 1.0 0.2 1.16E-02 1.0 0.9 n.d. 106 
Rank: 38 
PLJ02052B 0.6 0.0 1.16E-02 1.0 0.8 n.d. 133 
Rank: 40 
OS559 1.2 0.3 1.41E-02 0.8 0.9 0.1±0.1 135 
Rank: 41 
PLJ02238B 0.6 0.1 1.45E-02 0.8 0.8 < -1.5 157 
Rank: 42 
WS283 0.5 0.0 1.47E-02 0.8 0.8 0.5±0.0 105 
Rank: 42 
PLJ02173A 0.5 -0.2 1.47E-02 0.8 0.9 2.3±0.0 118 
Rank: 44 
PLJ03135A 0.8 -0.4 1.58E-02 0.7 0.9 2.0±0.1 65 
Rank: 45 
JX4-@0682 1.1 -0.2 1.59E-02 0.7 0.9 1.1* 78 
Rank: 46 
JXH-@065 2.0 -0.1 1.92E-02 0.6 0.9 n.d. 98 
Rank: 47 































































































JXH-2432 0.9 0.2 2.30E-02 0.5 0.7 2.4* 141 
Rank: 49 
PLJ01303A 1.2 1.1 2.31E-02 0.5 0.9 2.7±0.1 111 
Rank: 50 
PLJ02123A 1.1 -0.7 2.38E-02 0.5 0.9 1.2±0.0 64 
Rank: 51 
JXH-V0321 1.1 0.3 2.41E-02 0.5 0.9 n.d. 85 
Rank: 52 
OS492 1.8 -0.1 2.45E-02 0.5 0.9 1.6±0.1 75 
Rank: 53 




1.6 0.0 2.71E-02 0.4 0.9 2.6±0.1 75 
Rank: 55 
WS180 1.1 -0.9 2.84E-02 0.4 0.8 n.d. 59 
Rank: 56 
PLJ01159A 1.2 -0.4 2.92E-02 0.4 0.9 n.d. 152 
Rank: 57 
JXH-IV 003 0.8 0.0 2.94E-02 0.4 0.9 3.1±0.1 125 
Rank: 58 


































































































PLJ10301A 3.8 -0.6 2.95E-02 0.4 0.9 3.2±0.1 56 
Rank: 60 
JXH-IV-028 1.3 0.0 3.06E-02 0.4 0.8 2.8±0.0 85 
Rank: 61 
PLJ03061B 1.0 0.1 3.14E-02 0.4 0.9 n.d. 119 
Rank: 62 
WS395 1.0 0.0 3.20E-02 0.4 0.9 2.7±0.1 117 
Rank: 63 
PLJ01128A 1.4 0.5 3.34E-02 0.3 0.9 0.9±0.1 83 
Rank: 63 
PLJ03061E 1.2 0.0 3.34E-02 0.3 0.9 n.d. 133 
Rank: 65 
PF11 1.7 0.4 3.60E-02 0.3 0.9 1.6±0.1 139 
Rank: 66 
OS529 2.0 0.0 3.64E-02 0.3 0.9 0.4±0.1 76 
Rank: 66 
PLJ01178A 1.3 0.0 3.64E-02 0.3 0.9 1.8±0.1 147 
Rank: 68 
PLJ02115A 1.8 -0.2 3.65E-02 0.3 0.9 2.8±0.1 64 
Rank: 69 
OS531_2 1.1 0.0 3.67E-02 0.3 0.8 < -1.5 88 
Rank: 70 
PLJ01126A 1.2 0.5 3.70E-02 0.3 0.8 2.0±0.1 101 
Rank: 71 































































































































JXH-@101 2.1 -0.2 3.94E-02 0.3 0.9 1.8* 72 
Rank: 72 
OS394 3.2 -0.7 3.94E-02 0.3 0.9 0.1±0.0 34 
Rank: 74 
PLJ03061C 1.2 0.1 4.02E-02 0.3 0.9 n.d. 128 
Rank: 75 
JXH-III-034 2.2 0.3 4.10E-02 0.3 0.9 3.2±0.3 73 
Rank: 76 
PLJ03061D 1.2 0.0 4.15E-02 0.3 0.8 n.d. 100 
Rank: 77 
PLJ01179A 1.4 -0.1 4.17E-02 0.3 0.9 2.4±0.2 68 
Rank: 78 
WS280A 1.1 -0.1 4.18E-02 0.3 0.9 2.0±0.1 113 
Rank: 79 
JXH-V0322 1.5 0.3 4.31E-02 0.3 0.9 n.d. 8 
Rank: 80 
JXH-@0751 1.6 0.2 4.32E-02 0.3 0.9 3.4* 91 
Rank: 81 
PLJ01302B 1.2 0.4 4.37E-02 0.3 0.8 n.d. 94 
Rank: 81 
PLJ03136A 1.0 -0.2 4.37E-02 0.3 0.9 1.5±0.1 87 
Rank: 83 
JXH-IV-069 0.7 0.1 4.45E-02 0.3 0.7 1.7±0.1 128 
Rank: 84 






























































































































PLJ01194B 0.7 -0.2 4.62E-02 0.2 0.8 -0.8±0.1 71 
Rank: 86 
PF14.1 1.9 0.5 4.71E-02 0.2 0.8 -0.1±0.0 110 
Rank: 87 
PLJ01181A 1.4 0.0 4.74E-02 0.2 0.9 2.9±0.1 97 
Rank: 88 
WS291 1.9 -0.1 4.99E-02 0.2 0.9 n.d. 56 
Rank: 89 
JXH-232 1.2 0.1 5.08E-02 0.2 0.9 1.8* 108 
Rank: 90 
WS248 3.1 -0.6 5.11E-02 0.2 0.9 1.7±0.0 51 
Rank: 91 
WS312 6.6 -0.8 5.14E-02 0.2 1.0 2.4±0.1 51 
Rank: 92 
PLJ03127A 0.9 0.0 5.20E-02 0.2 0.8 n.d. 128 
Rank: 92 
WS294 3.5 0.3 5.20E-02 0.2 0.9 0.7±0.0 46 
Rank: 94 
WS063 2.4 0.0 5.24E-02 0.2 0.8 1.7±0.1 68 
Rank: 94 
JXH-@073 0.9 0.2 5.24E-02 0.2 0.8 1.6* 79 
Rank: 96 













































































































Compound	   RUB RUE koff t1/2 [min] R
2 logD7.4 FPSignal
Rank: 97 
WS284 1.3 -0.1 5.31E-02 0.2 0.9 1.0±0.0 53 
Rank: 98 
WS311 3.1 0.4 5.34E-02 0.2 0.9 0.9±0.1 54 
Rank: 99 
OS553 5.1 -0.3 5.46E-02 0.2 1.0 2.4±0.0 71 
Rank: 100 
PLJ02019C 1.1 0.4 5.56E-02 0.2 0.8 n.d. 85 
Rank: 100 
JHX-224 1.8 0.1 5.56E-02 0.2 0.9 1.8* 71 
Rank: 102 
WS310 4.2 -0.5 5.69E-02 0.2 0.9 1.8±0.1 45 
Rank: 103 
WS253 3.5 -0.4 5.70E-02 0.2 0.9 2.8±0.0 45 
Rank: 104 
JXH-III-044 0.9 0.2 5.72E-02 0.2 0.7 2.8±0.0 133 
Rank: 105 
JXH-III-047 1.1 0.1 5.89E-02 0.2 0.8 2.2±0.0 127 
Rank: 106 
WS322 3.4 -0.4 6.02E-02 0.2 0.9 n.d. 58 
Rank: 107 




OS461 1.8 0.9 6.44E-02 0.2 0.5 1.6±0.0 134 
Rank: 108 






















































































































WS253B 1.9 0.0 6.50E-02 0.2 1.0 n.d. 59 
Rank: 111 
JXH-IV-075 0.9 0.1 6.71E-02 0.2 0.6 2.00±0.0 130 
Rank: 112 
WS215B 3.3 -0.1 6.87E-02 0.2 1.0 1.8±0.1 66 
Rank: 113 
PLJ02126A 4.7 -0.2 7.00E-02 0.2 1.0 1.1±0.0 41 
Rank: 114 
PF14.2 3.1 -2.1 7.30E-02 0.2 0.9 0.7±0.1 52 
Rank: 115 
WS011 1.7 0.0 7.61E-02 0.2 0.9 2.3** 60 
Rank: 116 
JXH-III-032 1.4 0.4 7.69E-02 0.2 0.7 3.00±0.0 122 
Rank: 117 
WS257 3.8 -0.5 7.74E-02 0.1 0.9 1.7±0.1 45 
Rank: 118 
PLJ01175A 0.8 0.0 7.78E-02 0.1 0.6 2.7±0.1 106 
Rank: 118 
PLJ02045A 2.6 -0.4 7.78E-02 0.1 0.9 1.3±0.1 41 
Rank: 120 
PLJ01194A 1.3 0.2 8.90E-02 0.1 0.6 2.8±0.1 56 
Rank: 121 
PLJ01129A 0.9 0.3 9.32E-02 0.1 0.3 0.4±0.0 120 
Rank: 122 




























































































































OS487 0.8 -0.5 3.79E-02 0.0 0.8 -1.1±0.2 84 
Rank: 129 
OS488 0.5 -0.1 5.00E-03 0.0 0.8 1.5±0.1 85 
Rank: 123 
OS493 0.3 -0.6 7.72E-03 0.0 0.8 1.7±0.1 72 
Rank: 123 
OS498 0.8 -0.4 2.50E-02 0.0 0.8 0.3±0.1 86 
Rank: 123 
OS500 0.2 -0.5 5.45E-03 0.0 0.8 <-1.5 89 
Rank: 123 
OS534 0.9 -0.9 2.66E-02 0.0 0.8 0.1±0.1 65 
Rank: 123 
OS456 0.7 -0.2 2.15E-03 0.0 1.0 <-1.5 145 
Rank: 123 
OS457 1.1 0.1 2.48E-03 0.0 1.0 <-1.5 180 
Rank: 123 
OS459 0.3 0.1 5.12E-03 0.0 0.6 <-1.5 169 
Rank: 123 
OS421 0.3 -0.5 4.63E-03 0.0 0.8 -1.3±0.1 83 
Rank: 123 
JXH-@041 0.2 -0.1 9.69E-03 0.0 0.8 2.7* 172 
Rank: 123 
JXH-2431 0.8 0.1 1.00E-02 0.0 0.9 1.9* 90 
Rank: 123 





























































































































JXH-@097 0.1 -0.3 1.42E-02 0.0 0.8 n.d. 171 
Rank: 123 
JXH-III-020 0.4 0.0 2.98E-02 0.0 0.7 n.d. 144 
Rank: 123 
JXH-281 0.1 -2010.0 3.02E-08 0.0 n.d. 169 
Rank: 123 
JXH-III-033 0.2 -3861.0 2.19E-08 0.0 3.4±0.1 87 
Rank: 123 
JHX-III-045 0.5 0.1 2.28E-02 0.0 0.6 n.d. 135 
Rank: 123 
JHX-III-061 0.1 -0.9 1.01E-03 0.0 0.9 2.1±0.0 172 
Rank: 123 
JHX-III-066 0.3 -0.7 5.13E-04 0.0 0.8 3.4±0.1 109 
Rank: 123 
JHX-III-078 0.2 -0.4 2.39E-03 0.0 0.9 3.5±0.1 152 
Rank: 123 
JHX-III-084 0.2 ~ -257.7 ~ 1.15E-06 0.0 0.8 n.d. n.d.
Rank: 123 
JXH-IV-051 0.4 0.0 9.45E-03 0.0 0.8 2.3±0.0 123 
Rank: 123 
WS280B 1.3 0.1 5.04E+00 0.0 0.9 n.d. 124 
Rank: 123 







































































































WS301 0.1 -0.1 6.60E-03 0.0 0.4 1.6±0.1 161 
Rank: 123 
WS239 0.1 -0.1 7.87E-03 0.0 0.3 n.d. 172 
Rank: 123 
WS319 0.4 -0.2 9.04E-03 0.0 0.8 n.d. n.d.
Rank: 123 
PLJ01076A 0.5 0.1 5.42E-02 0.0 0.5 0.2±0.1 143 
Rank: 123 
PLJ01278B 0.2 -0.4 1.61E-04 0.0 0.3 <-1.5 149 
Rank: 123 
PLJ01175B 0.1 -0.1 7.36E-03 0.0 0.5 <-1.5 135 
Rank: 123 
PLJ01181B 0.6 -0.2 4.62E-02 0.0 0.8 0.8±0.1 114 
Rank: 123 
PLJ01192A 0.0 -0.2 3.69E-02 0.0 0.2 2.1±0.1 160 
Rank: 123 
OS373 -0.4 -8.1 2.23E-04 0.0 1.0 0.2 178 
Rank: 123 
O376 -0.4 ~ -577.8 1.33E-06 0.0 0.9 0.9 175 
Rank: 123 


























































































OS380 -0.2 -0.7 1.72E-03 0.0 0.8 1.5 175 
Rank: 123 
OS381 -0.1 ~ -288.7 9.86E-07 0.0 0.5 -1.0 183 
Rank: 123 
OS383 0.0 ~ -17.86 1.65E-05 0.0 0.7 -0.2
Rank: 123 
OS405 -0.4 0.0 1.41E-01 0.0 0.2 -0.4 185 
Rank: 123 
OS412 -0.5 0.0 4.04E-01 0.0 0.2 0.2 186 
Rank: 123 
OS413 -0.6 -0.1 2.00E-01 0.0 0.3 0.7 188 
Rank: 123 
OS416 -0.4 0.2 3.91E-01 0.0 0.2 1.1 185 
Rank: 123 
JXH@0192 0.0 -0.1 1.12E-03 0.0 0.1 n.d. 186 
Rank: 123 
JXH@031 0.0 0.1 4.65E-03 0.0 0.2 n.d. 194 
Rank: 123 
JXH@039 0.0 -5051.0 9.41E-09 0.0 n.d. 186 
Rank: 123 
JXH@13 -1.0 -1.2 3.45E-03 0.0 0.6 n.d. 192 
Rank: 123 
















































































JXH@138 0.1 0.1 5.89E-03 0.0 0.1 n.d. 196 
Rank: 123 
JXH@149 0.2 0.3 8.11E-04 0.0 0.1 n.d. 190 
Rank: 123 
JXH@158 0.1 ~ -5.782 2.42E-05 0.0 0.4 n.d. 189 
Rank: 123 
JXH@163 0.1 1123.0 2.94E-08 0.0 n.d. 192 
Rank: 123 
JXH@175 0.1 0.0 2.67E-03 0.0 0.2 n.d. 192 
Rank: 123 
JXH@235 0.3 -2599.0 8.27E-09 0.0 n.d. 195 
Rank: 123 
JXH@209 0.0 n.d. 191 
* published value (Jang et al., 2012, J. Med. Chem.)









































S4 Sensorgrams different shape types of dissociation 
The following figure displays the sensorgrams and dissociation phases (fitted with the 
1:1 Langmuir binding model) of hit compounds determined by the off-rate screen. Hit 
compounds are grouped according to their dissociation type (I-V). 












































































































































































































































































































































































































































































































































































































































































































































































































































Figure S3. Sensorgrams and dissociation phased of hit compounds grouped by the type of dissociation 
(I-V). 
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For many biological processes such as ligand binding, enzy-
matic catalysis, or protein folding, allosteric regulation of pro-
tein conformation and dynamics is fundamentally important.
One example is the bacterial adhesin FimH, where the C-termi-
nal pilin domain exerts negative allosteric control over binding
of the N-terminal lectin domain to mannosylated ligands on
host cells. When the lectin and pilin domains are separated
under shear stress, the FimH–ligand interaction switches in a
so-called catch-bond mechanism from the low- to high-affinity
state. So far, it has been assumed that the pilin domain is essen-
tial for the allosteric propagation within the lectin domain that
would otherwise be conformationally rigid. To test this hypoth-
esis, we generated mutants of the isolated FimH lectin domain
and characterized their thermodynamic, kinetic, and structural
properties using isothermal titration calorimetry, surface plas-
mon resonance, nuclear magnetic resonance, and X-ray tech-
niques. Intriguingly, some of the mutants mimicked the confor-
mational and kinetic behaviors of the full-length protein and,
even in absence of the pilin domain, conducted the cross-talk
between allosteric sites and the mannoside-binding pocket.
Thus, these mutants represent a minimalistic allosteric system
of FimH, useful for further mechanistic studies and antagonist
design.
The key step in urinary tract infections (UTI)4 is the adhesion
of uropathogenic Escherichia coli (UPEC) to urothelial cells of
the host (1, 2). This initial step enables the bacteria to invade
and colonize host cells but also to withstand clearance by the
bulk flow of urine. Adherence to the urothelial surface is medi-
ated by the adhesin FimH located at the tip of bacterial type 1
pili (3, 4). Full-length FimH (FimHFL) is composed of two
domains: the N-terminal lectin domain (FimHLD) which is con-
nected to the C-terminal pilin domain (FimHPD) by a short
linker (5). FimHLD contains the carbohydrate recognition
domain, which is responsible for binding to the highly manno-
sylated uroplakin 1a (UP1a) on the urothelial cell surface (6).
FimHPD is anchored to the core of the pilus via a donor strand of
the subsequent FimG subunit, a process termed donor strand
complementation (7, 8).
In the bladder, under static conditions, FimH exhibits only
weak interactions with the urothelial surface, which is highly
beneficial for bacterial motility and host cell invasion (9). How-
ever, when shear forces originating from urine flow occur, a
significant enhancement of the strength of the interaction (5,
10) due to a catch bond mechanism was observed (11, 12).
Catch bonds play pivotal roles in the regulation and fine-tuning
of cellular adhesion events, e.g. upon leukocyte recruitment by
selectins (13) and integrins (14), by cadherins controlling tissue
integrity (15, 16), in the epithelial adhesion of cancer cells (17),
or in T cell receptor interaction with peptide-bound major his-
tocompatibility complexes on antigen-presenting cells (18, 19).
Conformation and ligand-binding properties of FimHLD are
under the allosteric control of FimHPD (5, 20, 21). Recent X-ray
data of a recombinant FimHFL has provided structural evidence
for the different conformational states (22, 23). Under static
conditions, the interaction of the two domains of FimHFL sta-
bilizes the lectin domain in the low-affinity state, which is char-
acterized by a shallow binding pocket (Fig. 1). Binding to a man-
noside ligand induces a conformational change leading to the
medium-affinity state, in particular by the displacement of the
so-called clamp loop toward the binding pocket. This medium-
affinity state, where lectin and pilin domain are still in close
contact, is characterized by micromolar affinities and fast off-
rates (5, 23). However, upon shear stress, FimHLD and FimHPD
separate, inducing the high-affinity state with an up to 300-fold
enhanced affinity (20). Using donor–strand complemented
FimHFL and combining X-ray and small angle x-ray scattering
analyses, it was suggested that FimH is present in a two-state
conformational ensemble of low- and high-affinity states in
solution (22). This equilibrium can be influenced by sequence
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variations, thereby modulating the apparent binding affinity as
well as the binding mechanism (induced fit or conformational
selection), and thus influencing the infective potential of UPEC.
Because of the absence of negative allosteric regulation
exerted by the pilin domain, isolated FimHLD is locked in the
high-affinity state (24, 25). Mutations in the interdomain region
altering the interactions to the pilin domain clearly demon-
strated its contribution to the conformational change within
the lectin domain (20). Interestingly, the medium-affinity state
(domains interacting) and the high-affinity state (domains sep-
arated) exhibit nearly identical mannose-binding pockets, yet
possess a strikingly 105-fold difference in the off-rate for man-
nosides (23). This structural information in combination with
MD simulations and kinetics experiments (23, 26) led to the
concept of dynamic allosteric regulation, i.e. the allosteric sig-
nal of the pilin domain is transmitted to the proximal regions of
the lectin domain, whereas the binding pocket is regulated
purely by protein dynamics (27).
The isolated, recombinant FimHLD, which is locked in the
high-affinity state, exhibits high temporal and thermal stability
(24, 28, 29), and consequently, it was mostly used to generate
affinity data from antagonist screening and structural data from
X-ray crystallography (30 –35). However, recent data on the
conformational and dynamic regulation of FimHFL upon man-
noside binding raised doubt on the applicability of the confor-
mationally locked FimHLD for mimicking urinary tract infec-
tions in vivo (36, 37).
In a comparison of the low- and high-affinity states of
FimHLD, Le Trong et al. (5) identified four regions undergoing
conformational changes upon ligand binding, namely the
pocket zipper/clamp loop (Phe-1–Ile-11/Gly-8 –Gly-16), the
-bulge (Gln-59 –Ser-63), the -switch (Tyr-64 –Phe-71), and
the interdomain swing, insertion, and linker loops (Ala-25–
Leu-34, Pro-111–Ala-119, Asn-152–Thr-158) (Fig. 2). Later,
Rodriguez et al. (38) used RosettaDesign and MODIPDesign
(computer-based tools for protein structural analysis) to pre-
dict specific point mutations within the aforementioned
regions, causing the largest difference in energy between the
low- and high-affinity conformations and hence should stabi-
lize one of the affinity states.
The mutation A10P was predicted to favor the low-affinity
conformation through perturbation of the backbone hydrogen
bond of residue Ile-11 in the pocket zipper. In the -bulge
region, the point mutation R60P was predicted to prevent the
transition of the portion of Gln-59 –Ser-63 from a small loop to
a -strand and thus destabilize the high-affinity conformation.
In the -switch (Tyr-64 –Phe-71), the mutation V67K was
expected to prevent the conversion of this region to a -helix
and thus lock FimH in low-affinity conformation. The point
mutation A119L and the double mutation V27C/L34C at the
proximal end of the lectin domain were expected to preserve a
conformation of the interdomain loops that allows interaction
with the pilin domain and hence stabilizes the low-affinity con-
formation (5).
Figure 1. Schematic representation of the conformational states of FimHFL upon binding to mannosylated uroplakin 1a (UP1a) on the urothelium
(top), and the corresponding X-ray structures in the absence or presence of the model ligand n-heptyl--D-mannopyranoside (bottom). A, in the
unbound form, FimHLD and FimHPL interact and form the low-affinity state featuring a shallow binding pocket (PDB code 4XOD, donor strand of FimG in gray).
B, upon binding to UP1a in the absence of shear stress, FimHFL adopts the medium-affinity state, where FimHLD and FimHPD are still interacting but the clamp
loop (highlighted in green) is moved toward the mannoside ligand (in green) creating a deep, well-defined binding pocket (PDB code 4XOE). C, flow-induced
shear stress leads to a separation of FimHLD and FimHPD, causing the switch to the high-affinity state (PDB code 4XOB). D, isolated lectin domain is constitutively
present in the high-affinity state, both in the absence or presence of mannoside ligands (PDB code 4AUU, with ethanediol in the binding pocket, nearly
identical to the NMR solution structure, PDB code 3ZPD). E, structure of n-heptyl--D-mannopyranoside (1).
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The five FimH variants selected upon this analysis (A10P,
R60P, V67K, A119L, V27C/L34C) were expressed in E. coli in
the context of the entire pilus, and their affinity state was eval-
uated based on binding to mono- and trimannoside ligands as
well as their recognition by the conformation-specific mono-
clonal antibody mAb21 (38). This antibody recognizes an
epitope located in the interdomain region of the isolated WT
FimHLD (21, 39). Therefore, binding of mAb21 indicates that
FimH is in the high-affinity state, because only then is the
interdomain accessible. Furthermore, bacterial adhesion is
enhanced in the presence of mAb21, which stabilizes the high-
affinity state (21). In contrast, a monoclonal blocking antibody
directed against the FimHLD mutant V27C/L34C, presumably
locked in the low-affinity state, protected mice from bacterial
infection, thus demonstrating the relevance of considering
all conformational states for the design of therapeutic FimH
antagonists (40). Despite the intensive studies of the FimH vari-
ants mentioned above, structural, thermodynamic, and kinetic
data regarding the low-affinity conformation were not reported
so far.
To further elucidate the degree of conformational heteroge-
neity and the allosteric effects of mutants in the context of the
whole pilus (38), we recombinantly expressed five selected vari-
ants (A10P, R60P, V67K, V27C/L43C, and A119L) of isolated
FimHLD predicted to be stabilized in the low-affinity state, and
we analyzed their thermodynamic and kinetic binding proper-
ties, as well as their structural characteristics by NMR and
X-ray crystallography with the aim to reveal the allosteric cross-
talk between the regulatory regions within FimHLD. Further-
more, FimHLD mutants could also serve as easy-accessible
mimics of FimHFL for mechanistic studies as well as for the
development of FimH antagonists applicable for the anti-adhe-
sive therapy of UTI.
Results
Five FimHLD variants were generated with single- or double-
point mutations within the four allosteric regions assumed to
stabilize or even lock FimH in the low-affinity state (5, 38, 40).
The A10P mutation is located in the pocket zipper/clamp loop;
R60P and V67K are part of the -bulge and -switch regions,
respectively; and A119L and V27C/L34C are located within the
interdomain loops (Fig. 2). The purity and the monomeric state
of the WT and all variants were confirmed by native PAGE
analysis (data not shown).
Folding and stability of FimHLD mutants
The impact of these mutations on protein folding and stabil-
ity was evaluated by thermal shift-based differential-scanning
fluorimetry (42). In this assay, the fluorescence intensity of
SYPRO orange dye was recorded during heat denaturation of
the protein (42). The melting temperatures (Tm), which indi-
cate the thermal unfolding event, were in the same region for
WT FimHLD and the variants A10P, A119L, and R60P (Fig. S1
and Table S1) and were reduced by less than 8 °C for the
mutants V67K and V27C/L34C. Similar as for WT FimHLD, the
addition of n-heptyl -D-mannopyranoside (1) considerably
increased the thermal stability of all mutants, indicating bind-
ing of antagonist 1. However, for two mutants, R60P and V27C/
L34C, the extent of the thermal shift was significantly reduced,
suggesting a lower degree of stabilization, i.e. less efficient bind-
ing than for WT FimHLD (Table S1).
Correlation of structural and affinity changes of FimHLD
mutants
To examine the secondary and tertiary structures of WT
FimHLD and the five variants in the absence and presence of
mannoside 1, circular dichroism (CD) spectra were recorded
Figure 2. A, proposed allosteric regions of FimHLD mapped onto the X-ray structure of FimHFL in the low-affinity conformation within the assembled fimbrial
tip (PDB code 3JWN) (5). B, same regions in the X-ray structure of the isolated FimHLD (PDB code 4AUU) (41). Point mutations are shown as spheres. Data are
modified from Ref. 38.
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(Fig. 3 and Figs. S2 and S3). The far-UV (190 –250 nm) CD
spectrum of WT FimHLD is characteristic for a protein with a
high -sheet content (Fig. 3A) (43). Furthermore, upon addi-
tion of antagonist 1, the CD spectrum remained unchanged,
indicating a stable fold. Similar conformations are suggested for
the mutants A119L and A10P because their CD spectra in the
absence and presence of antagonist 1 were almost identical to
the WT (Fig. 3B and Fig. S2A). In contrast, the CD spectra of the
mutants V27C/L34C, R60P, and V67K in the absence of ligand
were clearly altered with an overall lower molar ellipticity, indi-
cating significant changes in the global protein conformation
and a reduction of the -sheet proportion (Fig. 3C and Fig. S2).
Surprisingly, the addition of mannoside 1 to these three
mutants re-established CD spectra nearly identical to WT
FimHLD.
Next, the geometry of aromatic side chains was analyzed with
near-UV CD (260 –320 nm) (Fig. 3, D–F, and Fig. S3). Consid-
ering the abundance of phenylalanine, tyrosine, and tryptophan
residues, many of them in close vicinity of the mannose-binding
pocket (Fig. S3, D–F), even small changes in the local protein
conformation should be detectable (44). Because near-UV CD
spectra of WT FimHLD in the absence and presence of manno-
side 1 were again superimposable, it can be assumed that the
protein conformation in the neighborhood of the aromatic res-
idues is highly conserved (Fig. 3D). For the mutants A10P and
A119L, the general shape and the curve maxima of the spectra
were similar to WT FimHLD, and the spectra of the mutants
V27C/L34C (Fig. 3F), R60P (Fig. S3B), and V67K (Fig. S3C)
were significantly altered with shifted maxima and partly
inverted signs of the molar ellipticity. Again, addition of antag-
onist 1 to these three mutants restored the near-UV CD spectra
compared with WT FimHLD to a large extent. These results
clearly indicate that mannose binding induces a significant con-
formational change toward the high-affinity conformation of
the so far uncharacterized apo-forms of R60P, V67K, and
V27C/L34C.
The dissociation constant KD of mannoside 1 binding to WT
FimHLD and the five mutants were determined with a fluores-
cence polarization (FP) assay (32). While WT FimHLD and the
mutants A119L and A10P exhibited affinities in the low nano-
molar range, the mutants R60P and V27C/L34C show reduced
affinity, namely by factors of 17 and 35, respectively (Table 1).
Finally, despite its altered CD spectra, the mutant V67K showed
only a 2-fold reduction in binding affinity. Thus, at this point it
cannot be speculated that the conformational changes observed in
the CD spectra result in an entropy penalty.
Distinct thermodynamic profiles of conformationally different
mutants
To assess the impact of the observed conformational changes
upon ligand binding on the thermodynamic fingerprint of the
mutants, isothermal titration calorimetry (ITC) experiments
were performed with mannoside 1 (Table 2) leading to KD val-
ues in the same range (within a factor of 2) as those obtained
Figure 3. Informative regions of CD spectra in the far-UV (A–C) and near-UV region (D–F) of WT FimHLD (A and D) and of the mutants A119L (B and E)
and V27C/L34C (C and F) in the absence and presence of mannoside 1. For comparison, the CD spectrum of WT FimHLD with 1 (blue) is shown in all graphs.
Bars in gray indicate the typical near-UV absorbance range for aromatic residues in FimHLD: Phe (250 –270 nm, 6 residues), Tyr (270 –290 nm, 10 residues), and
Trp (280 –300 nm, 2 residues).
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with the FP assay (Table 1). All mutants showed an enthalpy-
driven binding profile. Compared with WT FimHLD, they
exhibit a more unfavorable entropy term. In respect to
enthalpy, the mutants A119L and V67K benefit from an
improvement of up to 2.8 kJ/mol, whereas R60P and V27C/
L34C display penalties in a comparable magnitude (Fig. S4).
We hypothesized that the conformational changes of the
mutants R60P and V27C/L34C induced by ligand binding are
responsible for unfavorable conformational entropy terms.
Therefore, the entropy term obtained for R60P was dissected









The change in mixing entropy (Smix) reflecting the loss in
translational and rotational degrees of freedom of both interac-
tion partners upon binding is equal for WT FimHLD and the
R60P mutant (Equation 2, where R is the universal gas constant
and 55.6 is the molarity of water in molar).
S0mix  R ln 155.6 (Eq. 2)
The change in solvation entropy (Ssolv) was calculated
based on the change in heat capacity (Cp, Equation 3),
Cp  H0obsT  (Eq. 3)
which was determined by measuring the change of enthalpy
(H) as a function of temperature (Fig. 4).
S0solv, 298.15 K  Cpln298.15 K385 K  (Eq. 4)
By inserting the experimentally determined value for Cp
into Equation 4 at 385 K as the temperature of zero hydration
(TR), the change in solvation entropy (Ssolv) at room temper-
ature was obtained (47–49). Interestingly, the change of solva-
tion entropy for the interaction of R60P with mannoside 1 was
less favorable compared with WT FimHLD (TSsolv  15.9
kJ/mol) (Table 3). Considering that their ligand-bound struc-
tures are highly similar, a possible explanation may be a lower
degree of ordering of interfacial water molecules in the apo-
R60P, which presumably exhibits a broad and flexible binding
pocket. In contrast, the well-defined and narrow binding
pocket of WT FimHLD can establish a highly structured hydro-
gen bond network of water molecules supporting a more ben-
eficial solvation entropy upon ligand binding. Surprisingly, the
Figure 4. Determination of the heat capacity (Cp) of WT FimHLD and
mutant R60P binding to n-heptyl -D-mannopyranoside (1) by ITC mea-
surements at three and four different temperatures, respectively.
Table 1
Affinity of mannoside 1 for WT FimHLD and five mutants, as well as for
FimHFL obtained from the FP assay
KD (nM)a Relative KD
Variants of FimHLD
WT 19  2 1
A119L 5.2  0.5 0.27
A10P 16.5  1.5 0.87
V67K 37  3 1.9
R60P 322  52 17
V27C/L34C 661  56 35
Full-length FimH
WT FimHFLb 2300  100 121
a The assay was performed twice in duplicate measurements.
b Full-length WT FimH stabilized by FimG donor strand (23).
Table 2
Thermodynamic profiles of WT FimHLD and mutants thereof from ITC measurements with mannoside 1 at 298 K
The ITC assay was performed twice in duplicate measurements.
Variant KD G0 H0 TS0 c-value N
nM kJ/mol kJ/mol kJ/mol
WT 28.9  4.6 43.0  0.4 50.3  0.35 7.3  0.5 320 1.00
A119L 24.2  10.53 43.5  1.0 52.4  1.5 8.9  1.8 414 1.01
V67K 76.8  16.82 40.6  0.5 53.1  0.98 12.5  1.1 131 1.03
R60P 583  122.8 35.6  0.5 46.2  2.05 10.6  2.1 17.1 1.05
V27C/L34C 1117  271.03 34.0  0.6 45.3  2.54 11.3  2.6 13.4 0.93
Table 3
Entropy dissection of the binding of mannoside 1 to WT FimHLD and the mutant R60P
Variant Cp TSsolv TSconf TSmixa TSobs
kJ/K kJ/mol kJ/mol kJ/mol kJ/mol
WT FimHLD 0.907  0.016 69.1  1.22 66.4  1.24 10.0 7.27  0.245
R60P 0.698  0.098 53.2  7.47 53.8  7.51 10.0 10.6  0.724
a Smix quantifies the loss in translational and rotational degrees of freedom upon complex formation: calculated as Smix  Rln(1/55.6), with R being the universal gas con-
stant and 55.6 being the molarity of water in molar (47, 49). The assay was performed twice in duplicate measurements.
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conformational entropy TSconf of R60P was less unfavorable
compared with WT FimHLD (TSconf  12.6 kJ/mol).
This counter-intuitive observation remains to be investigated
and may require NMR dynamics studies that report on the dif-
ferent time scales on which ligand binding and protein confor-
mational changes can occur.
Similar binding kinetics for V27C/L34C mutant and WT FimHFL
To gain a detailed insight into the binding kinetics of the
interaction of FimH with mannoside ligands, surface plasmon
resonance (SPR) measurements were performed (Table 4). The
carboxyl-functionalized mannoside 5 (see supporting informa-
tion for structure and synthesis) was immobilized via an ethyl-
enediamine linker on a CM4 chip. WT FimHLD, mutants, and
FimHFL were injected in the mobile phase, and their association
and dissociation were monitored (Fig. 5 and Fig. S5). WT






Compared with other carbohydrate–lectin interactions (50),
the on-rate constant kon for WT FimHLD is in the typical range
of 103–104 M1 s1, whereas the off-rate constant koff is rather
low, resulting in a complex half-life t1⁄2 of 83.6 min. The binding
kinetic of the mutants A10P and A119L was similar to the WT
FimHLD (Table 4). For V67K, the kon was comparable with the
WT FimHLD, whereas the koff was 7-fold increased. In case of
FimHFL, kon was slightly increased, whereas the koff was drasti-
cally enhanced by a factor of 3700 resulting in a t1⁄2 of only 1.4 s.
The association and dissociation of FimHFL were characterized
by a multiphasic behavior (Fig. 5B) requiring fitting to a two-







A  B (Eq. 6)
In this model, the analyte (FimH, A) binds to the ligand
(mannoside, B) to form an initial complex (AB) and then under-
goes subsequent binding or conformational change to form a
more stable complex (AB).
When the multicycle kinetics measurement was repeated on
a chip surface with less densely immobilized ligand, the multi-
phasic behavior could be confirmed and steric hindrance as a
possible artifact excluded (data not shown). Similar findings
have recently been reported for FimH within the fully assem-
bled type I pili (51). A two-state binding process of FimHFL
featuring a second binding kinetic with a slow off-rate in the
range of WT FimHLD (Table 4) likely represents the slow con-
version of full-length FimH to the high-affinity state by separa-
tion of the lectin and pilin domains.
For the R60P mutant, kon was comparable with WT FimHLD,
whereas koff was increased 29-fold leading to a t1⁄2 of 2.9 min and
placing its kinetic profile between WT FimHLD and FimHFL.
Notably, the kinetic profile of the double-cysteine mutant
V27C/L34C was very similar to full-length FimHFL, except that
only a monophasic binding behavior was observed (Fig. 5A). In
comparison with WT FimHLD, the kon of V27C/L34C was
increased by a factor of 19 and koff by a factor of almost 2900,
resulting in a t1⁄2 of 1.7 s, i.e. very close to that of WT FimHFL. In
summary, the loss in affinity for R60P and especially for V27C/
L34C mainly originates from enhanced koff values, which is in
agreement with the concept of a dynamic allostery, i.e. the bind-
ing pockets in the medium- and high-affinity states of FimH
have nearly identical geometries, although the off-rates are
modulated by the flexibility of the binding pocket and the clamp
loop (23, 26). Consequently, we focused in the following sec-
tions on the two most interesting variants (R60P and V27C/
L34C) and the mutant A119L for comparison with an unaf-
fected variant.
Conformational fingerprints of selected FimHLD variants by
NMR
1H,15N HSQC experiments of uniformly 15N-labeled WT
FimHLD and the mutants R60P, V27C/L34C, and A119L were
measured in the absence and presence of mannoside 1 to assess
structural differences on a residue-based level. The backbone
assignment of WT FimHLD was available from previous studies
(25, 45). The 1H,15N HSQC spectrum of WT FimHLD showed
an excellent signal dispersion with numerous clearly isolated
peaks, especially those of the binding pocket residues (Fig. 6A).
Addition of mannoside 1 led to selective signal shifts of residues
around the binding pocket (Fig. 6B and Fig. S6) as expected
from direct ligand interactions (hydrogen bond formation) and
from indirect effects (small changes in the binding pocket
geometry, e.g. a conformational switch of the Tyr-48 side chain
when interacting with the n-heptyl aglycone) (45). Pronounced
Table 4
Kinetic parameters of WT FimHLD and FimHLD mutants and FimHFL with mannoside 5 determined by SPR
The table shows the mean value of 2– 4 independent measurements on a CM4 sensor chip with immobilized compound 5.
FimH variant KD, kinetic kon, 1 103 koff, 1 104 t1⁄2, 1a kon, 2 103 koff, 2 104 t1⁄2, 2a
nM M1s1 s1 min M1s1 s1 min
WT FimHLD 28.8  3.8b 4.8  0.4 1.4  0.1 83.6  8.6   
FimHLD A10P 41.6  1.7b 4.6  0.1 1.9  0.05 60.4  1.4   
FimHLD A119L 20.4  0.5b 10  0.2 2.1  0.03 54.8  0.7   
FimHLD V67K 179  7b 5.2  0.2 9.3  0.2 12.5  0.2   
FimHLD R60P 1656  203b 2.4  0.3 41  1.7 2.9  0.1   
FimHLD V27C/L34C 4361  471b 92  9 3998  186 1.7  0.1   
WT FimHFLc 6373  198d 33  0.3 5116  134 1.4  0.04 1.2  0.01 8.7  0.1 13  0.1
a Complex half-lives (t1⁄2) were calculated as follows: t1⁄2  ln2/koff.
b Kinetic KD value was determined by the following equation: KD  koff, 1/kon, 1.
c Full-length WT FimH was stabilized by the FimG donor strand (23).
d Kinetic KD value was determined according to the following equation: KD  koff, 1/kon, 1  (koff, 2/(koff, 2  kon, 2)).
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global conformational changes or allosteric effects upon man-
noside binding could be excluded in agreement with the X-ray
structural data (24, 25, 41, 45) and CD experiments (Fig. 3).
The 1H,15N HSQC spectra of the FimHLD mutant A119L in
the absence and presence of mannoside 1 were almost super-
imposable to that of the WT with only some deviations around
the point of mutation (Fig. S7) and a certain degree of peak
heterogeneity in the binding pocket region in the absence of
ligand (Fig. S8, see “Discussion”).
In contrast, significant changes in the 1H,15N HSQC finger-
print spectra were observed for the R60P and V27C/L34C vari-
ants in comparison with the WT, suggesting drastically altered
apo conformations (Fig. 6A). In particular, both mutants
showed no peaks in the near vicinity of isolated signals charac-
teristic for the binding pocket in the high-affinity state (Fig. 6A,
lower panel). As we observed, roughly the expected number of
peaks in the NMR spectra of the two mutants, this is unlikely to
be the result of extensive line broadening due to chemical
Figure 5. SPR sensorgrams (colored lines) of the analytes FimHLD mutant V27C/L34C (A) and FimHFL (B) WT, with immobilized mannoside 5 (see
supporting information). Gray dashed lines show kinetic fitting to a one-state binding model (A) or a two-state binding model (B). The measurements were
performed as detailed under “Experimental procedures.”
Figure 6. 1H,15N HSQC spectra of WT FimHLD (gray) and of the mutants R60P (blue) and V27C/L34C (red) in the absence (A) and presence of mannoside
1 (B). Spectral regions with residues of the binding pocket (indicated with dashed-line boxes) are expanded in the lower panel.
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exchange processes. Overlapping peaks in isolated spectral
regions suggest that the two mutants have similar apo confor-
mations (Fig. S9).
Strikingly, for both mutants, most signals of the binding
pocket were recovered upon addition of mannoside 1 (Fig. 6B).
Chemical shift maps for R60P and V27C/L34C, showing the
shifts of the peaks relative to WT FimHLD in the mannoside
1-bound form, indicate nearly identical chemical shifts in the
binding pocket (Fig. 7). This suggests similar conformations for
residues in direct contact with the mannosyl moiety (Fig. 7E:
backbone signals of Gly-14, Asp-47, Asp-54, and Asp-140 and
side chain signals of Gln-133 and Asn-135) as well as for the two
loops encompassing Tyr-48 and Tyr-137 involved in hydropho-
bic interactions with the n-heptyl aglycone of mannoside 1 (Fig.
7F). In chemical shift perturbation (CSP) experiments with
R60P and three different mannoside ligands (1-3, Fig. S10),
characteristic peak positions observed in the WT FimHLD with
each ligand could be restored, indicating identical ligand recog-
nition. As a note, all mannoside complexes of FimHLD WT and
mutants were in the slow or slow-intermediate regime as would
also be expected from the off-rate constants measured with SPR
(Table 4). Furthermore, for R60P and V27C/L34C, peak posi-
tions of the N-terminal pocket zipper and clamp-loop region
(residues 2–16) and parts of the -sheets were also recovered
upon addition of mannoside 1. However, both mutants exhibit
significant chemical shift differences compared with WT Fim-
HLD encompassing large parts of the -sheets distal from the
binding pocket, the -switch, and -bulge regions as well as the
interdomain loops (Fig. 7, C and D).
The 1H,15N HSQC spectrum of the V27C/L34C mutant
upon treatment with the reducing agent DTT closely resem-
bled that of WT FimHLD, in the absence or presence of manno-
side 1 (Fig. S11). Thus, in agreement with previous reports (5,
46), we confirmed that the additional disulfide bridge Cys-27–
Cys-34 in the interdomain region of the double mutant V27C/
L34C promotes the low-affinity conformation of FimHLD.
Low-affinity conformation of mutant R60P results from a
slightly altered clamp loop
X-ray crystallography was attempted with the FimHLD
mutants R60P and V27C/L34C to characterize their conforma-
tion on an atomic level. Although we did not succeed in grow-
ing crystals of the double mutant V27C/L34C, we obtained the
X-ray crystal structure of R60P at a resolution of 1.6 Å (PDB
code 5MCA) (Fig. 8 and Table S2). Whereas the structure was
only poorly superimposable (r.m.s.d. of 2.2 Å) (52) with WT
FimHLD (PDB code 4AUU) (41), it resembles the low-affinity
state of FimHFL (r.m.s.d. of 0.6 Å) as found in the crystal struc-
ture of the assembled fimbrial tip (PDB code 3JWN) (5). In both
structures, a twist in the -sandwich fold of the lectin domain
leads to a more compressed overall shape and, by a move of the
clamp loop by 3 Å, to a wider binding pocket in comparison
with the high-affinity conformation present in WT FimHLD
(Fig. 8A). In more detail, the conformation of the clamp loop of
the mutant R60P is located between the closed conformation
present in WT FimHLD and the completely open conformation
of the full-length FimH in the assembled fimbrial tip (Fig. 8B).
According to MD simulations of FimHFL, the clamp loop is
flexible in the absence of ligand (23), suggesting that its devia-
tion in R60P from the low-affinity structure of FimH of the
assembled fimbrial tip (PDB code 3JWN) might be incidental or
results from crystallization conditions.
Discussion
The catch bond behavior of the bacterial adhesin FimH rep-
resents a fascinating example of the allosteric regulation of
protein’s conformational and ligand-binding properties (53,
54). Although the structural basis for this regulation has been
elucidated (5, 23, 55), there is still a lack of experimental data on
the transmission of the allosteric signal from the interdomain
region to the distal binding pocket within FimHLD. Four regions
of FimHLD exhibit significant structural differences in their
low- and high-affinity conformation (Fig. 2) and are considered
to play an active role in this signal transmission (5). Based on
this information, the impact of site-specific mutations on the
conformation of the FimH lectin domain has been previously
investigated (38). Our own interest was initially focused on
mutations expected to stabilize the lectin domain in the low-
affinity state, because such mutants would allow a further eval-
uation of already available FimH antagonists until now mainly
tested against the high-affinity state (30 –33). To obtain such
mutants and to further unravel the allosteric regulation mech-
anism, we expressed and analyzed the FimHLD variants A10P,
R60P, V67K, A119L, and V27C/L34C (Fig. 2), and compared
their properties to WT FimHLD and WT FimHFL.
Our investigations show that not all point mutations were
effecting protein conformation and binding properties. For
instance, the mutations A10P (pocket zipper region) and
A119L (insertion loop of the interdomain region) had no influ-
ence on affinity and kinetics when compared with WT FimHLD
(Tables 1 and 4). In a previous study using full-length FimH
within the assembled pili of isogenic E. coli (38), these two
mutants stabilized the low-affinity state, indicated by a low
mono- versus trimannoside binding ratio. However, they
retained the ability to adopt the high-affinity state similar to the
WT variant as demonstrated by binding to the monoclonal
antibody mAb21 in the presence of mannose. Therefore, for
both mutants, these regions were assumed to show only weak
allosteric coupling (38). In our study with A10P and A119L, CD
analysis (Fig. 3 and Figs. S2 and S3) did not show any evidence of
a conformational switch, but instead they strongly supported a
high-affinity state similar to WT FimHLD, both in the absence
and presence of mannoside 1. In the 1H,15N HSQC spectrum of
apo-A119L (Fig. S7), double or triple peaks of binding pocket
residues very close to the position of the WT signals were
observed, indicating conformational flexibility. Upon addition
of mannoside 1, single peaks at positions identical to WT sig-
nals were observed, suggesting a rigidification of the binding
pocket (Fig. S8). In line with these results, ITC experiments
revealed an entropic penalty for A119L in comparison with WT
FimHLD, which, however, was compensated by a more favor-
able enthalpy term (Table 2). Despite this altered thermody-
namic profile, the binding kinetics were not affected (Fig. 9 and
Table 4). To sum up, similar to previous reports (38), we
observed only a weak coupling between residue Ala-119 of the
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Figure 7. Chemical shift differences between WT FimHLD and the mutants R60P (A and C) and V27C/L34C (B, D, E, and F) in the mannoside 1-bound
forms. A and B, CSP maps of the mutants relative to WT FimHLD in the presence of 1; red bars indicate lower limits according to tentative assignments to the
closest unassigned peak of the mutants; CSP effects of WT FimHLD upon addition of mannoside 1 are shown for reference to indicate the location of the binding
pocket (gray diamonds); secondary structure elements are indicated above; the positions of the mutations are marked with asterisks. C–F, X-ray structure of WT
FimHLD with 1 (PDB code 4BUQ) (35) colored according to CSP effects between the 1-bound forms of WT FimHLD and R60P (C) or WT FimHLD and V27C/L34C
(D–F).
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interdomain region with the binding pocket that, however, does
not affect the affinity or kinetics of the interaction.
CD analysis for V67K, R60P, and V27C/L34C (Fig. 3 and Figs.
S2 and S3) and NMR spectra for R60P and V27C/L34C mutants
(Figs. 6 and 7) revealed an altered protein conformation in the
ligand-free state that was converted to a conformation similar
to WT FimHLD upon mannoside addition. In contrast to previ-
ously suggested lock in the low-affinity conformation of these
mutants (5, 38, 40), this demonstrates for the first time a con-
siderable conformational change of the isolated FimHLD in the
absence of the regulatory pilin domain. For the mutant V67K,
designed to destabilize the helical -switch region of the high-
affinity FimHLD, binding affinity and kinetics were only mildly
affected, suggesting solely a weak coupling between the
-switch region and the binding pocket. However, in compar-
ison with WT FimHLD, R60P (-bulge) and V27C/L34C (inter-
domain region) showed drastically reduced binding affinities
(Table 1) as well as altered conformational (Figs. 6 and 8) and
kinetic properties (Table 4). The high resolution X-ray struc-
ture of R60P in the absence of ligand (PDB code 5MCA) clearly
showed that the mutant adopts a low-affinity conformation
similar to full-length FimH as present in the assembled pilus (5).
In particular, the clamp loop was not folded over the mannose-
binding pocket as observed in WT FimHLD (e.g. PDB code
4AUU) but was instead located several angstroms away similar
to the full-length structure (PDB code 3JWN, and Fig. 8).
1H,15N HSQC NMR spectra of R60P and V27C/L34C con-
firmed the drastically altered apo conformations, because
nearly all peaks were shifted relative to WT FimHLD (Fig. 6A).
However, addition of mannoside 1 led to a complete recovery of
NMR signals of the binding pocket, the clamp loop/pocket zip-
per, and large parts of the -sheets, whereas the signals of the
-switch, -bulge, and interdomain regions remained altered
(Fig. 7). Interestingly, such a conformation accurately resem-
bles the medium-affinity state observed in the crystal structure
of the mannoside-bound FimHFL (23). Indirectly, this is evi-
denced by the observation that an inhibitory antibody raised
against the FimHLD mutant V27C/L34C, with an epitope in the
binding pocket, strongly binds to FimH in the high-affinity state
(40), which displays a nearly identical geometry of the binding
pocket compared with the medium-affinity state (23). How-
ever, the exact conformation of V27C/L34C and R60P in the
bound state remains to be confirmed, e.g. by X-ray structures of
the mutants in complex with mannoside or comparative NMR
studies with 15N-labeled FimHFL.
The similarity of the FimHLD mutant V27C/L34C with
FimHFL was further substantiated by their almost identical
kinetic profiles (Fig. 9). Finally, the reduction of the disulfide
bond in the interdomain region of the V27C/L34C mutant
restores a high-affinity state similar to WT FimHLD (Fig. S11),
Figure 8. A, X-ray structures of FimHLD mutant R60P (blue, mutation indicated by blue sphere), WT FimHLD (gray, PDB code 4AUU), and full-length FimH from the
assembled fimbrial tip (lime, PDB code 3JWN). B, expansion of the mannose-binding pocket and the clamp loop with key residues shown as sticks.
Figure 9. Kinetic rate constants obtained from SPR measurements of
FimH variants with immobilized mannoside 5 as ligand: WT FimHLD
(gray) and mutants (color-coded as in Fig. 2) and FimHFL (gray). A, variants
with rate constants and KD values similar to WT FimHLD. B, variants with kon
values similar to WT FimHLD but with increased koff and decreased KD values.
C, mutant V27C/L34C and FimHFL have similar rate constants, which are, how-
ever, drastically different from WT FimHLD.
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thus confirming the involvement of the interdomain region in
the allosteric regulation of mannose binding (5).
Our data for the three mutants V67K, R60P, and V27C/L34C
are in good agreement with MD simulations of FimHLD, indi-
cating a weak coupling of the binding pocket to the -switch
region (V67K) but a strong coupling to the -bulge (R60P) and
to the interdomain regions (V27C/L34C) (26). These couplings
are supposed to regulate the dynamics in the clamp loop near
the binding pocket and to cause the renowned catch-bond
behavior of FimH. A higher flexibility of the clamp loop in the
medium-affinity state could be responsible for the dramatically
enhanced off-rates for mannosides relative to the high-affinity
state, despite nearly identical conformation of the binding
pocket (23, 26).
In future work, NMR dynamics experiments (56, 57) could be
used to address the higher flexibility of the clamp loop in the
medium-affinity state. However, in the case of labeled FimHFL,
the required expression in minimal media is hampered by the
cumbersome expression and purification procedure (23) as well
as the low yield.5 Therefore, the characterized mutants repre-
sent useful surrogates of full-length FimH as they can be readily
expressed with uniform 15N and 13C labeling in preparative
amounts (4 – 8 mg/liter) and benefit from their smaller size in
terms of spectral dispersion and relaxation properties.
Based on the global conformational changes in the mutants
of FimHLD, V67K, R60P, and V27C/L34C, we expected drastic
entropic consequences. Although all three mutants displayed
entropic penalties relative to WT FimHLD, large enthalpic pen-
alties were the major reason for the loss of affinity of R60P and
V27C/L34C. Obviously, an interpretation of the thermody-
namics of WT FimHLD and mutants thereof is highly specula-
tive in view of the many contributing factors. Thus, the intro-
duction of mutations may lead to local thermodynamic strain
within the protein and to unexpected entropic effects of coor-
dinated water molecules as a result of altered hydrophobic
regions. Consequently, the entropic penalty caused by the con-
formational changes may be partially compensated.
In summary, our data clearly demonstrate that by a single
mutation in the -bulge (R60P) or by a double-point mutation
introducing an additional disulfide bridge in the interdomain
region (V27C/L34C), the isolated FimHLD can be converted
from the high- into the low-affinity state and moreover can
retain the same intricate allosteric regulation as observed in the
full-length FimH. In particular, the kinetic profile of full-length
FimH as the hallmark of the catch bond behavior was almost
perfectly reproduced by the FimHLD mutant V27C/L34C (Fig.
9), thus clearly demonstrating the cross-talk between allosteric
sites within the lectin domain in the absence of the pilin
domain. Neither mutant was conformationally locked in the
low-affinity state, but instead a switch to the medium-affinity
state upon mannoside binding similar to the full-length protein
could be demonstrated. It remains to be seen whether a com-
bination of different point mutations would lead to a complete
lock of FimHLD in the low-affinity state, even in the presence of
a mannoside ligand.
The mutants characterized herein therefore represent an
easily accessible mimic of full-length FimH and may serve as
valuable tools for further mechanistic investigations of the
allosteric regulation. Ultimately, this knowledge will be
required for the design of effective anti-adhesive drugs and
antibody-based therapeutics for the treatment of UTI.
Experimental procedures
Cloning of FimHLD mutants
The FimHLD construct linked to a thrombin cleavage site
(Th) and a His6 tag on the C terminus was generated as
described (28). The mutants A10P, R60P, V67K, A119L, and
V27C/L34C were generated by the overlap extension PCR
method (58) using the WT-encoding plasmid as template. The
inserts were digested with HindIII and XbaI restriction
enzymes, gel-purified, and subsequently ligated into the corre-
sponding cloning site of pDsbA3 expression vector (59). The
vectors were then transformed separately into E. coli DH5
chemo-competent cells (Novagen, Lucerne, Switzerland). After
plasmid isolation and restriction control, the correctness of the
constructs was confirmed by DNA sequencing (Microsynth,
Balgach, Switzerland). Finally, the vectors were transformed
into the protease-deficient E. coli strain HM125 (60) for protein
expression and export into the periplasmic space.
Protein expression and purification
Bacterial clones were grown at 30 °C with vigorous shaking
(300 rpm) in M9 minimal medium (61) supplemented with 2
mM MgSO4, 0.1 mM CaCl2, 20% glucose, 10 M of each amino
acid, basal medium Eagle vitamin mix (Sigma, Buchs, Switzer-
land), and 100 g/ml ampicillin. When an A600 of 0.8 was
reached, the cells were induced with 1 mM isopropyl 1-thio--
D-galactopyranoside (Applichem, Germany) and further culti-
vated for 16 h at 30 °C and 300 rpm. Then the cells were cooled
on ice for 5 min and harvested by centrifugation at 5000 rpm for
20 min at 4 °C. The pellet was suspended in a cold solution of 50
mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, 1 mg/ml
polymyxin B sulfate (lysis buffer) and stirred for 2 h at 4 °C.
After centrifugation at 11,000 rpm for 20 min at 4 °C, the super-
natant (periplasmic extract) was dialyzed overnight against 50
mM NaH2PO4, 300 mM NaCl, and 10 mM imidazole, pH 8 (bind-
ing buffer), and applied to a nickel-nitrilotriacetic acid column
(Sigma, Buchs, Switzerland) attached to a BioLogic fast protein
liquid chromatography system (Bio-Rad, Reinach BL, Switzer-
land). The column was washed with binding buffer and after-
ward eluted with 50 mM NaH2PO4, 300 mM NaCl, and 250 mM
imidazole, pH 8 (elution buffer). The fractions containing
FimHLD-Th-His6 were pooled and dialyzed against 20 mM
HEPES buffer, pH 7.4, with 150 mM NaCl and 1 mM CaCl2
(assay buffer). The purity of the protein was verified by SDS-
PAGE analysis, and the monomeric state was confirmed by
native PAGE. The amount (4 –10 mg/liter of each of the five
mutants) was determined by direct absorption at 280 nm on an
ND-1000 nanodrop spectrophotometer (Thermo Fisher Scien-
tific). Aliquots of the proteins could be stored for up to 3
months at 4 °C. For long-term storage, the proteins were frozen
at 80 °C without additives. For protein crystallization, Fim-
HLD constructs (amino acids 1–158), lacking the His6 tag, were
5 S. Rabbani, B. Fiege, D. Eris, M. Silbermann, R. P. Jakob, G. Navarra, T. Maier,
and B. Ernst, unpublished data.
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generated following the same procedure described above and
purified by ion-exchange chromatography (29). FimHFL was
expressed and purified as described (23).
Differential scanning fluorimetry
Differential scanning fluorimetry was performed using a
Rotor-Gene Q 6plex quantitative PCR instrument according to
the procedure described previously (42). SYPRO Orange dye
was diluted 1:50 in the final samples and was used to monitor
the protein-denaturing profiles. The assay was performed in
assay buffer with 5 M protein and n-heptyl--D-mannopyra-
noside (1) (45, 62) at a final concentration of 5 mM.
Circular dichroism analysis
CD spectra of WT FimHLD and mutants were recorded in the
absence and presence of 1 mM mannoside 1 (63, 64). Far-UV
(180 –260 nm) and near-UV CD spectra (250 –350 nm) were
recorded with a Chirascan CD spectrometer (Applied Photo-
physics, Leatherhead, UK). For far-UV analysis, the proteins
were diluted to a concentration of 5 M in 10 mM sodium
phosphate buffer at pH 7.4 and measured at 20 °C using a
thermostat-controlled cell with 0.1-cm path length. The CD
spectra were recorded between 190 and 250 nm with 2 nm
bandwidth and 10 scans per sample. For near-UV analysis, all
samples were measured at a protein concentration of 1
mg/ml using a thermostat-controlled cell with a path length
of 1 cm and between 260 and 320 nm. Mannoside 1 was
added to a final concentration of 1 mM for both near- and
far-UV CD analysis. CD spectra were corrected by buffer
subtraction, and the CD signal was converted to molar ellip-
ticity ([]/degree cm2 dmol1).
FP assay
The fluorescence polarization assay was performed as
described previously (32). Briefly, a serial dilution of each
FimHLD mutant and WT (0.1 nM to 2.6 M) was mixed with a
constant concentration of 1 (5 nM with WT and mutants V67K
and A119L; 10 nM with mutants V27C/L34C and R60P) in a
final reaction volume of 100 l in 20 mM HEPES, pH 7.4, with
150 mM NaCl, and 50 g/ml BSA. The mixture was incubated at
room temperature in black, flat bottom, non-binding surface
96-well microtiter plates (Corning) for at least 24 h. Binding of
the tracer ligand 4 (3	-chloro-N-(2-(3-(3	,6	-dihydroxy-3-oxo-
3H-spiro-[isobenzofuran-1,9	-xanthen]-5-yl)-thioureido)-
ethyl)-4	-(-D-mannopyranosyloxy)-biphenyl-4-carboxam-
ide), synthesized as described previously (32) to each FimHLD
mutant was monitored via an increase in FP using a Synergy H1
hybrid microplate reader (BioTek). Samples were excited with
polarized light at 485 nm and emission was measured at 528
nm. FP data were fitted to a single-site binding model account-
ing for ligand depletion (65) to determine the KD value of 4 for
each FimHLD variant. The KD value for 1 was determined com-
petitively via the displacement of 4 by 1 and the associated
decrease in FP. For these competition assays, a serial dilution of
competitor 1 (7.6 nM to 500.0 M) was titrated into constant
concentrations of FimHLD and 4 (10 nM). The concentration of
each mutant was fixed such that it would be above KD and the
competitor concentration at 50% signal change would be in the
same approximate range for all mutants. Specifically, it was
fixed at 200 nM for V27C/L34C, 100 nM for R60P and V67K, and
50 nM for A119L and WT. FP was measured as described above,
and data were fitted to an equilibrium competition binding
function (66). Data fitting and analysis were performed using
Prism (GraphPad Software).
Isothermal titration calorimetry (ITC)
Prior to analysis, the proteins were dialyzed against 20 mM
HEPES buffer, pH 7.4, with 150 mM NaCl. ITC experiments
were performed at 15, 25, 31, and 37 °C using a VP-ITC micro-
calorimeter (Malvern Instruments, UK). Volumes ranging from
6 to 8 l of 150 M compound 1 were injected at 600-s intervals
into a reaction cell containing 1.45 ml of 10 –15 M FimHLD
WT or mutant. Baseline correction and peak integration were
completed using Origin (OriginLab). The resulting binding iso-
therm was imported into SEDPHAT (National Institutes of
Health) (69) for baseline subtraction and data fitting. The initial
2-l injection was not included for data analysis. Data were fit
to a single-site binding model to derive KD and H (change in
binding enthalpy) values from the binding isotherm. S0obs
(change in entropy) was calculated from the known thermody-
namic quantities and further dissected into conformational,
mixing, and solvation entropy according to the methodology as
described in Ref. 70. A concentration correction factor was
included as fitting parameter to account for the uncertainty
in determining FimHLD concentration. Statistical analysis to
determine best-fit values and 95% confidence intervals was per-
formed with SEDPHAT (69).
SPR
Kinetic data were obtained by SPR-based measurements
using a Biacore T200 system (GE Healthcare, Uppsala, Swe-
den). Compound 5 (see supporting information for synthesis
and structure) was immobilized on a carboxy-dextran-coated
CM4 sensor chip (GE Healthcare) in a two-step process. In the
first step, 1,2-diamino-ethane (0.1 M in borate buffer, pH 8.5)
was covalently coupled to the chip matrix through NHS-ester
chemistry using the amine coupling kit (GE Healthcare). The
carboxy-functionalized compound 5 was activated by NHS/
EDC. After raising the pH to 8.5 with 0.1 M borate buffer, the
derivatized ligand was injected into the system (0.5 mM for 30 s)
and reacted with the free amine groups of 1,2-diamino-ethane.
Ethanolamine at a 1 M concentration was used to block any
remaining activity on the surface. A reference cell was prepared
by immobilizing 8-hydroxyoctanoic acid using the amine
coupling kit (GE Healthcare) followed by blocking with 1 M
ethanolamine.
All SPR measurements were performed at 25 °C using
HBS-EP (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA,
0.005% surfactant P20, from GE Healthcare) as running buffer
at a flow rate of 30 l min1. Because of baseline drifts and
incomplete chemical regeneration (50 mM NaOH, 180 s), com-
plete dissociation of the protein (analyte) was achieved by suf-
ficiently long dissociation times. Because of the resulting long
measurement times for multicycle kinetic (MCK) assays, MCK
was only performed if the koff was above 103 s1. Otherwise,
the single cycle kinetics mode was used that includes a single
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dissociation phase to obtain kinetic information. Data pro-
cessing and kinetic evaluations were performed with the Bia-
core T200 control software and the Biacore T200 evaluation
software (both version 1.0), respectively. The Langmuir 1:1
model of interaction was used to determine kon, koff, and KD
values. For FimHFL, data were fitted using a two-state reaction
model. The bulk effect on the refractive index was set to zero
because of the reference cell subtraction.
NMR spectroscopy
All experiments were performed at 298 K on a Bruker Avance
III 600 MHz NMR spectrometer equipped with a 5-mm TXI
room temperature probe head. Samples contained 120 –240 M
15N-labeled WT FimHLD or mutant in 20 mM phosphate buffer,
pH 7.4, with 7% D2O. Mannosides 1, O-methyl--D-mannopy-
ranoside (2), and n-heptyl 4-deoxy-4-fluoro--D-mannopyra-
noside (3) (synthesized as described before (45, 62), see Fig. S10
for structures) were solved in D2O and added stepwise to the
protein up to a 10-fold molar excess. The mutant V27C/L34C
(150 M) was additionally measured in the presence of DTT (5
mM) in the absence or presence of compound 1 (2 mM). 1H,15N
HSQC experiments were acquired and processed with Topspin
3.2 (Bruker BioSpin, Switzerland) and analyzed with CcpNmr
Analysis (version 2.2) (67). The backbone assignment of
FimHLD was available from previous studies (25, 45). Partial
assignments of mutant proteins were done on the basis of
chemical shift proximity. Where applicable, combined chemi-
cal shift differences, AV, between the signals of WT and
mutant were calculated (68) as shown in Equation 7,
AV  (1HN)2  (0.215N)2 (Eq. 7)
As all tested compounds bound to all FimHLD variants in
the slow to intermediate–slow exchange regime on the NMR
time scale, partial assignments of the bound states could not
be easily transferred to the free states. For residues that can-
not be assigned unambiguously in the spectra of the mutants, a
lower limit of the AVG value was determined that corre-
sponds to the chemical shift difference between the WT peak
and the nearest unassigned peak in the mutant spectrum
(chemical shift maps in Fig. 7).
Protein crystallization and structure determination
FimHLD R60P crystals were grown (10 mg/ml in 20 mM
HEPES, pH 7.4) in 1.5 M (NH4)2SO4, 0.1 M BisTris, pH 6.5, at
20 °C. Crystals were cryopreserved by a quick soak in 2.5 M
Li2SO4 (71) and flash-cooled in liquid nitrogen. Data were col-
lected with synchrotron radiation at the X06DA beamline at the
Swiss Light Source (Paul Scherrer Institut, Switzerland).
Data were indexed, integrated, and scaled with the XDS
package (72). The structure was solved by molecular replace-
ment with PHASER (73) using the FimHLD– biphenyl -D-
mannopyranoside complex (PDB code 4X50) as a search
model (45). The structure was iteratively built using the
COOT software (74), refined with the PHENIX software
(75), and validated using MolProbity (76). The structure has
been deposited in the Protein Data Bank under the accession
code 5MCA.
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Target-directed Dynamic Combinatorial Chemistry: A Study on
Potentials and Pitfalls as Exemplified on a Bacterial Target
Priska Frei, Lijuan Pang, Marleen Silbermann, Deniz Eriş, Tobias Mehlethaler,
Oliver Schwardt, and Beat Ernst*[a]
Abstract: Target-directed dynamic combinatorial chemistry
(DCC) is an emerging technique for the efficient identifica-
tion of inhibitors of pharmacologically relevant targets. In
this contribution, we present an application for a bacterial
target, the lectin FimH, a crucial virulence factor of uropa-
thogenic E. coli being the main cause of urinary tract infec-
tions. A small dynamic library of acylhydrazones was formed
from aldehydes and hydrazides and equilibrated at neutral
pH in presence of aniline as nucleophilic catalyst. The major
success factors turned out to be an accordingly adjusted
ratio of scaffolds and fragments, an adequate sample prepa-
ration prior to HPLC analysis, and the data processing. Only
then did the ranking of the dynamic library constituents cor-
relate well with affinity data. Furthermore, as a support of
DCC applications especially to larger libraries, a new proto-
col for improved hit identification was established.
Introduction
Dynamic combinatorial chemistry (DCC) is a method for gener-
ating compound libraries by reversible reactions of scaffolds
and fragments. These libraries are under thermodynamic con-
trol and their composition is a result of the thermodynamic
stability of each member. Because of the continuous intercon-
version of their constituents, dynamic libraries are adaptive
and external stimuli or templates can influence their composi-
tion.[1] Target-directed DCC was first performed two decades
ago[2] and has since emerged as a valuable method for in situ
synthesis and affinity ranking of ligands for a wide range of
protein targets.[3] When the target protein binds and thus sta-
bilizes selected members of a dynamic library, a shift of its
composition occurs, that is, the target acts as a template that
biases the library composition, leading to the amplification of
ligands with high affinity at the expense of weaker ones
(Figure 1).
Major drawbacks of target-directed DCC are the limited
number of suitable reactions necessary for the assembly of dy-
namic libraries and the large consumption of the target pro-
tein. To establish the equilibrium in the presence and absence
of the target protein, the reaction of the scaffold with the frag-
ments should be reversible. On the other hand, for analytical
purposes, this equilibrium must be frozen. Furthermore, to
guarantee the stability of the target protein, near-physiological
reaction conditions should be applied. Because high protein
concentrations are generally necessary for target-directed DCC,
protein supply might be a significant issue.[3c]
Finally, an additional, but barely addressed challenge is the
analysis of the library composition. So far, besides NMR,[4] MS,[5]
and X-ray crystallography,[2a] analysis by high-performance
liquid chromatography (HPLC) has been predominantly ap-
plied.[2b, c, 5e, h, 6] In an ideal setup, HPLC delivers a separate signal
for each member of a library and therefore also information re-
garding its concentration. Generally, a comparison of HPLC
traces of the same library equilibrated in the absence and pres-
ence of the target protein allows the identification of binders.
Before HPLC analysis, bound ligands have to be released from
the target protein, which then has to be removed to avoid af-
fecting the result of the analysis.[1a] Standard techniques for
protein removal include microfiltration, microdialysis, denatura-
tion and aggregation with organic solvents, acids, bases, heat,
Figure 1. Schematic representation of target-directed DCC approach, indicat-
ing the different composition of a library at equilibrium in the absence and
presence of a target protein.
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or chaotropic agents.[7] However, these manipulations can po-
tentially alter the library composition, an effect that should be
clarified in advance. Whereas some authors thoroughly de-
scribe sample preparation prior to HPLC analysis,[6c, k] in most
reports detailed information is missing.
As target protein for our investigation, we used the bacterial
adhesin FimH, which plays an important role in urinary tract in-
fections, predominantly caused by uropathogenic Escherichia
coli (UPEC).[8] The interaction of FimH, located at the distal tip
of UPEC’s type 1 pili, with the highly mannosylated glycopro-
tein uroplakin 1a on urothelial cells of the host is the first step
of the infection.[9] Blocking FimH with aryl mannosides is a
promising strategy to prevent the initial bacterial adhesion
and therefore colonization of the bladder.[10] Since such FimH
antagonists are not bactericidal and therefore do not exert any
selection pressure, the probability of developing antimicrobial
resistance is expected to be reduced.[11]
To explore possible solutions to the above mentioned chal-
lenges, we decided to use only small dynamic libraries for our
proof-of-concept study, consisting of acylhydrazones formed
from aldehyde scaffolds 1 and 2 and the commercial hydra-
zides 3 a–d (Scheme 1).[6h, i, 12] Under acidic conditions, the equi-
librium is rapidly established. However, when physiological
conditions are applied, that is, neutral pH, the equilibrium is
only slowly established. Therefore, nucleophilic catalysis with
aniline was necessary, facilitating acylhydrazone formation with
aldehydes via an intermediate Schiff base.[6h, 12b] Finally, a pH in-
crease to basic conditions leads to the required irreversibility
and renders the library pseudostatic. To verify whether
changes in library composition provoked by FimH lead to a se-
lective amplification of those acylhydrazones exhibiting higher
affinities, the KD values of all library members were determined
by surface plasmon resonance (SPR). Furthermore, since the
equilibration could depend on deviating binding kinetics of
the acylhydrazones, half-lives t1=2 of the ligand–protein com-
plexes were derived from SPR data. Finally, the rates of the
chemical formation of acylhydrazones were examined to ex-
clude that differences in reaction kinetics might influence equi-
librium formation as well. Only when all members show com-
parable kinetic behavior, possible alterations by non-equilibri-
um states can be excluded.
Results and Discussion
Due to the mannose specificity of FimH[13] and previous studies
with O-aryl a-d-mannosides,[10g] the mannose scaffold 1 is ex-
pected to yield high-affinity FimH antagonists upon reaction
with the hydrazides 3 a–d (!4 a–d). In contrast, the acylhydra-
zones 5 a–d derived from the glucose scaffold 2 should exhibit
strongly diminished affinities and were therefore used as con-
trols. As target protein, the full-length FimH lectin (FimHFL)
[14]
was used. In each DCC experiment, the library was equilibrated
in the absence (blank library) and presence of the target pro-
tein (template library) and analyzed by UV-HPLC at 310 nm.
For sample preparation, that is, for the release of bound li-
gands and the removal of the target protein prior to HPLC
analysis, an adequate method is essential for a successful DCC
experiment. One possibility is microfiltration, a technique,
which was previously applied.[2b, 6c, g, h, k] However, in our case,
HPLC analysis after filtration with various commercially avail-
able filters revealed massive alterations in composition. Since
these could originate from the adherence of constituents of
the library to the filter material, addition of surfactant (Tween
20) as well as rinsing with EtOH were explored, but turned out
to have been in vain. Further efforts to remove the protein, in-
volving denaturation and precipitation by organic solvents
(MeOH, EtOH, and MeCN at 33.3 % v/v), urea (to a final concen-
tration of 8 m) and NaOH (pH 12) did not lead to the desired
separation of FimHFL. Further, addition of MeOH even resulted
in precipitation of non-protein constituents, most likely buffer
salts. Attempts using heat were discarded, as the acylhydra-
zones were not stable at elevated temperatures.
Finally, the problem could be solved by using biotinylated
full-length FimH (FimHFL-B), which consists of two domains, the
FimH lectin domain and the FimH pilin domain. In the assem-
bled pilus, the N-terminal donor strand of the adjacent FimG
subunit is essential for the stabilization of FimHFL. For the gen-
eration of stable FimHFL, this donor strand consisting of 15
amino acids has been used.[14] Incorporation of a donor strand
equipped with a C-terminally linked biotin yielded FimHFL–B.
After the dynamic library experiment, the biotinylated protein
was coupled to commercially available streptavidin–agarose
beads and removed by centrifugation.
Scheme 1. Aldehydes 1 and 2 were used as scaffolds and the hydrazides 3 a–d as fragments for the generation of acylhydrazone libraries. To support dissocia-
tion of library members from the target protein FimH, n-heptyl a-d-mannopyranoside (6)[13] was applied in the work-up procedure (see Figures 2 and 5).
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As depicted in Figure 2, in the first step of the optimized
work-up protocol, the pH was raised to 8.5 to freeze the acyl-
hydrazone composition (see Supporting Information). Then,
most of the bound ligand was displaced from the target pro-
tein by adding a large excess of n-heptyl a-d-mannoside (6 ;
Scheme 1), a known ligand of FimH.[13] Next, the protein was
captured by addition of streptavidin–agarose. A further pH-in-
crease to 12 guaranteed the complete displacement of bound
library members from the target protein. Both acylhydrazones
as well as the streptavidin–biotin binding were stable under
these harsh basic conditions. Finally, FimHFL–B coupled to strep-
tavidin–agarose beads could be removed quantitatively by
centrifugation and the supernatant was subjected to UV-HPLC
analysis. Absorption was measured at 310 nm, because at this
wavelength acylhydrazones strongly absorb whereas unreact-
ed scaffolds and fragments, aniline, and 6 do not. Blank and
template libraries were treated equally to avoid any influence
of the sample preparation falsifying the library composition.
Mannose library
The efficiency of our workup protocol was tested with a library
of four acylhydrazones generated from mannoside 1 and the
hydrazides 3 a–d (!4 a–d). Equimolar amounts (200 mm) of
mannoside 1 and each fragment were equilibrated in the ab-
sence and presence of 100 mm FimHFL–B for three days. With
longer equilibration times, no further change of the composi-
tion could be detected. After sample preparation as depicted
in Figure 2, the analysis was performed by UV-HPLC. For peak
assignment, scaffold 1 was reacted with each fragment individ-
ually in the presence of aniline, and the HPLC retention times
of the formed acylhydrazones were determined as reference
values (see Supporting Information). Because all acylhydra-
zones exhibit similar extinction coefficients (see Supporting In-
formation), the library composition could be assessed with the
relative peak area (RPA), that is, the sum of all peak areas was
set to 100 % and each peak was assigned its percentage (Fig-
ure 3 A). For quantifying the influence of FimHFL-B, the normal-
ized change of RPA was used [Eq. (1) ; Figure 3 B].
Normalized change of RPA ¼ RPAtemplate @ RPAblank
RPAblank
ð1Þ
A positive bar indicates amplification of an acylhydrazone in
the template sample, whereas a negative bar indicates deple-
tion. Next, the normalized changes of RPA of 4 a–d were com-
pared to their KD values determined with SPR (Table 1). Addi-
tionally, the affinity of scaffold 1 was determined to ensure
that reaction with 3 a–d yields antagonists with higher affinity,
so that potentially unreacted 1 does not interfere with target-
binding of 4 a–d. For these SPR measurements, FimHFL–B was
immobilized on a streptavidin coated sensor chip (for details
see Supporting Information).
Figure 2. Experimental protocol for target-directed DCC using FimHFL–B and
streptavidin-agarose. For increasing the pH, 1 m aqueous NaOH was added. Figure 3. Result of the DCC-library with mannoside 1 (200 mm), hydrazides
3 a–d (each at 200 mm), and aniline (10 mm). A) Mean relative peak area
(RPA) of each acylhydrazone of the library in the absence (blank) and pres-
ence (template) of FimHFL–B (100 mm). Error bars indicate standard deviation
(SD) over three experiments. B) Normalized change of RPA, see Equation (1).
Error bars indicate Gaussian error propagation (see Supporting Information).
Table 1. Dissociation constants KD and complex half-lives t1=2 by SPR.
Compound KD [mm] t1=2 [s]
1 3.16 46.3
4 a 0.52 2.57
4 b 0.55 2.04
4 c 0.33 3.51
4 d 0.76 1.98
2 194 5.26
5 a 491[a] 0.01
5 b 735[a] 0.01
5 c 405[a] 0.16
5 d 152[a] 0.40
6 7.20 0.22
[a] KD values are approximations, as the dissociations of 5 a–d were too
fast to be accurately detected by SPR.
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In the template library, the acylhydrazone 4 c with the high-
est affinity for the target (KD of 0.33 mm) experienced the high-
est amplification, whereas the worst binder 4 d (KD of 0.76 mm)
was depleted. The concentrations of the acylhydrazones 4 a
and 4 b with intermediate KD values (0.52 and 0.55 mm, respec-
tively) were neither amplified nor reduced in the presence of
the target protein. To exclude that different kinetic behavior of
the library members has an impact on the equilibration rate
(for association (kon) and dissociation rate constants (koff) see
Supporting Information), the half-lives (t1=2 = ln2/koff) of the
complexes formed by the antagonists and FimHFL–B were calcu-
lated (Table 1). Since 4 a--d show comparable half-lives, that is,
between 1.98 and 3.51 s, an influence on the equilibrium for-
mation can be excluded. Furthermore, 1 showed a 3- to 10-
fold lower affinity than 4 a–d (Table 1). Thus, a considerable
competition for the target’s binding site by unreacted scaffold
1 can be ruled out. Theoretically, the Schiff base formed from
1 with aniline might also possess affinity for the target. Howev-
er, since this intermediate is short-lived,[12b] an influence can be
neglected. Additionally, when the aniline-catalyzed formation
of the various acylhydrazones 4 a–d was monitored by UV-
HPLC, similar chemical reaction rates were obtained (see Sup-
porting Information).
Glucose library
A key question to be addressed is how the target protein af-
fects the equilibrium concentrations of acylhydrazones with
much lower FimH-affinities. Thus, a library formed from gluco-
side 2 and the hydrazides 3 a–d (!5 a–d) was examined. Due
to the mannose-specific binding of FimH, these acylhydrazones
show a much lower affinity for the target (Table 1). Their KD
values are approximations, since the dissociations of 5 a–d are
too fast to be accurately detected by SPR, as displayed by the
short t1=2. Overall, the observed much smaller differences be-
tween the blank and template library reflect the smaller com-
petition among the acylhydrazones (Figure 4 A).
Mixed libraries
When a combined library from equimolar amounts of the scaf-
folds 1 and 2 and the fragments 3 a-d (each at 200 mm) was
generated, the analysis of the template library exhibited
changes of the mannose containing components 4 a–d similar
to the previous experiment. However, the glucose containing
members of the library 5 a–d were, contradictory to their low
affinities, not decreased but hardly affected (Figure 4 B). This
can be explained by the excess of the hydrazide fragments
3 a–d that renders a real competition between aldehyde 1 and
2 impossible. Although aldehyde 1 yields better binders (!
4 a–d), hydrazides 3 a–d are still available to react with alde-
hyde 2, leaving the concentrations of the glucosides 5 a–d un-
affected. Consequently, depletion of a glucoside can only
occur when one of its fragments is incorporated into a better
binder. Following the same argumentation, 4 d was reduced
because scaffold 1 was consumed by hydrazide 3 c to form the
better inhibitor 4 c. It is important to note that depletion of a
compound might not coincide with weakness of affinity, but
could also be the result of a competition for the scaffolds.
To further evaluate this hypothesis, we adjusted the compo-
sition of the library components to allow a real competition by
keeping the concentrations of the aldehydes 1 and 2 at
200 mm and reducing the hydrazide concentrations to 50 mm.
After equilibration, the analysis revealed an amplification of
better binders 4 a–d, but a decrease of the low affinity gluco-
sides 5 a–d (Figure 4 C). The extent, to which the RPA of the
mannosides 4 a–d increased, correlates well with their KD
Figure 4. Results from libraries with different scaffold and fragment ratios;
A) 2 and 3 a–d at 200 mm ; B) 1, 2, and 3 a–d at 200 mm ; C) 1 and 2 at
200 mm, 3 a–d at 50 mm ; D) 1 and 2 at 200 mm, 3 a–d at 50 mm, 6 at 100 mm.
All samples contained aniline (10 mm) and were incubated in the presence
and absence of 100 mm FimHFL-B. Bars indicate normalized change of relative
peak area (RPA), see Equation (1), over three measurements. Error bars indi-
cate Gaussian error propagation (see Supporting Information).
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values (Table 1). This result clearly underlines that the ratio of
scaffolds and fragments largely influences the outcome of a
target-directed DCC experiment.
Finally, to clarify whether the composition of template libra-
ries is resulting from specific interactions of the acylhydrazones
with the binding site of FimHFL–B and is not biased by concur-
rent non-specific interactions, a control experiment was con-
ducted. For this purpose, a library composed of the scaffolds 1
and 2, each at 200 mm, the hydrazides 3 a–d at 50 mm, and a
large excess, that is, 100 mm, of the known FimH antagonist
6[13] (Table 1) was explored. When the heptyl mannoside (6)
blocked the binding site of FimHFL–B, its interaction with mem-
bers of the acylhydrazone library is prevented and therefore
the library composition remained unchanged (Figure 4 D), a
clear indication that the shift in composition of the template li-
brary is solely caused by the target’s binding site and not dis-
torted by non-specific interactions.
Capturing protocol
A target-directed DCC approach is only broadly applicable
when there is no need for detailed information regarding the
target’s binding site. However, for the protocols discussed
above, prior knowledge is required for adjusting scaffold and
fragment concentrations.
Therefore, a broader applicable protocol for larger and more
complex libraries was developed. Based on DCC approaches
employing immobilized targets[15] or building blocks[16] and
biotin-streptavidin supported separation techniques[17] a so-
called capturing protocol (Figure 5) was explored. The basis for
this approach is the fact that at pH 8.5 the acylhydrazone equi-
librium is effectively frozen (Figure 5 A), whereas the binding to
FimHFL–B is only slightly influenced (see Supporting Informa-
tion). Streptavidin–agarose beads added to the target library
interact with the FimHFL–B–ligand complex, allowing its separa-
tion from other library constituents by centrifugation (Fig-
ure 5 B). After removal of the supernatant containing unbound
ligand, the precipitate is suspended anew and the bound li-
gands are released by addition of n-heptyl mannoside (6). To
complete the ligand release, the pH is increased to 12. After a
second centrifugation step (Figure 5 C), the supernatant con-
taining previously bound ligand is analyzed. As before, blank
and template libraries were treated equally.
To validate the new protocol, a library consisting of the scaf-
folds 1 and 2 and the hydrazides 3 a–d (each at 200 mm) was
equilibrated. The analysis of the supernatant of the template li-
brary after ligand release, as compared to the blank library,
showed a clear depletion of glucosides 5 a–d whereas manno-
sides 4 a–d were altered according to their KD values (Fig-
ure 6 A). Compared to the protocol missing the capturing step
(Figure 4 B), the distinction between mannosides and gluco-
sides was vastly improved.
Additionally, a second library with reduced concentrations of
hydrazides (now each at 50 mm) was evaluated according to
the capturing protocol. Again, when comparing supernatants
after ligand release, the template sample showed an increase
of the mannosides 4 a–d, whereas the concentrations of the
glucosides 5 a–d were decreased (Figure 6 B).
A comparison of these two experiments reveals that the in-
crements in amplification of the mannosides 4 a–d were less
pronounced when restricting concentrations instead of an
excess of hydrazides were used (Figure 6 B and 6A, respective-
ly). In the former case, the restricted amount of hydrazides
limits the augmentation of the acylhydrazones’ concentration.
The best binder 4 c’s amplification is confined by 3 c, leaving
more aldehyde 1 to form 4 a, 4 b, and 4 d. In the latter case, in
Figure 5. Capturing protocol for a template library consisting of acylhydra-
zones 4 and 5 and FimHFL–B. A) Library after three days of equilibration and
pH increase to 8.5; B) addition of streptavidin–agarose beads and centrifuga-
tion; and C) after removal of the unbound fraction, addition of a large
excess of n-heptyl a-d-mannopyranoside (6), pH increase to 12 and centrifu-
gation, the acylhydrazones released to the supernatant are analyzed by UV-
HPLC.
Figure 6. Results of the capturing experiments ; Libraries were composed of
A) 1 and 2 at 200 mm and 3 a–d at 200 mm and B) 1 and 2 at 200 mm and
3 a–d at 50 mm, respectively. Equilibration was catalyzed by aniline (10 mm)
and carried out in presence and absence of FimHFL-B (100 mm). Bars indicate
normalized change of relative peak area (RPA) over three measurements, see
Equation (1). Error bars indicate Gaussian error propagation (see Supporting
Information).
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which 3 c is available in excess, a substantial increase of 4 c
and, consequently, decrease of the other mannosides is ob-
served, allowing a more distinct ranking. Given these points,
the rank order of mannosides is not merely the result of the in-
teraction with the target during the capturing step, but effec-
tuated by their amplification during library equilibration. There-
fore, the combination of a capturing step, where target-bound
ligands are separated from the unbound fraction, and target-
directed DCC synergistically leads to an improved hit identifica-
tion.
Conclusion
Employing target-directed DCC, antagonists of the bacterial
adhesin FimHFL could be identified and ranked according to
their affinities. In the presence and absence of the target pro-
tein, dynamic libraries of acylhydrazones from reversibly react-
ing aldehydes as scaffolds and hydrazides as fragments were
equilibrated and then analyzed by HPLC. Using the relative
peak area (RPA), the composition of blank and template libra-
ries could easily be compared and by calculating the normal-
ized change of RPA, the influence of the target assessed.
It was particularly interesting that sample preparation before
HPLC analysis turned out to be a crucial prerequisite for suc-
cess, especially since the majority of DCC applications has not
explicitly focused on this issue so far. The removal of the
target protein by microfiltration and various denaturation
methods failed because the composition of the library was al-
tered or FimHFL could not be separated from the sample.
Therefore, FimHFL equipped with a biotin tag (FimHFL–B) was
used, enabling the removal of the target protein with strepta-
vidin-agarose beads without affecting the library composition.
This protocol turned out to be highly sensitive. When applied
to a mannose library, the ranking of members with KD values
differing by less than a factor of 2 could be achieved.
Because the glucosides 5 a–d exhibit much lower affinities
than their mannose counterparts 4 a–d, FimHFL–B had a much
smaller impact on their library composition. Furthermore, with
a mixed library containing both the high-affinity mannosides
and the low-affinity glucosides, amplification and decrease of
individual members was heavily depending on the concentra-
tion ratio of scaffolds and fragments. Amplification of the
better binders, that is, the mannosides 4 a–d at the expense of
the worse binders, that is, the glucosides 5 a–d was only ob-
served, when the carbohydrate scaffolds vied for limited
amount of fragments. Lacking this competition, the manno-
sides were still ranked according to their affinity, but gluco-
sides stayed unaffected by the target.
However, since this approach requires knowledge of the pre-
ferred binding motif, a broader applicable capturing protocol
was developed. There, non-bound ligands are removed in a
first step, followed by release and analysis of the library mem-
bers bound to the target. This protocol allows a considerably
improved distinction between tight and weak binders.
As previously noted,[1a] the establishment of suitable analyti-
cal protocols should be considered a major challenge of
target-directed DCC, especially with increasing library sizes and
complexities. The herein presented approach is a contribution
to this challenge and a support for the design of future DCC
experiments. Obviously, hits identified by a DCC approach
need to be further optimized according to their physicochemi-
cal, pharmacokinetic as well as pharmacodynamics properties.
Experimental Section
Synthesis
A detailed description can be found in the Supporting Information.
Materials
UV-HPLC measurements were performed on an Agilent 1100/1200
system (Agilent). The synthetic non-biotinylated FimG donor strand
(DsG, sequence ADVTITVNGKVVAKR) and biotinylated version
(DsGbiotin) were purchased from JPT and had a>95 % purity. To
obtain DsGbiotin, the original peptide sequence of DsG[14, 18] was
amended on the C-term by a Ttds (trioxatridecan-succinamic acid)
linker and a biotinylated lysine. Affinity values and binding con-
stants were determined via SPR using a Biacore T200 system (GE
Healthcare).
Protein production and purification
FimHFL and FimHFL–B were purified essentially as described previ-
ously.[14] Briefly, FimH and FimC were co-expressed in E. coli
HM125[19] harboring the corresponding co-expression plasmid.
Cells were grown at 30 8C in LB medium containing ampicillin
(100 mg mL@1). When OD600 reached 1.5, co-expression of FimH and
FimC was induced by addition of isopropyl-ß-d-thiogalactoside
(IPTG) to a final concentration of 1 mm. Cells were grown for 12 to
16 h after induction and harvested by centrifugation before resus-
pension in 50 mm Tris (tris(hydroxymethyl)aminomethane; pH 7.5),
150 mm NaCl, 5 mm EDTA (ethylenediaminetetraacetic acid) and
1 mg mL@1 polymyxin B sulfate (13 mL per liter of culture medium).
The suspension was stirred for 1.5 h at 4 8C and centrifuged to col-
lect the supernatant (periplasmic extract). All subsequent purifica-
tion steps were performed at 4 8C. The periplasmic extract was dia-
lyzed against 20 mm Tris (pH 8.0) and loaded onto an Uno Q (Bio-
Rad) column equilibrated with the same buffer. The flow-through
containing FimH·FimC complex was collected, dialyzed against
10 mm MOPS (3-(N-morpholino)propanesulfonic acid; pH 7.0) and
loaded onto a Mono S column (GE Healthcare), which was equili-
brated with the same buffer. FimH·FimC was eluted with a linear
gradient from 0 to 300 mm NaCl. Fractions containing the complex
were pooled and dialyzed against a buffer containing 20 mm
NaH2PO4 (pH 7.4) and 50 mm NaCl. FimH·FimC complex was con-
centrated to 40 mm and incubated (48 h at 37 8C) with a 3-fold
molar excess of the DsG for FimHFL and DsG
biotin for FimHFL–B, re-
spectively. The resulting reaction mixture contained FimHFL
(FimH·DsG) or FimHFL–B (FimH·DsG
biotin), isolated FimC displaced
from the FimH·FimC complex by DsG or DsGbiotin, potentially un-
reacted FimH·FimC complex, and excess DsG or DsGbiotin. This mix-
ture was dialyzed against 20 mm acetic acid (pH 4.5) and loaded
onto a Mono S column equilibrated with the same buffer. Full-
length FimH was eluted with a linear gradient from 0 to 400 mm
NaCl. Fractions containing either FimHFL or FimHFL–B were pooled,
dialyzed against 50 mm NaH2PO4 (pH 7.0), analyzed by SDS–PAGE
(sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and
ESI-mass spectrometry (calculated mass for FimHFL : 30 635.3 Da,
measured mass: 30 635.0 Da; calculated mass for FimHFL–B :
Chem. Eur. J. 2017, 23, 11570 – 11577 www.chemeurj.org T 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim11575
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31 291.2 Da, measured mass: 31 291.0 Da, Functional Genomic
Center Zerich) and stored at @80 8C. The yields of purified FimHFL
and FimHFL–B were between 1–2 mg per liter culture medium.
DCC experiments
In a typical experiment, stock solutions of aldehydes and hydra-
zides in DMSO (dimethylsulfoxide) were combined appropriately.
From this combined stock, aliquots where taken and mixed with
buffer (50 mm NaH2PO4, pH 7.0) for the blank libraries or FimHFL-B
stock and buffer for the template libraries. Acylhydrazone forma-
tion was catalyzed by the addition of aniline (1 m stock in DMSO)
to a final concentration of 10 mm. The final volume of each sample
was set to 30 mL and the maximal DMSO concentration below
10 %. The libraries were equilibrated on a shaker (400 rpm, 25 8C)
for three days. Then, 0.6 mL of aq. NaOH (!pH 8.5) and 3 mL of 2 m
aq. 6 were added and the mixture incubated for 30 min at RT. Af-
terwards, 50 mL of High Capacity streptavidin–agarose slurry
(Thermo Scientific) were added. The mixture was incubated for
25 min at RT. Then, the pH was increased to 12 by addition of
2.4 mL aq. NaOH and the mixture incubated for 5 min before centri-
fugation (10 min, 4000 g, 25 8C). The supernatant was subjected to
UV-HPLC analysis: Column: Waters Altlantis T3, 3 mm, 2.1 V 150 mm
(Waters Corporation), A: H2O + 0.01 % TFA (trifluoroacetic acid); B:
MeCN + 0.01 % TFA. Detection: UV absorption at 310 nm. Gradient:
5 % B!20 % B (30 min)!60 % B (54 min), flow rate: 0.3 mL min@1,
injection volume: 20 mL.
In the capturing protocol, the pH was increased to 8.5, 50 mL strep-
tavidin–agarose slurry were added, and the mixture incubated for
25 min. After centrifugation, 50 mL of supernatant containing un-
bound ligand were removed. The sedimented streptavidin beads
were suspended in 50 mL buffer (pH 8.5), and 3 mL of 2 m aq. 6
were added. After 30 min incubation, the pH was increased to 12,
the mixture centrifuged, and the second supernatant analyzed
analogously.
Surface plasmon resonance
FimHFL–B (100 nm) was pulse-wise delivered to the surface of a
streptavidin sensor chip (SA) by an immobilization wizard (aimed
immobilization level: 2.000 RU; flow rate: 5 mL min@1). A reference
surface with biotin-poly(ethylenglycol)amine (100 nm) was pre-
pared (time: 60 s; flow rate: 10 mL min@1) in order to remove un-
specific binding events of the compounds with the streptavidin
surface. Multi-cycle kinetics with two-fold increasing compound
concentrations (see Supporting Information) were performed at
25 8C using HBS-EP (0.01 m HEPES (4-(2-hydroxyethyl)-1-piperazi-
neethanesulfonic acid) pH 7.4, 0.15 m NaCl, 3 mm EDTA (ethylene-
diaminetetraacetic acid), 0.005 % surfactant P20, from GE Health-
care) as running buffer. Compounds were dissolved in running
buffer and injected over the flow cells for 180 s at a flow rate of
30 mL min@1. Thereafter, a dissociation phase followed, in which
buffer flowed over the chip surface for 800 s with the same flow
rate. Due to fast dissociation rates, chemical regeneration of the
senor chip surface was not required. The Biacore T200 Control Soft-
ware and the Biacore T200 Evaluation Software (both Version 3.0)
were applied for data processing and kinetic evaluation. A 1:1
binding model was applied using double referenced sensorgrams
with RI (bulk refraction index) set to 0.
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Abstract 
Target-directed dynamic combinatorial chemistry (tdDCC) is a powerful method to screen ligands for 
pharmacologically relevant targets. Generating a dynamic library from reversibly reacting building blocks in 
the presence of a target protein leads to the amplification of the most potent library constituents. In previous 
studies on tdDCC, these compounds were identified in a qualitative “hit/no-hit”-manner. However, the precise 
relationship between the degree of amplification and the affinity of the library constituent has not yet been 
evaluated. To study the amplification–affinity relationship, we compared tdDCC experiments, employing 
reversible acylhydrazone formation and the bacterial adhesin FimH as a target, with affinities of the library 
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Introduction 
 
Dynamic combinatorial chemistry (DCC) describes the generation of dynamic compound libraries from 
reversibly reacting building blocks. These libraries, which are under thermodynamic control, remain adaptive 
by continuous interconversion of building blocks and products. Therefore, addition of a protein target alters 
their equilibrium composition by binding, thereby stabilizing, and ultimately amplifying specific library 
constituents. Target-directed DCC (tdDCC) exhibits a self-screening ability, leading to the amplification of those 
members of the library with the highest affinity for the protein target, as depicted for an acylhydrazone library 




Figure 1. Schematic illustration of tdDCC. Reversibly reacting hydrazide and aldehyde building blocks generate 
a dynamic acylhydrazone library, which, when challenged with the target FimH, responds with a shift in 
its equilibrium composition including amplification of selected high-affinity ligands. 
 
Whereas earlier reports focused on small libraries in a qualitative “hit/no-hit”-manner,3-6 a more precise 
affinity ranking is required to increase the value of tdDCC. So far, the relationship between the extent of 
amplification and affinity was addressed in detail only by Nasr et al.7 Furthermore, it has been noted that if 
several library constituents exhibit high affinity, the identification of the best binders might be difficult.8 
Finally, theoretical considerations regarding the relationship between host-ligand interactions and extent of 
amplification have been reported.9 
In this communication, we have examined in greater detail the relationship between the amplification of 
library members in tdDCC experiments and their dissociation constants (KD). As target protein we selected the 
bacterial adhesin FimH, located at the distal tip of type 1 pili of uropathogenic E. coli (UPEC) strains, which are 
the cause of the majority of urinary tract infections (UTI).10-12 In the initial step of infection, FimH binds to the 
highly mannosylated surface protein uroplakin 1a on urothelial host cells,13 a process which can be prevented 
with FimH antagonists such as aryl mannosides.14-20 
We have reported previously that in addition to ligand affinity, also the ratio of scaffold to fragment 
building blocks, sample preparation, analysis, and method of data processing can be crucial factors in dictating 
experiment success.21 Here, we extend the reported protocol for tdDCC using the bacterial adhesin FimH as 
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target protein to a larger scale. When aldehyde scaffold 121 reacts reversibly with hydrazide fragments 
2a-u (→ 3a-u; Scheme 1), the acylhydrazone library 3a-u is obtained. At neutral pH in aqueous media, 






















































































Scheme 1.  Aldehyde scaffold 1 and hydrazide fragments 2a-u used for the reversible generation of 
acylhydrazones 3a-u at neutral pH with aniline promotion. 
 
Equilibration was carried out in the absence (blank library) or presence (template library) of biotinylated 
full-length FimH (FimHFL-B)23 for three days.21 The reversibility of the acylhydrazone exchange reaction was 
then blocked by an adjustment in pH, which effectively locks in the library composition and renders the library 
suitable for analysis.24 Prior to UV-HPLC analysis, the protein–ligand complex was captured using commercially 
available streptavidin agarose, and any unbound ligand removed from the sample (Figure 2A and 2B). The 
protein-bound ligand was then released by a further increase in pH together with addition of the FimH 
antagonist n-heptyl α-D-mannopyranoside25 (4, Figure 2C). The supernatant was then analyzed with HPLC and 
the chromatograms of template libraries compared to those of equally treated blank samples. 
On account of toxicological and stability concerns over the acylhydrazone moiety, we subsequently 
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Figure 2.  Schematic representation of the experimental tdDCC set-up.21  
 
A. After sufficient equilibration, the library composition is made static through a pH increase (pH 8.5), and 
then the biotinylated target protein – including bound ligands – is captured with commercially available 
streptavidin agarose.  
B. After centrifugation, the supernatant (containing unbound ligands) is discarded and the agarose-
protein-ligand complex resuspended.  
C. Bound ligands are released from the captured FimH into bulk solvent by the addition of excess of 
n-heptyl α-D-mannopyranoside (4) 25 and a further pH increase (pH 12). After a final centrifugation step, 
the supernatant is removed and analyzed by HPLC. 
 
 
Results and Discussion 
 
Target-directed dynamic combinatorial chemistry (tdDCC) 
Because the outcomes of tdDCC experiments are influenced not only by the ratio of scaffolds to fragments,21 
but also by the ratio of library constituents to target protein,26 we studied this issue in more detail by 
employing different amounts of building blocks, while keeping the protein concentration constant. Dynamic 
libraries were generated with varying concentrations of aldehyde scaffold 1 (600 µM, 400 µM, and 200 µM) 
together with hydrazide fragments 2a-u each at 100 µM. All libraries were equilibrated in the presence and 
absence of 100 µM FimHFL-B (measured in triplicates). In this experimental design, the amount of scaffold 1 is 
determining the maximum attainable acylhydrazone concentration. Assuming full conversion of the aldehyde, 
facilitated by the addition of excess hydrazides, concentration ratios of 6:1, 4:1, and 2:1 between 
acylhydrazones and target protein should be reached. With a 1:1 ratio, accurate detection was not possible 
due to an insufficient amount of acylhydrazones, while unsatisfactory solubility became an issue at higher 
protein concentrations. The libraries were analyzed by UV-HPLC, detecting optical density at 310 nm. 
Conveniently, only acylhydrazones absorb UV light at this particular wavelength, but not other library 
constituents such as aniline, unreacted hydrazides, or n-heptyl α-D-mannopyranoside (4). Peaks in the 
resulting chromatograms were assigned using reference samples. Because both 3f and 3g, as well as 3m and 
3n, gave overlapping signals which could not be resolved, we treated these signals as containing equal 
amounts of both constituents.  
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Composition of each library was determined based on the relative peak area (RPA), where the summated 
peak areas in each chromatogram were set to 100% and each peak assigned its fraction. Based on this 
information, the normalized change of RPA21 between template and blank samples could be calculated and 
the influence of FimHFL-B on the library composition assessed (Figure 3). A positive value indicates 




Figure 3.  Normalized change of RPA21 between template and blank libraries. Bars from light to dark grey 
indicate 6:1, 4:1, and 2:1 concentration ratios of total acylhydrazones to FimHFL-B. Triplicates of all 
libraries were generated in the presence and absence of 100 µM FimHFL-B. Error bars indicate error 
propagation of standard deviations of RPAs over three measurements.21 
 
The most pronounced influence of FimHFL-B on the library composition was observed when core aldehyde 1 
was present at 200 µM, resulting in a 2:1 ratio of acylhydrazones to target protein. When the scaffold was 
employed at higher concentrations (400 µM and 600 µM), changes in composition of the libraries were less 
pronounced. To evaluate if the normalized changes of RPA correlated with the affinities of the corresponding 
acylhydrazones, KD values for 3a-u were determined by surface plasmon resonance (SPR) using a previously 
established procedure.21 Owing to the structural similarity of the compounds, differences in observed KD 
values were not drastic (267 nM to 760 nM; Table 1). Obviously, this narrow distribution of affinities places 
highest demands on the applied analytical tools. 
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Table 1.  Affinities measured by surface plasmon resonance. 
Compound KD [nM] Compoun
d 
KD [nM] 
1 316021 3k 427 
3a 359 3l 508 
3b 52021 3m 484 
3c 358 3n 390 
3d 267 3o 440 
3e 492 3p 377 
3f 55021 3q 286 
3g 461 3r 337 
3h 642 3s 536 
3i 33021 3t 376 
3j 462 3u 76021 
 
Results of tdDCC experiments are commonly reported in a “hit/no-hit”-manner. Amplification (“hit”) and 
depletion (“no-hit”) were only considered significant when the propagated error did not cross the baseline 
(Figure 3). Otherwise, compound concentrations were regarded as unchanged. Ligands 3d, 3i, 3p and 3q were 
amplified by the target in each of the three described experimental designs, whereas 3a and 3t were only 
amplified in the replicates with a 2:1 acylhydrazones to FimHFL-B ratio. The investigation of compounds with a 
negative normalized change of RPA revealed that signals 3l, 3u, and overlapping 3f and 3g were decreased, in 
accordance with lower affinities. For acylhydrazones with intermediate affinities, the combined signal of 3m 
and 3n stayed unchanged with 200 µM and 400 µM, but was slightly increased with 600 µM of core aldehyde 1. 
Finally, 3j (KD of 462 nM) and 3o (KD of 440 nM) remained unchanged in all libraries. 
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Figure 4.  Quantitative relationship between the normalized change of relative peak area (RPA) and the 
dissociation constant (KD) for different acylhydrazones. Pearson’s correlation coefficient r is given as a 
measure of alignment. 
 
Even though the majority of normalized changes of RPA correlated with the affinity data obtained by SPR, 
deviations were found for some acylhydrazones: albeit exhibiting rather high affinities of 358 nM and 337 nM, 
the normalized changes of RPA for 3c and 3r remained unchanged, while 3e with a KD of only 492 nM was 
amplified. Furthermore, 3b, 3h, and 3s with rather low affinities of 523 nM, 642 nM, and 536 nM, respectively, 
remained unchanged, whereas 3k with an affinity of 427 nM was decreased. Some of these aberrations could 
potentially result from the fast binding kinetics (both on- and off-rates) between acylhydrazones and FimHFL-B, 
as was observed in the SPR experiments (see Supporting Information). Since the kinetic constants could not be 
uniquely determined in all cases, some of the reported KD values may be erroneous. Apart from the fast 
binding kinetics21 which may have impeded the SPR measurements, we currently have no explanation for 
these outliers. However, it is important to keep in mind that when different techniques for affinity 
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measurements are utilized, deviations resulting from some inherent errors of measurements are often 
unavoidable.  
To assess the quantitative relationship between tdDCC and SPR results, the normalized change of RPA for 
each acylhydrazone was plotted against its KD value. In the case of overlapping signals in the tdDCC 
experiment, the KD value used was the average of the two acylhydrazones. Linear regression of the 
experimental data obtained using a 6:1 substrate ratio showed a moderate Pearson’s correlation coefficient (r) 
of -0.502 (Figure 4A). For the 4:1 substrate ratio, the correlation coefficient slightly increased to -0.574 (Figure 
4B), and for the 2:1 ratio, the highest correlation with an r-value of -0.655 was obtained (Figure 4C). 
Overall, the tdDCC experiments delivered results comparable to SPR. Given the narrow range of KD-values 
in the compound series, this clearly highlights the sensitivity of tdDCC. Furthermore, the tdDCC approach 
offers great economy of time: while SPR often requires independent synthesis and purification prior to affinity 
measurement, tdDCC combines the two steps into a single assay, thus clearly accelerating the process of hit 
identification. An additional benefit is that the described tdDCC protocol requires only standard laboratory 
equipment, while SPR requires an elaborate and costly instrument. 
Bioisosteric replacement 
Besides their use in tdDCC,21,24,27-31 several acylhydrazones have been reported to exhibit therapeutic 
properties32 in areas such as cancer,33-34 viral35-36 and bacterial37-38 infection, and pain and inflammation.39 
Furthermore, hydrazone linkages have been exploited for pH-responsive drug delivery.40 However, both the 
cytotoxic activity inherently linked to anti-cancer drugs and the instability of the hydrazone moiety which 
affords its pH-responsiveness give rise to general concerns towards inclusion of the acylhydrazone group in 
potential FimH antagonists. Jumde et al. recently reported on bioisosteric replacement of the acylhydrazone 
moiety.41 Therefore, in an effort to improve on stability and reduce toxicity, we generated a small library of 
bioisosteric analogues. 
To explore possible bioisosteres of acylhydrazone, six alternatives to 3f were synthesized (→ 5-10; 
Table 2). Conveniently, reduction of 3f with NaBH3CN yielded hydrazide 5. Ureas 6 and 7 were synthesized 
from the corresponding anilines and amines, which were coupled via intermediates formed from 4-
nitrophenyl chloroformate. Thioureas 8 and 9 were generated from the same aniline and amine starting 
materials through activation with 1,1’-thiocarbonyldiimidazole. Lastly, amide 10 was obtained by first 
assembling the aglycone from acid and amine precursors using standard peptide coupling, followed by 
mannosylation.  
The affinities of compounds 5-10 were evaluated in a competitive fluorescence polarization assay 
(FPA),14,17 using a non-biotinylated version of the FimH full-length protein (FimHFL).23 In type 1 pili of UPECs, 
the FimH subunit is stabilized by the N-terminal donor strand of the adjacent FimG subunit. Because isolated 
FimH turned out to be unstable, FimHFL-B and FimHFL required stabilization by a peptide consisting of the 15 
terminal amino acids of FimG which mimics the donor strand. In the case of FimHFL-B, biotin was linked to the 
pentadecapeptide, which does not alter FimHFL-B’s binding properties as compared to FimHFL. Hence, affinities 
determined with either of the constructs should be comparable. In the competitive FPA, the compounds under 
investigation displace a fluorescently labeled FimH antagonist (see 11 in the Supporting Information)14 whose 
fluorescence polarization depends on target binding. By running a ligand dilution series, the dissociation 
constants could be determined and are summarized in Table 2. For 3f, a KD value of 515 nM was obtained, 
which is in excellent agreement with the affinity measured by SPR (550 nM; Table 1). All bioisosteres except for 
amide 10 exhibited a diminished affinity for FimHFL. Noteworthy, only when the benzoyl moiety of the 
acylhydrazone was preserved as in hydrazide 5 and amide 10, a strong loss of affinity could be avoided.  
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In summary, as evidenced by antagonist 10, and as described by Jumde et al.41 replacement by an amide 
provides a good starting point for further optimization of acylhydrazones. 
 






































































































































In tdDCC experiments, the resulting composition is generally only qualitatively ranked in a “hit/no-hit”-
manner. One goal of this communication was to explore whether a tdDCC ranking correlated to an affinity 
ranking that had been determined using surface plasmon resonance (SPR) experiments. We therefore 
established a 21-membered acylhydrazone library using aldehyde scaffold 1 and the commercially available 
hydrazide fragments 2a-u (→ 3a-u). TdDCC acylhydrazone libraries were generated both in the absence and 
presence of biotinylated target protein FimHFL-B, and then analyzed using UV-HPLC. By calculating the 
normalized changes of relative peak area (RPA) between template and blank libraries, the influence of FimHFL-B 
could be assessed. Surprisingly, the library composition observed post-equilibration was influenced by the 
acylhydrazones/FimHFL-B ratio (6:1, 4:1, and 2:1), where differences between components became more 
enhanced with greater relative amounts of FimHFL-B (i.e. up- or down-regulation was more pronounced). When 
the tdDCC results were qualitatively ranked in a “hit/no-hit”-manner, the majority of amplified acylhydrazones 
indeed also exhibited high affinities in SPR experiments, whereas lower KDs correlated with down-regulated 
compounds. Next, when the normalized changes of RPA were plotted against KD values, a linear correlation 
was observed. The best alignment was obtained from the libraries with a 2:1 ratio of acylhydrazone to protein 
target, but the correlation was diminished when libraries with the 4:1 and 6:1 ratios were evaluated. These 
results suggest that a stoichiometric ratio between library constituents and target protein would be ideal for 
the generation of libraries in which all members exhibit affinity. However, different ratios are conceivable for 
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libraries, which cover a wider range of affinities. In a situation where only a few good binders are present, 
their formation would more efficiently outcompete the others. 
In subsequent efforts, replacement of the potentially hazardous acylhydrazone moiety with various 
bioisosteres was investigated. Whereas urea (→ 6 and 7) and thiourea (→ 8 and 9) analogues of parent 
compound 3f exhibited decreased affinities, hydrazide derivative 5 retained affinity and amide analogue 10 
mildly enhanced the affinity, indicating that the latter two bioisosteres could represent a good starting point 
for further optimization of acylhydrazone hits from tdDCC.  
In summary, applying tdDCC to FimHFL-B using acylhydrazone libraries of structurally related mannosides 
successfully confirmed the high sensitivity of this approach. Most importantly, a linear association between 





General. Affinity values were determined using a Biacore T200 system (GE Healthcare). UV-HPLC 
measurements were made using an Agilent 1100/1200 system (Agilent). FPA was measured on a Synergy H1 
hybrid multimode microplate reader (BioTek Instruments Inc., Winooski, VT, USA). 
FPA,14,17 protein production,21 SPR measurements,21 and tdDCC experiments21 were conducted as previously 
described. UV-HPLC analysis of libraries: Column: Waters Altlantis T3, 3 µm, 2.1 x 150 mm (Waters 
Corporation), solvent A: H2O + 0.01% TFA (trifluoroacetic acid); solvent B: MeCN + 0.01% TFA. Detection: UV 
absorption at 310 nm. Gradient: 5% → 25% B (35 min) → 50% B (65 min), flow rate: 0.3 mL/min, injection 
volume: 20 µL. 
 
Synthesis 
General. NMR spectra were recorded on a Bruker Avance DMX-500 (500.1 MHz) spectrometer. Assignment of 
1H NMR and 13C NMR spectra was achieved using 2D methods (COSY, HSQC). Chemical shifts are expressed in 
ppm using residual CHCl3, MeOH, or DMSO as references. Optical rotations were measured with a PerkinElmer 
Polarimeter 341 and infrared spectra were measured on a PerkinElmer Spectrum One FT-IR Spectrometer. 
Electrospray ionization mass spectrometry (ESI-MS) data were obtained on a Waters Micromass ZQ 
instrument. High resolution (HR)MS analysis were carried out using an Agilent 1100 LC equipped with a 
photodiode array detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Reactions 
were monitored by thin layer chromatography (TLC) using glass plates coated with silica gel 60 F254 (Merck) 
and visualized by UV light and/or by charring with a molybdate solution (0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Medium pressure liquid 
chromatography (MPLC) separations were carried out on a CombiFlash Rf (Teledyne ISCO, Inc.) with RediSep 
disposable normal-phase or RP-18 (LiChroprepRP18, Merck) reversed-phase flash columns. Commercially 
available reagents were purchased from Fluka, Aldrich, Alfa Aesar, Fluorochem, and Apollo. Solvents were 
purchased from Sigma-Aldrich, Acros Organics, or VWR. 
Synthesis of the acylhydrazone library 
General procedure A for acylhydrazone formation. A flask was charged with a magnetic stirrer, then aldehyde 
121 and hydrazide 2a,c-e,g-h,j-t were dissolved in H2O/MeCN (2 mL, 7:3). AcOH (100 µL) was added and the 
mixture was stirred at r.t. for 5-22 h until only product was detected by MS. Then, the mixture was neutralized 
with 1 M aq. NaOH and the solvents were removed under reduced pressure. The residue was purified by MPLC 
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on RP-18 (H2O/MeCN, 5:95 to 20:80) to give the desired products 3a,c-e,g-h,j-t. For synthesis of 3b, 3f, 3i and 
3u, please see reference 21. 
Note: Compounds 3a, 3d, and 3l were obtained as inseparable mixtures of E- and Z-isomers, with the E-isomer 
most likely representing the bigger fraction due to its sterically more favorable conformation. For further 
evaluation, we conducted a high temperature NMR measurement (CD3OD, 60 °C) with compound 3l, which 
clearly showed a decreased resolution, suggesting faster conversion of the two isomers. Further, HPLC traces 
at concentrations similar to the DCC experiments showed only one peak. When the reaction was catalyzed by 
aniline instead of AcOH, the same E/Z-ratio was obtained. Thus, the ratio of isomers is expected to be similar 
in tdDCC and SPR experiments. 
N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]nicotinohydrazide (3a). Prepared according to general 
procedure A from aldehyde 1 (10 mg, 33.1 µmol) and nicotinic hydrazide (2a, 4.5 mg, 33.1 µmol). Yield: 8.1 mg 
(58%) as an inseparable mixture of E- and Z-isomers (approx. 5:1). NMR data are given for the E-conformer. 
D
  20[]  +129.0 (c 0.35, MeOH); 1H NMR (500 MHz, (CD3)2SO):  = 3.39–3.54 (m, 4H, H-4, H-5, H-6a, H-6b), 3.60 
(dd, J 3.8, 10.6 Hz, 1H), 3.69 (d, J 7.8 Hz, 1H, H-3), 3.88 (s, 1H, H-2), 4.47 (s, 1H, OH-4), 4.89 (m, 2H, OH-3, OH-
6), 5.14 (s, 1H, OH-2), 5.50 (s, 1H, H-1), 7.45 (t, J 8.3 Hz, 1H, Ar-H), 7.50 (d, J 8.6 Hz, 1H, Ar-H), 7.52–7.58 (m, 
1H, Ar-H), 7.61 (d, J 11.9 Hz, 1H, Ar-H), 8.25 (d, J 7.7 Hz, 1H, Ar-H), 8.38 (s, 1H, HC=N), 8.75 (d, J 4.3 Hz, 1H, Ar-
H), 9.06 (s, 1H, Ar-H), 12.05 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO):   60.9 (C-6), 66.5 (C-4), 69.8 (C-2), 70.5 
(C-3), 75.5 (C-5), 99.7 (C-1), 113.9 (d, JC,F  20 Hz), 118.6, 123.6, 124.3, 129.1 (d, JC,F  6 Hz), 129.4, 135.4, 145.4 
(d, JC,F  11 Hz; 8C, Ar-C), 146.9 (d, JC,F  2 Hz, HC=N), 148.6, 152.1 (2C, Ar-C), 152.5 (d, JC,F  245 Hz, Ar-C), 161.8 
(C=O); IR (KBr):  3429 (vs, OH, NH), 1652 (vs, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C19H20FN3NaO7 
[M+Na]+: 444.1183, found: 444.1181. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-2-methylthiazole-5-carbohydrazide (3c). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 2-methyl-thiazole-4-carboxylic acid 
hydrazide (2c, 5.2 mg, 33.1 µmol). Yield: 8.4 mg (57%). D
  20[]  +117.7 (c 0.24, MeOH); 1H NMR (500 MHz, 
(CD3)2SO):  2.75 (s, 3H, CH3), 3.41 (m, 1H, H-5), 3.44–3.54 (m, 2H, H-6a, H-4), 3.60 (dd, J 5.7, 11.2 Hz, 1H, H-
6b), 3.88 (s, 1H, H-3), 3.69 (s, 1H, H-2), 4.46 (t, J 5.7 Hz, 1H, OH-6), 4.82 (d, J 5.4 Hz, 1H, OH-3), 4.87 (d, J 5.5 Hz, 
1H, OH-4), 5.11 (d, J 3.3 Hz, 1H, OH-2), 5.49 (s, 1H, H-1), 7.38–7.49 (m, 2H, Ar-H), 7.55 (d, J 11.7 Hz, 1H, Ar-H), 
8.29 (s, 1H, Ar-H), 8.51 (s, 1H, HC=N), 11.79 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO):   18.8 (CH3), 60.9 (C-6), 
66.5 (C-4), 69.8 (C-2), 70.6 (C-3), 75.5 (C-5), 99.7 (C-1), 113.7 (d, JC,F  20 Hz), 118.6, 124.4 (d, JC,F  2 Hz), 125.4, 
129.3 (d, J 7 Hz), 145.3 (d, JC,F  11 Hz; 6C, Ar-C), 147.1 (HC=N), 148.3, 152.5 (d, JC,F  245 Hz), 156.9 (3C, Ar-C), 
166.5 (C=O); IR (KBr):  3413 (vs, OH, NH), 1659 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C18H20FN3NaO7S 
[M+Na]+: 464.0904, found: 464.0905. 
N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-2,4-dimethylthiazole-5-carbohydrazide (3d). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 2,4-dimethyl-thiazole-5-carboxylic 
acid hydrazide (2d, 5.7 mg, 33.1 µmol). Yield: 3.2 mg (21%) as a 5:1 mixture of E- and Z-conformer. NMR data 
are given for the E-conformer. D
  20[]  +110.5 (c 0.11, MeOH); 1H NMR (500 MHz, (CD3)2SO):  2.51, 2.66 (2 s, 6H, 
2 CH3), 3.41 (d, J 7.8 Hz, 1H, H-5), 3.43–3.55 (m, 2H, H-4, H-6a), 3.60 (dd, J 5.3, 11.1 Hz, 1H, H-6b), 3.68 (d, J 8.4 
Hz, 1H, H-3), 3.88 (s, 1H, H-2), 4.46 (t, J 5.7 Hz, 1H, OH-6), 4.85 (s, 1H, OH-3), 4.88 (d, J 12.0 Hz, 1H, OH-4), 5.13 
(s, 1H, OH-2), 5.49 (s, 1H, H-1), 7.45 (m, 1H, Ar-H), 7.50 (d, J 7.2 Hz, 1H, Ar-H), 7.57 (d, J 11.7 Hz, 1H, Ar-H), 8.02 
(s, 1H, HC=N), 11.72 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO): 18.5 (2C, 2 CH3), 60.9 (C-6), 66.5 (C-4), 69.8 (C-
2), 70.6 (C-3), 75.5 (C-5), 99.7 (C-1), 114.2 (d, JC,F  19 Hz), 118.8, 124.2 (d, JC,F  3 Hz), 128.9, 142.3, 145.2 (d, JC,F  
11 Hz; 6C, Ar-C), 150.5 (HC=N), 152.4 (d, JC,F  245 Hz), 160.3, 162.2 (3C, Ar-C), 170.2 (C=O); IR (KBr):   3436 
(OH, NH, vs), 1646 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C19H22FN3NaO7S [M+Na]+: 478.1060, found: 
478.1061. 
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(E)-6-Chloro-N’-[3-fluoro-4-(α-D-mannopyranosyloxy)benzylidene]nicotinohydrazide (3e). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 6-chloropyridine-3-carbohydrazide 
(2e, 5.7 mg, 33.1 µmol). Yield: 3.8 mg (25%). D
  20[]  +74.1 (c 0.30, MeOH); 1H NMR (500 MHz, (CD3)2SO):   
3.38–3.60 (m, 4H, H-6a, H-6b, H-5, H-4), 3.68 (d, J 9.1 Hz, 1H, H-3), 3.88 (s, 1H, H-2), 5.47 (s, 1H, H-1), 7.41 (m, 
1H, Ar-H), 7.45 (d, J 8.6 Hz, 1H, Ar-H), 7.60 (s, 1H, Ar-H), 7.62 (d, J 3.0 Hz, 1H, Ar-H), 8.35 (d, J 8.3 Hz, 1H, 
HC=N), 8.37 (d, J 9.6 Hz, 1H, Ar-H), 8.93 (s, 1H, Ar-H); 13C NMR (125 MHz, (CD3)2SO):   60.9 (C-6), 66.4 (C-4), 
69.8 (C-2), 70.5 (C-3), 75.5 (C-5), 99.8 (C-1), 113.7 (d, JC,F  20 Hz), 118.50, 123.8, 124.1, 138.9 (8C, Ar-C), 147.0 
(HC=N), 149.3, 151.9, 152.4 (d, JC,F  244 Hz; 3C, Ar-C), 174.0 (C=O); IR (KBr):   3436 (vs, OH, NH), 1634 (s, C=N-
NH-C=O) cm-1; HRMS: m/z: Calcd for C19H19ClFN3NaO7 [M+Na]+: 478.0793, found: 478.0799. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-1-methyl-1H-pyrrole-2-carbohydrazide (3g). 
Prepared according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 1-methyl-1H-pyrrole-2-
carboxylic acid hydrazide (2g, 4.6 mg, 33.1 µmol). Yield: 9.5 mg (68%). D
  20[]  +132.5 (c 0.61, MeOH); 1H NMR 
(500 MHz, CD3OD):  3.65 (m, 1H, H-5), 3.69–3.81 (m, 3H, H-4, H-6a, H-6b), 3.93 (dd, J 3.1, 9.6 Hz, 1H, H-3), 
3.96 (s, 3H, CH3), 4.08 (s, 1H, H-2), 5.56 (s, 1H, H-1), 6.13 (s, 1H, Ar-H), 6.93 (s, 2H, Ar-H), 7.41 (t, J 8.1 Hz, 1H, 
Ar-H), 7.45 (d, J 8.6 Hz, 1H, Ar-H), 7.71 (d, J 11.9 Hz, 1H, Ar-H), 8.15 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD): 
  37.0 (CH3), 62.6 (C-6), 68.2 (C-4), 71.8 (C-2), 72.3 (C-3), 76.0 (C-4), 101.2 (C-1), 108.7, 115.2 (d, JC,F  20 Hz), 
119.5, 124.8, 125.7 (d, J 4 Hz), 130.7, 131.4 (d, JC,F  7 Hz; 7C, Ar-C), 146.7 (d, JC,F  6 Hz, HC=N), 147.0 (d, JC,F  11 
Hz, Ar-C), 152.4 (C=O), 154.6 (d, JC,F  246 Hz, Ar-C); IR (KBr):   3436 (vs, OH, NH), 1634 (s, C=N-NH-C=O) cm-1; 
HRMS: m/z: Calcd for C19H22FN3NaO7 [M+Na]+: 446.1339, found: 446.1341. 
(E)-N’-(3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene)-2-methylfuran-3-carbohydrazide (3h). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 2-methyl-furan-carboxylic acid 
hydrazide (2h, 4.6 mg, 33.1 µmol). Yield: 9.1 mg (65%). D
  20[]  +98.9 (c 0.56, MeOH); 1H NMR (500 MHz, 
CD3OD):  2.63 (s, 3H, CH3), 3.67 (d, J 3.6 Hz, 1H, H-5), 3.72–3.83 (m, 3H, H-4, H-6a, H-6b), 3.95 (dd, J 2.8, 9.4 
Hz, 1H, H-3), 4.10 (s, 1H, H-2), 5.59 (s, 1H, H-1), 6.85 (s, 1H, Ar-H), 7.42–7.52 (m, 3H, Ar-H), 7.76 (d, J 11.9 Hz, 
1H, Ar-H), 8.22 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD):   13.7 (CH3), 62.6 (C-6), 68.2 (C-4), 71.7 (C-2), 72.3 
(C-3), 76.0 (C-5), 101.2 (C-1), 109.4, 115.0, 115.3 (d, JC,F = 20 Hz), 119.4, 126.0, 142.1, 147.3 (d, JC,F  11 Hz; 8C, 
Ar-C), 147.9 (d, JC,F  1 Hz, HC=N), 154.6 (d, JC,F  246 Hz), 160.0 (2C, Ar-C), 163.1 (C=O); IR (KBr):   3414 (vs, OH, 
NH), 1619 (vs, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C19H21FN2Na O8 [M+Na]+: 447.1182, found: 447.1182. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-4-methoxybenzhydrazide (3j). Prepared according 
to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 4-methoxybenzhydrazide (2j, 5.5 mg, 33.1 
µmol). Yield: 4.0 mg (27%). D
  20[]  +106.6 (c 0.26, MeOH); 1H NMR (500 MHz, CD3OD):   3.64 (m, 1H, H-5), 
3.69–3.81 (m, 3H, H-4, H-6a, H-6b), 3.88 (s, 3H, CH3), 3.93 (dd, J 3.0, 9.4 Hz, 1H, H-3), 4.08 (s, 1H, H-2), 5.57 (s, 
1H, H-1), 7.05 (d, J 8.5 Hz, 2H, Ar-H), 7.43 (t, J 8.2 Hz, 1H, Ar-H), 7.49 (d, J 8.5 Hz, 1H, Ar-H), 7.77 (d, J 11.9 Hz, 
1H, Ar-H), 7.92 (d, J 8.6 Hz, 2H, Ar-H), 8.25 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD):   56.0 (CH3), 62.6 (C-6), 
68.2 (C-4), 71.7 (C-2), 72.3 (C-3), 76.0 (C-5), 101.2 (C-1), 115.0 (2C), 115.4 (d, JC,F  20 Hz), 119.5, 125.96, 126.07 
(d, JC,F  2 Hz; 6C, Ar-C), 130.7 (2C), 131.1 (d, JC,F  7 Hz), 147.3 (d, JC,F  10 Hz; 4C, Ar-C), 148.4 (HC=N), 154.6 (d, JC,F  
246 Hz, Ar-C), 164.5 (C=O), 166.7 (Ar-C); IR (KBr):   3439 (vs, OH, NH), 1648 (s, C=N-NH-C=O) cm-1; HRMS: m/z: 
Calcd for C21H23FN2NaO8 [M+Na]+: 473.1336, found: 473.1336. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-1H-indole-2-carbohydrazide (3k). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 1H-indole-2-carboxylic acid 
hydrazide (2k, 5.8 mg, 33.1 µmol). Yield: 7.7 mg (51%). D
  20[]  +100.9 (c 0.47,MeOH); 1H NMR (500 MHz, 
CD3OD):  3.65 (m, 1H, H-5), 3.70–3.82 (m, 3H, H-4, H-6a, H-6b), 3.93 (dd, J 3.0, 9.4 Hz, 1H, H-3), 4.09 (s, 1H, H-
2), 5.56 (s, 1H, H-1), 7.15–7.27 (m, 2H, Ar-H), 7.38–7.50 (m, 3H, Ar-H), 7.73 (s, 1H, Ar-H), 8.06 (d, J 6.4 Hz, 1H, 
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Ar-H), 8.17 (s, 1H, HC=N), 8.22 (d, J 7.1 Hz, 1H, Ar-H); 13C NMR (125 MHz, CD3OD):   62.6 (C-6), 68.2 (C-4), 71.8 
(C-2), 72.3 (C-3), 76.0 (C-5), 101.2 (C-1), 112.8, 115.2 (d, JC,F  19 Hz), 119.5, 122.25, 122.31, 123.9, 125.7, 127.6, 
127.7, 129.6, 131.5 (d, JC,F  7 Hz), 138.0 (12C, Ar-C), 146.2 (HC=N), 147.0 (d, JC,F  11 Hz), 154.6 (d, JC,F  246 Hz; 2C, 
Ar-C), 157.3 (C=O); IR (KBr):   3415 (vs, OH, NH), 1619 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for 
C22H22FN3NaO7 [M+Na]+: 482.1339, found: 482.1340. 
N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-2-(1H-indol-2-yl)acetohydrazide (3l). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and indole-3-acetic hydrazide (2l, 6.3 
mg, 33.1 µmol). Yield: 12.8 mg (82%) as a 2:1 mixture of E- and Z-conformation. D
  20[]  +99.1 (c 0.39, MeOH); 1H 
NMR (500 MHz, CD3OD; E:Z = 2:1, normalized to E conformation):   3.61–3.68 (m, 1.5H, H-5 E+Z), 3.70–3.81 
(m, 6.5H, CH2 E, H-6a E+Z, H-6b E+Z, H-4 E+Z), 3.91–3.96 (m, 1.5H, H-3 E+Z), 4.08 (dd, J 1.9, 3.3 Hz, 1H, H-2 E), 
4.10 (dd, J 1.9, 3.4 Hz, 0.5H, H-3 Z), 4.20 (s, 1H, CH2 Z), 5.57 (d, J 1.6 Hz, 1H, H-1 E), 5.58 (d, J 1.6 Hz, 0.5H, H-1 
Z), 6.99–7.07 (m, 2H, Ar-H E+Z), 7.08–7.15 (m, 1.5H, Ar-H E+Z), 7.21 (s, 0.5H, Ar-H Z), 7.25 (s, 1H, Ar-H E), 7.47–
7.33 (m, 4.5H, 3 Ar-H E, 3 Ar-H Z), 7.57 (d, J 12.6 Hz, 0.5H, Ar-H Z), 7.61 (d, J 7.9 Hz, 1H, Ar-H E), 7.65 (d, J 8.0 
Hz, 0.5H, Ar-H Z), 7.70 (dd, J 1.6, 12.0 Hz, 1H, Ar-H E), 7.91 (s, 0.5H, CH=N Z), 8.06 (s, 1H, CH=N E); 13C NMR 
(125 MHz, CD3OD; only E conformer):  32.7 (CH2), 62.6 (C-6), 68.2 (C-4), 71.8 (C-2), 72.3 (C-3), 76.0 (C-5), 
101.2 (C-1), 126.1, 124.9, 122.6, 122.4, 120.0, 119.4, 115.5, 112.4, 101.4, 148.1 (16 C, 14 Ar-C, HC=N, C=O); IR 
(KBr):  3429 (vs, OH, NH), 1651 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C23H24FN3NaO7 [M+Na]+: 
496.1496 found: 496.1496. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-4-methylbenzohydrazide (3m). Prepared according 
to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and p-toluic hydrazide (2m, 5.0 mg, 33.1 µmol). 
Yield: 7.7 mg (54%). D
  20[]  +104.2 (c 0.47, MeOH); 1H NMR (500 MHz, CD3OD):  2.42 (s, 3H, CH3), 3.65 (d, J 5.4 
Hz, 1H, H-5), 3.70–3.81 (m, 3H, H-4, H-6a, H-6b), 3.93 (d, J 9.3 Hz, 1H, H-3), 4.08 (s, 1H, H-2), 5.57 (s, 1H, H-1), 
7.34 (d, J 7.8 Hz, 2H, Ar-H), 7.43 (t, J 8.2 Hz, 1H, Ar-H), 7.49 (d, J 8.5 Hz, 1H, Ar-H), 7.76 (d, J 11.9 Hz, 1H, Ar-H), 
7.83 (d, J 7.7 Hz, 2H, Ar-H), 8.25 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD):  21.5 (CH3), 62.6 (C-6), 68.2 (C-4), 
71.7 (C-2), 72.3 (C-3), 76.0 (C-5), 101.2 (C-1), 115.4 (d, JC,F 21 Hz), 119.4, 126.1, 128.8 (2C), 130.4 (2C), 131.0 (d, 
JC,F 7 Hz), 131.2, 144.3, 147.4 (d, JC,F 12 Hz; 11C, Ar-C), 148.8 (HC=N), 154.6 (d, JC,F 246 Hz, Ar-C), 167.1 (C=O); IR 
(KBr):  3421 (vs, OH, NH), 1651 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C21H23FN2NaO7 [M+Na]+: 
457.1387, found: 457.1387. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-5-methylthiophene-2-carbohydrazide (3n). 
Prepared according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 5-methyl-thiophene-2-
carboxylic acid hydrazide (2n, 5.2 mg, 33.1 µmol). Yield: 7.8 mg (54%). D
  20[]  +156.0 (c 0.47, MeOH); 1H NMR 
(500 MHz, (CD3)2SO):  2.52 (s, 3H, CH3), 3.39–3.55 (m, 3H, H-4, H-5, H-6a), 3.60 (dd, J 4.9, 10.9 Hz, 1H, H-6b), 
3.69 (d, J 8.9 Hz, 1H, H-3), 3.88 (s, 1H, H-2), 4.46 (t, J 5.8 Hz, 1H, OH-6), 4.83 (d, J 3.6 Hz, 1H, OH-3), 4.87 (t, J 
8.4 Hz, 1H, OH-4), 5.12 (d, J 3.0 Hz, 1H, OH-2), 5.50 (s, 1H, H-1), 6.92 (s, 1H, Ar-H), 7.39–7.66 (m, 3H, Ar-H), 
7.78 (m, 1H, Ar-H), 8.18 (s, 1H, HC=N), 11.75 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO):  15.1 (CH3), 60.9 (C-6), 
66.5 (C-5), 69.9 (C-2), 70.6 (C-3), 75.5 (C-4), 99.7 (C-1), 114.03 (d, JC,F  38 Hz), 118.8, 124.2, 125.4, 129.2, 135.1, 
142.5, 145.49 (d, JC,F 79 Hz), 152.5 (d, JC,F 245 Hz), 161.2 (11C, 10 Ar-C, HC=N), 166.4 (C=O); IR (KBr):   3413 
(vs, OH, NH), 1619 (vs, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C19H21FN2NaO7S [M+Na]+: 463.0951, found: 
463.0954. 
(E)-4-Chloro-N’-[3-fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-carbohydrazide (3o). Prepared according 
to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 4-chlorobenzhydrazide (2o, 5.6 mg, 33.1 
µmol). Yield: 4.5 mg (30%). D
  20[]  +112.4 (c 0.24, MeOH); 1H NMR (500 MHz, CD3OD):  = 3.63 (ddd, J 2.2, 5.3, 
9.5 Hz, 1H, H-5), 3.69–3.82 (m, 3H, H-4, H6a, H-6b), 3.93 (dd, J 3.4, 9.4 Hz, 1H, H-3), 4.08 (dd, J 1.7, 3.1 Hz, 1H, 
H-2), 5.57 (s, 1H, H-1), 7.44 (t, J 8.3 Hz, 1H, Ar-H), 7.50 (d, J 9.2 Hz, 1H, Ar-H), 7.54 (d, J 8.5 Hz, 2H, Ar-H), 7.76 
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(m, 1H, Ar-H), 7.92 (d, J 8.5 Hz, 2H, Ar-H), 8.26 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD):   62.6 (C-6), 68.2 (C-
4), 71.7 (C-2), 72.3 (C-3), 76.0 (C-5), 101.1 (C-1), 115.5 (d, JC,F 20 Hz), 119.4, 126.2, 130.0 (2C), 130.5 (2C), 130.8 
(d, JC,F 7 Hz), 132.8, 139.5, 147.5 (d, JC,F 11 Hz; 11C, Ar-C), 149.3 (HC=N), 154.6 (d, JC,F 246 Hz, Ar-C), 165.9 
(C=O); IR (KBr):  3436 (vs, OH, NH), 1651 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C20H20ClFN2NaO7 
[M+Na]+: 477.0841, found: 477.0841. 
(E)-3-Chloro-N’-[(3-fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-4-methylthiophene-2-carbohydrazide 
(3p). Prepared according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 3-chloro-4-methyl-2-
thiophenecarboxylic acid hydrazide (2p, 6.3 mg, 33.1 µmol). Yield: 5.4 mg (34%). D
  20[]  +90.7 (c 0.15, MeOH); 
1H NMR (500 MHz, (CD3)2SO):  2.20 (s, 3H, CH3), 3.37–3.55 (m, 3H, H-6a, H-4, H-5), 3.60 (dd, J 3.6, 11.2 Hz, 1H, 
H-6b), 3.68 (dd, J 2.9, 9.0 Hz, 1H, H-3), 3.87 (s, 1H, H-2), 4.47 (s, 1H, OH-6), 4.90 (s, 2H, OH-3, OH-4), 5.13 (s, 
1H, OH-2), 5.49 (s, 1H, H-1), 7.40–7.48 (m, 2H, Ar-H), 7.56 (d, J 11.9 Hz, 1H, Ar-H), 7.65 (m, 1H, Ar-H), 8.06 (m, 
1H, Ar-H), 11.77 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO):   14.3 (CH3), 60.9 (C-6), 66.5 (C-4), 69.8 (C-2), 70.5 
(C-3), 75.5 (C-5), 99.7 (C-1), 113.9 (d, JC,F 20 Hz), 118.6 (d, JC,F 6 Hz), 124.3, 129.1, 131.2, 136.6, 143.6, 143.8 (d, 
JC,F 9 Hz), 145.3 (9C, Ar-C), 146.8 (HC=N), 152.4 (d, JC,F = 245 Hz, Ar-C), 171.2 (C=O); IR (KBr):  3430 (vs, OH, 
NH), 1642 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C19H20ClFN2NaO7S [M+Na]+: 497.0561, found: 
497.0561. 
(E)-5-Chloro-N’-[3-fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-thiophene-2-carbohydrazide (3q). 
Prepared according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 5-chlorothiophene-2-
carboxylic acid hydrazide (2q, 5.6 mg, 33.1 µmol). Yield: 3.9 mg (26%). D
  20[]  +138.3 (c 0.15, MeOH); 1H NMR 
(500 MHz, (CD3)2SO):  3.40–3.56 (m, 3H, H-4, H-5, H-6a), 3.62 (dd, J 4.1, 11.2 Hz, 1H, H-6b), 3.70 (dd, J 3.0, 9.1 
Hz, 1H, H-3), 3.90 (s, 1H, H-2), 4.49 (t, J 5.6 Hz, 1H, OH-4), 4.89 (m, 2H, OH-3, OH-6), 5.15 (s, 1H, OH-2), 5.53 (s, 
1H, H-1), 7.29 (d, J 4.1 Hz, 1H, Ar-H), 7.43–7.69 (m, 3H, Ar-H), 8.39 (m, 2H, Ar-H, HC=N), 12.00 (s, 1H, NH); 13C 
NMR (125 MHz, (CD3)2SO):  61.0 (C-6), 66.5 (C-5), 69.8 (C-2), 70.5 (C-3), 75.5 (C-4), 99.7 (C-1), 114.4 (d, JC,F 19 
Hz), 118.8, 124.4, 126.6, 128.6 (d, JC,F 6 Hz), 130.4, 134.5, 137.3 (8C, Ar-C), 143.5 (HC=N), 145.4 (d, JC,F 11 Hz), 
152.4 (d, JC,F 245 Hz; 2C, Ar-C), 160.0 (C=O); IR (KBr):  3436 (vs, OH, NH), 1651 (s, C=N-NH-C=O) cm-1; HRMS: 
m/z: Calcd for C18H18ClFN2NaO7S [M+Na]+: 483.0405, found: 483.0406. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-2-naphthohydrazide (3r). Prepared according to 
general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 2-naphthhydrazide (2r, 6.2 mg, 33.1 µmol). 
Yield: 3.9 mg (25%). D
  20[]  +81.6 (c 0.16, MeOH); 1H NMR (500 MHz, CD3OD):  3.65 (m, 1H, H-5), 3.69–3.82 (m, 
3H, H-4, H-6a, H-6b), 3.93 (dd, J 2.1, 9.4 Hz, 1H, H-3), 4.09 (s, 1H, H-2), 5.58 (s, 1H, H-1), 7.45 (t, J 8.2 Hz, 1H, 
Ar-H), 7.53 (d, J 8.5 Hz, 1H, Ar-H), 7.57–7.66 (m, 2H, Ar-H), 7.80 (d, J 11.9 Hz, 1H, Ar-H), 7.94–8.06 (m, 4H, Ar-
H), 8.32 (s, 1H, HC=N), 8.50 (s, 1H, Ar-H); 13C NMR (125 MHz, CD3OD):  62.6 (C-6), 68.2 (C-4), 71.8 (C-2), 72.3 
(C-3), 76.1 (C-5), 101.2 (C-1), 115.5 (d, JC,F = 20 Hz), 119.5, 125.0, 126.2, 128.1, 128.9, 129.2, 129.5, 129.6, 
130.1, 131.0 (d, JC,F 7 Hz), 131.3, 134.0, 136.6, 147.5 (d, JC,F 11 Hz; 15C, Ar-C), 149.0 (HC=N), 154.6 (d, JC,F 246 
Hz, Ar-C), 167.1 (C=O); IR (KBr):  3422 (vs, OH, NH), 1651 (s, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for 
C24H23FN2NaO7 [M+Na]+: 493.1387 found: 493.1388. 
(E)-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]-4-(trifluoromethyl)benzo-hydrazide (3s). Prepared 
according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 4-(trifluoromethyl)benzhydrazide 
(2s, 6.8 mg, 33.1 µmol). Yield: 8.6 mg (53%). D
  20[]  +98.8 (c 0.39, MeOH); 1H NMR (500 MHz, CD3OD):  3.64 (d, 
J 6.2 Hz, 1H, H-5), 3.69–3.81 (m, 3H, H-4, H-6a, H-6b), 3.93 (dd, J 2.2, 9.3 Hz, 1H, H-3), 4.08 (s, 1H, H-2), 5.58 (s, 
1H, H-1), 7.45 (t, J 8.2 Hz, 1H, Ar-H), 7.51 (d, J 8.5 Hz, 1H, Ar-H), 7.77 (d, J 11.8 Hz, 1H, Ar-H), 7.84 (d, J 8.0 Hz, 
2H, Ar-H), 8.10 (d, J 8.0 Hz, 2H, Ar-H), 8.28 (s, 1H, HC=N); 13C NMR (125 MHz, CD3OD):  62.6 (C-6), 68.2 (C-4), 
71.7 (C-2), 72.3 (C-3), 76.1 (C-5), 101.1 (C-1), 115.5 (d, JC,F 20 Hz), 119.4 (2C, Ar-C), 125.2 (q, JC,F 267 Hz, CF3), 
126.3 (d, J 3 Hz), 126.7 (q, J 3 Hz, 2C), 129.6 (2C), 130.7 (d, JC,F 7 Hz), 134.6 (q, JC,F 33 Hz), 137.9, 147.6 (d, JC,F 11 
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Hz; 9C, Ar-C), 149.7 (HC=N), 154.6 (d, JC,F 246 Hz, Ar-C), 165.6 (C=O); IR (KBr):  3430 (vs, OH, NH), 1663 (vs, 
C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C21H20F4N2NaO7 [M+Na]+: 511.1104 found: 511.1107. 
(E)-4-N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzylidene]benzo[b]thiophene-2-carbohydrazide (3t). 
Prepared according to general procedure A from aldehyde 1 (10 mg, 33.1 µmol) and 3-chloro-
benzo[b]thiophene acid hydrazide (2t, 7.5 mg, 33.1 µmol). Yield: 4.2 mg (25%). D
  20[]  +82.4 (c 0.18, MeOH); 1H 
NMR (500 MHz, (CD3)2SO):  3.38–3.51 (m, 3H, H-6a, H-6b, H-5), 3.59 (s, 1H, H-4), 3.68 (s, 1H, H-3), 3.88 (s, 1H, 
H-2), 4.47 (s, 1H, OH-4), 4.71–4.96 (m, 2H, OH-3, OH-6), 5.11 (s, 1H, OH-2), 5.49 (s, 1H, H-1), 7.35–7.69 (m, 5H, 
Ar-H), 8.44–8.84 (m, 3H, 2 Ar-H, HC=N), 12.09 (s, 1H, NH); 13C NMR (125 MHz, (CD3)2SO):  60.9 (C-6), 66.5 (C-
4), 69.8 (C-2), 70.5 (C-3), 75.5 (C-5), 99.8 (C-1), 114.2 (d, JC,F 20 Hz), 118.6, 122.4, 122.6, 123.4, 124.4, 126.0, 
127.4, 127.7, 132.6, 143.5, 145.4, 147.5, 152.5 (d, JC,F 245 Hz; 15C, Ar-C, HC=N), 160.2 (C=O); IR (KBr):  3460 
(vs, OH, NH), 1656 (vs, C=N-NH-C=O) cm-1; HRMS: m/z: Calcd for C22H20ClFN2NaO7S [M+Na]+: 533.0561 found: 
533.0562. 
Synthesis of bioisosteres 
General procedure B for deprotection of acetylated mannosides. Protected mannosides were dissolved in dry 
MeOH (2 mL) under argon atmosphere and freshly prepared 1 M NaOMe (100 µL) was added. The mixtures 
were stirred at r.t. for 30-45 min, until TLC (CH2Cl2/MeOH, 9:1) showed no remaining starting material. The 
mixtures were neutralized with amberlite ion-exchange resin (H+-form, IR120, Sigma Aldrich), filtered, and 
concentrated in vacuo. The residues were purified by MPLC (RP-18; H2O/MeCN, 95:5 to 20:80) to yield 60-82% 





























Scheme 2.  Reagents and conditions: a) NaBH3CN, aq. HCl., MeOH, r.t., 23 h, 95%. 
 
N’-[3-Fluoro-4-(α-D-mannopyranosyloxy)benzyl]benzohydrazide (5). Compound 3f (4.5 mg, 10.7 µmol, 1 eq.) 
was dissolved in MeOH (3 mL) and NaBH3CN (6.7 mg, 107 µmol, 10 eq.) and five drops of 36% aq. HCl. were 
added. The mixture was flushed with argon for 5 min and stirred at r.t. After 23 h the mixture was neutralized 
with solid NaOH and concentrated. The residue was purified by MPLC on RP-18 (H2O/MeCN, 95:5 to 20:80) to 
give 5 (4.3 mg, 95%). D
  20[]  +66.3 (c 0.22, MeOH); 1H NMR (500 MHz, CD3OD):  3.64–3.79 (m, 4H, H-4, H-5, H-
6a, H-6b), 3.91 (dd, J 3.4, 9.3 Hz, 1H, H-3), 4.00 (s, 2H, CH2), 4.06 (dd, J 1.8, 3.3 Hz, 1H, H-2), 5.46 (d, J 1.5 Hz, 
1H, H-1), 7.13 (d, J 8.4 Hz, 1H, Ar-H), 7.24 (dd, J 1.9, 11.9 Hz, 1H, Ar-H), 7.31 (t, J 8.4 Hz, 1H, Ar-H), 7.42 (t, J 7.5 
Hz, 2H, Ar-H), 7.50 (m, 1H, Ar-H), 7.69–7.75 (m, 2H, Ar-H); 13C NMR (125 MHz, CD3OD):  = 55.5 (CH2), 62.6 (C-
6), 68.2 (C-4), 71.9 (C-2), 72.3 (C-3), 75.8 (C-5), 101.6 (C-1), 117.9 (d, JC,F = 19 Hz), 120.0, 126.2 (d, JC,F 3 Hz), 
128.2, 129.5, 132.6, 134.5, 134.8 (d, JC,F 17 Hz), 144.8 (d, JC,F = 11 Hz), 154.5 (d, JC,F 245 Hz; 12C, Ar-C), 169.0 
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R = Ac: 17





Scheme 3.  Reagents and conditions: a) BF3∙Et2O, CH2Cl2, MS 4Å, 50 °C, 21 h, 39%; b) H2, Pd(OH)2, THF/ MeOH 
(2:1), r.t., 2h, 75%; c) 4-nitrophenyl chloroformate, DIPEA, CH2Cl2, 2 h; d) benzylamine, DIPEA, THF, 2.5 h, 
29% (over two steps); e) NaOMe, MeOH, r.t., 45 min, 70%. 
 
2-Fluoro-4-nitrophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (14). In a two-necked flask, activated MS 
4Å (ca. 500 mg), peracetylated D-mannose (12, 500 mg, 1.28 mmol, 1.2 eq.), 3-fluoro-4-nitrophenol (13, 168 
mg, 1.07 mmol, 1.0 eq.), and dry CH2Cl2 (10 mL) were mixed and cooled down in an ice bath. Under argon 
atmosphere, BF3∙Et2O (395 µL, 3.20 mmol, 3.0 eq.) was added dropwise and the reaction heated to 50 °C. The 
mixture was refluxed for 21 h. Then it was cooled down to r.t., diluted with EtOAc, and filtered over celite. The 
filtrate was subsequently washed with satd. aq. NaHCO3 and brine. The organic layer was dried over Na2SO4, 
filtered, and concentrated in vacuo. The residue was purified by MPLC on silica (petroleum ether/EtOAc, 1:0 to 
4:6) to give 14 (241 mg, 39%). D
  20[]  +92.8 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3):  2.03, 2.05, 2.07, 2.22 (4 
s, 12H, 4Ac-CH3), 4.06–4.15 (m, 2H, H-5, H-6a), 4.27 (dd, J 5.9, 12.8 Hz, 1H, H-6b), 5.39 (t, J 9.9 Hz, 1H, H-4), 
5.52 (dd, J 1.8, 3.5 Hz, 1H, H-2), 5.55 (dd, J 3.5, 9.9 Hz, 1H, H-3), 5.65 (d, J 1.5 Hz, 1H, H-1), 7.36 (m, 1H, Ar-H), 
8.02–8.08 (m, 2H, Ar-H); 13C NMR (125 MHz, CDCl3):  20.63, 20.64, 20.65, 20.8 (4 Ac-CH3), 61.9 (C-6), 65.6 (C-
4), 68.4 (C-3), 68.9 (C-2), 70.2 (C-5), 96.9 (C-1), 113.0 (d, JC,F 23 Hz), 117.1 (d, JC,F 1 Hz), 120.5 (d, JC,F 4 Hz), 143.0 
(d, JC,F 7 Hz), 148.8 (d, JC,F 11 Hz), 151.9 (d, JC,F 254 Hz; 6C, Ar-C), 169.6, 169.8, 169.9, 170.4 (4 C=O); ESI-MS: 
m/z: Calcd for C20H22FNNaO12 [M+Na]+: 510.10, found: 510.14. 
4-Amino-2-fluorophenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside (15). A two-necked flask equipped with 
a magnetic stirrer was charged with 14 (241 mg, 0.527 mmol). Under argon atmosphere, THF/MeOH (2:1, 15 
mL) and Pd(OH)2/C (25 mg) were added. The flask was evacuated five times and filled with H2. Under hydrogen 
atmosphere, the mixture was stirred at r.t. until TLC (CH2Cl2/MeOH, 8:2) indicated completion of the reaction. 
The mixture was filtered over celite and concentrated. Purification by MPLC (petroleum ether/EtOAc, 1:0 to 
0:1) gave 15 (181 mg, 75%). D
  20[]  +74.5 (c 2.01, CHCl3); 1H NMR (500 MHz, CDCl3):  1.97, 2.00, 2.01, 2.12 (4 s, 
12H, 4 Ac-CH3), 3.71 (s, 2H, NH2), 4.07 (dd, J 1.8, 12.1 Hz, 1H, H-6a), 4.18–4.28 (m, 2H, H-5, H-6b), 5.22 (s, 1H, 
H-1), 5.29 (t, J 9.9 Hz, 1H, H-4), 5.44 (dd, J 1.7, 3.3 Hz, 1H, H-2), 5.47 (dd, J 3.4, 9.9 Hz, 1H, H-3), 6.29 (m, 1H, Ar-
H), 6.37 (dd, J 2.6, 12.5 Hz, 1H, Ar-H), 6.86 (t, J 8.8 Hz, 1H, Ar-H); 13C NMR (125 MHz, CDCl3):  20.46, 20.49, 
20.6 (4C, 4 Ac-CH3), 62.1 (C-6), 65.8 (C-4), 68.7 (C-3), 69.2 (2C, C-3, C-5), 98.6 (d, JC,F  1 Hz, C-1), 103.3 (d, JC,F 22 
Hz), 110.2 (d, JC,F 3 Hz), 121.4 (d, JC,F 2 Hz), 134.9 (d, JC,F 12 Hz), 144.1 (d, JC,F 10 Hz), 154.3 (d, JC,F 246 Hz; 6C, Ar-
C), 169.6, 169.7, 169.8, 170.4 (4 C=O); ESI-MS: m/z: Calcd for C20H24FNNaO10 [M+Na]+: 480.13, found: 480.13. 
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4-Nitrophenyl (4’-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorophenyl)carbamate (16). In a two-
necked flask, 4-nitrophenyl chloroformate (20.7 mg, 0.103 mmol, 1 eq.) was dissolved in dry CH2Cl2 (2 mL). 
Under argon atmosphere, a solution of 15 (47 mg, 0.103 mmol, 1 eq.) and DIPEA (17.6 µL, 0.103 mmol, 1 eq.) 
in dry CH2Cl2 (2 mL) was added dropwise. The mixture was stirred at r.t. for 2 h, until TLC (petroleum 
ether/EtOAc, 1:1) showed completion of the reaction. The mixture was diluted with EtOAc and washed with 1 
M aq. HCl. The organic layer was dried over Na2SO4, filtered, and concentrated to give 16 (quant.) which was 
used without further purification. ESI-MS: m/z: Calcd for C27H27FN2NaO14 [M+Na]+: 645.13, found: 645.16. 
1-Benzyl-3-[4’-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorophenyl]urea (17). Crude 16 was 
dissolved in dry THF (2 mL) and benzylamine (11.3 mg, 0.103 mmol, 1 eq.) and DIPEA (17.6 µL, 0.103 mmol, 1 
eq.) were added. The reaction was stirred for 1.5 h, until TLC (CH2Cl2/MeOH, 9:1) indicated full consumption of 
the starting material. The mixture was concentrated, dissolved in EtOAc, washed with 1 M aq. HCl and the 
aqueous layer re-extracted with EtOAc (3x). The organic layer was dried over Na2SO4, filtered and the solvent 
removed. Purification by MPLC (petroleum ether/EtOAc, 1:0 to 0:1) gave 17 (17.1 mg, 29% over two steps). 
D
  20[]  +35.8 (c 0.89, CHCl3); 1H NMR (500 MHz, CDCl3):  2.01, 2.02, 2.06, 2.18 (4 s, 12H, 4 Ac-CH3), 4.08 (dd, J 
3.4, 13.2 Hz, 1H, H-6a), 4.21–4.28 (m, 2H, H-6b, H-5), 4.37 (d, J 5.7 Hz, 2H, CH2), 5.32–5.38 (m, 2H, H-4, H-1), 
5.41 (t, J 5.6 Hz, 1H, NH), 5.49 (dd, J 1.8, 3.4 Hz, 1H, H-2), 5.52 (dd, J 3.5, 9.9 Hz, 1H, H-3), 6.91 (dd, J 1.2, 8.9 
Hz, 1H, Ar-H), 6.94 (s, 1H, NH), 7.00 (t, J 8.8 Hz, 1H, Ar-H), 7.21–7.27 (m, 4H, Ar-H), 7.27–7.32 (m, 2H, Ar-H); 13C 
NMR (125 MHz, CDCl3):  20.65, 20.66, 20.8 (4C, 4 Ac-CH3), 44.2 (CH2), 62.1 (C-6), 65.8 (C-3), 68.9 (C-2), 69.3 
(C-4), 69.5 (C-5), 98.1 (C-1), 109.1 (d, JC,F 23 Hz), 115.6 (d, JC,F 3 Hz), 120.1 (d, JC,F  2 Hz), 127.4, 127.5, 128.7, 
135.5 (d, JC,F 9 Hz), 138.6, 138.8 (d, JC,F 12 Hz), 153.5 (d, JC,F 247 Hz; 12C, Ar-C), 155.4 (NC=O), 169.8, 170.0, 
170.7 (4C, 4 C=O); ESI-MS: m/z: Calcd for C28H31FN2Na O11 [M+Na]+: 613.18, found: 613.22. 
1-Benzyl-3-[3’-fluoro-4’-(α-D-mannopyranosyloxy)phenyl]urea (6). Prepared according to general procedure 
B from 17 (17.7 mg, 30.0 µmol). Yield: 8.8 mg (70%). D
  20[]  +109.9 (c 0.44, MeOH); 1H NMR (500 MHz, CD3OD): 
 3.70–3.81 (m, 4H, H-4, H-5, H-6a, H-6b), 3.90 (m, 1H, H-3), 4.06 (dd, J 1.8, 3.3 Hz, 1H, H-2), 4.37 (s, 2H, CH2), 
5.35 (d, J 1.7 Hz, 1H, H-1), 6.95 (ddd, J 1.3, 2.4, 8.9 Hz, 1H, Ar-H), 7.19–7.27 (m, 2H, Ar-H), 7.29–7.34 (m, 4H, 
Ar-H), 7.38 (dd, J 2.5, 13.3 Hz, 1H, Ar-H); 13C NMR (125 MHz, CD3OD):  44.5 (CH2), 62.7 (C-6), 68.3 (C-4), 71.9 
(C-2), 72.3 (C-3), 75.7 (C-5), 102.3 (C-1), 108.8 (d, JC,F  24 Hz), 115.7 (d, JC,F 3 Hz), 121.2 (d, JC,F 2 Hz), 128.1, 
128.3, 129.6, 137.1 (d, JC,F 10 Hz), 140.4 (d, JC,F  11 Hz), 140.9, 154.7 (d, JC,F 243 Hz; 12C, Ar-C), 158.0 (C=O); IR 
(KBr):  3347 (vs, OH), 1635 (s, C=O), 1515 (vs, NH) cm-1; HRMS: m/z: Calcd for C20H24FN2NaO7 [M+Na]+: 
445.1387, found: 445.1392. 
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Scheme 4.  Reagents and conditions: a) BF3∙Et2O, CH2Cl2, MS 4Å, 50 °C, 29 h, 60%; b) H2, Pd(OH)2, THF/MeOH 
(2:1), r.t., 2 h, 64%; c) 4-nitrophenyl chloroformate, DIPEA, CH2Cl2, r.t., 22 h, 53%; d) DIPEA, THF, r.t., 2 h, 
19%; e)NaOMe/MeOH, r.t., 45 min, 83%. 
 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorobenzonitrile (19). In a two-necked flask, 
activated MS 4Å (500 mg), peracetylated D-mannose (12, 500 mg, 1.28 mmol, 1.2 eq.), 3-fluoro-4-
hydroxybenzonitrile (18, 146 mg, 1.07 mmol, 1.0 eq.), and dry CH2Cl2 (10 mL) were mixed and cooled down in 
an ice bath. Under argon atmosphere, BF3∙Et2O (395 µL, 3.20 mmol, 3 eq.) was added slowly and the reaction 
heated to 50 °C. The mixture was refluxed for 29 h. Then, it was diluted with EtOAc, filtered over celite, and 
subsequently washed with satd. aq. NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered, and 
concentrated. The residue was purified by MPLC (toluene/EtOAc, 1:0 to 6:4) to give 19 (356 mg, 60%). D
  20[]  
+88.6 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3):  2.03, 2.04, 2.07, 2.21 (4 s, 12H, 4 Ac-CH3), 4.06–4.14 (m, 2H, 
H-5, H-6a), 4.27 (dd, J 6.0, 12.9 Hz, 1H, H-6b), 5.38 (t, J 9.9 Hz, 1H, H-4), 5.51 (dd, J 1.8, 3.4 Hz, 1H, H-2), 5.53 
(dd, J 3.5, 9.9 Hz, 1H, H-3), 5.63 (d, J 1.4 Hz, 1H, H-1), 7.34 (t, J 8.3 Hz, 1H, Ar-H), 7.42–7.48 (m, 2H, Ar-H); 13C 
NMR (125 MHz, CDCl3):  20.37, 20.39, 20.41, 20.5 (4 Ac-CH3), 61.7 (C-6), 65.4 (C-4), 68.2 (C-3), 68.7 (C-2), 69.9 
(C-5), 96.6 (C-1), 107.0 (d, JC,F 8 Hz), 117.1 (d, JC,F 2 Hz), 120.3 (d, JC,F 22 Hz), 129.2 (d, JC,F  4 Hz), 147.2 (d, JC,F 11 
Hz), 152.2 (d, JC,F 252 Hz; 7C, Ar-C, CN), 169.4, 169.5, 169.6, 170.1 (4 C=O); IR (KBr):   2232 (w, CN), 1751 (vs, 
C=O) cm-1; ESI-MS: m/z: Calcd for C21H22FNNaO10 [M+Na]+: 490.11, found: 490.06. 
4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorophenylmethanamine (20). A two-neckeds flask 
was charged with 19 (50 mg, 0.107 mmol) and a magnetic stirrer. Under argon atmosphere, THF/MeOH (6 mL, 
2:1) and Pd(OH)2/C (15 mg) were added. The flask was evacuated five times and filled with H2. Under hydrogen 
atmosphere, the mixture was stirred at r.t. until TLC (CH2Cl2/MeOH, 8:2) indicated completion of the reaction. 
The mixture was filtered over celite, and concentrated. Purification by MPLC (CH2Cl2/MeOH, 1:0 to 8:2) gave 
20 (32.2 mg, 64%). D
  20[]  +93.4 (c 1.00, CHCl3); 1H NMR (500 MHz, CDCl3):  2.03, 2.04, 2.07, 2.20 (4 s, 12H, 4 
Ac-CH3), 3.83 (s, 2H, CH2), 4.10 (d, J 10.3 Hz, 1H, H-6a), 4.22–4.30 (m, 2H, H-5, H-6b), 5.37 (t, J 10.0 Hz, 1H, H-
4), 5.46 (d, J 1.6 Hz, 1H, H-1), 5.52 (dd, J 1.8, 3.4 Hz, 1H, H-2), 5.57 (dd, J 3.5, 10.0 Hz, 1H, H-3), 7.02 (d, J 8.3 Hz, 
1H, Ar-H), 7.09–7.16 (m, 2H, Ar-H); 13C NMR (125 MHz, CDCl3):  20.60, 20.63, 20.8 (4C, 4 Ac-CH3), 45.3 (CH2), 
62.1 (C-6), 65.8 (C-4), 68.7 (C-3), 69.3 (C-2), 69.5 (C-5), 97.7 (C-1), 115.5 (d, JC,F 19 Hz), 119.4 (d, JC,F 1 Hz), 122.9 
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(d, JC,F 3 Hz), 139.7 (d, JC,F 6 Hz), 141.9 (d, JC,F 11 Hz), 153.4 (d, JC,F 248 Hz; 6C, Ar-C), 160.7, 169.8, 169.8, 170.5 
(4 C=O); ESI-MS: m/z: Calcd for C21H27FNO10 [M+H]+: 472.16, found: 472.13. 
4-Nitrophenyl phenylcarbamate (22). To a mixture of aniline (21, 49.0 µL, 0.537 mmol) and 4-nitrophenyl 
chloroformate (108 mg, 0.537 mmol) in THF (2 mL) was added DIPEA (91.9 µL, 0.537 mmol). The mixture was 
stirred at r.t. After 22 h, TLC (toluene/EtOAc, 1:1) indicated no remaining starting materials. The mixture was 
diluted with EtOAc and washed with 1 M aq. HCl. The aqueous layer was extracted with EtOAc, the combined 
organic layers were dried over Na2SO4, filtered and concentrated. The residue was purified by MPLC 
(toluene/EtOAc, 1:0 to 1:1) to give 22 (72.8 mg, 52%). 1H NMR (500 MHz, CDCl3):   7.06 (s, 1H, NH), 7.16 (t, J 
7.4 Hz, 1H, Ar-H), 7.34–7.41 (m, 4H, Ar-H), 7.45 (d, J 7.8 Hz, 2H, Ar-H), 8.25–8.31 (m, 2H, Ar-H); 13C NMR (125 
MHz, CDCl3):  119.0 (2C), 122.1 (2C), 124.6, 125.2 (2C), 129.3 (2C), 136.6, 145.1 (12C, Ar-C), 150.1 (C=O), 
155.4 (Ar-C). 
1-[4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluoro]-3-phenylurea (23). A mixture of 20 (50 mg, 
107 µmol), DIPEA (18.2 µL, 107 µmol) and 22 (27.4 mg, 107 µmol) in dry THF (2 mL) was stirred at r.t. for 2 h, 
until TLC (CH2Cl2/MeOH, 9:1) showed no remaining starting material. The mixture was diluted with EtOAc and 
washed with 1 M aq. HCl. The aqueous layer was extracted three times with EtOAc, and the combined organic 
layers were dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by MPLC 
(CH2Cl2/MeOH, 1:0 to 9:1) to give 23 (12.1 mg, 19%). D
  20[]  +51.2 (c 0.61, CHCl3); 1H NMR (500 MHz, CDCl3):   
= 2.02, 2.03, 2.06, 2.19 (4 s, 12H, 4 Ac-CH3), 4.08 (dd, J 2.0, 12.1 Hz, 1H, H-6a), 4.20 (ddd, J 2.0, 5.2, 10.0 Hz, 1H, 
H-5), 4.25 (dd, J 5.2, 12.1 Hz, 1H, H-6b), 4.32 (d, J 5.9 Hz, 2H, CH2), 5.33–5.39 (m, 2H, H-4, NH), 5.42 (d, J 1.5 Hz, 
1H, H-1), 5.49 (dd, J 1.8, 3.4 Hz, 1H, H-2), 5.54 (dd, J 3.5, 10.0 Hz, 1H, H-3), 6.80 (s, 1H, NH), 6.96 (d, J 8.4 Hz, 
1H, Ar-H), 7.03 (dd, J 1.8, 11.4 Hz, 1H, Ar-H), 7.05–7.11 (m, 2H, Ar-H), 7.24–7.30 (m, 4H, Ar-H); 13C NMR (125 
MHz, CDCl3):   20.6, 20.7, 20.8 (4C, 4 Ac-CH3), 43.2 (CH2), 62.1 (C-6), 65.8 (C-4), 68.8 (C-3), 69.2 (C-2), 69.6 (C-
5), 97.6 (C-1), 115.8 (d, JC,F  19 Hz), 119.4, 121.1, 123.3 (d, JC,F  4 Hz), 124.1, 129.3, 135.9 (d, JC,F  6 Hz), 138.2, 
142.3 (d, JC,F  11 Hz), 153.4 (d, JC,F  249 Hz; 12C, Ar-C), 155.8 (C=O(NH)2), 169.7, 169.9, 170.0, 170.6 (4 C=O); ESI-
MS: m/z: Calcd for C28H31FN2NaO11 [M+Na]+: 613.18, found: 613.31. 
1-(3’-Fluoro-4’-α-D-mannopyranosyloxy)-3-phenylurea (7). Prepared according to general procedure B from 
23 (12.1 mg, 20.5 µmol). Yield: 7.2 mg (83%). D
  20[]  +88.1 (c 0.36, MeOH); 1H NMR (500 MHz, CD3OD):   3.66–
3.80 (m, 4H, H-4, H-5, H6a, H-6b), 3.91 (dd, J 3.4, 9.2 Hz, 1H, H-3), 4.06 (dd, J 1.8, 3.3 Hz, 1H, H-2), 5.44 (d, J 1.6 
Hz, 1H, H-1), 6.97 (t, J 7.4 Hz, 1H, Ar-H), 7.07 (d, J 8.4 Hz, 1H, Ar-H), 7.11 (dd, J 1.9, 11.9 Hz, 1H, Ar-H), 7.21–
7.28 (m, 2H, Ar-H), 7.31 (t, J 8.4 Hz, 1H, Ar-H), 7.35 (dd, J 1.0, 8.5 Hz, 2H, Ar-H); 13C NMR (125 MHz, CD3OD):  
43.6 (CH2), 62.6 (C-6), 68.2 (C-4), 71.9 (C-2), 72.3 (C-3), 75.8 (C-5), 101.7 (C-1), 116.2 (d, JC,F  19 Hz), 120.3, 
123.6, 124.3 (d, JC,F 3 Hz), 129.8, 137.0 (d, JC,F  6 Hz), 140.8, 144.4 (d, JC,F  11 Hz), 154.6 (d, JC,F 246 Hz; 12 C, Ar-
C), 158.2 (C=O); IR (KBr):  3371 (vs, OH), 1651 (s, C=O) cm-1; HRMS: m/z: Calcd for C20H24FN2NaO7 [M+Na]+: 








































Scheme 5. Reagents and conditions: a) i. TCDI, CH2Cl2, r.t., 17 h; ii. benzylamine, CH2Cl2, r.t., 3 h, 52% (over two 
steps); b) NaOMe, MeOH, 0 °C, 45 min, 71%. 
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1-Benzyl-3-[4’-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorophenyl]thiourea (24). Compound 15 
(47.0 mg, 0.103 mmol) and 1,1’-thiocarbonyldiimidazole (TCDI; 18.3 mg, 0.103 mmol.) were dissolved in dry 
CH2Cl2 (2 mL). The mixture was stirred at r.t. for 17 h. Then benzylamine (11.2 µL, 0.103 mmol) was added and 
the mixture was stirred for 3 h until TLC (petroleum ether/EtOAc, 1:1) showed no remaining starting material. 
The mixture was diluted with CH2Cl2, and washed with 1 M aq. HCl, satd. aq. NaHCO3 and brine. The organic 
layer was dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by MPLC 
(petroleum ether/EtOAc, 1:0 to 0:1) to give 24 (32.3 mg, 52%). D
  20[]  +51.6 (c 1.07, CHCl3); 1H NMR (500 MHz, 
CDCl3):   1.96, 1.99, 2.02, 2.15 (4 s, 12H, 4 Ac-CH3), 4.04 (dd, J 2.4, 12.1 Hz, 1H, H-6a), 4.12 (ddd, J 2.3, 5.2, 
10.1 Hz, 1H, H-5), 4.20 (dd, J 5.2, 12.2 Hz, 1H, H-6b), 4.81 (d, J 5.2 Hz, 2H, CH2), 5.32 (t, J 10.1 Hz, 1H, H-4), 5.41 
(s, 1H, H-1), 5.43 (dd, J 1.8, 3.3 Hz, 1H, H-2), 5.48 (dd, J 3.4, 10.0 Hz, 1H, H-3), 6.23 (s, 1H, NH), 6.92 (d, J 8.7 Hz, 
1H, Ar-H), 7.02 (dd, J 2.2, 11.0 Hz, 1H, Ar-H), 7.16 (t, J 8.7 Hz, 1H, Ar-H), 7.22–7.27 (m, 3H, Ar-H), 7.27–7.32 (m, 
2H, Ar-H), 7.96 (s, 1H, NH); 13C NMR (125 MHz, CDCl3):   20.59, 20.61, 20.62, 20.8 (4 Ac-CH3), 49.4 (CH2), 62.1 
(C-6), 65.7 (C-4), 68.5 (C-3), 69.1 (C-2), 69.7 (C-5), 97.5 (C-1), 114.4 (d, JC,F  20 Hz), 119.9 (d, JC,F  2 Hz), 121.6 (d, 
JC,F  4 Hz), 127.7, 127.9, 128.8, 137.0, 142.4 (d, JC,F  11 Hz), 153.4 (d, JC,F  252 Hz; 12C, Ar-C), 169.7, 169.8, 169.9, 
170.4 (4 C=O), 181.1 (C=S); ESI-MS: m/z: Calcd for C28H32FN2O10S [M+H]+: 607.18, found: 607.30. 
1-Benzyl-3-[3-fluoro-4-(α-D-mannopyranosyloxy)phenyl]thiourea (8). Prepared according to general 
procedure B from 24 (32.2 mg, 53.1 µmol). Yield: 16.7 mg (71%). D
  20[]  +95.6 (c 0.84, MeOH); 1H NMR (500 
MHz, CD3OD):   3.65–3.81 (m, 4H, H-4, H-5, H-6a, H-6b), 3.90 (dd, J 3.4, 9.1 Hz, 1H, H-3), 4.06 (dd, J 1.8, 3.3 
Hz, 1H, H-2), 4.80 (s, 2H, CH2), 5.45 (d, J 1.6 Hz, 1H, H-1), 7.03 (ddd, J 1.4, 2.3, 8.8 Hz, 1H, Ar-H), 7.25 (m, 1H, 
Ar-H), 7.27–7.36 (m, 6H, Ar-H); 13C NMR (125 MHz, CD3OD):   49.0 (CH2), 62.7 (C-6), 68.2 (C-4), 71.8 (C-2), 72.3 
(C-3), 75.9 (C-5), 101.7 (C-1), 114.5 (d, JC,F  21 Hz), 120.4, 121.9 (d, JC,F  5 Hz), 128.2, 128.6, 129.5, 135.1 (d, JC,F  9 
Hz), 139.9, 143.2 (d, JC,F  11.0 Hz), 154.3 (d, JC,F  246 Hz; 12C, Ar-C), 182.9 (C=S); IR (KBr):   3295 (vs, OH), 1563 









































Scheme 6. Reagents and conditions: a) i. TCDI, CH2Cl2, r.t., 18 h; ii. 20, CH2Cl2, r.t., 6 h, 7% (over two steps); b) 
NaOMe, MeOH, r.t., 45 min, 66%. 
 
1-[4’-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3’-fluorobenzyl]-3-phenylthiourea (25). 1,1’-Thio-
carbonyldiimidazole (18.9 mg, 0.106 mmol) was dissolved in dry CH2Cl2 (2 mL) and 21 (9.7 µL, 0.106 mmol) was 
added. The mixture was stirred at r.t. for 18 h until TLC (toluene/EtOAc, 1:1) showed no remaining aniline. 
Then, 20 (50 mg, 0.106 mmol) in dry CH2Cl2 (2 mL) was added and the mixture stirred for another 6 h. Then, it 
was diluted with CH2Cl2 and subsequently washed with 1 M aq. HCl, satd. aq. NaHCO3, and brine. The organic 
layer was dried over Na2SO4, filtered, and the solvent removed. The residue was purified by MPLC 
(toluene/EtOAc, 1:0 to 1:1) to give 25 (4.8 mg, 7 %). D
  20[]  +49.8 (c 0.24, CHCl3); 1H NMR (500 MHz, CDCl3):   
2.03, 2.06, 2.19 (3 s, 12H, 4 Ac-CH3), 4.09 (dd, J 1.9, 12.2 Hz, 1H, H-6a), 4.20 (ddd, J 1.8, 5.2, 9.9 Hz, 1H, H-5), 
4.26 (dd, J 5.3, 12.1 Hz, 1H, H-6b), 4.83 (d, J 5.7 Hz, 2H, CH2), 5.36 (t, J 10.0 Hz, 1H, H-4), 5.45 (s, 1H, H-1), 5.49 
(m, 1H, H-2), 5.55 (dd, J 3.5, 10.0 Hz, 1H, H-3), 6.22 (s, 1H, NH), 7.01 (d, J 8.4 Hz, 1H, Ar-H), 7.09 (dd, J 1.5, 11.3 
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Hz, 1H, Ar-H), 7.12 (t, J 8.2 Hz, 1H, Ar-H), 7.15–7.26 (m, 2H, Ar-H), 7.34 (m, 1H, Ar-H), 7.44 (t, J 7.8 Hz, 2H, Ar-
H), 7.72 (s, 1H, NH); 13C NMR (125 MHz, CDCl3):   20.66, 20.67, 20.68, 20.8 (4 Ac-CH3), 48.3 (CH2), 62.1 (C-6), 
65.8 (C-4), 68.7 (C-3), 69.3 (C-2), 69.6 (C-5), 97.6 (C-1), 116.1 (d, JC,F  19 Hz), 119.3, 123.6 (d, JC,F  4 Hz), 125.6, 
127.8, 128.8, 130.4, 134.0 (d, J 6 Hz), 142.8 (d, JC,F  11 Hz), 153.4 (d, JC,F  249 Hz; 12C, Ar-C), 169.7, 169.8, 169.9, 
170.5 (4 C=O), 181.3 (C=S); ESI-MS: m/z: Calcd for C28H31FN2NaO10S [M+H]+: 629.16, found: 629.15. 
1-(3-Fluoro-4-α-D-mannopyranosyloxybenzyl)-3-phenylthiourea (9). Prepared according to general procedure 
B from 25 (4.6 mg, 7.9 µmol). Yield: 2.3 mg (66%). D
  20[]  +61.4 (c 0.12, MeOH); 1H NMR (500 MHz, CD3OD):  = 
3.66–3.79 (m, 4H, H-4, H-5, H-6a, H-6b), 3.91 (dd, J 3.4, 9.1 Hz, 1H, H-3), 4.06 (dd, J 1.8, 3.4 Hz, 1H, H-2), 4.76 
(s, 2H, CH2), 5.45 (d, J 1.7 Hz, 1H, H-1), 7.09 (d, J 8.4 Hz, 1H, Ar-H), 7.15 (dd, J 2.0, 11.9 Hz, 1H, Ar-H), 7.21 (m, 
1H, Ar-H), 7.28–7.39 (m, 5H, Ar-H); 13C NMR (125 MHz, CD3OD):   48.2 (CH2), 62.6 (C-6), 68.2 (C-4), 71.9 (C-2), 
72.3 (C-3), 75.8 (C-5), 101.7 (C-1), 116.6 (d, JC,F  19 Hz), 120.2 (d, JC,F  1 Hz), 124.7 (d, JC,F  3 Hz), 125.9 (d, JC,F  3 
Hz), 127.0, 130.3, 139.5, 144.4, 154.5 (d, JC,F  246 Hz; 12C, Ar-C), 182.8 (C=S); IR (KBr):   3422 (vs, OH), 1514 



























R = Ac: 29






Scheme 7.  Reagents and conditions: a) HBTU, HOBt, DIPEA, DMF, r.t., 2.5 h, 18%; b) 11, BF3∙Et2O, CH2Cl2/ 
MeCN, MS 4Å, 50-75 °C, 48 h, 12%; c) NaOMe, MeOH, r.t., 45 min, 60%. 
 
3-Fluoro-4-hydroxy-N-(2-oxo-2-phenylethyl)benzamide (28). 3-Fluoro-4-hydroxybenzoic acid (26, 50.0 mg, 
0.641 mmol, 1 eq.), HBTU (243 mg, 1.28 mmol, 2 eq.), HOBt hydrate (12% water; 98.4 mg, 0.205 mmol, 2 eq.), 
and 2-aminoacetophenone hydrochloride (27, 35.2 mg, 1.28 mmol, 2 eq.) were dissolved in anhydrous DMF 
(1.5 mL). Then, DIPEA (110 µL, 2.56 mmol, 4 eq.) was added and the mixture was stirred at r.t. for 2.5 h. Then, 
it was diluted with EtOAc and subsequently washed with 1 M aq. HCl and brine. The organic layer was dried 
over Na2SO4, filtered and the solvents were removed in vacuo. The residue was purified by MPLC 
(toluene/EtOAc, 1:0 to 1:1) to give 28 (31.8 mg, 18%). 1H NMR (500 MHz, CD3OD):   4.86 (s, 2H, CH2), 6.99 (t, J 
8.5 Hz, 1H, Ar-H), 7.53 (t, J 7.7 Hz, 2H, Ar-H), 7.60 (dd, J 2.1, 8.4 Hz, 1H, Ar-H), 7.62–7.67 (m, 2H, Ar-H), 8.02–
8.08 (m, 2H, Ar-H); 13C NMR (125 MHz, CD3OD):   47.7 (CH2), 116.5 (d, JC,F 20 Hz), 118.5 (d, JC,F 3 Hz), 125.3 (d, 
JC,F 3 Hz), 126.7 (d, JC,F 6 Hz), 129.0, 129.9, 134.8, 136.5, 150.0 (d, JC,F 13 Hz), 152.4 (d, JC,F 242 Hz; 12C, Ar-C), 
169.1 (CONH), 196.4 (C=O); ESI-MS: m/z: Calcd for C15H12FNNaO3 [M+Na]+: 296.07, found: 295.49. 
4-(2,3,4,6-Tetra-O-acetyl-α-D-mannopyranosyloxy)-3-fluoro-N-(2-oxo-2-phenylethyl)benzamide (29). A two-
necked flask was charged with activated MS 4Å (50 mg), peracetylated D-mannose (12, 54.5 mg, 0.140 mmol, 
1.2 eq.) and dry CH2Cl2 (2 mL). Under argon atmosphere, 28 (31.8 mg, 0.116 mmol, 1 eq.) in dry MeCN (2 mL) 
was added. The mixture was refluxed at 50 °C for 24 h, and another 24 h at 75°C. When TLC (petroleum 
ether/EtOAc, 1:1) showed no remaining mannose precursor, the mixture was diluted with EtOAc, filtered over 
celite, and washed with satd. aq. NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and 
concentrated. The residue was purified by MPLC (petroleum ether/EtOAc, 1:0 to 1:1) to yield 29 (8.3 mg, 12%). 
Unreacted 28 (15.5 mg, 49%) could be recovered. D
  20[]  +60.1 (c 0.42, CHCl3); 1H NMR (500 MHz, CDCl3):  
186
Arkivoc 2019, iv, 0-0  Frei, P. et al. 
 ©ARKAT USA, Inc 
2.04, 2.04, 2.07, 2.21 (4 s, 12H, 4 Ac-CH3), 4.09 (dd, J 2.1, 12.2 Hz, 1H, H-6a), 4.16 (ddd, J 1.9, 5.3, 9.9 Hz, 1H, H-
5), 4.28 (dd, J 5.4, 12.3 Hz, 1H, H-6b), 4.94 (d, J 4.1 Hz, 2H, CH2), 5.38 (t, J 10.1 Hz, 1H, H-4), 5.53 (dd, J 1.8, 3.3 
Hz, 1H, H-2), 5.55–5.60 (m, 2H, H-3, H-1), 7.22 (s, 1H, NH), 7.28 (t, J 8.2 Hz, 1H, Ar-H), 7.53 (t, J 7.7 Hz, 2H, Ar-
H), 7.62 (d, J 8.6 Hz, 1H, Ar-H), 7.65 (t, J 7.4 Hz, 1H, Ar-H), 7.70 (dd, J 1.9, 11.1 Hz, 1H, Ar-H), 8.03 (d, J 7.5 Hz, 
2H, Ar-H); 13C NMR (125 MHz, CDCl3):  20.64, 20.65, 20.66, 20.8 (4 Ac-CH3), 46.9 (CH2), 62.0 (C-6), 65.7 (C-4), 
68.6 (C-3), 69.1 (C-2), 69.8 (C-5), 97.0 (C-1), 116.2 (d, JC,F 20 Hz), 118.1, 123.4 (d, JC,F 4 Hz), 128.0, 129.0, 129.9 
(d, JC,F 6 Hz), 134.2, 134.4, 146.1 (d, JC,F 11 Hz), 152.8 (d, JC,F 250 Hz; 12C, Ar-C), 165.4, 169.7, 169.8, 169.9, 
170.5, 194.0 (6 C=O); ESI-MS: m/z: Calcd for C29H30FNNaO12 [M+Na]+: 626.17, found: 626.24. 
3-Fluoro-4-α-D-mannopyranosyloxy-N-(2-oxo-2-phenylethyl)benzamide (10). Prepared according to general 
procedure B from 29. Yield: 3.6 mg (60%). D
  20[]  +88.3 (c 0.18, MeOH); 1H NMR (500 MHz, CD3OD):  3.62 (ddd, 
J 2.4, 5.6, 9.8 Hz, 1H, H-5), 3.68–3.81 (m, 3H, H-4, H-6a, H-6b), 3.93 (dd, J 3.4, 9.5 Hz, 1H, H-3), 4.09 (dd, J 1.8, 
3.4 Hz, 1H, H-2), 4.87 (s, 2H, CH2), 5.62 (d, J 1.5 Hz, 1H, H-1), 7.50 (t, J 8.5 Hz, 1H, Ar-H), 7.55 (t, J 7.7 Hz, 2H, Ar-
H), 7.66 (t, J 7.4 Hz, 1H, Ar-H), 7.68–7.74 (m, 2H, Ar-H), 8.04–8.08 (m, 2H, Ar-H); 13C NMR (125 MHz, CD3OD):  
62.6 (C-6), 68.2 (C-4), 71.7 (C-2), 72.3 (C-3), 76.1 (C-5), 101.0 (C-1), 116.6 (d, JC,F 20 Hz), 119.0, 125.2 (d, JC,F 4 
Hz), 129.1, 130.0, 134.9, 136.5, 148.5 (d, JC,F 11 Hz), 153.9 (d, JC,F 246 Hz; 12C, Ar-C), 168.7 (CONH), 196.3 
(C=O); IR (KBr):  3412 (vs, OH, NH), 1646 (s, C=O) cm-1; HRMS: m/z: Calcd for C21H23FNNaO8 [M+Na]+: 





For Surface Plasmon Resonance Experiments and Fluorescence Polarization Assay please refer to the 
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Lectins belong to the most challenging targets in drug discovery due to the unique binding 
properties of their polyhydroxylated carbohydrate ligands. Whereas the hydroxyl groups 
provide directionality and specificity, the high desolvation costs of carbohydrates are the 
origin for their notoriously low affinities.  
 
Nonetheless, some lectins with high affinity to monovalent carbohydrate ligands have been 
reported.(1-6) One of these rare examples is the bacterial lectin FimH, located at the tip of the 
pili of uropathogenic E. coli (UPEC). It mediates adhesion to the mannosylated glycoproteins 
uroplakin Ia on urothelial host cells. By combining computational methods (QM, MD 
simulations) with structural information (X-ray, NMR) and binding data (FP, ITC, kinITC) 
the complex and cooperative hydrogen bond network formed by mannoside ligands 
interacting with FimH was elucidated. Deoxy- and deoxy-halogeno derivatives of n-heptyl α-
D-mannoside (1) reveal that the loss individual hydroxyl groups not only leads to a decrease 
of the association rate (kon), but also to an increased dissociation rate (koff) and as a result to a 
dramatic drop of affinity (KD). Furthermore, a comparison of thermodynamic profiles 
obtained by isothermal titration calorimetry (ITC) indicates that the loss in affinity 
(corresponding to a ΔΔG° of 15-21 kJ/mol per hydroxyl group) originates from unfavorable 






It is generally accepted that hydrogen bonds (H-bonds) provide directionality and therefore 
specificity to ligand-receptor interactions, whereas hydrophobic interactions, although rather 
unspecific, predominantly contribute to binding energies.(7) Since carbohydrate-lectin 
interactions are mainly based on H-bond formation, they are characterized by a high degree of 
specificity, but often suffer from a lack of affinity.(8) The high specificity allows 
carbohydrates to fulfill their broad biological tasks, such as signal transduction,(9,10) cell 
recognition(11,12) or cell adhesion.(13) Furthermore, considering their fundamental importance 
in numerous disease-related processes, carbohydrate mimetic drugs offer potential new 
therapeutic applications.(14) However, the polar character of carbohydrates creates 
pharmacokinetic challenges related to oral availability, plasma half-live or renal excretion. 
Moreover, tight interactions with lectins seem to be against the nature of most carbohydrates, 
mainly due to the high desolvation costs related to their numerous hydroxyl groups. Toone et 
al. appraised these limitations of carbohydrate-lectin interactions as “fundamental, severe, and 
likely insurmountable”(7) and Hopkins et al. regarded the likelihood of modulating a lectin 
with an orally available small molecule drug to be very low.(15) Therefore, to analyze and 
solve the structural drawbacks common to carbohydrates is of fundamental importance when 
therapeutic applications are envisaged. 
 
In the present study, the bacterial lectin FimH - one of the rare examples of a lectin 
undergoing high-affinity interactions with carbohydrates - is analyzed and the role of the 
individual hydroxyl groups in terms of thermodynamic and kinetic contribution to binding is 
studied. FimH, a virulence factor of uropathogenic E. coli (UPEC), is located at the tip of 
bacterial type 1 pili.(16,17) By interacting with the urothelial glycoprotein uroplakin Ia, it 
mediates the bacterial adhesion to the bladder wall as the initial step in urinary tract infections 
(UTI). A high-affinity interaction between FimH and the oligomannosides of the host’s 
uroplakin Ia is a prerequisite to prevent UPEC to be washed out of the bladder by the urinary 
bulk flow.(18,19) 
 
With the goal to reveal their individual contributions of the various hydroxyl groups to 
binding, the thermodynamic and kinetic properties of the reference compound n-heptyl 
α-D-mannopyranoside (1) were compared with those of derivatives deoxygenated in the 2-, 
3-, 4- or 6-position and those where the hydroxyl groups were replaced by halogens. By 
 
 196
combining structural data from X-ray crystallography and solution NMR experiments with 
computational methods (quantum mechanics, QM) as well as thermodynamic (ITC) and 
kinetic data (kinITC) the individual contributions of the various hydroxyl groups to binding 






Results and Discussion 
The mannose-binding pocket of FimH (Figure 1). The interaction of -D-mannosides with 
the lectin domain of FimH (FimHLD) has been extensively studied. The pronounced loss of 
affinity induced by the replacement of the D-mannose moiety by other hexoses, e.g. D-
glucose or D-galactose,(30) corroborates the importance of the extended hydrogen-bond 
network which can be established by mannose (Figure 1). As a result, D-mannose exhibits a 
for carbohydrate-lectin interactions remarkable micromolar affinity of 2.3 μM.24 Furthermore, 
alkyl or aryl aglycones can establish beneficial hydrophobic interactions with the so-called 
tyrosine gate (residues Tyr48 and Tyr137) forming the entrance to the mannose-binding 
pocket.(31-35) This effect leads to a further 100-fold improvement of affinity as documented by 








O (2-OH) N (N-terminus) 2.70 161.8 127.2 
O (H2O) O (2-OH) 2.68 134.8 112.1 
O (3-OH) N (Gln133) 3.02 173.0 123.0 
O (Asp140) O (3-OH) 2.78 155.8 119.1 
O (4-OH) N (Asn135) 2.95 155.8 114.8 
O (Asp54) O (OH-4) 2.60 165.6 140.6 
O (6-OH) N (Asp47) 2.96 159.2 115.0 
O (6-OH) N (N-terminus) 2.76 165.6 116.9 
O (Asp54) O (6-OH) 2.56 173.6 120.6 
 
Figure 1. Two-dimensional schematic representation of n-heptyl α-D-mannoside (1, HM) binding to FimH 
according to X-ray crystallography (PDB code 4XO8). H-bonds donated by 1 are shown in blue, those 
accepted in red, the structural water W1 is highlighted in blue; to avoid overlaps, Gln133 was drawn twice. In 
the table, angles and distances from co-crystal structure FimHLD in complex with n-heptyl α-D-mannoside (1). 



























































The extraordinary high affinity of this carbohydrate-lectin interaction originates from a 
multitude of factors. First, the interaction of -D-mannopyranosides with FimHLD (e.g. PDB 
code 4XO8, 4CST, 4BUQ) is characterized by a total of 9 hydrogen bonds (Figure 1). They 
exhibit optimal geometries related to distance, donor and acceptor angles (see Table in Figure 
1) with the high degree of complementarity necessary for tight binding.(29,37) According to 
MD simulations, the charge-assisted hydrogen bonds formed by Asp54 (acceptor) as well as 
by the positively charged N-terminus (donor) provide the largest energy contributions.(38) 
Furthermore, compared to a solvent-exposed binding site, electrostatic interactions in the 
deeply buried binding pocket of FimH benefit from a much lower dielectric constant and thus 
render increased contribution to binding (Table S1).(39)  
 
Second, the loss of rotational freedom of each hydroxyl group is penalized by entropic costs. 
However, since all hydroxyl groups of the mannose moiety form multiple hydrogen bonds, 
entropic costs arise only for the first interaction of a given hydroxyl group. Subsequent 
interactions from the same hydroxyl group do not induce additional entropic penalty.  
 
Third, the high desolvation costs of 26 kJ/mol associated with one hydroxyl group(40) might 
be lowered by perturbed water molecules in the solvation shell of the interaction surfaces due 
to their polyamphiphilic character.(29) However, the high desolvation penalty cannot be 
compensated by the formation of single hydrogen bond.(41) Desolvation costs (ΔG°solv) for the 
ligand n-heptyl α-D-mannoside and deoxy derivatives thereof were calculated (AMSOL 7.1) 
and considered for the calculations of the bond energies. The complete desolvation of n-
heptyl α-D-mannoside was calculated to cost 38.8 kJ/mol, which is almost as much as the 
entire binding energy between n-heptyl α-D-mannoside and FimHLD (ΔG° = -43.7 kJ/mol) 
(Table 2). Hence, forming multiple interactions allows compensating the high desolvation 
penalty, which has to be paid only once, more efficiently.  
  
Fourth, H-bonds strengthen each other due to a phenomenon called ‘cooperative hydrogen 
bonding’.(42-45) When a hydroxyl group acts as hydrogen bond donor, the electron density on 
its oxygen lone pair is slightly increased and therefore its hydrogen bond accepting properties 
are improved. Since every hydroxyl group of the mannose moiety is involved in at least two 
hydrogen bond, the formation of a cooperative hydrogen bond network is favored. The 
structural water (Figure 1, W1) introduces positive cooperativity by interacting with the 
backbone of Phe1 and thereby increasing the positive charge of the N-terminus that forms 
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charged hydrogen bonds with 2-OH and 6-OH. Opposed to that, negative cooperativity is 
presumed between 6-OH and 2-OH and between 4-OH and 6-OH, which both have to share a 
charge on their interaction partners (Asp54, N-terminus). Positive cooperativity is furthermore 
occurring when multiple amino acids of one protein loop form interactions with the ligand, 
i.e. observed in the FimH binding site between Asp140 and Asn135 interacting with 3-OH 
and 4-OH, respectively. This is favorable because the interactions stabilize each other and the 
entropic costs for the loss of the loop mobility are redundant.(46,47) It is therefore delicate to 
investigate contributions of a single hydroxyl group in a cooperative system as a pyranose, as 
any change might affect the whole H-bond network.(48) Consequently, to attribute the energy 
loss to the removal of a certain hydroxyl group and to exclude changes of the whole 
interaction system we carefully considered structural changes observed by NMR and X-ray.  
 
Protein pre-organization. In a previous study, we exemplified the rigidity of FimHLD, which 
accommodates also 7-membered ring analogs of D-mannose without any conformational 
adaption.(49) In order to demonstrate the rigidity of FimHLD, the “pseudo-apo” structure 
(PDB-Code: 4AUU, containing thioethanol in the binding site) and the crystal structure co-
crystallized with n-heptyl α-D-mannoside (1, HM) (PDB-Code: 4XO8) were compared. An 
RMSD of 0.266 considering the 7 heavy atoms directly interacting with the mannose moiety 
(see Figure 1, heavy atoms highlighted in green) revealed that ligand binding-induced only 
minor rearrangements.  
 
Ligand pre-organization (Figure 2). In order to derive information regarding the degree of 
pre-organization of n-heptyl α-D-mannoside (1) in the bioactive conformation, torsion angles 
of solution structures obtained by molecular dynamics simulations (ωMD) were compared with 
its structure (ωX-ray) in complex with FimHLD (PDB-Code: 4XO8). To classify the energy 
profile of each hydroxyl group, they were rotated stepwise around their torsion angles (ω1-ω6) 
while calculating the energies of the resulting structures by quantum mechanics (QM). The 
solution conformations are broadly distributed because they are separated only by low energy 
barriers. The conformational energy in the bound state was found to be more favorable than 
the averaged energies of the solution conformations (Table 1) in four out of six analyzed 




Figure 2. Calculated energy as a function of the torsion angles of methyl α-D-mannopyranoside. Dotted 
lines correspond to the energy of a given torsion angle. Left y-axis: calculated energy in kJ/mol, right y-axis: 
frequency of solution conformation from MD simulation, x-axis: torsion angle, conformation of heptyl α-D-
mannopyranoside co-crystallized with FimH-CRD (PDB-Code: 4XO8) shown as a black bar, frequency 
distribution of solution conformation shown in blue bars.  
 
 
Table 1. Comparing the energy of the torsion angles ω1-6 of n-heptyl α-D-mannopyranoside (1) in solution 
and bound to FimHLD. Torsion angles (ωX-ray) according to the co-crystal structure (PDB-code: 4XO8) and the 
corresponding calculated energy of the bound conformation in comparison with the averaged energy of the 




Solution conformation  Bound conformation  
Gain (-) /loss (+) of conformational 











ω1 1.5  68.5° 0.1  - 1.4 
ω2 9.9  64.7° 4.6  - 5.3 
ω3 8.8  155.4° 6.8  - 2.0 
ω4 6.8  -86.9° 9.0  + 2.2 
ω5 8.2  -57.4° 0.4  - 7.8 







Synthesis of deoxy- and deoxy-halogeno-derivatives of n-heptyl α-D-mannosides. To 
study the contribution of the individual hydroxyl groups, a series of deoxy- and deoxy-
halogeno-derivatives of n-heptyl α-D-mannoside (1) were synthesized (Figure 3). Since 
fluorine shares a comparable polarity and a close isosteric relationship with oxygen but is 
unable to form H-bonds,(50,51) a comparison of the parent mannoside 1 with fluorine analogs 
will allow discriminating between the contribution of H-bonds and other electrostatic 
interactions. Because the micromolar affinity of unsubstituted D-Man would lead to 
substantial protein consumption for the thermodynamic analysis, derivatives with an n-heptyl 
aglycone leading to a significantly improved affinity for FimHLD were used (D-Mannose: KD 
= 2.3 μM; n-heptyl α-D-mannoside (1): KD = 22 nM).
(30,36) This enabled the study of even 
those deoxy- and deoxy-halogeno-derivatives that have severely diminished affinities 
compared to the unmodified mannoside. The synthesis of compounds 2-4, 6, 7 and 9-11 is 
summarized the Supporting Information, while the syntheses of 1, 5 and 8 have been 
published recently.(36) 
 
Figure 3. Structure of n-heptyl α-D-mannoside (1) and the deoxy- and deoxy-halogeno-derivatives 2 - 11.  
 
Structural analysis of deoxy- (5, 7 & 9) and deoxy-fluoro-derivatives (2, 6 & 8) of n-
heptyl α-D-mannoside (1) bound to FimHLD. To analyze how the substitution of an 
individual hydroxyl group influences ligand and lectin conformation, the structures 2 & 5 - 9 
co-crystallized with FimHLD were determined applying conditions we previously reported for 
n-heptyl α-D-mannoside (1).(32,36) Resolutions between 1.9 and 2.1 Å (except, 7 at 3.0 Å) and 








1:     R2, R3, R4, R6 = OH
2:     R2 = F, R3, R4, R6 = OH
3:     R2 = Cl, R3, R4, R6 = OH
4:     R2 = Br, R3, R4, R6 = OH
5:     R2 = H, R3, R4, R6 = OH
6:     R3 = F, R2, R4, R6 = OH
7:     R3 = H, R2, R4, R6 = OH
8:     R4 = F, R2, R3, R6 = OH
9:     R4 = H, R2, R3, R6 = OH
10:   R6 = F, R2, R3, R4 = OH




Figure 4. Superimposition of co-crystal structures of FimHLD with n-heptyl α-D-mannoside and six deoxy- 
and deoxy-fluoro derivatives. A) The parent n-heptyl α-D-mannoside (1) (PDB code 4XO8) and all proteins 
are shown in grey, while the deoxy- (5, 7 & 9) and the deoxy-fluoro-derivatives (2, 6 & 8) are colored as 
indicated. B) Important binding pocket residues and the structural water (W1) are shown as sticks and spheres, 
respectively. 
 
Superposition of the crystal structures revealed RMSD values for the protein backbone 
between 0.11 and 0.20 Å (Figure 4A) and almost identical binding pockets (Figure 4B). All 
binding modes were identical, except for the 2-deoxy-mannoside 5 which, however, was 
slightly tilted (Figure S1). In all crystal structures, the structural water W1 mediates the H-
bond interaction of the 2-hydroxyl group with the backbone amides of Phe1 and Gly14, and 
as well as to the side chain of Gln133 (Figure 1). In case of the 2-deoxy-2-fluoro-derivative 2, 
this water molecule is located significantly closer to the protein (Figure 4B).   
 
To analyze the dynamics of the hydrogen bond network of the various complexes 1H,15N-
HSQC NMR spectra were recorded. Whereas 1H chemical shifts of backbone and side chain 
amides report on H-bond formations, 15N shifts respond sensitively to changes in the dihedral 
angles of the protein backbone and side chains.(52) We measured 1H,15N-HSQC fingerprint 
spectra of FimHLD in presence of 2 and 5-10 and assigned the signals on the basis of chemical 
shift proximity to the spectrum with unmodified n-heptyl α-D-mannoside (1). Because of low 
affinity, mannoside 10 (6-F) and 11 (6-H) modified in 6-position of the mannose moiety 
could not be evaluated by ITC (Table 2). From the 1H,15N-HSQC NMR spectrum of 10 (6-F) 
it was apparent that 10 (6-F) binds very weakly to FimHLD, as even at high ligand 
concentration (20 mM) no chemical shift perturbations were observed. Since the affinity of 11 
(6-H) was expected to be even lower than for 10 (6-F), 11 was not subjected to NMR 
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experiments. For all other deoxy- and deoxy-fluoro mannosides, chemical shift perturbation 
of residues in the binding pocket indicated specific interactions with the protein, while no 
chemical shift changes of residues remote from the binding pocket were observed (Figure S2; 
Figure S3).  
 
Downfield shifts indicate new H-bond formation or strengthening, while upfield shifts 
indicate H-bond weakening or disruption. It was of particular interest to observe chemical 
shift changes of signals of backbone amide and side chain signals that function as H-bond 
donors to the ligand’s OH groups, i.e. of Gly14 HN (W1 H-bond to 2-OH), Asp47 H
N (to 
6-OH), Gln133 Hε22 (to 3-OH) and Asn135 Hδ21 (to 4-OH) (Figure 5).  
 
The chemical shifts of Gly14 HN are almost identical for 5 (2-H), 6 (3-F), 8 (4-F) and 9 (4-H), 
indicating a similar orientation of W1, even though for 5 (2-H) the interacting hydroxyl group 
does not exist (Figure 5). The slight proton upfield shift of Gly14 HN with all ligands 
indicates that the coordination of mannose weakens the H-bond of this residue to W1. In 
agreement with this, the data suggest the strongest Gly14-water interaction for 5 (2-H), for 
which W1 is more “free” to coordinate with Gly14. For 2 (2-F), Gly14 cannot be assigned and 
may be shifted significantly due to the close fluorine atom. Indeed, in the co-crystal structure 
with 2 (2-F), W1 is more buried (Figure 4B) which may contribute to the large chemical shift 
change of Gly14. The relative chemical shift changes of Asp47 HN suggest that compared to 
n-heptyl α-D-mannoside the direct H-bond to 6-OH is weakened (upfield shift) for the ligand 
6 (3-F) and 7 (3-H), strengthened for 9 (4-H) whereas no significant changes were observed 
for 2 (2-F), 5 (2-H) and 8 (4-F) (Figure 5). The Hε22 of the Gln133 amide side chain signal is 
shifted downfield by almost 0.8 ppm upon addition of n-heptyl α-D-mannoside indicative for 
the H-bond formation to 3-OH (Figure 5). For 2 (2-F), 5 (2-H) and 9 (4-H), similar downfield 
shifts demonstrate H-bond formation to 3-OH, although the smaller shifts (0.33–0.50 ppm) 
suggest slightly weaker H-bonds. Importantly, the Gln133 Hε22 signals with 6 (3-F) and 7 
(3-H) show dramatic upfield shifts [ca. −1.64 ppm relative to n-heptyl α-D-mannoside (1)] as 
direct evidence for the absence of the corresponding H-bond. Similarly, Asn135 Hδ21 is 
strongly shifted downfield by 0.70 to 0.96 ppm upon addition of n-heptyl α-D-mannoside (1), 
2 (2-F), 5 (2-H), 6 (3-F) and 7 (3-H) as a consequence of H-bond formation to 4-OH. With 9 
(4-H), a relative upfield shift of this signal reports on the absence of the corresponding H-




In summary, the structural information obtained by NMR and X-ray is in good agreement and 
the conformational changes of protein and ligand are remarkably small upon the loss of 
relevant interactions. This qualifies FimHLD as a model to investigate contributions of distinct 




Figure 5. 1H,15N-HSQC spectral regions of binding pocket residues directly involved in H-bond donation 
to the mannosyl moiety. Boxes in case of side chain signals of Gln133 and Asn135 indicate relative downfield 
and upfield proton shifts, respectively. Peaks not of interest were faded-out to improve the clarity. 
 
Thermodynamic analysis of deoxy- and deoxy-halogeno-derivatives of n-heptyl α-D-
mannoside (1) (Table 2). Measuring interaction by ITC is valuable in several respects. First, 
it is a label-free method that allows the determination of the change in enthalpy of binding 
(ΔH°), association constant (KA) and stoichiometry (N) in one experiment, and second, recent 
progress in data analysis now allows the deviation of kinetic rate constants for association and 
dissociation from the same raw data. ITC experiments (Table 2) were carried out at 25 °C in 
10 mM HEPES buffer at pH 7.4 containing 150 mM NaCl. Measurements in other buffering 
systems revealed a significant heat of ionization (ΔH°ion) originating from a partial proton 
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transfer from the solvent to the N-terminus of the FimHLD protein (Figure S4, Table S3).
(53,54) 
By measuring the enthalpy of n-heptyl α-D-mannoside (1) binding to FimHLD in different 
buffers at pH 7.4 (Cacodylate, HEPES, Tris), pH 8.5 (Bicine, Tricine, TAPS, Tris) and pH 9.0 
(Bicine; TAPS, Tris), the pKa of the N-terminus was determined to be approximately 8.3. 
This proton transfer is endothermic and therefore the intrinsic enthalpy is underestimated 
applying standard experiment conditions. However, the relevant ΔΔ-values are constant and 
we decided to omit correction for the heat of ionization in this publication to maintain the 
comparability with earlier publications.  
Table 2. Change in thermodynamic parameters of FimHLD binding to n-heptyl α-D-mannoside (1) and 
deoxy- (5, 7 & 9) and deoxy-halogeno derivatives (2-4, 6 & 8) thereof. All values are relative to the absolute 
values of mannoside 1. Measurements were carried out at 298.15 K in 10 mM HEPES buffer containing 
150 mM NaCl at pH 7.4. Protein and ligand concentrations, confidence intervals and stoichiometries are part of 
the supplementary information (Table S5). Affinities from a fluorescence polarization (FP) assay are shown for 
comparison.  
 
 FP: KD [μM] ITC: KD [μM] ΔG°  [kJ/mol] ΔH° [kJ/mol] -TΔS°  [kJ/mol] 
n-heptyl 
mannoside (1) 
0.028(32) 0.022 -43.7 -50.5 6.7 
   ΔΔG° [kJ/mol] ΔΔH°  [kJ/mol]  -TΔΔS° [kJ/mol] 
2 (2-F) 0.44 0.53 7.9 22.7 -14.8 
3 (2-Cl) 2.26 1.34 10.2 25.9 -15.8 
4 (2-Br) 4.24 1.83 11.0 29.6 -18.7 
5 (2-H) 13.95 9.77 15.1 31.1 -16.0 
6 (3-F) 0.45 1.19 9.9 19.1 -9.2 
7 (3-H) 23.35 19.88 16.9 25.7 -8.8 
8 (4-F) 135.2 103.43 21.0 29.9 -9.0 
9 (4-H) 101.2 88.40 20.6 30.6 -10.0 
10 (6-F) n.d. >1000    
11 (6-H) n.d. >1000    
 
Deoxygenation and substitution of 2-OH of mannose. Substitutions in the 2-position of the 
mannose moiety have the lowest impact on the free energy of binding [e.g. ΔΔG° = 
15.1 kJ/mol for 5 (2-H)]. However, 2-deoxy mannoside 5 suffers from the largest loss in 
enthalpy of the whole series relative to 1 (ΔΔH° = 31.1 kJ/mol), which is partially 
compensated by a gain in entropy (-TΔΔS° = −16.0 kJ/mol). Overall, this leads to a 440-fold 
loss in affinity. The unusually high enthalpic loss originates from the excellent H-bond of the 
2-OH group with the positively charged N-terminus. Furthermore, structural analysis by 
X-ray indicated that the mannose moiety of 5 (2-H) is slightly twisted relative to the parent n-
heptyl α-D-mannoside (1), weakening the H-bond network and thus increasing the flexibility 
of the ligand in the binding pocket (Figure S1). However, the twist could not be confirmed by 
NMR data, as all binding pocket residues have nearly identical chemical shifts compared to 1. 
Phe1 might indeed be more flexible due to the absence of the H-bond to 2-OH, but 
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unfortunately the N-terminal Phe1 signal cannot be observed directly in the NMR 
experiments. A further insight into the binding mode was obtained when the 2-hydroxyl 
group was replaced by halogens. It was expected that the electrostatic interaction exerted by 
the former oxygen atom can be maintained, whereas obviously the H-bonds formed with W1 
and Phe1 are lost. The increasing electronegativity of bromine < chlorine < fluorine induces a 
repulsion of the structural water W1 (Figure 4B), while the interaction with the positively 
charged N-terminus becomes more beneficial. The difference between the loss of all 
electrostatic interactions for 5 (2-H) (ΔΔG° = 15.1 kJ/mol) and the loss of only the H-bonds 
of 2 (2-F) (ΔΔG° = 7.9 kJ/mol) leads to the conclusion that the permanent dipole-buried 
charge interaction contributes approximately 7.2 kJ/mol to the free energy of binding.  
 
Deoxygenation and substitution of 3-OH of mannose. Deoxygenation of the 3-position of n-
heptyl α-D-mannoside (1) (→ 7) leads to a substantial loss in enthalpy (ΔΔH° = 25.7 kJ/mol), 
which is only partially compensated by an entropy gain (-TΔΔS° = -8.8 kJ/mol). As a result, a 
900-fold loss in affinity was observed. Compared to 7 (3-H), the introduction of a fluoro 
substituent [→ 6 (3-F)] results in an enthalpic gain (ΔΔH° = -6.6 kJ/mol), as well as a small 
entropic advantage (-TΔΔS° = -0.4 kJ/mol). Interestingly, crystal structures of n-heptyl α-D-
mannoside (1) and the 3-fluoro derivative 6 co-crystallized with FimHLD (PDB QQ & PDB 
QQ) reveal repulsion between the fluorine atom and the negative charge on Asp140 and 
consequently an increased distance (0.5 Å) between the interacting heavy atoms. However, 
Asp140 is part of a loop and its perpendicular position to the ligand allow for a rearrangement 
with minor impact on binding energy. The difference between the intrinsic loss of all 
electrostatic interactions for 7 (3-H) (ΔΔG° = 16.9 kJ/mol) and the loss of only the H-bonds 
to Gln133 and Asp140 of 6 (3-F) (ΔΔG° = 9.9 kJ/mol) discloses a contribution of 
approximately 7.0 kJ/mol for the charge-permanent dipole interaction and 9.9 kJ/mol for the 
H-bonds to the free energy of binding of 3-OH. The close contact of two complementary 
surfaces in the absence of solvent water may be an explanation for the large contribution of 
the charge-dipole interaction.(55-57) 
 
Deoxygenation and substitution of 4-OH of mannose.  The 4-deoxy derivative 9 (4-H) 
suffers from a 4’000-fold loss of affinity. Compared to the effect of the substitution of the 3-
hydroxyl group, the affinity is reduced by another factor of 4, although number and type of H-
bond interactions of 3-OH and 4-OH are comparable. However, C-4 is buried more deeply in 
the pocket than C-3, where a lower dielectric constant and consequently an increased energy 
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for electrostatic interactions are expected.(58)  Interestingly, in contrast to the 2- or 3-position, 
the introduction of a fluorine substituent in the 4-position does not improve binding energy 
compared to the 4-deoxy derivative. Most likely, the electronegative fluoride induces a 
repulsion of the negatively charged Asp54, which is part of a rigid β-sheet. Crystal structures 
reveal a change of the orientation between 4-OH and 4-F (dihedral angle HO4-C4-C5-O = -
174.9° and F4-C4-C5-O = -167.3°), which supports this assumption. Therefore, the loss of 
binding energy upon the removal of 4-OH [→ 9 (4-H), ΔΔG° = 20.6 kJ/mol] is almost 
identical resulting from the loss of the hydrogen bonds [→ 8 (4-F), ΔΔG° = 21.0 kJ/mol]. 
 
Deoxygenation and substitution of 6-OH of mannose. Finally, modifications in the 6-
position of the mannose moiety have the most severe impact on the binding energy. 
Competitive ITC titrations with n-heptyl mannoside (1) when FimHLD was preincubated with 
a 300-fold excess of 10 (6-F) or 11 (6-H) did neither induce a change in binding affinity nor 
enthalpy. Furthermore, direct titration with a 6 mM solution of mannoside 10 (6-F) did not 
result in a signal change in the ITC isotherm. We conclude that the binding affinity of 10 (6-
F) and 11 (6-H) can be expected to be below 1 mM. The 6-hydroxy group forms 3 excellent 
hydrogen bonds, whereof two are charge assisted (N-terminus, Asp54). Considering the 
reduced desolvation costs and number of rotational bonds of derivatives deoxygenated or 
fluorated in the 6-position when compared to mannoside 1, an approximate 30’000-fold loss 
in affinity is surprising and reveals the tremendous importance of this deeply buried hydroxyl 
group.   
 
Kinetic analysis of n-heptyl deoxy- and deoxy-halogeno-α-D-mannosides (Table 3). With 
kinetic isothermal titration calorimetry (kinITC) kinetic data are accessible from ITC 
measurements.(59) It measures the time that the differential power curve takes to return to 
baseline after an injection of ligand solution that is a function binding kinetics. Narrower 
peaks at the beginning and the end of the titration, and wider peaks around the inflection point 
yield a bell-shaped equilibration time curve (ETC) that can be analyzed to determine 
dissociation rate constant koff. The association rate constant kon is calculated from koff and the 





Table 3. Kinetic binding parameters for the interaction of FimHLD with deoxy- and deoxy-halogeno 
derivatives of n-heptyl α-D-mannoside (1) determined by kinITC. Confidence intervals of the fitted 
parameters kon, koff, KD, and the response time are part of the supplementary information (Table S7). Relative 











1 (HM) ITC 3.32*104 1.0 7.27*10-4 1.0 15.90 
2 (2-F) ITC 2.04*104 1.6 1.02*10-2 14.0 1.14 
3 (2-Cl) ITC 8.90*103 3.7 1.19*10-2 16.4 0.97 
4 (2-Br) ITC 7.90*103 4.2 1.45*10-2 19.9 0.80 
5 (2-H) ITC 5.35*103 6.2 4.13*10-2 56.8 0.28 
5 (2-H) SPR 1.05*104 3.1 5.08*10-2 71.1 0.23 
6 (3-F) ITC 1.66*104 2.0 1.98*10-2 27.3 0.58 
7 (3-H) ITC 6.50*103 5.1 1.29*10-1 177.9 0.09 
8 (4-F) ITC 1.00*103 33.2 1.03*10-1 142.3 0.11 
9 (4-H) ITC 9.56*102 34.7 8.45*10-1 116.3 0.14 
 
Binding kinetics for 5 (2-H) determined either by surface plasmon resonance (SPR) or 
kinITC-ETC are in excellent agreement and exhibited deviations smaller than a factor of 2 
(Table 3). In contrast to other carbohydrate-lectin interactions, FimHLD is characterized by 
unusually slow dissociation rates.(60) The reduced affinity of all deoxy- and deoxy-halogeno 
derivatives is mainly resulting from increased koff values, leading to substantially reduced 
complex half-lives (t1/2 = ln2/koff). For example, while t1/2 of n-heptyl α-D-mannoside is more 
than 16 minutes, it is reduced to less than a minute for all deoxy derivatives. Although the 
removal of a hydroxyl group in general has a smaller effect on the kon than koff values, the 
association rates deliver an interesting insight into the binding process. Especially the most 
buried and charge-assisted interaction of 4-OH turns out to be important for the association of 
9 (4-H), since its removal leads to a more than 30-fold reduction of the kon value. A much 
smaller effect was observed for 5 (2-H) and 7 (3-H). An interesting trend can be observed for 
halogen substituents in 2-position, where the decreasing electronegativity (fluorine > chlorine 
> bromine) affects the kon values to a significantly greater extent than koff values. However, 
we can not rule out that increasing atomic radii could have a steric effect on the formation of 
the protein-ligand complexes. In summary, We hypothesize that changes in the short-range 
electrostatic interactions of FimH-mannoside complexes (e.g. hydrogen bonds, dipole-dipole 
interactions) mainly affect the dissociation rate, while medium-range electrostatics, such as 
the dipole-charged interaction of 2-OH with the N-terminus, are additionally of importance 







We demonstrated how the lectin FimH applies a broad spectrum of strategies to overcome the 
intrinsically low binding affinities of a carbohydrate ligand. In particular, quantum 
mechanically derived torsional barriers of a mannoside ligand were calculated and the 
solution conformations were compared to the bound conformation obtained from crystal 
structures. FimHLD turned out to be well pre-organized and to bind hydroxyl groups mainly in 
low energy orientations. 
Furthermore, it was possible to analyze the contributions of three hydroxyl groups of 1 (HM) 
and its deoxy- and deoxy-halogeno derivatives by ITC thermodynamically and kinetically by 
considering their structural binding properties. As expected, the removal of a hydroxyl group 
was accompanied by a loss of enthalpy (ΔΔH° = 26 – 31 kJ/mol) and a smaller gain in 
entropy (-TΔΔS° = -9 – -16 kJ/mol). Hence, contributions to ΔG° could be determined as 
15 kJ/mol for 2-OH close to the protein surface, 17 kJ/mol for 3-OH with a medium position, 
and 21 kJ/mol for the most buried hydroxyl group 4-OH. We observed a general tendency 
that deeper buried hydroxyl groups contribute more to the overall binding affinity of 
mannoside ligands. This effect was most stark for removal of the hydroxyl group in position 
C-6, resulting in the total loss of binding upon. Furthermore,  
 
It furthermore became clear that the contribution of a single hydroxyl group is larger than the 
sum of the loss of its H-bonds and van der Waals interactions. Summing up the ΔG° values of 
the hydroxyl groups 2-4 (without including the essential 6-OH) yields a cumulative 
contribution of 53 kJ/mol which exceeds the total free binding energy ΔG° of n-heptyl α-D-
mannoside. The explanation is that H-bonds build a cross-linked network in which only the 
cooperative interplay between multiple H-bonds is stabilizing the protein-ligand complex. 
Consequently, the loss of one single hydroxyl group (6-OH) can prevent a molecule from 
binding, although the remaining hydroxyl groups could form 6 hydrogen bonds that are 
structurally identical to those observed for the unmodified ligand. 
 
Moreover, by performing an analysis with kinITC, additional kinetic values were obtained. 
As expected, the loss of hydroxyl groups had a stronger influence on koff than on kon. 
However, the short-range electrostatic H-bonds were found to be less important for kon, while 
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the medium-range electrostatic interactions with the positively charged N-terminus (2-OH) 
and the negatively charged Asp54 (4-OH) were of great importance for an increased 
association rate.  
 
The detailed dissection of mannose binding to FimHLD enhances our general understanding of 
carbohydrate binding, and give insights how nature successfully developed high affinity 
carbohydrate-protein interactions. We believe, this knowledge will be of great importance for 
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Supporting Information 
Table S1. Calculated surface accessible solvation area. SASA was calculated in a bound and unbound 
state of HM and its deoxy and deoxy-fluoro derivatives. Values are given in Å2. 
1 (HM) 2 (2-F) 5 (2-H) 6 (3-F) 7 (3-H) 8 (4-F) 9 (4-H) 
Ligand donor_unbound 52 38 38 35 37 40 40 
Ligand donor_bound 0 0 0 0 0 0 0 
Ligand donor_delta 52 38 38 35 37 40 40 
Ligand donor_delta % 100% 100% 100% 100% 100% 100% 100% 
Ligand acceptor_unbound 123 99 101 98 100 98 100 
Ligand acceptor_bound 1 0 3 0 2 0 0 
Ligand acceptor_delta 123 99 98 98 98 98 100 
Ligand acceptor_delta % 99% 100% 97% 100% 98% 100% 100% 
Ligand total_unbound 552 547 541 548 544 548 544 
Ligand total_bound 137 136 135 135 173 134 111 
Ligand total_delta 415 410 405 412 372 414 432 
Ligand total_delta % 75% 75% 75% 75% 68% 76% 80% 
Receptor total_unbound 532 531 542 506 438 531 598 
Receptor total_bound 337 335 352 321 255 331 405 
Receptor total_delta 195 197 190 185 183 201 192 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure S1. Superimposition of X-ray co-crystal structures of FimHLD with HM and 2-H. Both proteins 
are shown in grey, the ligands are shown in pink 1 (HM) and blue 5 (2-H). The missing contact of 2-OH to 
the structural water molecule (W1) and the positively charged N-terminus of 5 slightly tilts its mannose 
moiety, which potentially affects the interactions of the remaining hydroxyl groups to the protein. 
However, the structural changes are within the error of the measurement.  
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Figure S2. Overlap of 1H,15N-HSQC spectra of FimH in absence of ligand (grey) and in presence of 1 (HM, 
black), 2 (2-F, cyan), 5 (2-H, blue), 6 (3-F, light green), 7 (3-H, green), 8 (4-F, orange) and 9 (4-H, red). The 
spectrum in presence of 10 (6-F) is not shown due to the absence of any chemical shift changes. 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S4. Thermodynamic and kinetic fits of n-heptyl α-D-mannopyranoside mannoside (1) binding to 
FimHLD in varying buffers and pH. Measurements were analyzed using AFFINImeter software. 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table S6: Structure, and thermodynamic and kinetic fits of n-heptyl α-D-mannopyranoside mannoside (1) 
and its deoxy- and deoxy-halogeno derivatives (2-9) binding to  FimHLD. All measurements were 
performed at 25°C in HEPES buffer adjusted to pH 7.4, containing 150 mM NaCl. Two independent 
experiments were carried out for each ligand and analyzed using AFFINImeter software. 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Protein preparation. FimHLD from E.coli K-12 strain was expressed with a C-terminal 
thrombin cleavage site and a 6His-tag (FimHLD-Th-6His, 173 residues) following a 
previously published protocol.(1) Briefly, the clone containing the FimHLD construct was 
expressed in the protease-deficient E.coli HM 125 strain at 30°C and 180 rpm in M9 
minimal medium supplemented with 100 µg/mL ampicillin. The protein expression was 
induced by 1 mM IPTG at an OD600 of 0.8. The cells were further cultivated for 16 hrs, 
harvested by centrifugation for 20 min at 5’000 rpm and 4°C. The pellet was resuspended 
in lysis buffer containing 50 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA and 
1 mg/mL polymyxin B sulfate. The supernatant containing the periplasmic extract was 
dialyzed against sodium phosphate buffer and purified on Ni-NTA columns. The protein 
was finally dialyzed against assay buffer containing 20 mM HEPES pH 7.4, 150 mM 
NaCl and 1 mM CaCl2. For long time storage the protein was frozen at -80°C. For the 
production of uniformly 15N-labeled FimHLD-Th-6His for NMR experiments, E.coli 
HM125 was cultivated in M9 minimal medium containing 1 g/L 15NH4Cl (CortecNet, 
France) as the sole source of nitrogen. The labeled protein was purified as described 
above and dialyzed against 20 mM phosphate buffer pH 7. The exact molecular weight 
(18860.2 Da) was determined by mass spectrometry.  
Fluorescence polarization assay. Competitive FP assays were essentially performed as 
described previously [1]. Briefly, a serial dilution of unlabeled competitor was titrated 
into constant concentrations of GNFP4 (final concentration 5 nM) and FimHLD (final 
concentration 15 nM) in the presence of 5% DMSO. All solutions were prepared in a 
buffer containing 20 mM HEPES (pH 7.4), 150 mM NaCl and 50 µg/ml BSA. Mixtures 
were incubated for 24 hours in a final volume of 100 µl per well in black, flat bottom, 
NBS-treated, 96-well microtiter plates (Corning, U.S.A.). Competitor KDs were 
determined via the displacement of GNFP4. The associated decrease in fluorescence 
polarization was recorded at 528 nm (excitation at 485 nm) through appropriately 
oriented polarizing filters. Resulting binding isotherms were fit to an equilibrium 
competition function(2) and analyzed using Prism (GraphPad Software, U.S.A.). The KD 
of GNFP4 and FimH was defined as constraint and set to 1.7 nM during curve fitting.(3) 
 
Co-crystallization, data processing, and structure refinement. For crystallization, 
FimHLD (residues 1-158) at a final concentration of 12 mg/mL (ca. 0.8 mM) with a 
threefold molar excess of ligand (2.5 mM) in 20 mM HEPES buffer pH 7.4. Crystals 
were grown in sitting-drop vapor diffusion at 4°C, 12°C and 20°C in 0.2 M (NH4)2SO4, 
0.1 M HEPES pH 7 and 25-30% PEG3350. Plate-like crystals appeared after 2 weeks, 
were cryopreserved by addition of 20% glycerol (v/v) and flash-cooled with liquid 
nitrogen. Data were collected at the SLS beamlines X06DA and X06SA of the Swiss 
Light Source (Paul Scherrer Institute, Switzerland) and indexed, integrated and scaled 
with XDS.(4,5) Structures were solved by molecular replacement with PHASER(6) using 
the FimHLD-n-heptyl α-D-mannopyranoside complex  (PDB code 4XO8) as search 
model. The structures were built using the COOT software(7) and periodically refined 
with the PHENIX and Buster-TNT software.(8,9) Geometric restraints for the ligands were 
generated with PRODRG(10) and Molprobity(11) was used for validation. The atomic 
coordinates have been deposited in the RCSB Protein Data Bank and are available under 
the accession code 5L4T, 5L4U, 5L4V, 5L4W, 5L4X, and 5L4Y, respectively.  
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RMSD calculation. RMSD was calculated from the FimHLD apo structure (PDB-Code: 
4AUU) and the co-crystal structure in complex with 1 (HM) (PDB-Code: 4XO8). From 
both structures, the heavy atoms involved in ligand binding (Phe1: N from N-terminus; 
Asp47: N from backbone; Asp54: 2xO form side chain; Gln133: N from side chain; 
Asn135: N from side chain; Asp140: O from side chain) were compared using 
Schrödinger Suite 2014-4.  
 
Ab initio calculations. The lowest energy conformer of n-heptyl α-D-mannoside from a 
conformational analysis with MacroModel 10.6(12) using the OPLS 2005 force field was 
subjected to geometrical optimization and energy calculation using the density functional 
theory (DFT) with the B3LYP functional and the 6-31G(d,p) basis-set in the gas-phase as 
implemented in Gaussian 09.(13) The torsional potential was determined using a relaxed 
energy potential surface scan with a 2° step size. Vibrational frequency calculations were 
carried out to confirm these minima. No imaginary frequencies were found. 
 
Molecular dynamics simulations. Molecular dynamics simulations were carried out 
using Desmond(14-18) and the OPLS 2005 force field. Default parameters were applied 
unless stated otherwise. TIP3P was selected as water model and a physiological salt 
concentration (0.15 M) was added to the protein-complex simulation. An energy barrier 
of 5 kcal/mol restricted backbone movement. The MD simulation for the solution 
conformation was run for 9.6 ns, whereas the protein-complex simulation was run for 
4.8 ns. The energies of the per-residue interactions were calculated from 1000 extracted 
MD frames using Prime.(19-21) 
 
NMR experiments. 1H,15N-HSQC NMR experiments were measured at 298 K on a 
Bruker Avance III 600 MHz NMR spectrometer equipped with a 5 mm TXI room 
temperature probe head. Samples contained 120 of 15N-labeled FimHLD in 20 mM 
phosphate buffer pH 7.4 in water with 7% D2O. Deoxy- and deoxy-fluoro derivatives 
were solved in H2O at 10 to 20 mM concentrations and added stepwise up to 2- to 5-fold 
molar excess. In case of 10 (6-F), the required amount of ligand was added directly as a 
lyophilized powder to the protein. NMR spectra were acquired and processed with 
Topspin 3.2 (Bruker BioSpin, Switzerland) and analyzed with CcpNmr Analysis (version 
2.2).(22) The backbone assignment of FimHLD was available from previous studies.
(23) 
Combined chemical shift differences, ΔδAV, between free and ligand-bound protein signals 
were calculated as in equation 1(24) 
 
 ∆𝛿𝐴𝑉 = √(∆𝛿
1𝐻𝑁)2 +  (0.2∆𝛿15)2 (eq. 1) 
 
Isothermal titration calorimetry. ITC experiments were performed at 25°C using a 
VP-ITC (Malvern Instruments, Worcestershire, UK) with an injection volume between 4 
and 10 μl, a reference power of 10 μcal/sec, a stirring speed of 307 rpm, high feedback, a 
spacing time between 360 and 600 seconds and a filter period of 2 seconds. Preceding the 
measurements, FimHLD-Th-His6 was dialyzed against 10 mM of the experimental buffer 
containing 150 mM NaCl. Two independent experiments with 1 (HM) and deoxy- and 
deoxy-halogeno derivatives thereof were performed in a HEPES buffer at pH 7.4. 
Protonation experiments were carried out in different buffers at pH 7.4, pH 8.5 and 
pH 9.0 (Cacodylate pH 7.4; Tris-HCl 7.4, 8.5 and 9.0; Bicine pH 8.5 and 9.0; Tricine 
pH 8.5; TAPS pH 8.5 and 9.0). Ligand and protein were dissolved in the same buffer. 
Protein concentration was determined by NanoDrop ND-1000 Spectrophotometer 
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(Thermo Scientific, MA, USA) using an extinction coefficient of 24’180 M-1 cm-1.(25) The 
ligand and protein concentrations used for the titrations are given in the Supporting 
Information (Table S3). Baseline adjustment and peak integration to determine the 
thermodynamic parameters KA (association constant) and ΔH° (change in enthalpy), the 
kinetic parameters kon (association rate constant) and koff (dissociation rate constant) as 
well as N (stoichiometry), were performed using the fully automated analysis software 
AFFINImeter.(26,27) For the evaluation of the weak binding ligands 7 (3-H), 8 (4-F) and 9 
(4-H) it was necessary to fix the stoichiometry (N=1) for fitting. ΔG° (free energy of 
binding) and ΔS° (change in entropy) were calculated from equation 2 
 
 ΔG° = ΔH° − TΔS° = −RT lnKA (eq. 2) 
 





General methods. Commercially available reagents were purchased from Aldrich, 
Merck or Alfa Aesar. Methanol was dried by distillation from sodium methoxide. 
Dichloromethane (CH2Cl2) was dried by filtration through Al2O3 (Fluka, basic; 0.05-0.15 
mm). Toluene was dried by distillation from sodium/benzophenone. Optical rotations 
were measured at 20°C on a Perkin Elmer 341 polarimeter with a path length of 1 dm. 
Concentrations are given in g/100 mL. NMR spectra were obtained on a Bruker Avance 
500 UltraShield spectrometer at 500.13 MHz (1H) or 125.76 MHz (13C). Chemical shifts 
are given in ppm and were calibrated on residual solvent peaks or to tetramethyl silane as 
internal standard. Multiplicities are specified as s (singulet), d (doublet), dd (doublet of a 
doublet), t (triplet), q (quartet) or m (multiplet). Assignment of the 1H and 13C NMR 
spectra was achieved using 2D methods (COSY, HSQC). ESI mass spectra were 
recorded on a Waters micromass ZQ instrument. High-resolution mass spectra were 
obtained on an ESI Bruker Daltonics micrOTOF spectrometer equipped with a TOF 
hexapole detector. Reactions were monitored by TLC using glass plates coated with 
silica gel 60 F254 and visualized by using UV light and/or by charring with a molybdate 
solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium 
molybdate tetrahydrate in aqueous 10% H2SO4) with heating to 140°C for 5 min. 
Column chromatography was performed on a CombiFlash Companion (ISCO, Inc.) 
using RediSep normal phase disposable flash columns (silica gel). Reversed phase 
chromatography was performed on LiChroprepRP-18 (Merck, 40- 63 m). 
Synthesis of 1 (6-F) (n-Heptyl 6-Fluoro-6-deoxy--D-mannopyranoside) 
Scheme S1. a) i. Trityl chloride, pyridine, DMAP, 80°C, overnight, ii. benzoyl chloride, two steps in one 
pot, (98%); b) FeCl3, DCM, rt, overnight, (87%); c) DAST, DCM, rt, overnight, (45%); d) 0.5 M 
CH3ONa/CH3OH, (80%). 
n-Heptyl 2,3,5-tri-O-benzoyl-6-O-triphenylmethyl-α-D-mannopyranoside (12)(28)
To a solution of 1 (310 mg, 1.114 mmol) in pyridine (4.0 mL) was added TrCl (388 mg,
1.392 mmol) and catalytic amount of 4-dimethylaminopyridine (DMAP). The mixture









































mixture was added a premixed solution of BzCl (0.52 mL) in pyridine (0.5 mL) dropwise. 
The reaction mixture was stirred at 50°C overnight and then poured into ice-cold water, 
extracted with EtOAc, the organic layer was washed with aqueous NaHCO3, water, 
brine and dried over Na2SO4. The solvent was removed in vacuo and the residue was 
purified by flash chromatography on silica gel (PE-EE, 10:1-6:1) to afford the desired 
compound as a white solid (642 mg, 98%). 1H-NMR (500 MHz, CDCl3):  8.16 (d, J = 
7.5 Hz, 2H), 7.83 (d, J = 8.0 Hz, 2H), 7.73 (d, J = 8.0 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 
7.50-7.40 (m, 10H), 7.31 (t, J = 8.0 Hz, 2H), 7.26 (t, J = 7.5 Hz, 2H), 7.16-7.07 (m, 9H), 
6.01 (t, J = 10.0 Hz, 1H, H-4), 5.79 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 5.67 (m, 1H, H-2), 
5.12 (s, 1H, H-1), 4.18 (m, 1H, H-5), 3.86 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 3.58 
(dt, J = 9.5, 7.0 Hz, 1H, H-OCH2C6H13), 3.37 (dd, J = 10.5, 2.0 Hz, 1H,H-6a), 3.27 (dd, J 
= 10.5, 5.0 Hz, 1H,H-66), 1.71 (m, 2H), 1.43-1.32 (m, 8H), 0.90 (t, J = 7.0 Hz, 3H). 13C-
NMR (125 MHz, CDCl3):  165.70, 165.54, 165.11 (3xCO), 143.75, 133.38, 133.01, 
132.96, 129.94, 129.74, 129.65, 129.59, 129.36, 129.26, 129.62, 128.60, 128.23, 128.13, 
127.66, 126.80, 97.48 (C-1), 86.54, 70.97 (C-2), 70.66 (C-3), 70.31 (C-5), 68.36 
(OCH2C6H13), 67.08 (C-4), 62.31 (C-6), 31.82, 29.45, 29.14, 26.16, 22.64, 14.12 
(OCH2C6H13). ESI-MS Calcd for [M+Na]
+, 855.35, found 855.28. 
n-Heptyl 2,3,5-tri-O-benzoyl-α-D-mannopyranoside (13)(29)
To a solution of 12 (583 mg, 0.7 mmol) in DCM (10 mL) was added FeCl3 (hydroscopic
solid) (284 mg, 1.75 mmol) at rt. The reaction mixture was stirred at rt overnight, diluted
with DCM, washed with brine, dried over Na2SO4. The solvent was removed in vacuo
and the residue was purified by flash chromatography on silica gel (PE-EE, 10:1-4:1) to
afford the desired compound as a white solid (359 mg, 87%). []D
20 = -126.79 (c = 0.60,
DCM). 1H-NMR (500 MHz, CDCl3):  8.10 (d, J = 7.5 Hz, 2H), 7.98 (d, J = 7.5 Hz, 2H),
7.82 (dd, J = 8.0, 1.0 Hz, 2H), 7.62 (t, J = 7.5 Hz, 1H), 7.55-7.48 (m, 3H), 7.45-7.38 (m,
3H), 7.26 (m, 2H), 5.99 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.82 (t, J = 10.0 Hz, 1H, H-4),
5.66 (dd, J = 3.0, 1.5 Hz, 1H, H-2), 5.09 (d, J = 1.0 Hz, 1H, H-1), 4.06 (m, 1H, H-5),
3.85-3.75 (m, 3H, H-6a, H-6b, H-OCH2C6H13), 3.54 (dt, J = 9.5, 6.5 Hz, 1H, H-
OCH2C6H13), 2.63 (m, 1H, 6-OH), 1.68 (m, 2H), 1.42-1.25 (m, 8H), 0.91 (t, J = 7.0 Hz,
3H). 13C-NMR (125 MHz, CDCl3):  166.56, 165.57, 165.49 (3xCO), 133.66, 133.52,
133.16, 129.91, 129.68, 129.33, 129.14, 128.73, 128.62, 128.50, 128.29, 97.68 (C-1),
70.82 (C-2), 70.77 (C-5), 69.69 (C-3), 68.67 (OCH2C6H13), 67.39 (C-4), 61.39 (C-6), 31.77,




To a solution of 13 (125 mg, 0.2116 mmol) in dry DCM (0.5 mL) was added DAST (0.44
mL) at 0°C, then stirred at rt overnight. After cooling to 0°C, the reaction mixture was
quenched with methanol, concentrated, the residue was purified by flash
chromatography on silica gel using PE-EE (9:1-6:1) to afford the desired compound as
colorless oil (56 mg, 45%). []D
20 = -126.76 (c = 0.61, DCM). 1H-NMR (500 MHz,
CDCl3):  8.10 (m, 2H), 7.97 (m, 2H), 7.83 (m, 2H), 7.62 (t, J = 7.0 Hz, 1H), 7.55-7.48
(m, 3H), 7.45-7.38 (m, 3H), 7.26 (m, 2H), 5.92 (dd, J = 10.0, 3.0 Hz, 1H, H-3), 5.88 (t, J
= 10.0 Hz, 1H, H-4), 5.67 (dd, J = 3.0, 1.5 Hz, 1H, H-2), 5.09 (d, J = 1.5 Hz, 1H, H-1),
4.64 (ddd, J = 47.5, 10.5, 4.5 Hz, 1H, H-6a), 4.60 (ddd, J = 47.0, 10.5, 2.5 Hz, 1H, H-
6b), 4.28 (m, 1H, H-5), 3.82 (dt, J = 9.5, 6.5 Hz, 1H, H-OCH2C6H13), 3.57 (dt, J = 9.5, 6.5
Hz, 1H, H-OCH2C6H13), 1.71 (m, 2H), 1.37 (m, 8H), 0.91 (t, J = 7.0 Hz, 3H). 
13C-NMR
(125 MHz, CDCl3):  165.56, 165.51, 165.45 (3xCO), 133.52, 133.17, 129.91, 129.80,
227
129.70, 129.28, 129.05, 128.86, 128.60, 128.47, 128.29, 97.59 (C-1), 81.75 (d, J = 173.88 
Hz, C-6), 70.55 (C-2), 69.94 (C-3), 69.59 (d, J = 19.0 Hz, C-5), 68.81 (OCH2C6H13), 66.36 
(d, J = 9.0 Hz, C-4), 31.77, 29.36, 29.06, 26.06, 22.63, 14.10 (OCH2C6H13). HR-MS Calcd 
for C34H37FO8 [M+Na]
+, 615.2370, found 615.2373. 
 
n-Heptyl 6-deoxy-6-fluoro--D-mannopyranoside (10) 
To a solution of n-heptyl 14 (44.8 mg, 0.0756 mmol) in dry methanol (1.0 mL) was added 
0.5 M CH3ONa/MeOH (80 µL) at rt. The reaction mixture was stirred overnight, then 
neutralized HOAc, concentrated to dryness. The residue was purified by flash 
chromatography on silica gel (DCM:MeOH 15:1 to 10:1) to afford 10 as a colorless syrup 
(17 mg, 80%). []D
20 = +98.8 (c = 0.28, DCM). 1H-NMR (500 MHz, CD3OD):  4.73 (d, 
J = 1.5 Hz, 1H, H-1), 4.65 (m, 1H, H-6a), 4.55 (m, 1H, H-6b), 3.79 (dd, J = 3.0, 2.0 Hz, 
1H, H-2), 3.72-3.61 (m, 4H, H-OCH2C6H13, H-3, H-4, H-5), 3.42 (dt, J = 9.5, 6.5 Hz, 1H, 
H-OCH2C6H13), 1.59 (m, 2H), 1.32 (m, 8H), 0.91 (t, J = 7.0 Hz, 3H, CH3). 
13C-NMR (125 
MHz, CD3OD):  101.74 (C-1), 84.23 (d, J = 169.88 Hz, C-6), 73.35 (d, J = 17.75 Hz, C-
5), 72.63 (C-3), 72.10 (C-2), 68.71 (OCH2C6H13), 67.48 (d, J = 7.25 Hz, C-4), 32.99, 30.60, 
30.21, 27.32, 23.69, 14.42 (OCH2C6H13).
 19F-NMR (376 MHz, CD3OD):  -230.46 (m). 
ESI-MS Calcd for [M+Na]+, 303.16, found 303.07. HR-MS Calcd. for C13H25FO5 
[M+Na]+, 303.1578, found 303.1575.  
 
Synthesis of 54 (6-H) (n-Heptyl 6-deoxy--D-mannopyranoside) 
 
 
Scheme S2. a) i. CBr4, Ph3P, pyr, 0-65°C, 3 h, ii. Ac2O/pyr, DMAP, two steps (81%); b) Bu3SnH/toluene, 
reflux, overnight, (80%); c) CH3ONa/CH3OH, (66%). 
 
n-Heptyl 2,3,4-tri-O-acetyl-6-bromo-6-deoxy--D-mannopyranoside (15) 
To a solution of 1 (110 mg, 0.359 mmol) in pyridine (3 mL) was added 
triphenylphosphine (189 mg, 0.72 mmol) in one portion at 0°C, then added CBr4 (179 
mg, 0.54 mmol) in portions at 0°C. The reaction mixture was stirred at 0°C for 0.5 h, 
then was heated at 65°C for 3 h. After cooling, methanol (2 mL) was added dropwise and 
the mixture was concentrated to dryness. The residue was acetylated with Ac2O (1 mL), 
pyridine (2 mL) and DMAP (2 mg). The reaction mixture was stirred at rt for 3 h and 
then concentrated, the residue was purified by flash chromatography on silica gel (PE-EA 
6:1-4:1) to give the desired product (136 mg, 81%) as a colorless syrup. []D
20 = +51.60 (c 
= 0.89, CHCl3);
 1H NMR (500 MHz, CDCl3):  5.33 (m, 1H, H-3), 5.21 (d, J = 1.0 Hz, 
1H, H-2), 5.16 (t, J = 10.0 Hz, 1H, H-4), 4.81 (s, 1H, H-1), 3.97 (m, 1H, H-5), 3.76 (m, 
1H, OCH2C6H13), 3.42 (m, 3H, H-6a, H-6b, OCH2C6H13), 2.13, 2.06, 1.98 (3xs, 9H, 
3xCOCH3), 1.59  (m, 2H), 1.30 (m, 8H, OC2H4C4H8CH3), 0.87 (t, J = 6.5 Hz, 3H, 
OC2H4C4H8CH3); 
13C NMR (125 MHz, CDCl3):  170.06, 169.84 (3xCOCH3), 97.28 (C-
1), 69.88 (C-5), 69.67 (C-2), 68.91 (C-3), 68.84 (C-4), 68.41 (OCH2C6H13), 31.44 (C-6), 
31.68, 29.16, 28.98, 25.99, 22.57, 14.05 (OCH2C6H13), 20.86, 20.74, 20.66 (3xCOCH3); 
ESI-MS Calcd for [M+Na+2]+, 491.13, found 491.11. HR-MS Calcd. for C19H31BrO8 
[M+Na]+, 489.1100, found 489.1099. 
 
n-Heptyl 2,3,4-tri-O-acetyl-6-deoxy--D-mannopyranoside (16) 
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A solution of Bu3SnH (0.26 mL, 0.96 mmol) in toluene (2.5 mL) was added dropwise to 
a gently refluxing solution of 15 (300 mg, 0.64 mmol) in toluene (4 mL) over 10 min and 
the mixture was refluxing overnight. After cooling, the mixture was concentrated and the 
residue was purified by flash chromatography on silica gel (PE-EA 3:1-3:2) to give the 
desired compound (198 mg, 80%) as a colorless oil. []D
20 = +52.72 (c = 0.30, MeOH); 
1H NMR (500 MHz, CDCl3):  5.30 (dd, J = 10.0, 3.5 Hz, 1H, H-3), 5.22 (dd, J = 3.5, 
1.5 Hz, 1H, H-2), 5.05 (t, J = 10.0 Hz, 1H, H-4), 4.71 (s, 1H, H-1), 3.87 (m, 1H, H-5), 
3.65 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 3.40 (dt, J = 9.5, 6.5 Hz, 1H, OCH2C6H13), 
2.15, 2.05,1.98 (3xs, 9H, 3xCOCH3), 1.57 (m, 2H, OCH2CH2C5H11), 1.30 (m, 8H, 
OC2H4C4H8CH3), 1.21 (d, J = 6.0 Hz, 3H, H-6), 0.88 (t, J = 7.0 Hz, 3H, 
OC2H4C4H8CH3); 
13C NMR (125 MHz, CDCl3):  170.21, 170.05, 170.00 (3xCOCH3), 
97.38 (C-1), 71.23 (C-4), 70.02 (C-2), 69.18 (C-3), 68.23 (OCH2C6H13), 66.16 (C-5), 17.40 
(C-6), 31.73, 29.30, 29.01, 26.00, 22.59, 14.06 (OCH2C6H13), 20.95, 20.81, 20.74 
(3xCOCH3); HR-MS calcd. for C19H32O8 [M+Na]
+, 411.1995, found 411.1992. 
n-Heptyl 6-deoxy--D-mannopyranoside (11)
To a solution of 16 (80 mg, 0.206 mmol) in methanol (2 mL) was added 0.5 M
CH3ONa/MeOH (41 µL) at rt. The reaction mixture was stirred at rt overnight, then
neutralized with Amberlyst 15. The reaction mixture was filtered and the residue was
washed thoroughly with MeOH. The filtrate was concentrated and the residue was
purified with flash chromatography on silica gel (PE:EA 1:1-1:2) to give compound 11
(36 mg, 66%) as a colorless oil. []D
20 = +50.40 (c = 0.33, MeOH); 1H NMR (500 MHz,
CD3OD):  4.65 (s, 1H, H-1), 3.78 (m, 1H, H-2), 3.69-3.62 (m, 2H, H-OCH2C6H13, H-3),
3.57 (m, 1H, H-5), 3.42-3.35 (m, 2H, H-OCH2C6H13, H-4), 1.58 (m, 2H,
OCH2CH2C5H11), 1.32 (m, 8H, OC2H4C4H8CH3), 1.26 (d, J = 6.0 Hz, 3H, H-6), 0.91 (t, J
= 7.0 Hz, 3H, OC2H4C4H8CH3); 
13C NMR (125 MHz, CD3OD):  101.61 (C-1), 73.96 (C-
4), 72.44 (C-3), 72.34 (C-2), 69.70 (C-5), 68.52 (OCH2C6H13), 32.97, 30.64, 30.20, 27.30,
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Anti-adhesive glycomimetics have emerged as a promising alternative to conventional 
antibiotics for the treatment of urinary tract infections (UTIs). Known as FimH antagonists, 
these glycomimetics avert UTIs by binding and blocking the bacterial lectin FimH, which 
mediates adhesion to the host urothelium. The natural ligands of FimH are high-mannose N-
glycans, which form highly conserved interactions in the binding pocket and additional 
hydrophobic stacking interactions with a structural element adjacent to the binding pocket, 
known as the tyrosine gate. It is the prevailing view that the affinity of synthetic FimH 
antagonists is primarily determined by how well they mimic the hydrophobic interactions 
between natural ligands and the tyrosine gate. We measured the binding affinities of several 
di- and oligomannoses with isothermal titration calorimetry (ITC), showing that neither
variation of the glycosidic linkages nor variation in the number of mannose residues in 
oligomannoses affects binding affinities. Previous studies had suggested otherwise, arguing 
that the tyrosine gate was sensitive to changes in oligomannose structures because of its 
significant contributions to ligand binding. Partial or complete removal of the tyrosine gate 
had no effect on the binding affinity of a dimannose, supporting our suspicion that the 
significance of the tyrosine gate has been overestimated. Molecular dynamics simulations 
confirmed ITC results, showing that interactions between di- and oligomannoses and the 
tyrosine gate were limited, especially compared to synthetic FimH antagonists. Indeed, rather 
than for natural ligand binding, the tyrosine gate seems to be important for synthetic ligands 
and may be aptly described as an evolutionary remnant. 
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Introduction 
In contrast, pathogens have co-evolved means to exploit human cell-surface glycosides in the 
form of lectins that can mediate adherence to host cells and the formation of biofilms, both of 
which are key factors for their survival (13, 14). Examples of such opportunistic bacterial 
species include Pseudomonas aeruginosa with its membrane lectin LecB that has been 
implicated in biofilm formation (15, 16), and Burkholderia cenocepacia, where the 
characteristic B. cenocepacia lectin A (BC2L-A) binds host mannosides with high affinity. 
BC2L-A is believed to play an important role in the social life of a bacterial cell (17, 18). 
Another example is the bacterial lectin FimH, which plays a crucial role in urinary tract 
infections (UTIs) by enabling uropathogenic Escherichia coli (UPEC) to adhere to urothelial 
host cells (19, 20). FimH-mediated bacterial adhesion represents the first and most critical 
step in an UTI, triggering a cascade of pathogenic processes that ultimately leads to an 
infection. FimH binds to mannose residues on high-mannose N-glycans (Fig. 1) of the 
urothelial glycoprotein uroplakin Ia (UPIa) (21). The corresponding mannose binding pocket 
is located in the N-terminal lectin domain of FimH (FimHLD) (22). The prerequisite role of 
FimH in UTI pathogenesis has turned it into an attractive target to prevent and treat UTIs. 
Saturation of all FimH receptors with a glycomimetic FimH antagonist can thwart bacterial 
adhesion, effectively preventing an UTI by removing the requisite on which every subsequent 
pathogenic mechanism is predicated. 
The binding pocket of FimH is well-defined and accommodates a single α-D-mannose (1) 
molecule in an extensive and strong hydrogen bond network (23, 24). Accordingly, any 
modifications on mannose hydroxyl groups virtually abolish binding affinity (24, 25). Facing 
outward, (C1)-OH is the only hydroxyl group of 1 susceptible to modifications without 
simultaneously jeopardizing binding affinity. Early studies of potential FimH antagonists 
identified several aliphatic groups, e.g., methyl α-D-mannoside (10) (26) and n-heptyl 
mannoside (11) (23), and aromatic groups (27) as potent (C1)-OH modifications, leading  
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researchers to speculate about a hydrophobic region adjacent to the binding pocket. This 
assumption proved to be true when FimHLD was crystallized in complex with various ligands, 
including the natural glycan known as oligmannose-3 (Table 2) (28). This crystal structure 
revealed that Manα1-3Manß1-4GlcNAc (Fig. 1, red), hereafter shortened to 7, is the binding 
epitope, engaging in several polar and hydrophobic interactions with the FimH lectin. Most 
notably among these interactions, the trisaccharide epitope stacks onto Tyr48, which together 
with Tyr137 forms the aptly named tyrosine gate (23). Comparing the crystal structure of the 
natural glycan with the aliphatic FimH antagonist n-butyl mannoside showed how the 
aliphatic chain was following the α1-3 and ß1-4 glycosidic linkages of oligomannose-3 
through the tyrosine gate (28). This lead researchers to conclude that the affinity of synthetic 
FimH antagonists was dependent on how well the antagonist was mimicking the binding 
epitope of this natural glycan. Accordingly, high binding affinities of aromatic FimH 
antagonists, which have been shown to exceed the affinity of 1 by up to three orders of 
magnitude (29–35), were rationalized solely on the basis of improved hydrophobic stacking 
interactions with the tyrosine gate. 
Intrigued by the concept of FimH antagonists mimicking the binding mode of the natural 
ligand by interacting with the tyrosine gate, we set out to analyze other mannose-sensitive 
receptors expecting to find similar structural elements. While the significance of the tyrosine 
gate for FimH antagonists is unambiguous, our findings made us ponder whether the same 
degree of certainty is warranted for natural glycans. Consequently, we used isothermal 
titration calorimetry (ITC) to analyze the binding affinities of several mannose ligands 
corresponding to sequences that are terminally exposed in natural glycans, which includes the 
7 binding epitope (Table 2). In addition, we analyzed the interactions of these ligands with the 
FimHLD in molecular dynamics (MD) simulations. In this study, we provide an answer to the 
question: is the tyrosine gate involved in natural ligand binding or is it rather an 
opportune evolutionary remnant?
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Figure 1. Structure of oligomannose-9, which is the largest biosynthesized high-mannose N-glycan.  As a target of α-
mannosidases in the endoplasmic reticulum and the Golgi complex, it is usually trimmed down to smaller oligomannoses 
before being transferred to the appropriate protein. The Manα1-3Manß1-4GlcNAc sequence is the presumed binding 
epitope of the FimH lectin and highlighted in red. Glycosidic linkages are indicated in bold font. 
Results 
Binding affinities of mono-, di-, and oligomannose ligands for FimHLD. We have 
determined the dissociation constants (KD) of FimHLD and 1 as well as several mono-, di-, and 
oligomannose ligands using ITC (Table 2 and Table 3). As the minimal binding epitope of 
FimH, 1 was an integral part of the ligand series, as was its congeneric α-anomer, 10. 
Additionally, all α-linked dimannoses were measured to assess the influence of the glycosidic 
linkage on stacking interactions between the second mannose moiety and Tyr48. Measured 
oligomannoses included 6, which corresponds to the terminal mannose sequence on the α1-6 
branch of high-mannose N-glycans, and 8, which matches the 6 sequence and additionally 
includes the α1-6 linked mannose unit of the core sequence of GlcNAcß1 linked N-glycans 
(Fig. 1 and Table 2). Identified as the highest affinity mannose sequence on high-mannose N-

























































Table 1. Mannose ligands of the experimental series in this study.  
Experimental mannose ligand series 
D-mannose (1)
Manα1-2Man (2) Manα1-3Man (3) Manα1-4Man (4) Manα1-6Man (5) 
Manα1-6[Manα1-3]Man (6) Manα1-3Manβ1-4GlcNAc (7) 
Manα1-6[Manα1-3]Manα1-6Man (8) 
Oligomannose-3 (9) 
Methyl α-D-mannose (10) n-Heptyl α-D-mannoside (11) Biphenyl mannoside 12 
Further relevant oligomannoses 
Oligomannose-5 (13) 
Oligomannose-6 (14) 
ITC experiments with ligands (Table 1) and the lectin domain of FimH (FimHLD). 
Interestingly, the heat signals in the thermograms of all tested mannose ligands were 
characterized by relatively slow equilibration times. Heat signal curvatures of mannose 
ligands amenable to kinetic analysis revealed remarkably slow on rate constants in the range 
of 103 M-1 s-1 (SI Appendix, Table S6) as a potential cause for the slowly equilibrating heat 
signals. The influence of slow kinetics on the heat signal necessitated longer spacing intervals 
between the injections and higher injection volumes to compensate for the peak broadening 
(SI Appendix, Table S2 and Table S4). 
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Table 2. Binding affinities 








[µM]   
Y48A/Y137A 
mutant of FimHLD 
[µM]   
D-Mannose (1) 617.3 2.7 - - - 
Manα1-2Man (2) 345.4 2.4 - - - 
Manα1-3Man (3) 152.2 1.1 1.4 2.4 1.5 
Manα1-4Man (4) 384.9 1.2 - - - 
Manα1-6Man (5) 787.4 3.3 - - - 
Manα1-6[Manα1-3]Man (6) 105.7 1.2 - - - 
Manα1-3Manβ1-4GlcNAc (7) - 1.2 - - - 
Manα1-6[Manα1-3]Manα1-
6Man (8) 114.1 1.5 - - - 
Oligomannose-3 (9) - 2.7 0.9 6.9 3.9 
Methyl α-D-mannose (10) 529.5 1.2 - - - 
n-Heptyl α-D-mannoside (11) - 3 × 10-2 - - - 
Biphenylmannoside (12) - 1 × 10-3 - - -
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Table 3. Binding thermodynamics of mannose ligands and FimHLD as determined by ITC. Thermodynamic 
parameters are indicated in kJ mol-1. 68.3% confidence intervals for fitted parameters are given in parentheses. If 
not stated otherwise, experiments were performed once. The N parameter was averaged for ligands that were 
measured more than once. Individual N parameters are given in Table S2. 
Ligand KD [µM] LE[d] ∆G°obs ∆H°obs -T∆Sobs N 
D-Mannose (1) 2.7 (2.2 – 3.2) 0.63 -31.8
-41.6
(-43.5 – -39.8) 9.8 0.91 
Manα1-2Man (2) 2.4 (1.9 – 3.0) 0.33 -32.1
-33.6
(-35.3 – -32.1) 1.5 1.01 
Manα1-3Man (3)[a] 1.1 (0.9 – 1.4) 0.32 -34.0
-43.3
(-44.9 – -41.7) 9.2 0.95 
Manα1-4Man (4) 1.2 (0.9 – 1.5) 0.35 -33.9
-34.0
(-35.7 – -32.5) 0.1 0.98 
Manα1-6Man (5)[a] 3.3 (2.5 – 4.4) 0.33 -31.3
-28.6
(-30.4 – -27.1) -2.7 1.08 
Manα1-6[Manα1-3]Man (6)[a,b] 1.2 (0.9 – 1.7) 0.23 -33.8
-35.3
(-36.8 – -34.0) 1.6 0.93 
Manα1-3Manβ1-4GlcNAc (7)[a] 1.2 (0.9 – 1.5) 0.22 -33.9
-41.1




(1.0 – 2.2) 0.18 -33.3
-36.6
(-39.0 – -34.5) 3.3 0.95 
Oligomannose-3 (9) 2.7 (2.1 – 3.5) 0.12 -31.8
-36.2
(-38.1 – -34.4) 4.4 1.02 
Methyl α-D-mannose (10) 1.2 (0.9 – 1.6) 0.62 -33.9
-35.3
(-36.8 – -33.9) 1.4 0.93 
n-Heptyl α-D-mannoside (11)[c] 3 × 10-2 0.54 -43.0 -50.3 7.3 1.00 
Biphenylmannoside (12)[c] 1 × 10-3 0.45 -50.7 -60.9 10.1 1.01 
[a]Experiments were performed at least twice. [b]Binding isotherms were fitted to a 2:1 binding model. [c]Values
taken from ref. 32. [d]Ligand efficiency. 
The inflection point of an ITC binding isotherm indicates the stoichiometric ratio of titrant 
(here: mannose ligand) to cell material (here: FimHLD). Designated simply as N in Table 3 
and SI Appendix Table S2 and Table S4, this parameter is used to infer the binding 
stoichiometry of the reaction or the protein fraction incompetent of binding. For 1:1 binding, 
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the N parameter is expected to be close to 1, which was the case for most of the mannose 
ligands in this series. However, 6, 8, and 9 were prominent exceptions to this observation and 
initially showed N values around 0.5. Considering that the same FimHLD batch was used 
throughout the series of ITC experiments, partly inactive FimHLD could be reasonably 
excluded as possible reason. Instead, an N value of 0.5 signified a 2:1 binding stoichiometry 
of oligomannose to FimHLD. As a consequence, we have adjusted the binding model from 1:1 
to 2:1 binding (see Materials and Methods for details). If this adjustment is not undertaken, 
the KD and ∆H° of these oligomannoses will be inadvertently overestimated. After applying 
appropriate binding models to the binding isotherms, the resulting KD values of all mannose 
ligands showed a remarkable congruence, only ranging between 1.1 to 3.3 µM (Table 3). 
Most notably, this includes Man2GlcNAc1 and Man3GlcNAc2 with KD values of 1.2 and 
2.7 µM, respectively, which demonstrates that their binding affinities do not exceed those of 
any other mannose ligands tested in this series. 
Binding affinities of FimHLD with a partly or completely defunct tyrosine gate. FimHLD 
constructs with an incomplete or nonexistent tyrosine gate would be expected to have 
diminished binding affinities for di- and oligomannose ligands, provided that stacking 
interactions with the tyrosine gate contribute significantly to the overall binding affinity. To 
that end, we generated a FimH-Y48A and FimH-Y137A mutant, as well as a double mutant 
with both tyrosine residues mutated to an alanine residue. ITC experiments were performed 
with 3 as representative mannose ligand. Heat signals of the FimHLD mutants and 3 were 
characterized by comparably slow equilibration times as observed for heat signals of the wild 
type FimHLD measurements. KD values of 3 and all tyrosine gate mutants were strikingly 
similar, ranging between 1.1 and 2.4 µM (Table 4). The mutational study demonstrated that 
partial or complete loss of the tyrosine gate did not affect the binding affinity of a mannose 
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ligand presumed to engage it in crucial stacking interactions. This result reinforced our 
findings of the previous ITC experimental series. 
Table 4. Comparison of binding thermodynamics of Manα1-3Man (3) with FimHLD and several tyrosine gate mutants of 
FimHLD. Thermodynamic parameters are indicated in kJ mol-1. 68.3% confidence intervals for fitted parameters are given 
in parentheses. If not stated otherwise, experiments were performed at least twice. The N parameter was averaged for 
ligands that were measured more than once. Individual N parameters are given in Table S4. 
FimHLD KD [µM] ∆°Gobs ∆°Hobs -T∆S°obs N 
Wild type 1.1 (0.9 – 1.4) -34.0
-43.3
(-44.9 – -41.7) 9.2 0.95 
Y48A mutant 1.4 (1.1 – 1.8) -33.4
-45.6
(-47.2 – -44.0) 12.1 1.00 
Y137A mutant 2.4 (1.9 – 3.0) -32.1
-39.0




(1.2 – 1.9) -33.2
-41.9
(-43.0 – -40.8) 8.6 1.00 
[a]Experiment performed once.
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ITC experiments with ligands (Table 1) and full-length FimH (FimHFL). 
Table 5. Binding thermodynamics of mannose ligands and FimHFL as determined by ITC. Thermodynamic parameters 
are indicated in kJ mol-1. 68.3% confidence intervals for fitted parameters are given in parentheses. If not stated otherwise, 
experiments were performed once. The N parameter was averaged for ligands that were measured more than once. 
Individual N parameters are given in Table S2. 
Ligand KD [µM] LE[a] ∆G°obs ∆H°obs -T∆Sobs N 
D-Mannose (1) 2.7 (2.2 – 3.2) - -31.8 
-41.6
(-43.5 – -39.8) 9.8 0.91 
Manα1-2Man (2) 345.4 (334.4 – 356.7) 0.21 -19.8
-62.0
(-63.7 – -60.4) 42.3 1.0
[d] 
Manα1-3Man (3) 152.2 (138.8 – 167.3) 0.23 -21.8
-75.7
(-81.9 – -70.3) 53.9 1.0
[d] 
Manα1-4Man (4) 384.9 (367.5 – 403.0) 0.20 -19.5
-45.9
(-47.6 – -44.3) 26.4 1.0
[d] 
Manα1-6Man (5) 787.4 (757.2 – 818.8) 0.18 -17.7
-63.1
(-65.4 – -60.9) 45.4 1.0
[d] 
Manα1-6[Manα1-3] 
Manα1-6Man (8) - - - - - - 
Oligomannose-3 (9) - - - - - - 
Methyl α-D-mannose (10) 1.2 (0.9 – 1.6) 0.62 -33.9
-35.3
(-36.8 – -33.9) 1.4 0.93 
n-Heptyl α-D-mannoside (11)[c]
28.9 
(25.8 – 32.3) 
0.54 -43.0 -50.3(-50.2 – -50.7) 7.3 1.00 
Biphenylmannoside 12[c] - - - - - - 
[a]Ligand efficiency;  [b]Binding isotherms were fitted to a 2:1 binding model; [c]Values taken from ref. 32; [d] 
fixed to 1.
Dynamic and quantum mechanical interaction with tyrosine gate. (Figure 2) Quantitative 
analysis of ligand–protein interactions of 1000 ns MD simulations revealed that C6 of 1 
interacts with the side-chain of Ile52 to a small extent, which is true for all analyzed ligands. 
The additional methyl group of 10 is able to form further interactions with Tyr48, while the 
dimannoses (2– 5), trimannose (6) and tetramannose (8) ligands are rarely in contact with the 
tyrosine gate residues because of the linked mannose that is less versatile than the methyl 
group of 10. The natural binding epitope 7 as well as 9 donate a hydrogen bond with their N- 
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acetylglucosamine (C6)-OH to Thr51 in 63% of the simulation time. This is the reason why 
additional interactions with Tyr137 can be observed in contrast to the other oligomannoses 
that lack N-acetylglucosamine at the same position. Both synthetic ligands 11 and 12 showed 
an increased interaction with the tyrosine gate residues, most notably with Tyr48. These 
results are in good agreement with ITC experiments. 
From the MD simulations it was apparent that the first mannose was heavily involved in 
hydrogen bonding to FimH and hydrophobic contact with Ile52, and that the second mannose 
moiety or the synthetic aglycones were mainly in contact with the tyrosine gate, especially 
Tyr48. Therefore, ab initio quantum mechanical (QM) calculations were carried out, which 
revealed that from the tested moieties the second mannose moiety with only -12.1 kJ mol-1 
interacted the weakest with Tyr48. Replacing this mannose by an exemplary cyclohexane 
improved the interaction energy to -15.9 kJ mol-1. However, synthetic ligands benefited much 
more from stacking interactions with Tyr48. The n-heptyl aglycone, as seen in 11, showed an 
improved interaction energy of -16.8 kJ mol-1, while the biphenyl agylcone of 12 improved 
even further upon that energy value through optimal π-π stacking, showing an interaction 
energy of -35.7 kJ mol-1. 
Figuge 2. Analysis of the tyrosine gate interaction frequency of different mannose (1) and methyl mannoside (10), di- (2-
4), tri- (6), and tetramannose (8) ligands, as well the natural epitopes (7 and 9) and synthetic ligands (11 and 12). 
Hydrophobic interactions with Ile52 are colored in yellow, with Tyr48 in cyan, and with Tyr137 in orange. A frequency 
of 1.0 corresponds to an interaction that is present during the entire simulation time. 
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Discussion 
FimH is not only different in this regard, but also in the fact that from the analyzed mannose 
binding receptors, it is the only one to feature a hydrophobic structure flanking the mannose 
binding site. Known as the tyrosine gate and consisting of the two tyrosine residues Tyr48 
and Tyr137 (23), this structural element is believed to be engaged in significant interactions 
with natural high-mannose N-glycans; most notably including hydrophobic stacking 
interactions between a mannose moiety of the glycan and Tyr48 of FimH (28). To this effect, 
oligomannose structures with varying numbers of variously linked mannose moieties would 
be expected to have varying binding affinities depending on how well mannose moieties align 
and interact with the tyrosine gate. As it happens, binding affinities of various di- and 
oligomannoses have been the subject of much research over the past decades and were 
determined in a variety of assays, including agglutination assays (27, 45, 46), an ELISA (49), 
a bead-based assay (50), a glycan microarray (51), a radioligand displacement assay, and an 
SPR-based assay (23, 28, 52). Although outcomes of these assays have been partly in conflict 
with each other, some results have been consistent throughout several studies. For instance, 
oligomannoses were generally stronger FimH ligands than dimannoses. Among oligomannose 
structures of high-mannose N-glycans, 7 was found to be the highest affinity carbohydrate 
sequence (27, 45, 46). In a crystal structure of FimHLD in complex with oligomannose-3 (9), 
the 7 sequence was identified as the principal binding epitope, forming optimal interactions 
with the tyrosine gate and imparting the oligomannose ligand with its high affinity. Indeed, 
this seemed to be in line with observations of the higher affinity of small oligomannose 
ligands such as oligomannose-3 and -5 (52), both of which expose Man2GlcNAc1 on their 
non-reducing ends (Table 2). In the bigger congeners oligomannose-6, -7, -8, and -9, the 7 
sequence is capped with one or two additional α1-2 linked mannose residues (Fig. 1). Both 
the α1-2 linkage and the additional mannose unit(s) are thought to disrupt the optimal binding 
mode of the 7 binding epitope, thereby negatively impacting the binding affinity. However, 
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when results of a glycan microarray showed preferential binding of FimH to oligomannose-6 
instead of oligomannose-3 and -5 (51), the purported significance of the 7 sequence was 
inadvertently brought into question. 
Notably, all mentioned assays are characterized as being competitive binding experiments 
and/or as having one of the binding partners immobilized. When investigating oligomannose 
binding where interactions may not be exclusively monovalent, such assay conditions can 
impose further complexity to a system that already has the potential to be considerably 
complex. As a consequence, we opted for ITC as our method of choice in determining the 
binding affinities of several previously characterized mannose ligands. ITC offers the 
advantage of being a homogeneous assay and the possibility to measure FimH-ligand binding 
directly. In addition, it indicates the binding stoichiometry of the reaction, which is a crucial 
piece of information when investigating oligomannose binding. Indeed, our ITC experiments 
revealed that 6, 8, and 9 bind to FimHLD in a 2:1 fashion. By applying the appropriate 2:1 
binding model to the isotherm instead of a 1:1 model, fitted KD values were revised upward, 
meaning that affinities decreased as a result. In retrospect, KDs of oligomannoses determined 
in previous assays might have been overestimated in much the same way by not accounting 
for bi- or multivalent binding in the applied binding model. 
The KD values of all mannose ligands tested in this study, including 7 and 9, were almost 
identical (Table 3), implying that additional mannose moieties or the glycosidic linkages 
between them have little to no effect on the binding affinities of di- and oligomannoses. This 
suggests that the first mannose moiety, which forms an extensive hydrogen bond network in 
the binding pocket, is the primary factor determining the binding affinity. As a consequence, 
the concept of the tyrosine gate playing a significant role in binding natural ligands becomes 
less tenable. Indeed, partial or complete removal of the tyrosine gate from FimHLD had 
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marginal or no impact on the binding affinity of 3 (Table 4), which was used as representative 
mannose ligand in this mutational study. 
Results of ITC experiments were mirrored in MD simulations, in which we could observe that 
the interaction of di- and oligomannoses was limited with Tyr48 and not present at all with 
Tyr137. Furthermore, the interaction energy of mannose with Tyr48 was calculated to be -
12.1 kJ mol-1, which was the weakest interaction among all calculated structures. This could 
explain the measured affinities from ITC experiments, which were the same for the natural 
binding epitope and the oligomannoses. Due to the hydrogen bond formed with Thr51, the 
interaction frequency of the natural epitope with the tyrosine gate was elevated in MD 
simulations - yet the interaction was still weak in comparison to synthetic FimH antagonists 
that formed stronger and more frequent interactions with Tyr48. 
Indeed, in the design of synthetic FimH antagonists researchers have exploited the tyrosine 
gate for the purpose of π-π stacking by attaching a hydrophobic aryl aglycone to the vital 
mannose moiety. This has lead to continuously improved affinities of synthetic FimH 
antagonists (29–35, 53). In contrast, and as demonstrated in this study, di- and oligomannose 
structures that are terminally exposed in high-mannose N-glycans did not benefit from 
improved affinities with increasing size and complexity. This is reflected in a decreasing 
ligand efficiency (LE, Table 3), which is a metric commonly used in drug discovery (54). 
While 1 and 10 showed good LEs of 0.63 and 0.62, respectively, the introduction of a second 
mannose (2–5) halved the LEs of dimannoses to a range between 0.32 and 0.35. The LE of 
trimannose 6 is reduced further to 0.23, and with an added fourth mannose unit (8) the LE 
drops even lower to 0.17. The natural binding epitope of FimH (7) has a ligand efficiency of 
only 0.20, contrasted by synthetic FimH antagonists 11 and 12, which exhibit a high LE of 
0.54 and 0.45, respectively. Evidently, the synthetically added aglycone moieties establish the 
intended beneficial interactions with FimH. 
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As previously mentioned, the prevailing hypothesis has been that these interactions mimic 
those of the natural 7 binding epitope. In this study, we performed ITC experiments and MD 
simulations to provide evidence suggesting that 7 does not have an advantage in terms of 
binding affinity over other di- or oligomannoses. Moreover, the relevance of 7 as natural 
binding epitope may be overestimated. For instance, one of two major mannosylated 
glycoproteins involved in UTIs is the transmembrane UPIa glycoprotein (21). Inspection of 
murine UPIa glycosylation patterns revealed that oligomannose-5 is entirely absent in the 
glycomoiety (55). Significantly, oligomannose-5 is the only biosynthesized oligomannose 
structure terminally exposing the 7 sequence. Instead, the major glycoform in UPIa is 
constituted by oligomannose-8 (43%) (55). As mentioned previously, in structures larger than 
oligomannose-5, the 7 sequence is buried under one or two α1-2 linked mannose moieties 
(Fig. 1). Another major glycoprotein with high-mannose N-glycans is Tamm-Horsfall 
glycoprotein (THP). As the most abundant urinary glycoprotein in mammals, THP carries 
mostly oligomannose-6 residues (75%) and only marginal amounts of oligomannose-5 (8%) 
(56). These results attenuate the significance of the 7 sequence as the natural binding epitope, 
making it rather unlikely that the high affinity of FimH antagonists originates from mimicking 
the binding mode of a carbohydrate sequence that rarely partakes in mannose ligand binding. 
Altogether, these findings have lead us to conclude that the tyrosine gate is not involved in 
binding of natural oligomannose ligands. Instead, we believe it to be a bygone remnant that is 
serendipitously located close to the binding site where it represents an important structural 
target for synthetic ligands. 
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Materials and Methods 
Crystal Structure Preparation. Protein-Ligand complexes from the crystal structures were 
processed with the Protein Preparation Wizard (57) and further refined using local 
optimization sampling in Prime 4.2 (58, 59) within 5.0 Å of the ligand using the OPLS3 
force-field and VSGB solvation model. 
Crystallization and structure determination of FimH/methyl α-D-mannoside. FimHLD/10 
was crystallized by sitting-drop vapor diffusion at 4°C. FimHLD (residues 1–158) was used at 
a final concentration of 10 mg mL−1 (ca. 0.5 mM) with a threefold molar excess of 10 in 
HEPES buffer (pH 7.4, 20 mM). After four weeks equilibration, plate like crystals appeared 
in 0.2 M (NH4)2SO4, 0.1 M HEPES pH 7.0, 30% PEG 3350 (w/v) and were flash-cooled to 
100 K by addition of 20% ethylene glycol (Hampton Research, USA). Data were collected 
with synchrotron radiation at the PXIII beamline of the Swiss Light Source (Paul Scherrer 
Institute, Switzerland). Data were indexed, integrated, and scaled with XDS (60, 61). 
Structures were solved by molecular replacement with PHASER (62) with use of the 
4X50.pdb (35) as search model. The structures were built in COOT (63, 64) and refined with 
the PHENIX software (65, 66). Geometric restraints for the ligands were generated with 
PRODRG (67) and Molprobity (68) was used to validate the available atomic coordinates. 
The structures are deposited in the Protein Data Bank with PDB codes: 5JCQ and 5JCR. 
Molecular dynamics simulations. MD Simulations were carried out using Desmond 4.4 and 
the OPLS3 force field (69–71). Default parameters were applied unless stated otherwise. 
TIP3P was the selected water model and a physiological salt concentration (0.15 M) was 
added to the simulation. An energy barrier of 1 kcal/mol restricted Cα movement during the 
1000 ns MD simulations. Energies and trajectories were recorded at 100 ps intervals resulting 
in 10,000 recorded frames, which were post-processed using the Simulation Interactions 
Diagram implemented in Desmond. 
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Mannose ligands. 1 and 10 were purchased from Sigma-Aldrich Chemie (Buchs, 
Switzerland). All di- and oligomannose ligands with the exception of 7 were purchased from 
Dextra Laboratories (Reading, UK). 
Expression and purification of FimHLD. FimHLD corresponding to the E. coli laboratory K-
12 strain was expressed recombinantly with a C-terminal  thrombin cleavage site and His6-tag 
in the protease-deficient E. coli HM125 strain (72), and purified by affinity chromatography 
as described previously (73). Appropriate point mutations were inserted by overlap extension 
PCR (74). 
Isothermal titration calorimetry (ITC). ITC experiments were performed with an iTC200 
calorimeter (Malvern Instruments, Worcestershire, UK) and carried out in a buffer containing 
20 mM HEPES, pH 7.4 and 150 mM NaCl. Before starting with the experiment, FimH 
solutions were extensively dialyzed against the assay buffer. Mannose ligands were weighed 
and directly dissolved in the same buffer. Prior to the experiment, FimH concentrations were 
adjusted via the specific absorbance at 280 nm. The molar extinction coefficients used were 
24,180, 29,250, 22,900, and 21,620 M-1 cm-1 for wild type FimHLD, FimHLD-Y48A, FimHLD-
Y137A, and FimHLD-Y48A/Y137A, respectively. The cell of the calorimeter contained the 
FimH solution and holds a volume of 203.7 µl. Mannose ligands were injected into the cell in 
regular intervals. These intervals as well as the injection volumes varied among experiments. 
Details of individual measurements, including these two parameters, are available in the SI 
Appendix, Table S2 and Table S4. Some parameters were constant throughout the 
measurements, such as temperature (25 °C), feedback mode (high), stirring speed (750 rpm), 
and reference power (6 µcal s-1). Baseline correction as well as peak detection and integration 
was performed automatically with NITPIC (version 1.1.5; University of Texas Southwestern 
Medical Center, Texas, USA) (75). The resulting binding isotherm was fitted in SEDPHAT 
(version 12.1c; National Institutes of Health, Maryland, USA) (76) with a 1:1 binding model 
and the following fitting parameters: change in enthalpy (∆H°), association constant (KA), 
248
molar ratio (N), and heat of dilution (∆Hdil). The dissociation constant KD was obtained 
through the relationship KD = KA-1. The KD was converted into the corresponding Gibbs 
energy change (∆G°), from which the change in entropy (∆S°) was calculated according to: 
∆G° = ∆H° − T∆S° = RT ln(KD) 
Statistical analysis to obtain 68.3% confidence intervals of the fitted parameters was done in 
SEDPHAT. Isotherms were fitted globally, if multiple data sets were available for a particular 
ligand. For 6, 8, and 9 the binding model was changed from 1:1 to 2:1 binding. Consequently, 
two fitting parameters were available for each KA and ∆H°; one parameter set for each 
binding event. No indications of potential cooperativity were observed in the isotherms of 6, 
8, and 9, and binding sites were presumed to be equivalent. As a result, the logarithmic ratio 
of KAs (“log10(Ka2/Ka1)” in SEDPHAT) was fixed to -0.602. To obtain the microscopic KA 
of the interaction, the KA of the first binding event (“log(Ka1)” in SEDPHAT) was multiplied 
by 2. 
Ab initio calculations. To quantify the van-der-Waals interactions of the tyrosine gate and its 
interacting moieties, the refined protein-ligand complexes were subjected to energy 
calculations using the density functional theory (DFT) with the empirical corrected B3LYP-
MM functional, which has been specifically parameterized to properly describe non-covalent 
interactions, and the cc-pVDZ++ basis-set in the gas-phase as implemented in Jaguar 9.0 (77, 
78). 
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General methods. All commercial reagents were used as supplied unless otherwise 
stated, and solvents were dried and distilled using standard techniques. Thin layer 
chromatography was performed on silica-coated glass plates (TLC Silica Gel 60 F254, 
Merck) with detection by fluorescence, charring with 5% H2SO4(aq), or staining with a 
ceric ammonium molybdate solution. Organic solutions were concentrated and/or 
evaporated to dry under vacuum in a water bath (<50 °C). Molecular sieves were 
dried at 400 °C under vacuum for 20-30 minutes prior to use. Amberlite IR-120H 
resin was washed extensively with MeOH and dried under vacuum prior to use. 
Medium-pressure liquid chromatography (MPLC) was performed using a CombiFlash 
Companion equipped with RediSep normal-phase flash columns, and solvent 
gradients refer to sloped gradients with concentrations reported as % v/v. NMR 
spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer, and 
assignments achieved with the assistance of 1D NOESY, 1D TOCSY, 2D gCOSY, 
2D gTOCSY, 2D gHSQC, 2D gHMBC, and 2D gNOESY; chemical shifts are 
expressed in ppm and referenced to either Si(CH3)4 (for CDCl3), residual CHD2OD 
(for CD3OD), or MeOH (for D2O). Electron-spray ionization mass spectrometry (ESI-
MS) was performed using a Waters micromass ZQ. High resolution mass 
spectrometry was performed using an Agilent 1100 LC equipped with a photodiode 
array detector, and a Mircromass QTOF I equipped with a 4 GHz digital-time 
converter. Optical rotation was determined in a 10 cm cell at 20 °C using a Perkin-
Elmer Model 341 polarimeter. HPLC analysis was performed using an Agilent 1100 





































(a) MeOH, BF3•Et2O, CH2Cl2, 71%; (b) NaOMe, MeOH/CH2Cl2, 0 °C to rt, quant.;
(c) PhCH(OMe)2, CSA, CH3CN, quant.; (d) BnBr, NaH, DMF, 0 °C to rt, 92%;









Methyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-b-D-glucopyranoside (16). The 
starting material (15; 2.193 g, 4.593 mmol),[ref1] MeOH (0.37 mL, 9.1 mmol), and 
BF3Et2O (1.73 mL, 13.8 mmol) were added to anhydrous CH2Cl2 (20 mL) and left 
mixing at ambient temperature under Ar. After 48 hours, the reaction mixture was 
neutralized with Et3N (to pH 8), diluted with CH2Cl2 (20 mL), and then the organic 
phase was washed with saturated NaHCO3(aq) solution (200 mL), saturated NaCl(aq) 
solution (200 mL), dried with Na2SO4, filtered, and evaporated to dry. The crude 
material was then purified via MPLC on silica gel using 0→30% EtOAc – toluene to 
afford the pure product as a white solid (1.465 g, 3.260 mmol, 71% yield). Rf = 0.58 
(1:4 acetone : toluene). [α]D20: +42° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 
7.88 – 7.84 (m, 2H, Ar), 7.77 – 7.73 (m, 2H, Ar), 5.79 (dd, 1H, J = 9.9, 9.9 Hz, H-3), 
5.31 (d, 1H, J = 8.5 Hz, H-1), 5.19 (dd, 1H, J = 9.6, 9.6 Hz, H-4), 4.35 (dd, 1H, J = 
12.2, 4.4 Hz, H-6a), 4.34 – 4.29 (m, 1H, H-2), 4.20 (dd, 1H, J = 12.1, <2 Hz, H-6b), 
3.90 – 3.87 (m, 1H, H-5), 3.45 (s, 3H, OCH3), 2.12 (s, 3H, Ac), 2.04 (s, 3H, Ac), 1.86 
(s, 3H, Ac). 13C NMR (CDCl3, 125 MHz): δC 170.87 (Ac), 170.30 (Ac), 169.62 (Ac), 
167.54 (Phth), 134.45 (Ar), 131.62 (Ar), 123.77 (Ar), 99.20 (C-1), 72.01 (C-5), 70.95 
(C-3), 69.15 (C-4), 62.13 (C-6), 57.20 (OCH3), 54.68 (C-2), 20.91 (Ac), 20.78 (Ac), 
20.59 (Ac). ESI-MS m/z calc’d for C21H23NO10 (M+Na)+: 472.12; found: 472.08. 
 
Methyl 2-deoxy-2-phthalimido-b-D-glucopyranoside (17). The starting material 
(16; 1.465 g, 3.260 mmol) was dissolved into anhydrous MeOH/CH2Cl2  (3:1; 20 
mL), cooled to 0 °C, and then NaOMe solution added drop-wise (1.5 M NaOMe in 
MeOH; to pH 10). After 1 hour, the reaction flask was warmed to ambient 
temperature, and after an additional 30 minutes was then neutralized with acidic resin 
(Amberlite IR-120H; to pH 6), filtered, and evaporated to dry to afford the pure 
product as a white solid (1.050 g, 3.248 mmol, quantitative yield). Rf = 0.10 (1:19 
MeOH : CH2Cl2). [α]D20: -10° (c 1.0, MeOH). 1H NMR (MeOD, 500 MHz): δH 7.89 
– 7.80 (m, 4H, Ar), 5.09 (d, 1H, J = 8.5 Hz, H-1), 4.24 (dd, 1H, J = 10.7, 8.1 Hz, H-
3), 3.96 (dd, 1H, J = 10.7, 8.5 Hz, H-2), 3.94 (dd, 1H, J = 12.0, 2.1 Hz, H-6a), 3.76 
(dd, 1H, J = 11.9, 5.3 Hz, H-6b), 3.46 – 3.38 (m, 5H, H-5, OCH3, and H-4). 13C NMR 
(MeOD, 125 MHz): δC 169.96 (Phth), 135.66 (Ar), 133.20 (Ar), 124.34 (Ar), 100.82 
(C-1), 78.45 (C-5), 72.78 (C-3), 72.74 (C-4), 62.86 (C-6), 58.60 (C-2), 57.19 (OCH3). 





Methyl 4,6-O-benzylidene-2-deoxy-2-phthalimido-b-D-glucopyranoside (18). The 
starting material (17; 1.050 g, 3.248 mmol), PhCH(OMe)2 (0.68 mL, 4.5 mmol), and 
camphorsulfonic acid (to pH 3) were added to anhydrous MeCN (10 mL) and left 
mixing at ambient temperature under Ar. After 14 hours, additional PhCH(OMe)2 
(0.30 mL, 2.0 mmol) was added to react with remaining starting material, and after 
another 6 hours the mixture was neutralized with Et3N (to pH 8) and evaporated to 
dry. The crude material was purified via MPLC on silica gel using 0→15% EtOAc – 
toluene to afford the pure product as a white solid (1.333 g, 3.240 mmol, quantitative 
yield). Rf = 0.61 (1:4 acetone : toluene). [α]D20: -26° (c 1.0, CHCl3). 1H NMR (CDCl3, 
500 MHz): δC 7.82 – 7.79 (m, 2H, Ar), 7.68 – 7.65 (m, 2H, Ar), 7.50 – 7.47 (m, 2H, 
Ar), 7.36 – 7.33 (m, 3H, Ar), 5.55 (s, 1H, PhCH), 5.15 (d, 1H, J = 8.5 Hz, H-1), 4.60 
– 4.56 (m, 1H, H-3), 4.37 (dd, 1H, J = 10.6, 4.6 Hz, H-6a), 4.21 – 4.17 (m, 1H, H-2), 
3.81 (dd, 1H, J = 9.8, 9.8 Hz, H-6b), 3.59 (ddd, 1H, J = 9.3, 9.3, 4.6 Hz, H-5), 3.56 
(dd, 1H, J = 9.2, 9.2 Hz, H-4), 3.41 (s, 3H, OCH3), 2.95 (d, 1H, J = 3.6 Hz, 3-OH). 
13C NMR (CDCl3, 125 MHz): δC 168.33 (Phth), 137.18 (Ar), 134.23 (Ar), 131.79 
(Ar), 129.42 (Ar), 128.47 (Ar), 126.47 (Ar), 123.62 (Ar), 101.99 (PhCH), 99.95 (C-
1), 82.34 (C-4), 68.79 (C-6), 68.65 (C-3), 66.27 (C-5), 57.18 (OCH3), 56.70 (C-2). 
ESI-MS m/z calc’d for C22H21NO7 (M+Na)+: 434.12; found: 434.16. 
 
Methyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-b-D-gluco-
pyranoside (19). The starting material (18; 1.323 g, 3.216 mmol) and BnBr (0.50 mL, 
4.2 mmol) were added to anhydrous DMF (12 mL), and then NaH was added portion-
wise (60% oil dispersion; 193 mg, 4.82 mmol) at 0 °C under Ar. After 30 minutes, the 
reaction flask was warmed up to ambient temperature and after an additional 6 hours, 
further BnBr (0.10 mL, 0.84 mmol) and NaH (81 mg, 2.0 mmol) were added. After 
another 2 hours the reaction was quenched via the slow addition of MeOH (5 mL), 
evaporated to dry, and then redissolved into EtOAc (60 mL). The organic phase was 
washed with saturated NaCl(aq) solution (2 x 60 mL), dried with Na2SO4, filtered, and 
evaporated to dry. The crude material was purified via MPLC on silica gel using 
0→30% EtOAc – toluene to afford the pure product as a white solid (1.478 g, 2.947 
mmol, 92% yield). Rf = 0.86 (1:4 acetone : toluene). [α]D20: +46° (c 1.0, CHCl3). 1H 
NMR (CDCl3, 500 MHz): δH 7.86 – 7.60 (m, 4H, Ar), 7.54 – 7.51 (m, 2H, Ar), 7.42 – 
7.35 (m, 3H, Ar), 7.00 – 6.98 (m, 2H, Ar), 6.94 – 6.86 (m, 3H, Ar), 5.63 (s, 1H, 




1H, J = 12.3 Hz, PhCHaHb), 4.45 – 4.40 (m, 2H, H-3 and H-6a), 4.23 – 4.19 (m, 1H, 
H-2), 3.86 (dd, 1H, J = 10.3, 10.3 Hz, H-6b), 3.81 (dd, 1H, J = 9.2, 9.2 Hz, H-4), 3.64 
(ddd, 1H, J = 9.7, 9.7, 5.0 Hz, H-5), 3.40 (s, 3H, OCH3). 13C NMR (CDCl3, 125 
MHz): δC 168.01 (Phth), 138.07 (Ar), 137.51 (Ar), 134.00 (Ar), 131.84 (Ar), 129.19 
(Ar), 128.47 (Ar), 128.20 (Ar), 128.19 (Ar), 127.55 (Ar), 126.23 (Ar), 123.52 (Ar), 
101.49 (PhCH), 100.02 (C-1), 83.30 (C-4), 74.78 (C-3), 74.26 (PhCH2), 68.96 (C-6), 
66.23 (C-5), 57.15 (OCH3), 55.88 (C-2). ESI-MS m/z alc’d for C29H27NO7 (M+Na)+: 
524.17; found: 524.13. 
 
Methyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-b-D-glucopyranoside (20).  
A solution of the starting material (19; 1.999 g, 3.986 mmol) in anhydrous CH2Cl2 (20 
mL) was cooled to 0 °C under Ar, and then Et3SiH (3.2 mL, 20 mmol) and BF3Et2O 
(1.0 mL, 8.0 mmol) were slowly added. After 6 hours, the reaction mixture was 
neutralized with Et3N (to pH 8), warmed back to ambient temperature, and then 
quenched via the slow addition of MeOH (5 mL). The crude mixture was evaporated 
to dry, and then purified via MPLC on silica gel using 0→30% EtOAc – toluene to 
afford the pure product as a white solid (1.595 g, 3.168 mmol, 79% yield). Rf = 0.13 
(1:9 EtOAc : toluene). [α]D20: +42° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 
7.81 – 7.63 (m, 4H, Ar), 7.37 – 7.27 (m, 5H, Ar), 7.04 – 7.02 (m, 2H, Ar), 6.96 – 6.91 
(m, 3H, Ar), 5.05 (d, 1H, J = 8.4 Hz, H-1), 4.73 (d, 1H, J = 12.2 Hz, PhCHaHb), 4.64 
(d, 1H, J = 12.0 Hz, PhCHaHb), 4.58 (d, 1H, J = 12.0 Hz, PhCHaHb), 4.51 (d, 1H, J = 
12.2 Hz, PhCHaHb), 4.22 (dd, 1H, J = 10.6, 8.4 Hz, H-3), 4.13 (dd, 1H, J = 10.6, 8.4 
Hz, H-2), 3.83 (dd, 1H, J = 10.1, 4.9 Hz, H-6a), 3.83 – 3.79 (m, 1H, H-5), 3.78 (dd, 
1H, J = 10.1, 5.1 Hz, H-6b), 3.63 (ddd, 1H, J = 9.5, 4.9, 4.9 Hz, H-5), 3.36 (s, 3H, 
OCH3), 2.90 (d, 1H, J = <1 Hz, 4-OH). 13C NMR (CDCl3, 125 MHz): δC 167.89 
(Phth), 138.38 (Ar), 137.82 (Ar), 133.99 (Ar), 128.73 (Ar), 128.36 (Ar), 128.12 (Ar), 
128.05 (Ar), 128.02 (Ar), 127.62 (Ar), 99.43 (C-1), 78.92 (C-3), 74.71 (C-4), 74.53 
(PhCH2), 74.01 (PhCH2), 73.73 (C-5), 70.90 (C-6), 56.87 (OCH3), 55.46 (C-2). ESI-









































(a) Ac2O, Py, 60 °C; (b) p-TolSH, BF3•Et2O, CH2Cl2, quant. over 2 steps;
(c) NaOMe, MeOH, 50 °C, quant.; (d) PhCH(OMe)2, CSA, CH3CN/DMF, 60%;





p-Methylphenyl 2,3,4,6-tetra-O-acetyl-1-thio-a-D-mannopyranoside (21). The 
starting material (1; 8.15 g, 45.2 mmol) was dissolved into pyridine (40 mL) and 
Ac2O (40 mL) and left mixing at 65 °C, and after 3 hours was concentrated to a syrup 
via co-evaporation with toluene (3 x 50 mL). The crude mixture, p-methylthiophenol 
(6.803 g, 54.77 mmol), and BF3Et2O (7.4 mL, 59 mmol) in anhydrous CH2Cl2 (150 
mL) were then left mixing under Ar at ambient temperature. After 20 hours, 
additional p-methylthiophenol (1.774 g, 14.28 mmol) was added to react with some 
remaining starting material. After another 24 hours, the reaction mixture was 
neutralized with the addition of Et3N (to pH 8), diluted further with CH2Cl2 (300 mL), 
washed with saturated NaCl(aq) solution (2 x 500 mL), dried with Na2SO4, filtered, 
and evaporated to dry. The crude material was then purified via MPLC on silica gel 
using 0→30% acetone – toluene to afford the pure product as a white solid (20.34 g, 
44.75 mmol, quantitative yield over 2 steps). Rf = 0.71 (2:3 acetone : toluene). [α]D20: 
+103° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.39 – 7.36 (m, 2H, Ar), 7.13 
– 7.10 (m, 2H, Ar), 5.50 (dd, 1H, J = <2, <2 Hz, H-2), 5.42 (d, 1H, J = 1.0 Hz, H-1), 
5.36 – 5.30 (m, 2H, H-4 and H-3), 4.59 – 4.52 (m, 1H, H-5), 4.30 (dd, 1H, J = 12.2, 
6.0 Hz, H-6a), 4.10 (dd, 1H, J = 12.2, 2.3 Hz, H-6b), 2.32 (s, 3H, PhCH3), 2.13 (s, 3H, 
Ac), 2.07 (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.01 (s, 3H, Ac). 13C NMR (CDCl3, 125 
MHz): δC 170.51 (Ac), 169.90 (Ac), 169.80 (Ac), 169.76 (Ac), 138.46 (Ar), 132.69 
(Ar), 130.01 (Ar), 128.86 (Ar), 86.05 (C-1), 70.91 (C-2), 69.50 (C-5), 69.43 (C-3), 
66.47 (C-4), 62.54 (C-6), 21.15 (PhCH3), 20.87 (Ac), 20.73 (Ac), 20.70 (Ac), 20.65 






p-Methylphenyl 1-thio-a-D-mannopyranoside (22). The starting material (21; 20.34 
g, 44.75 mmol) was dissolved into anhydrous MeOH (200 mL), and then NaOMe 
solution was added drop-wise (1.5 M NaOMe in MeOH; to pH 10). After 1 hour at 
ambient temperature, followed by 1 hour at 50 °C, the reaction mixture was 
neutralized with acidic resin (Amberlite IR-120H; to pH 6), filtered, and then 
evaporated to dry to afford the pure product as a white solid (13.09 g, 45.71 mmol, 
quantitative yield). Rf = 0.63 (3:17 MeOH : CH2Cl2). [α]D20: +203° (c 1.0, MeOH). 1H 
NMR (MeOD, 500 MHz): δH 7.41 – 7.39 (m, 2H, Ar), 7.14 – 7.11 (m, 2H, Ar), 5.36 
(d, 1H, J = 1.2 Hz, H-1), 4.08 (dd, 1H, J = 3.0, 1.5 Hz, H-2), 4.05 (ddd, 1H, J = 9.1, 
5.3, 2.5 Hz, H-5), 3.82 (dd, 1H, J = 12.0, 2.5 Hz, H-6a), 3.77 (dd, 1H, J = 12.0, 5.3 
Hz, H-6b), 3.73 (dd, 1H, J = 9.3, 9.3 Hz, H-4), 3.70 (dd, 1H, J = 9.3, 3.0 Hz, H-3), 
2.30 (s, 3H, PhCH3). 13C NMR (MeOD, 125 MHz): δC 139.02 (Ar), 133.62 (Ar), 
132.21 (Ar), 130.88 (Ar), 90.88 (C-1), 75.64 (C-5), 73.85 (C-2), 73.26 (C-3), 68.83 
(C-4), 62.74 (C-6), 21.24 (PhCH3). ESI-MS m/z calc’d for C13H18O5S (M+Na)+: 
309.08; found: 309.05. 
 
p-Methylphenyl 4,6-O-benzylidene-1-thio-a-D-mannopyranoside (23).  
The starting material (22; 13.09 g, 45.71 mmol), PhCH(OMe)2 (8.9 mL, 59 mmol), 
and camphorsulfonic acid (to pH 3) were added to anhydrous MeCN (140 mL) and 
anhydrous DMF (50 mL) and left mixing at ambient temperature under Ar. After 16 
hours, the mixture was neutralized with Et3N (to pH 8) and evaporated to dry. The 
crude material was purified via MPLC on silica gel using 0→20% MeOH – CH2Cl2 to 
afford the pure product as a white solid (10.32 g, 27.56 mmol, 60% yield).  Rf = 0.62 
(1:9 MeOH : CH2Cl2). [α]D20: +276° (c 0.50, CHCl3). 1H NMR (MeOD, 500MHz): 
δH 7.53 – 7.51 (m, 2H, Ar), 7.39 – 7.34 (m, 5H, Ar), 7.18 – 7.16 (m, 2H, Ar), 5.62 (s, 
1H, PhCH), 5.41 (d, 1H, J = <1 Hz, H-1), 4.25 (ddd, 1H, J = 9.8, 9.8, 4.9 Hz, H-5), 
4.16 (dd, 1H, J = 3.2, 1.0 Hz, H-2), 4.13 (dd, 1H, J = 10.2, 4.9 Hz, H-6a), 4.02 (dd, 
1H, J = 9.7, 9.7 Hz, H-4), 3.94 (dd, 1H, J = 9.9, 3.3 Hz, H-3), 3.83 (dd, 1H, J = 10.2, 
10.2 Hz, H-6b), 2.33 (s, 3H, CH3). 13C NMR (MeOD, 125 MHz): δC 139.39 (Ar), 
139.35 (Ar), 133.67 (Ar), 131.64 (Ar), 131.04 (Ar), 130.06 (Ar), 129.19 (Ar), 127.68 
(Ar), 103.55 (PhCH), 91.51 (C-1), 80.45 (C-4), 74.27 (C-2), 70.14 (C-3), 69.64 (C-6), 







(24). The starting material (23; 1.633 g, 4.361 mmol) and allyl bromide (0.91 mL, 11 
mmol) were added to anhydrous DMF (15 mL), and then NaH (60% oil dispersion; 
531 mg, 13.3 mmol) was slowly added portion-wise under Ar. After 16 hours, the 
reaction was quenched via the slow addition of MeOH (5 mL), evaporated to dry, and 
then redissolved into EtOAc (200 mL). The organic phase was washed with saturated 
NaCl(aq) solution (2 x 200 mL), dried with Na2SO4, filtered, and evaporated to dry. 
The crude material was purified via MPLC on silica gel using 0→10% EtOAc – 
toluene to afford the pure product as a white solid (1.927 g, 4.239 mmol, 97% yield). 
Rf = 0.44 (1:19 EtOAc : toluene). [α]D20: +160° (c 0.50, CHCl3). 1H NMR (CDCl3, 
500 MHz): δH 7.51 – 7.49 (m, 2H, Ar), 7.39 – 7.33 (m, 5H, Ar), 7.14 – 7.12 (m, 2H, 
Ar), 5.98 – 5.88 (m, 2H, 2x OCH2CH=CH2), 5.61 (s, 1H, PhCH), 5.47 (d, 1H, J = <1 
Hz, H-1), 5.35 – 5.28 (m, 2H, 2x OCH2CH=CHaHb), 5.22 – 5.19 (m, 2H, 2x 
OCH2CH=CHaHb), 4.36 – 4.28 (m, 2H, OCHaHbCH=CH2 and H-5), 4.25 – 4.17 (m, 
5H, H-6a, OCHaHbCH=CH2, 2x OCHaHbCH=CH2, and H-4), 4.03 (dd, 1H, J = <2, <2 
Hz, H-2), 3.90 – 3.84 (m, 2H, H-3 and H-6b), 2.34 (s, 3H, PhCH3). 13C NMR (CDCl3, 
125 MHz): δC 138.15 (Ar), 137.82 (Ar), 135.01 (OCH2CH=CH2), 134.79 
(OCH2CH=CH2), 132.32 (Ar), 130.28 (Ar), 130.15 (Ar), 129.07 (Ar), 128.41 (Ar), 
126.30 (Ar), 118.14 (OCH2CH=CH2), 117.17 (OCH2CH=CH2), 101.75 (PhCH), 
87.89 (C-1), 79.43 (C-4), 78.35 (C-2), 75.98 (C-3), 72.68 (OCH2CH=CH2), 72.31 
(OCH2CH=CH2), 68.76 (C-6), 65.43 (C-5), 21.33 (PhCH3). ESI-MS m/z calc’d for 

























Benzoyl 2,3,4,6-tetra-O-benzoyl-D-mannopyranose (25). The starting material (1; 
3.70 gm, 20.5 mmol) and benzoyl chloride (14.5 mL, 125 mmol) were added to 
anhydrous pyridine (40 mL), and after 5 minutes at ambient temperature was begun 
heating at 60 °C. After 5 hours, the reaction mixture was heated at 100 °C for 15 
minutes, and then cooled back to ambient temperature and quenched via the addition 
of excess ice. The mixture was further diluted with EtOAc (400 mL), then washed 




to dry. The crude material was then purified via MPLC on silica gel using 0→10% 
EtOAc – toluene to afford the a-/b-product mixture as a white solid (14.50 g, 20.69 
mmol, quantitative yield).[ref2] ESI-MS m/z calc’d for C41H32O11 (M+Na)+: 723.18; 
found: 723.33. 
 
2,3,4,6-Tetra-O-benzoyl-a-D-mannopyranosyl bromide (26). The starting material 
(25; 14.50 g, 20.69 mmol) was added to anhydrous CH2Cl2 (100 mL) and HBr/AcOH 
solution (33 wt.%; 50 mL) and left mixing at ambient temperature. After 24 hours, the 
solution was concentrated to a syrup via co-evaporation with toluene, and then 
purified via MPLC on silica gel using 0→10% EtOAc – toluene to afford the pure 
product as a white solid (12.83 g, 19.45 mmol, 94% yield).  Rf = 0.75 (1:4 EtOAc : 
toluene). [α]D20: -18° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 8.12 – 8.10 (m, 
2H, Ar), 8.04 – 8.02 (m, 2H, Ar), 7.99 – 7.97 (m, 2H, Ar), 7.85 – 7.83 (m, 2H, Ar), 
7.61 – 7.56 (m, 2H, Ar), 7.53 – 7.50 (m, 1H, Ar), 7.44 – 7.36 (m, 7H, Ar), 7.28 – 7.24 
(m, 2H, Ar), 6.59 (d, 1H, J = <1 Hz, H-1), 6.30 (dd, 1H, J = 10.2, 2.9 Hz, H-3), 6.26 
(dd, 1H, J = 9.9, 9.9 Hz, H-4), 5.93 – 5.92 (m, 1H, H-2), 4.75 (dd, 1H, J = 12.5, 2.0 
Hz, H-6a), 4.68 – 4.65 (m, 1H, H-5), 4.52 (dd, 1H, J = 12.5, 3.6 Hz, H-6b). 13C NMR 
(CDCl3, 125 MHz): δC 166.10 (C=O), 165.53 (C=O), 165.46 (C=O), 165.13 (C=O), 
133.94 (Ar), 133.84 (Ar), 133.56 (Ar), 133.36 (Ar), 130.06 (Ar), 130.05 (Ar), 129.97 
(Ar), 129.94 (Ar), 128.87 (Ar), 128.71 (Ar), 128.67 (Ar), 128.56 (Ar), 83.49 (C-1), 
73.31 (C-5), 73.13 (C-2), 69.28 (C-3), 66.11 (C-4), 61.93 (C-6). ESI-MS m/z calc’d 




























(a) 1-benzenesulfinyl piperidine, 2,4,6-tri-ter t-butylpyrimidine, Tf2O, CH2Cl2, -60 °C to rt, 25%;
(b) Pd(OAc)2, PPh3, 1,3-dimethylbarbituric acid, MeOH/CH2Cl2, 40 °C, 74%; (c) AgOTf, CH2Cl2,
-60 °C to -40 °C, 40%; (d) NH2NH2•H2O, EtOH, 70 °C; then LiOH, 50 °C; then NaHCO3, H2O, Ac2O;






































benzyl-2-deoxy-2-phthalimido-b-D-glucopyranoside (27). The glycosyl donor (24; 
84 mg, 0.18 mmol), 1-benzenesulfinyl piperidine (41 mg, 0.20 mmol), 2,4,6-tri-tert-
butylpyrimidine (92 mg, 0.37 mmol), and crushed molecular sieves (4 Å, 213 mg) in 
anhydrous CH2Cl2 (5.0 mL) were left mixing at ambient temperature under Ar [ref3]. 
After 1 hour, the flask was cooled to –60 °C and then Tf2O (87 µL, 0.52 mmol) was 
added. After 5 minutes, a solution of the glycosyl acceptor (20; 108 mg, 0.214 mmol) 
in anhydrous CH2Cl2 (1.0 mL) was added, and after another 2 minutes the reaction 
mixture was warmed to ambient temperature over 15 minutes. The reaction solution 
was filtered, diluted with CH2Cl2 (20 mL), and then washed with saturated 
NaHCO3(aq) solution (20 mL), saturated NaCl(aq) solution (20 mL), dried with Na2SO4, 
filtered, and evaporated to dry. The crude material was purified via MPLC on silica 
gel using 0→30% EtOAc – toluene to afford the pure product as a white solid (38 mg, 
0.046 mmol, 25% yield). Rf = 0.84 (1:4 acetone : toluene). [α]D20: +20° (c 0.53, 
CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.79 – 7.61 (m, 4H, Ar), 7.44 – 7.42 (m, 
2H, Ar), 7.39 – 7.29 (m, 8H, Ar), 7.00 – 6.98 (m, 2H, Ar), 6.89 – 6.83 (m, 3H, Ar), 
5.98 (dddd, 1H, J = 17.2, 10.5, 5.5, 5.5 Hz, OCH2CH=CH2), 5.90 (dddd, 1H, J = 17.2, 
10.6, 5.2, 5.2 Hz, OCH2CH=CH2), 5.47 (s, 1H, PhCH), 5.34 – 5.28 (m, 2H, 2x 
OCH2CH=CH2), 5.18 – 5.15 (m, 2H, 2x OCH2CH=CH2), 5.06 (d, 1H, J = 8.5 Hz, 
GlcN_H1), 4.89 (d, 1H, J = 12.3 Hz, PhCHaHb), 4.77 (d, 1H, J = 12.1 Hz, PhCHaHb), 
4.58 (d, 1H, J = <1 Hz, Man_H1), 4.54 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.46 (d, 1H, J 
= 12.3 Hz, PhCHaHb), 4.36 – 4.22 (m, 4H, 3x OCH2CH=CH2 and GlcN_H3), 4.18 – 
4.14 (m, 2H, GlcN_H2 and Man_H6a), 4.10 – 4.05 (m, 2H, OCH2CH=CH2 and 
GlcN_H4), 3.95 (dd, 1H, J = 9.6, 9.6 Hz, Man_H4), 3.82 – 3.76 (m, 2H, GlcN_H6a 
and GlcN_H6b), 3.69 (dd, 1H, J = 2.4, <1 Hz, Man_H2), 3.63 – 3.60 (m, 1H, 
GlcN_H5), 3.53 (dd, 1H, J = 10.2, 10.2 Hz, Man_H6b), 3.40 (s, 3H, OCH3), 3.33 (dd, 
1H, J = 9.9, 2.9 Hz, Man_H3), 3.14 (ddd, 1H, J = 9.7, 9.7, 4.9 Hz, Man_H5). 13C 
NMR (CDCl3, 125 MHz): δC 168.0 (Phth), 138.83 (Ar), 137.89 (Ar), 137.66 (Ar), 
135.57 (OCH2CH=CH2), 134.97 (OCH2CH=CH2), 133.71 (Ar), 131.80 (Ar), 128.79 
(Ar), 128.57 (Ar), 128.15 (Ar), 127.99 (Ar), 127.85 (Ar), 127.83 (Ar), 126.98 (Ar), 
126.07 (Ar), 123.26 (Ar), 116.79 (OCH2CH=CH2), 116.44 (OCH2CH=CH2), 101.71 
(Man_C1), 101.34 (PhCH), 99.32 (GlcN_C1), 79.10 (GlcN_C4), 78.65 (Man_C4), 
78.12 (Man_C3), 77.15 (GlcN_C3), 76.96 (Man_C2), 74.88 (GlcN_C5), 74.61 




(GlcN_C6), 68.57 (Man_C6), 67.26 (Man_C5), 56.60 (OCH3), 55.60 (GlcN_C2). 
ESI-MS m/z calc’d for C48H51NO12 (M+Na)+: 856.33; found: 856.40. 
 
Methyl 4,6-O-benzylidene-a-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-
2-phthalimido-b-D-glucopyranoside (28). A solution of Pd(OAc)2 (13 mg, 0.060 
mmol) and PPh3 (60 mg, 0.23 mmol) in anhydrous MeOH/CH2Cl2 (2:1, 3.0 mL) were 
left mixing at ambient temperature under Ar. After 20 minutes, the bright yellow 
solution was transferred to a flask containing the starting material (27; 177 mg, 0.212 
mmol) and 1,3-dimethylbarbituric acid (134 mg, 0.858 mmol) and left mixing in a 
sealed flask at 40 °C [ref4]. After 30 hours, the solution was diluted with CH2Cl2 (100 
mL), washed with saturated Na2CO3(aq) solution (100 mL), and the aqueous layer re-
extracted with CH2Cl2 (50 mL). The combined organic phases were then washed with 
saturated NaCl(aq) solution (2 x 100 mL), dried with Na2SO4, filtered, and evaporated 
to dry. The crude material was purified via MPLC on silica gel using 0→40% acetone 
– petroleum ether to afford the nearly pure product as a pale yellow solid (119 mg, 
0.158 mmol, 74% yield). Rf = 0.25 (2:3 acetone : petroleum ether). [α]D20: +41° (c 1.0, 
CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.76 – 7.64 (m, 4H, Ar), 7.47 – 7.44 (m, 
2H, Ar), 7.41 – 7.34 (m, 8H, Ar), 7.03 – 7.01 (m, 2H, Ar), 6.95 – 6.86 (m, 3H, Ar), 
5.46 (s, 1H, PhCH), 5.04 (d, 1H, J = 8.5 Hz, GlcN_H1), 4.81 (d, 1H, J = 12.1 Hz, 
PhCHaHb), 4.77 (d, 1H, J = 12.0 Hz, PhCHaHb), 4.73 (d, 1H, J = <1 Hz, Man_H1), 
4.53 (d, 1H, J = 12.0 Hz, PhCHaHb), 4.43 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.38 (dd, 
1H, J = 10.6, 8.7 Hz, GlcN_H3), 4.18 (dd, 1H, J = 10.7, 8.5 Hz, GlcN_H2), 4.16 (dd, 
1H, J = 10.5, 5.0 Hz, Man_H6a), 4.14 – 4.10 (m, 1H, GlcN_H4), 3.92 – 3.91 (m, 1H, 
Man_H2), 3.83 (dd, 1H, J = 11.3, 3.1 Hz, GlcN_H6a), 3.79 – 3.74 (m, 2H, GlcN_H6b 
and Man_H4), 3.64 (ddd, 1H, J = 9.7, 2.5, 2.5 Hz, GlcN_H5), 3.59 (ddd, 1H, J = 9.9, 
6.8, 3.4 Hz, Man_H3), 3.56 (dd, 1H, J = 10.2, 10.2 Hz, Man_H6b), 3.39 (s, 3H, 
OCH3), 3.13 (ddd, 1H, J = 9.7, 9.7, 5.0 Hz, Man_H5), 2.80 (d, 1H, J = 2.1 Hz, 
Man_2OH), 2.66 (d, 1H, J = 6.8 Hz, Man_3OH). 13C NMR (CDCl3, 125 MHz): δC 
138.49 (Ar), 137.76 (Ar), 137.38 (Ar), 133.98 (Ar), 132.35 (Ar), 132.27 (Ar), 132.17 
(Ar), 132.15 (Ar), 131.88 (Ar), 129.37 (Ar), 128.81 (Ar), 128.76 (Ar), 128.67 (Ar), 
128.48 (Ar), 128.34 (Ar), 128.31 (Ar), 128.21 (Ar), 127.81 (Ar), 127.43 (Ar), 126.48 
(Ar), 123.52 (Ar), 102.26 (PhCH), 100.77 (1JC,H = 158 Hz, Man_C1), 99.53 (1JC,H = 
162 Hz, GlcN_C1), 79.06 (GlcN_C4), 78.66 (Man_C4), 78.03 (GlcN_C3), 74.93 




(GlcN_C6), 68.63 (Man_C6), 66.82 (Man_C5), 56.89 (OCH3), 55.82 (GlcN_C2). 




glucopyranoside (29). The glycosyl acceptor (28; 119 mg, 0.158 mmol), glycosyl 
donor (26; 129 mg, 0.196 mmol), and crushed molecular sieves (3 Å, 207 mg) in 
anhydrous CH2Cl2 (2.0 mL) were left mixing for 20 minutes at ambient temperature 
under Ar. The foil-covered reaction flask was then cooled to –60 °C, and AgOTf (52 
mg, 0.20 mmol) was added over 5 minutes. After 1 hour, the flask was warmed to –40 
°C, and after another 1.5 hours additional glycosyl donor (26; 50 mg, 0.076 mmol) 
was added. After 1 hour, the solution was neutralized with Et3N (to pH 8), warmed to 
ambient temperature, diluted with CH2Cl2 (30 mL), and then filtered over Celite. The 
organic phase was washed with NH4OH(aq) solution (0.5 M; 2 x 30 mL), saturated 
NaCl(aq) solution (30 mL), dried with Na2SO4, filtered, and evaporated to dry. The 
crude material was purified via MPLC on silica gel using 0→20% acetone – toluene 
to afford the pure product as a white solid (84 mg, 0.063 mmol, 40% yield). Rf = 0.47 
(2:3 acetone : petroleum ether). [α]D20: -27° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 
MHz): δH 8.09 – 8.07 (m, 2H, Ar), 8.06 – 8.04 (m, 2H, Ar), 7.97 – 7.95 (m, 2H, Ar), 
7.83 – 7.67 (m, 6H, Ar), 7.64 – 7.58 (m, 2H, Ar), 7.52 – 7.23 (m, 22H, Ar), 7.05 – 
7.03 (m, 2H, Ar), 6.98 – 6.90 (m, 3H, Ar), 6.10 (dd, 1H, J = 10.1, 10.1 Hz, 
Man_H4’), 6.01 (dd, 1H, J = 10.1, 3.3 Hz, Man_H3’), 5.81 (dd, 1H, J = 3.2, 1.9 Hz, 
Man_H2’), 5.54 (s, 1H, PhCH), 5.41 (d, 1H, J = 1.7 Hz, Man_H1’), 5.04 (d, 1H, J = 
8.5 Hz, GlcN_H1), 4.83 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.77 (d, 1H, J = 12.1 Hz, 
PhCHaHb), 4.70 – 4.65 (m, 3H, Man_H6a’, Man_H5’, and Man_H1), 4.51 (d, 1H, J = 
12.2 Hz, PhCHaHb), 4.51 – 4.47 (m, 1H, Man_H6b’), 4.44 (d, 1H, J = 12.1 Hz, 
PhCHaHb), 4.35 (dd, 1H, J = 10.7, 8.6 Hz, GlcN_H3), 4.20 (dd, 1H, J = 10.7, 8.5 Hz, 
GlcN_H2), 4.16 (dd, 1H, J = 10.4, 4.8 Hz, Man_H6a), 4.14 – 4.10 (m, 2H, Man_H2 
and GlcN_H4), 4.09 (dd, 1H, J = 9.6, 9.6 Hz, Man_H4), 3.80 – 3.74 (m, 2H, 
GlcN_H6a and GlcN_H6b), 3.73 (dd, 1H, J = 9.9, 3.2 Hz, Man_H3), 3.57 (dd, 1H, J = 
10.2, 10.2 Hz, Man_H6b), 3.55 (ddd, 1H, J = 9.8, 2.5, 2.5 Hz, GlcN_H5), 3.41 (s, 3H, 
OCH3), 3.13 (ddd, 1H, J = 9.7, 9.7, 4.9 Hz, Man_H5), 2.56 (d, 1H, J = 2.1 Hz, 
Man_2OH). 13C NMR (CDCl3, 125 MHz): δC 166.44 (C=O), 165.77 (C=O), 165.58 




(Ar), 133.49 (Ar), 133.34 (Ar), 131.94 (Ar), 130.07 (Ar), 130.06 (Ar), 129.96 (Ar), 
129.95 (Ar), 129.59 (Ar), 129.35 (Ar), 129.22 (Ar), 128.95 (Ar), 128.85 (Ar), 128.79 
(Ar), 128.64 (Ar), 128.49 (Ar), 128.34 (Ar), 128.24 (Ar), 128.23 (Ar), 127.77 (Ar), 
127.43 (Ar), 126.24 (Ar), 123.54 (Ar), 101.57 (PhCH), 100.35 (1JC,H = 157 Hz, 
Man_C1), 99.52 (1JC,H = 164 Hz, GlcN_C1), 99.13 (1JC,H = 175 Hz, Man_C1’), 78.73 
(GlcN_C4), 77.94 (Man_C3), 77.82 (GlcN_C3), 77.23 (Man_C4), 74.80 (PhCH2), 
74.67 (GlcN_C5), 73.86 (PhCH2), 71.30 (Man_C2), 70.62 (Man_C2’), 69.99 
(Man_C3’), 69.44 (Man_C5’), 68.58 (Man_C6 and GlcN_C6), 67.63 (Man_C4’), 
67.04 (Man_C5), 63.40 (Man_C6’), 56.88 (OCH3), 55.79 (GlcN_C2). ESI-MS m/z 
calc’d for C76H69NO21 (M+Na)+: 1354.43; found: 1354.73. 
 
Methyl a-D-mannopyranosyl-(1→3)-a-D-mannopyranosyl-(1→4)-2-acetamido-2-
deoxy-b-D-glucopyranoside (7). The starting material (29; 62 mg, 0.047 mmol) and 
NH2NH2 H2O (45 µL, 0.92 mmol) in EtOH (1.5 mL) were heated at 70 °C. After 48 
hours, LiOH(aq) solution (1 M; to pH 9) was added and the reaction mixture heated at 
50 °C for 30 minutes, and cooled back to ambient temperature; NaHCO3 (396 mg, 
4.71 mmol) and H2O (1.5 mL) were then added, followed by Ac2O (0.44 mL, 4.7 
mmol). After 30 minutes at ambient temperature, the solution was evaporated to dry 
and then purified via MPLC on silica gel using 0→25% MeOH – CH2Cl2 to afford the 
product as a white solid, which was directly dissolved into MeOH (1.5 mL). Pd(OH)2 
(20% w/w; 12 mg, 0.017 mmol) was added, and the flask subjected to positive-
pressure H2(g) using a balloon. After 24 hours, the catalyst was removed via filtration, 
the solution evaporated to dry, and then the crude mixture purified via reverse-phase 
column chromatography using 0→40% H2O – MeCN to afford the pure product as a 
white solid (26 mg, 0.046 mmol, 99% yield). [α]D20: -613° (c 0.35, H2O). 1H NMR 
(D2O, 500 MHz): δH 5.10 (d, 1H, J = 1.3 Hz, Man_H1’), 4.77 (d, 1H, J = <1 Hz, 
Man_H1), 4.45 (d, 1H, J = 8.0 Hz, GlcNAc_H1), 4.22 (dd, 1H, J = 3.0, <1 Hz, 
Man_H2), 4.06 (dd, 1H, J = 3.3, 1.6 Hz, Man_H2’), 3.93 – 3.86 (m, 4H, Man_H6a, 
Man_H6a’, GlcNAc_H6a, and Man_H3’), 3.79 (ddd, 1H, J = 10.0, 6.9, 1.7 Hz, 
Man_H5’), 3.81 – 3.68 (m, 7H, Man_H3, Man_H6b’, GlcNAc_H6b, Man_H6b, 
GlcNAc_H2, GlcNAc_H3, and GlcNAc_H4), 3.68 (dd, 1H, J = 9.8, 9.8 Hz, 
Man_H4), 3.62 (dd, 1H, J = 9.8, 9.8 Hz, Man_H4’), 3.56 – 3.53 (m, 1H, 
GlcNAc_H5), 3.49 (s, 3H, OCH3), 3.45 (ddd, 1H, J = 9.7, 6.4, 2.1 Hz, Man_H5), 2.02 




Man_C1’), 102.56 (1JC,H = 162 Hz, GlcNAc_C1), 100.58 (1JC,H = 161 Hz, Man_C1), 
81.12 (Man_C3), 79.70 (GlcNAc_C4), 76.84 (Man_C5), 75.20 (GlcNAc_C5), 74.07 
(Man_C5’), 73.05 (GlcNAc_C3), 70.98 (Man_C3’), 70.92 (Man_C2), 70.64 
(Man_C2’), 67.52 (Man_C4’), 66.51 (Man_C4), 61.78 (Man_C6’), 61.47 (Man_C6), 
60.80 (GlcNAc_C6), 57.75 (OCH3), 55.50 (GlcNAc_C2), 22.80 (NHAc). ESI-HRMS 
m/z calc’d for C21H37NO16 (M+Na)+: 582.2010; found: 582.2009. HPLC purity 
































(a) p-TolSH, BF3•Et2O, CH2Cl2, 86%; (b) NaOMe, MeOH/CH2Cl2, 97%;






glucopyranoside (30). The starting material (15; 4.999 g, 10.47 mmol), p-
methylthiophenol (2.092 g, 16.84 mmol), and BF3Et2O (4.0 mL, 32 mmol) in 
anhydrous CH2Cl2 (50 mL) were left mixing under Ar at ambient temperature. After 
24 hours, the reaction mixture was neutralized with the addition of Et3N (to pH 8), 
diluted further with CH2Cl2 (200 mL), washed with saturated NaCl(aq) solution (2 x 
250 mL), dried with Na2SO4, filtered, and evaporated to dry. The crude material was 
then purified via MPLC on silica gel using 0→30% EtOAc – toluene to afford the 
pure product as a white solid (4.885 g, 9.020 mmol, 86% yield). Rf = 0.64 (1:4 
acetone : toluene). [α]D20: +37° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.88 
– 7.85 (m, 2H, Ar), 7.77 – 7.75 (m, 2H, Ar), 7.32 – 7.29 (m, 2H, Ar), 7.09 – 7.07 (m, 
2H, Ar), 5.78 (dd, 1H, J = 9.7, 9.7 Hz, H-3), 5.65 (d, 1H, J = 10.5 Hz, H-1), 5.12 (dd, 
1H, J = 9.6, 9.6 Hz, H-4), 4.34 – 4.30 (m, 1H, H-2), 4.28 (dd, 1H, J = 12.2, 4.8 Hz, H-
6a), 4.21 (dd, 1H, J = 12.1, <2 Hz, H-6b), 3.90 – 3.86 (m, 1H, H-5), 2.33 (s, 3H, 
PhCH3), 2.11 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.83 (s, 3H, Ac). 13C NMR (CDCl3, 125 
MHz): δC 170.78 (Ac), 170.26 (Ac), 169.61 (Ac), 167.99 (Phth), 167.13 (Phth), 




(Ar), 127.14 (Ar), 123.86 (Ar), 83.30 (C-1), 76.03 (C-5), 71.85 (C-3), 68.90 (C-4), 
62.38 (C-6), 53.79 (C-2), 21.34 (PhCH3), 20.93 (Ac), 20.78 (Ac), 20.57 (Ac). ESI-MS 
m/z calc’d for C27H27NO9S (M+Na)+: 564.13; found: 564.15. 
 
p-Methylphenyl 2-deoxy-2-phthalimido-1-thio-b-D-glucopyranoside (31). The 
starting material (30; 4.826 g, 8.911 mmol) was dissolved into anhydrous MeOH–
CH2Cl2  (1:1; 40 mL) and then NaOMe solution was added drop-wise (1.5 M NaOMe 
in MeOH; to pH 10). After 1 hour, the reaction flask was neutralized with acidic resin 
(Amberlite IR-120H; to pH 6), filtered, and evaporated to dry to afford the pure 
product as a white solid (3.603 g, 8.672 mmol, 97% yield). Rf = 0.16 (1:19 MeOH : 
CH2Cl2). [α]D20: +59° (c 0.8, MeOH). 1H NMR (MeOD, 500 MHz): δH 7.92 – 7.81 
(m, 4H, Ar), 7.27 – 7.25 (m, 2H, Ar), 7.05 – 7.03 (m, 2H, Ar), 5.51 (d, 1H, J = 10.4 
Hz, H-1), 4.23 (dd, 1H, J = 10.2, 8.2 Hz, H-3), 4.07 (dd, 1H, J = 10.3, 10.3 Hz, H-2), 
3.93 (dd, 1H, J = 12.1, 2.0 Hz, H-6a), 3.74 (dd, 1H, J = 12.1, 5.3 Hz, H-6b), 3.45 (ddd, 
1H, J = 9.8, 5.3, 2.1 Hz, H-5), 3.42 (dd, 1H, J = 9.8, 8.1 Hz, H-4), 2.26 (s, 3H, 
PhCH3). 13C NMR (MeOD, 125 MHz): δC 169.91 (Phth), 169.44 (Phth), 139.30 (Ar), 
135.77 (Ar), 135.72 (Ar), 133.64 (Ar), 133.29 (Ar), 133.09 (Ar), 130.79 (Ar), 130.67 
(Ar), 124.59 (Ar), 124.28 (Ar), 85.81 (C-1), 82.81 (C-5), 73.99 (C-3), 72.40 (C-4), 
62.99 (C-6), 58.11 (C-2), 21.22 (PhCH3). ESI-MS m/z calc’d for C21H21NO6S 
(M+Na)+: 438.10; found: 438.19. 
 
p-Methylphenyl 4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-b-D-
glucopyranoside (32). The starting material (31; 3.603 g, 8.672 mmol), PhCH(OMe)2 
(2.4 mL, 16 mmol), and camphorsulfonic acid (to pH 3) were added to anhydrous 
MeCN–DMF (1:1; 40 mL) and left mixing at ambient temperature under Ar. After 16 
hours, more PhCH(OMe)2 (2.0 mL, 13 mmol) was added, and after another 8 hours 
the mixture was neutralized with Et3N (to pH 8) and evaporated to dry. The crude 
material was purified via MPLC on silica gel using 0→20% EtOAc – toluene to 
afford the pure product as a white solid (3.556 g, 7.062 mmol, 81% yield). Rf = 0.70 
(1:4 acetone : toluene). [α]D20: +26° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 
7.87 – 7.80 (m, 2H, Ar), 7.72 – 7.67 (m, 2H, Ar), 7.48 – 7.43 (m, 2H, Ar), 7.35 – 7.32 
(m, 3H, Ar), 7.28 – 7.25 (m, 2H, Ar), 7.06 – 7.04 (m, 2H, Ar), 5.60 (d, 1H, J = 10.5 
Hz, H-1), 5.53 (s, 1H, PhCH), 4.57 (ddd, 1H, J = 9.4, 9.4, <2 Hz, H-3), 4.35 (dd, 1H, 




10.2 Hz, H-6b), 3.61 (ddd, 1H, J = 9.6, 9.6, 4.9 Hz, H-5), 3.53 (dd, 1H, J = 9.2, 9.2 
Hz, H-4), 2.76 (d, 1H, J = <2 Hz, 3-OH), 2.29 (s, 3H, PhCH3). 13C NMR (CDCl3, 125 
MHz): δC 168.43 (Phth), 167.72 (Phth), 138.57 (Ar), 137.10 (Ar), 134.36 (Ar), 
133.45 (Ar), 131.82 (Ar), 131.74 (Ar), 129.88 (Ar), 129.51 (Ar), 128.52 (Ar), 128.05 
(Ar), 126.49 (Ar), 124.01 (Ar), 123.50 (Ar), 102.07 (PhCH), 84.64 (C-1), 82.02 (C-4), 
70.44 (C-5), 69.86 (C-3), 68.72 (C-6), 55.84 (C-2), 21.30 (PhCH3). ESI-MS m/z 
calc’d for C28H25NO6S (M+Na)+: 526.13; found: 526.29. 
 
p-Methylphenyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-b-
D-glucopyranoside (33). The starting material (32; 3.556 g, 7.062 mmol) and BnBr 
(1.5 mL, 13 mmol) were added to anhydrous DMF (30 mL), and then NaH was added 
portion-wise (60% oil dispersion; 623 mg, 15.6 mmol) under Ar. After 6 hours the 
reaction was quenched via the slow addition of MeOH (5 mL), evaporated to dry, and 
then redissolved into EtOAc (250 mL). The organic phase was washed with saturated 
NaCl(aq) solution (2 x 250 mL), dried with Na2SO4, filtered, and evaporated to dry. 
The crude material was purified via MPLC on silica gel using 0→10% EtOAc – 
toluene to afford the pure product as a white solid (4.126 g, 6.950 mmol, 98% yield). 
Rf = 0.62 (1:9 EtOAc : toluene). [α]D20: +52° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 
MHz): δH 7.86 – 7.84 (m, 1H, Ar), 7.74 – 7.62 (m, 3H, Ar), 7.52 – 7.50 (m, 2H, Ar), 
7.40 – 7.35 (m, 3H, Ar), 7.25 – 7.23 (m, 2H, Ar), 7.05 – 7.03 (m, 2H, Ar), 6.98 – 6.96 
(m, 2H, Ar), 6.92 – 6.84 (m, 3H, Ar), 5.61 (s, 1H, PhC  H), 5.55 (d, 1H, J = 10.5 Hz, 
H-1), 4.76 (d, 1H, J = 12.3 Hz, PhCHaHb), 4.48 (d, 1H, J = 12.3 Hz, PhCHaHb), 4.43 
– 4.39 (m, 2H, H-3 and H-6a), 4.26 (dd, 1H, J = 10.2, 10.2 Hz, H-2), 3.83 (dd, 1H, J = 
10.2, 10.2 Hz, H-6b), 3.77 (dd, 1H, J = 9.1, 9.1 Hz, H-4), 3.69 (ddd, 1H, J = 9.6, 9.6, 
4.8 Hz, H-5), 2.29 (s, 3H, PhCH3). 13C NMR (CDCl3, 125 MHz): δC 167.97 (Phth), 
167.40 (Phth), 138.60 (Ar), 137.89 (Ar), 137.49 (Ar), 134.16 (Ar), 134.00 (Ar), 
133.63 (Ar), 131.79 (Ar), 129.84 (Ar), 129.21 (Ar), 128.47 (Ar), 128.34 (Ar), 128.22 
(Ar), 127.84 (Ar), 127.61 (Ar), 126.24 (Ar), 123.71 (Ar), 123.51 (Ar), 101.48 
(PhCH), 84.42 (C-1), 83.00 (C-4), 75.68 (C-3), 74.39 (PhCH2), 70.54 (C-5), 68.86 (C-
6), 55.00 (C-2), 21.32 (PhCH3). ESI-MS m/z calc’d for C35H31NO6S (M+Na)+: 



























































(a) TMSOTf, NIS, CH2Cl2, -70 to 0 °C,
92%; (b) Et3SiH, BF3•Et2O, CH2Cl2,
0 °C, quant.; (c) (i) 1-benzenesulfinyl
piperidine, 2,4,6-tri-ter t-butylpyrimidine,
Tf2O, 24, -60 °C to rt; (d) Pd(OAc)2,
PPh3, 1,3-dimethylbarbituric acid,
MeOH/CH2Cl2, 40 °C, 70% over 2 steps;











(34). The glycosyl acceptor (20; 1.595 g, 3.168 mmol), glycosyl donor (33; 2.363 g, 
3.980 mmol), and crushed molecular sieves (3 Å, 2.027 g) were added to anhydrous 
CH2Cl2 (30 mL) and left mixing at ambient temperature under Ar. After 2 hours, the 
reaction flask was cooled to -70 °C, NIS (1.502 g, 6.676 mmol) and TfOH (53 µL, 
0.60 mmol) were slowly added, and the flask was warmed to 0 °C over 1 hour. After 
18 hours, more glycosyl donor (33; 1.880 g, 3.167 mmol) and NIS (1.376 g, 6.116 
mmol) were added, and after another 4 hours the solution was neutralized with the 
addition of Et3N (to pH 8) and warmed to ambient temperature. The crude reaction 
mixture was filtered over Celite, diluted with CH2Cl2 (200 mL), and then washed with 
saturated NaHCO3(aq) solution (250 mL), saturated NaCl(aq) solution (250 mL), H2O 
(250 mL), dried with Na2SO4, filtered, and then evaporated to dry. The crude material 
was purified via MPLC on silica gel using 0→20% EtOAc – toluene to afford the 
pure product as a white solid (2.827 g, 2.905 mmol, 92% yield). Rf = 0.32 (1:9 EtOAc 
: toluene). [α]D20: +23° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.92 – 7.59 
(m, 8H, Ar), 7.50 – 7.48 (m, 2H, Ar), 7.41 – 7.25 (m, 8H, Ar), 7.06 – 7.04 (m, 2H, 
Ar), 6.99 – 6.97 (m, 2H, Ar), 6.95 – 6.87 (m, 6H, Ar), 5.51 (s, 1H, PhCH), 5.38 (d, 
1H, J = 8.4 Hz, GlcN_H1’), 4.88 (d, 1H, J = 8.4 Hz, GlcN_H1), 4.82 (d, 1H, J = 12.4 
Hz, PhCHaHb), 4.78 (d, 1H, J = 12.3 Hz, PhCHaHb), 4.50 – 4.47 (m, 3H, 2x PhCHaHb 
and PhCHaHb), 4.45 – 4.41 (m, 2H, GlcN_H3’ and PhCHaHb), 4.24 – 4.15 (m, 4H, 




3.71 (dd, 1H, J = 9.2, 9.2 Hz, GlcN_H4’), 3.53 (dd, 1H, J = 10.2, 10.2 Hz, 
GlcN_H6b’), 3.50 (dd, 1H, J = 10.9, <1 Hz, GlcN_H6a), 3.39 (ddd, 1H, J = 9.7, 9.7, 
4.9 Hz, GlcN_H5’), 3.37 (dd, 1H, J = 10.9, 3.9 Hz, GlcN_H6b), 3.34 – 3.30 (m, 1H, 
GlcN_H5), 3.27 (s, 3H, OCH3). 13C NMR (CDCl3, 125 MHz): δC 168.31 (Phth), 
167.68 (Phth), 138.74 (Ar), 138.47 (Ar), 138.13 (Ar), 137.59 (Ar), 134.19 (Ar), 
133.85 (Ar), 131.92 (Ar), 129.17 (Ar), 128.45 (Ar), 128.23 (Ar), 128.17 (Ar), 128.15 
(Ar), 127.94 (Ar), 127.70 (Ar), 127.58 (Ar), 127.50 (Ar), 127.24 (Ar), 126.28 (Ar), 
123.84 (Ar), 123.44 (Ar), 101.41 (PhCH), 99.18 (GlcN_C1), 97.94 (GlcN_C1’), 
83.37 (GlcN_C4’), 77.13 and 76.55 (GlcN_C3 and GlcN_C4), 74.73 (GlcN_C5 and 
GlcN_C3’), 74.56 (PhCH2), 74.30 (PhCH2), 72.90 (PhCH2), 68.93 (GlcN_C6’), 68.18 
(GlcN_C6), 65.94 (GlcN_C5’), 56.76 (GlcN_C2), 56.58 (OCH3), 55.70 (GlcN_C2’). 
ESI-MS m/z calc’d for C57H52N2O13 (M+Na)+: 995.37; found: 995.64. 
 
Methyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-b-D-glucopyranosyl-(1→4)-3,6-
di-O-benzyl-2-deoxy-2-phthalimido-b-D-glucopyranoside (35). A solution of the 
starting material (34; 2.660 g, 2.734 mmol) in anhydrous CH2Cl2 (25 mL) was cooled 
to 0 °C under Ar, and then Et3SiH (2.2 mL, 14 mmol) and BF3Et2O (0.70 mL, 5.6 
mmol) were slowly added. After 3.5 hours, more Et3SiH (1.0 mL, 6.3 mmol) was 
added and then after another 2 hours the reaction mixture was neutralized with Et3N 
(to pH 8), warmed back to ambient temperature, and then quenched via the slow 
addition of MeOH (5 mL). The crude mixture was evaporated to dry, and then 
purified via MPLC on silica gel using 0→20% EtOAc – toluene to afford the pure 
product as a white solid (2.634 g, 2.701 mmol, quantitative yield). Rf = 0.29 (1:4 
EtOAc : toluene). [α]D20: +13° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.89 
– 7.56 (m, 8H, Ar), 7.37 – 7.24 (m, 10H, Ar), 7.04 – 6.93 (m, 7H, Ar), 6.86 – 6.81 (m, 
3H, Ar), 5.30 (d, 1H, J = 8.3 Hz, GlcN_H1’), 4.87 (d, 1H, J = 8.0 Hz, GlcN_H1), 
4.79 (d, 1H, J = 12.5 Hz, PhCHaHb), 4.79 (d, 1H, J = 12.2 Hz, PhCHaHb), 4.53 (d, 1H, 
J = 11.9 Hz, PhCHaHb), 4.52 (d, 1H, J = 12.2 Hz, PhCHaHb), 4.50 – 4.45 (m, 4H, 
PhCHaHb and 3x PhCHaHb), 4.25 (dd, 1H, J = 10.7, 8.3 Hz, GlcN_H3’), 4.19 – 4.07 
(m, 4H, GlcN_H4, GlcN_H2’, GlcN_H3, and GlcN_H2), 3.81 (ddd, 1H, J = 9.6, 8.2, 
2.0 Hz, GlcN_H4’), 3.70 (dd, 1H, J = 9.9, 4.4 Hz, GlcN_H6a’), 3.55 (dd, 1H, J = 
11.1, <1 Hz, GlcN_H6a), 3.53 (dd, 1H, J = 9.8, 6.3 Hz, GlcN_H6b’), 3.43 (dd, 1H, J = 
11.0, 3.7 Hz, GlcN_H6b), 3.38 (ddd, 1H, J = 9.4, 6.0, 4.6 Hz, GlcN_H5’), 3.31 (ddd, 




GlcN_4-OH’). 13C NMR (CDCl3, 125 MHz): δC 168.64 (Phth), 167.85 (Phth), 138.83 
(Ar), 138.60 (Ar), 138.53 (Ar), 137.72 (Ar), 134.20 (Ar), 134.06 (Ar), 133.81 (Ar), 
131.96 (Ar), 131.71 (Ar), 128.74 (Ar), 128.43 (Ar), 128.29 (Ar), 128.08 (Ar), 128.06 
(Ar), 128.04 (Ar), 127.97 (Ar), 127.93 (Ar), 127.58 (Ar), 127.52 (Ar), 127.10 (Ar), 
123.84 (Ar), 123.37 (Ar), 99.21 (GlcN_C1), 97.18 (GlcN_C1’), 78.52 (GlcN_C3’), 
76.95 (GlcN_C3), 75.96 (GlcN_C4), 75.67 (GlcN_C4’), 74.77 (GlcN_C5), 74.53 
(PhCH2), 74.42 (PhCH2), 73.91 (PhCH2), 72.99 (GlcN_C5’), 72.88 (PhCH2), 71.19 
(GlcN_C6’), 68.33 (GlcN_C6), 56.60 (OCH3), 56.31 (GlcN_C2’), 55.74 (GlcN_C2). 




deoxy-2-phthalimido-b-D-glucopyranoside (36). The glycosyl donor (24; 183 mg, 
0.403 mmol), 1-benzenesulfinyl piperidine (85 mg, 0.41 mmol), 2,4,6-tri-tert-
butylpyrimidine (201 mg, 0.809 mmol), and crushed molecular sieves (3 Å, 453 mg) 
in anhydrous CH2Cl2 (10 mL) were left mixing at ambient temperature under Ar 
[ref3]. After 2 hours, the flask was cooled to –60 °C and then Tf2O (75 µL, 0.45 
mmol) was added. After 5 minutes, a solution of the glycosyl acceptor (35; 585 mg, 
0.600 mmol) in anhydrous CH2Cl2 (4 mL) was added, and after another 2 minutes the 
reaction mixture was warmed to ambient temperature over 5 minutes. The reaction 
solution was diluted with CH2Cl2 (50 mL), and then washed with saturated 
NaHCO3(aq) solution (60 mL), saturated NaCl(aq) solution (60 mL), dried with Na2SO4, 
filtered, and evaporated to dry. The crude material was purified via MPLC on silica 
gel using 0→30% EtOAc – toluene to afford some pure material, as well as 
compound that had co-eluted with the undesired a-configured by-product; all fractions 
were combined and used directly for the subsequent step. Rf = 0.51 (1:4 EtOAc : 
toluene). [α]D20: +17° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 MHz): δH 7.88 – 7.53 
(m, 8H, Ar), 7.44 – 7.41 (m, 2H, Ar), 7.35 – 7.24 (m, 13H, Ar), 7.02 – 7.00 (m, 2H, 
Ar), 6.98 – 6.95 (m, 2H, Ar), 6.93 – 6.86 (m, 3H, Ar), 6.80 – 6.74 (m, 3H, Ar), 5.98 
(dddd, 1H, J = 17.3, 10.4, 5.7, 5.7 Hz, 2-OCH2CH=CH2), 5.90 (dddd, 1H, J = 17.2, 
10.5, 5.3, 5.3 Hz, 3-OCH2CH=CH2), 5.45 (s, 1H, PhCH), 5.32 (dddd, 1H, J = 17.3, 
1.6, 1.6, 1.6 Hz, 2-OCH2CH=CHaHb), 5.30 (dddd, 1H, J = 17.3, 1.7, 1.7, 1.7 Hz, 3-
OCH2CH=CHaHb), 5.29 (d, 1H, J = 8.4 Hz, GlcN_H1’), 5.18 – 5.15 (m, 2H, 2-
OCH2CH=CHaHb and 3-OCH2CH=CHaHb), 4.92 (d, 1H, J = 12.2 Hz, PhCHaHb), 4.87 
270
 
(d, 1H, J = 8.2 Hz, GlcN_H1), 4.85 (d, 1H, J = 12.8 Hz, PhCHaHb), 4.60 (d, 1H, J = 
<1 Hz, Man_H1), 4.59 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.55 – 4.50 (m, 3H, PhCHaHb 
and 2x PhCHaHb), 4.48 – 4.44 (m, 2H, 2x PhCHaHb), 4.34 (dddd, 1H, J = 12.8, 5.6, 
1.4, 1.4 Hz, 2-OCHaHbCH=CH2), 4.32 – 4.19 (m, 5H, 2-OCHaHbCH=CH2, 
GlcN_H3’, 3-OCHaHbCH=CH2, GlcN_H4, and GlcN_H2’), 4.15 – 4.05 (m, 5H, 
GlcN_H3, Man_H6a, GlcN_H2, GlcN_H4’, and 3-OCHaHbCH=CH2), 3.94 (dd, 1H, J 
= 9.6, 9.6 Hz, Man_H4), 3.70 (dd, 1H, J = 3.1, <1 Hz, Man_H2), 3.67 (dd, 1H, J = 
11.3, 1.8 Hz, GlcN_H6a’), 3.59 – 3.56 (m, 2H, GlcN_H6a and GlcN_H6b’), 3.50 (dd, 
1H, J = 10.3, 10.3 Hz, Man_H6b), 3.44 (dd, 1H, J = 11.1, 3.8 Hz, GlcN_H6b), 3.34 
(dd, 1H, J = 9.9, 3.1 Hz, Man_H3), 3.32 (ddd, 1H, J = 9.8, 3.7, 1.3 Hz, GlcN_H5), 
3.28 – 3.24 (m, 4H, OCH3 and GlcN_H5’), 3.11 (ddd, 1H, J = 9.7, 9.7, 4.8 Hz, 
Man_H5). 13C NMR (CDCl3, 125 MHz): δC 168.73 (Phth), 167.80 (Phth), 139.13 
(Ar), 138.84 (Ar), 138.71 (Ar), 138.15 (Ar), 137.85 (Ar), 135.77 (2-OCH2CH=CH2), 
135.16 (3-OCH2CH=CH2), 134.23 (Ar), 134.01 (Ar), 133.76 (Ar), 132.02 (Ar), 
131.96 (Ar), 131.70 (Ar), 128.98 (Ar), 128.75 (Ar), 128.40 (Ar), 128.34 (Ar), 128.22 
(Ar), 128.05 (Ar), 128.02 (Ar), 128.01 (Ar), 127.94 (Ar), 127.89 (Ar), 127.55 (Ar), 
127.52 (Ar), 127.17 (Ar), 127.06 (Ar), 126.25 (Ar), 123.87 (Ar), 123.33 (Ar), 117.05 
(2-OCH2CH=CH2), 116.69 (3-OCH2CH=CH2), 101.93 (1JC,H = 158 Hz, Man_C1), 
101.52 (PhCH), 99.28 (1JC,H = 163 Hz, GlcN_C1), 97.23 (1JC,H = 167 Hz, GlcN_C1’), 
79.25 (GlcN_C4’), 78.86 (Man_C4), 78.29 (Man_C3), 77.15 (GlcN_C3’ and 
Man_C2), 77.00 (GlcN_C3), 75.96 (GlcN_C4), 74.90 (GlcN_C5’), 74.86 (PhCH2), 
74.76 (GlcN_C5), 74.60 and 74.57 (PhCH2 and 2-OCH2CH=CH2), 73.58 (PhCH2), 
72.86 (PhCH2), 71.91 (3-OCH2CH=CH2), 68.76 (Man_C6), 68.41 (GlcN_C6), 68.26 
(GlcN_C6’), 67.44 (Man_C5), 56.81 (GlcN_C2’), 56.65 (OCH3), 55.81 (GlcN_C2). 
ESI-MS m/z calc’d for C76H76N2O18 (M+Na)+: 1327.50; found: 1327.96. 
Methyl 4,6-O-benzylidene-b-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-
2-phthalimido-b-D-glucopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido-b-D-glucopyranoside (37). A solution of Pd(OAc)2 (33 mg, 0.15
mmol) and PPh3 (146 mg, 0.557 mmol) in anhydrous MeOH/CH2Cl2 (2:1, 9 mL)
were left mixing at ambient temperature under Ar. After 20 minutes, the solution was
transferred to a flask containing an a-/b-mixture of the substrate (36; 945 mg, 0.724
mmol) and 1,3-dimethylbarbituric acid (452 mg, 2.89 mmol) and left mixing at 40 °C




saturated Na2CO3(aq) solution (300 mL), and the aqueous layer re-extracted with 
CH2Cl2 (300 mL). The combined organic phases were then washed with saturated 
NaCl(aq) solution (2 x 300 mL), dried with Na2SO4, filtered, and evaporated to dry. 
The crude material was purified via MPLC on silica gel using 0→50% acetone – 
toluene to afford the pure product as a white solid (619 mg, 0.505 mmol, 70% yield 
over 2 steps) together with the a-anomeric byproduct (226 mg, 0.184 mmol, 25% 
yield over 2 steps). Rf = 0.64 (2:3 acetone : toluene). [α]D20: +18° (c 1.0, CHCl3). 1H 
NMR (CDCl3, 500 MHz): δH 7.87 – 7.54 (m, 8H, Ar), 7.46 – 7.44 (m, 2H, Ar), 7.37 – 
7.24 (m, 13H, Ar), 7.03 – 7.01 (m, 2H, Ar), 6.98 – 6.89 (m, 5H, Ar), 6.80 – 6.76 (m, 
3H, Ar), 5.45 (s, 1H, PhCH), 5.28 (d, 1H, J = 8.4 Hz, GlcN_H1’), 4.87 (d, 1H, J = 8.3 
Hz, GlcN_H1), 4.86 (d, 1H, J = 12.6 Hz, PhCHaHb), 4.82 (d, 1H, J = 12.1 Hz, 
PhCHaHb), 4.74 (d, 1H, J = <1 Hz, Man_H1), 4.59 (d, 1H, J = 12.0 Hz, PhCHaHb), 
4.54 (d, 1H, J = 11.9 Hz, PhCHaHb), 4.53 – 4.50 (m, 2H, 2x PhCHaHb), 4.46 (d, 1H, J 
= 12.0 Hz, PhCHaHb), 4.42 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.39 (dd, 1H, J = 10.7, 8.6 
Hz, GlcN_H3’), 4.28 – 4.23 (m, 1H, GlcN_H4), 4.23 (dd, 1H, J = 10.7, 8.4 Hz, 
GlcN_H2’), 4.15 – 4.11 (m, 4H, GlcN_H4’, Man_H6a, GlcN_H2, and GlcN_H3), 
3.94 – 3.92 (m, 1H, Man_H2), 3.75 (dd, 1H, J = 9.5, 9.5 Hz, Man_H4), 3.65 (dd, 1H, 
J = 11.4, 1.7 Hz, GlcN_H6a’), 3.62 – 3.56 (m, 3H, GlcN_H6a, Man_H3, and 
GlcN_H6b’), 3.53 (dd, 1H, J = 10.3, 10.3 Hz, Man_H6b), 3.44 (dd, 1H, J = 11.2, 3.6 
Hz, GlcN_H6b), 3.32 – 3.28 (m, 5H, GlcN_H5, GlcN_H5’, and OCH3), 3.12 (ddd, 
1H, J = 9.8, 9.8, 5.0 Hz, Man_H5), 2.69 (d, 1H, J = 2.0 Hz, Man_2-OH), 2.54 (d, 1H, 
J = 6.8 Hz, Man_3-OH). 13C NMR (CDCl3, 125 MHz): δC 168.72 (Phth), 167.74 
(Phth), 138.80 (Ar), 138.62 (Ar), 138.58 (Ar), 137.79 (Ar), 137.36 (Ar), 134.26 (Ar), 
134.10 (Ar), 133.78 (Ar), 131.98 (Ar), 131.64 (Ar), 129.37 (Ar), 128.81 (Ar), 128.48 
(Ar), 128.45 (Ar), 128.22 (Ar), 128.21 (Ar), 128.19 (Ar), 128.06 (Ar), 127.74 (Ar), 
127.60 (Ar), 127.49 (Ar), 127.45 (Ar), 127.12 (Ar), 126.47 (Ar), 123.92 (Ar), 123.40 
(Ar), 102.26 (PhCH), 100.62 (1JC,H = 163 Hz, Man_C1), 99.28 (1JC,H = 166 Hz, 
GlcN_C1), 97.15 (1JC,H = 166 Hz, GlcN_C1’), 78.93 (GlcN_C4’), 78.70 (Man_C4), 
77.89 (GlcN_C3’), 76.91 (GlcN_C3), 75.81 (GlcN_C4), 74.94 (PhCH2), 74.72 
(GlcN_C5’), 74.60 (GlcN_C5), 74.58 (PhCH2), 73.71 (PhCH2), 72.86 (PhCH2), 
70.96, 70.93 (Man_C2 and Man_C3), 68.63 (Man_C6), 68.34 (GlcN_C6), 68.02 
(GlcN_C6’), 66.78 (Man_C5), 56.77 (GlcN_C2’), 56.63 (OCH3), 55.79 (GlcN_C2). 






b-D-glucopyranoside (38). The starting material (37; 684 mg, 0.558 mmol) and 
BH3THF (1 M solution; 2.8 mL, 2.8 mmol) in anhydrous CH2Cl2 (6.0 mL) were left 
mixing for 5 minutes at ambient temperature under Ar, and then Cu(OTf)2 (40 mg, 
0.11 mmol) which had immediately prior been co-evaporated with toluene (3x) was 
added to the solution [ref5]. After 6 hours, the reaction mixture was neutralized with 
Et3N (to pH 8) and then quenched via the slow addition of MeOH (2 mL). The crude 
mixture was evaporated to dry and then purified via MPLC on silica gel using 
0→40% EtOAc – toluene to afford the pure product as a white solid (603 mg, 0.491 
mmol, 88% yield). Rf = 0.55 (2:3 acetone : toluene). [α]D20: +23° (c 1.0, CHCl3). 1H 
NMR (CDCl3, 500 MHz): δH 7.87 – 7.53 (m, 8H, Ar), 7.36 – 7.23 (m, 15H, Ar), 7.04 
– 7.02 (m, 2H, Ar), 6.98 – 6.90 (m, 5H, Ar), 6.80 – 6.75 (m, 3H, Ar), 5.28 (d, 1H, J =
8.4 Hz, GlcN_H1’), 4.89 – 4.84 (m, 3H, GlcN_H1 and 2x PhCHaHb), 4.78 (d, 1H, J =
11.4 Hz, PhCHaHb), 4.67 (d, 1H, J = <1 Hz, Man_H1), 4.61 (d, 1H, J = 11.4 Hz,
PhCHaHb), 4.58 – 4.50 (m, 3H, 2x PhCHaHb and PhCHaHb), 4.50 (d, 1H, J = 11.8 Hz,
PhCHaHb), 4.48 (d, 1H, J = 12.1 Hz, PhCHaHb), 4.44 (d, 1H, J = 12.1 Hz, PhCHaHb),
4.40 (dd, 1H, J = 10.7, 8.7 Hz, GlcN_H3’), 4.27 – 4.21 (m, 2H, GlcN_H4 and
GlcN_H2’), 4.15 – 4.09 (m, 3H, GlcN_H3, GlcN_H4’, and GlcN_H2), 3.83 – 3.82
(m, 1H, Man_H2), 3.72 (ddd, 1H, J = 11.9, 6.6, 2.5 Hz, Man_H6a), 3.64 (dd, 1H, J =
11.5, 1.9 Hz, GlcN_H6a’), 3.60 – 3.55 (m, 2H, GlcN_H6b’ and GlcN_H6a), 3.54 –
3.47 (m, 3H, Man_H4, Man_H6b, and Man_H3), 3.43 (dd, 1H, J = 11.1, 3.7 Hz,
GlcN_H6b), 3.32 – 3.29 (m, 2H, GlcN_H5 and GlcN_H5’), 3.27 (s, 3H, OCH3), 3.11
(ddd, 1H, J = 8.9, 5.0, 2.5 Hz, Man_H5), 2.72 (d, 1H, J = 3.2 Hz, ManC2_OH), 2.47
(d, 1H, J = 7.4 Hz, ManC3_OH), 2.07 (dd, 1H, J = 6.8, 6.8 Hz, ManC6_OH). 13C
NMR (CDCl3, 125 MHz): δC 168.72 (Phth), 167.74 (Phth), 138.77 (Ar), 138.58 (Ar),
138.36 (Ar), 138.32 (Ar), 137.78 (Ar), 134.29 (Ar), 134.13 (Ar), 133.75 (Ar), 131.94
(Ar), 131.58 (Ar), 128.78 (Ar), 128.71 (Ar), 128.43 (Ar), 128.37 (Ar), 128.23 (Ar),
128.15 (Ar), 128.11 (Ar), 128.08 (Ar), 128.02 (Ar), 127.59 (Ar), 127.57 (Ar), 127.46
(Ar), 127.44 (Ar), 127.08 (Ar), 123.92 (Ar), 123.38 (Ar), 99.89 (1JC,H = 159 Hz,
Man_C1), 99.25 (1JC,H = 164 Hz, GlcN_C1), 97.15 (1JC,H = 167 Hz, GlcN_C1’), 78.15
(GlcN_C4’), 77.98 (GlcN_C3’), 76.93 (GlcN_C3), 75.87 (GlcN_C4), 75.80
(Man_C4), 75.52 (Man_C5), 75.00 (PhCH2), 74.91 (PhCH2), 74.79, 74.71 (GlcN_C5
and GlcN_C5’), 74.65 (PhCH2), 74.36 (Man_C3), 73.67 (PhCH2), 72.84 (PhCH2),
273
 
70.98 (Man_C2), 68.31 (GlcN_C6), 67.72 (GlcN_C6’), 62.23 (Man_C6), 56.75 
(GlcN_C2’), 56.61 (OCH3), 55.78 (GlcN_C2). ESI-MS m/z calc’d for C70H70N2O18 
























































(a) AgOTf, CH2Cl2, -60 °C to -50 °C, 24%; (b) (i) NH2NH2•H2O, EtOH, 70 °C;








benzyl-2-deoxy-2-phthalimido-b-D-glucopyranoside (39). The glycosyl acceptor 
(38; 586 mg, 0.477 mmol), glycosyl donor (26; 1.015 g, 1.539 mmol), and crushed 
molecular sieves (3 Å, 428 mg) in anhydrous CH2Cl2 (6.0 mL) were left mixing for 
30 minutes at ambient temperature under Ar. The foil-covered reaction flask was 
cooled to –60 °C, and then AgOTf (373 mg, 1.45 mmol) was added. After 1.5 hours, 
additional glycosyl donor (26; 186 mg, 0.282 mmol) was added to the reaction 
mixture, followed by a second additional portion of glycosyl donor (26; 169 mg, 
0.256 mmol) after another hour had passed. The reaction flask was warmed to –50 °C, 
and then after 3 hours was neutralized with Et3N (to pH 8), warmed to ambient 
temperature, diluted further with CH2Cl2 (200 mL), and filtered over Celite. The 
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organic phase was washed with NH4OH(aq) solution (0.5 M; 2 x 250 mL), saturated 
NaCl(aq) solution (250 mL), dried with Na2SO4, filtered, and evaporated to dry. The 
crude material was purified via MPLC on silica gel using 0→50% EtOAc – toluene to 
afford the pure product as a white solid (269 mg, 0.113 mmol, 24% yield) as a well as 
a mixture of mono-mannosylated intermediates (543 mg, 0.301 mmol, 63% yield). Rf 
= 0.41 (1:4 EtOAc : toluene). [α]D20: -11° (c 1.0, CHCl3). 1H NMR (CDCl3, 500 
MHz): δH 8.15 – 8.13 (m, 2H, Ar), 8.10 – 8.08 (m, 2H, Ar), 8.04 – 8.02 (m, 2H, Ar), 
8.00 – 7.98 (m, 2H, Ar), 7.90 – 7.85 (m, 6H, Ar), 7.79 – 7.77 (m, 2H, Ar), 7.74 – 7.14 
(m, 47H, Ar), 6.93 – 6.91 (m, 2H, Ar), 6.82 – 6.79 (m, 2H, Ar), 6.75 – 6.69 (m, 3H, 
Ar), 6.57 – 6.51 (m, 3H, Ar), 6.23 (dd, 1H, J = 10.2, 10.2 Hz, Man_H4’3), 6.09 (dd, 
1H, J = 10.2, 3.1 Hz, Man_H3’3), 6.00 (dd, 1H, J = 9.9, 9.9 Hz, Man_H4’6), 5.88 (dd, 
1H, J = 10.1, 3.3 Hz, Man_H3’6), 5.79 – 5.78 (m, 1H, Man_H2’3), 5.68 (dd, 1H, J = 
3.2, 1.7 Hz, Man_H2’6), 5.38 (d, 1H, J = 1.4 Hz, Man_H1’6), 5.23 (d, 1H, J = 8.4 Hz, 
GlcN_H1’), 5.22 (d, 1H, J = 11.6 Hz, PhCHaHb), 5.21 (d, 1H, J = <2 Hz, Man_H1’3), 
5.05 (ddd, 1H, J = 10.2, 3.2, 3.2 Hz, Man_H5’3), 4.90 (d, 1H, J = 11.4 Hz, PhCHaHb), 
4.84 (d, 1H, J = 12.7 Hz, PhCHaHb), 4.83 (d, 1H, J = 8.3 Hz, GlcN_H1), 4.80 (d, 1H, 
J = 12.6 Hz, PhCHaHb), 4.75 (dd, 1H, J = 12.2, 2.3 Hz, Man_H6a’3), 4.71 (d, 1H, J = 
<1 Hz, Man_H1), 4.56 (d, 1H, J = 12.2 Hz, PhCHaHb), 4.56 (dd, 1H, J = 12.2, 4.1 Hz, 
Man_H6b’3), 4.51 – 4.44 (m, 5H, Man_H6a’6, PhCHaHb, and 3x PhCHaHb), 4.39 (d, 
1H, J = 12.6 Hz, PhCHaHb), 4.35 – 4.29 (m, 2H, Man_H6b’6 and Man_H5’6), 4.28 
(dd, 1H, J = 10.5, 8.6 Hz, GlcN_H3’), 4.23 – 4.12 (m, 5H, Man_H2, Man_H4, 
GlcN_H4, GlcN_H2’, and GlcN_H4’), 4.09 (dd, 1H, J = 10.6, 8.0 Hz, GlcN_H2), 
4.08 (dd, 1H, J = 10.6, 8.0 Hz, GlcN_H3), 4.03 (dd, 1H, J = 12.1, 2.8 Hz, Man_H6a), 
3.94 (dd, 1H, J = 12.2, <2 Hz, Man_H6b), 3.67 (dd, 1H, J = 11.2, <2 Hz, GlcN_H6a’), 
3.58 – 3.55 (m, 2H, GlcN_H6b’ and Man_H3), 3.49 (dd, 1H, J = 10.9, <2 Hz, 
GlcN_H6a), 3.37 (dd, 1H, J = 11.1, 3.8 Hz, GlcN_H6b), 3.34 – 3.31 (m, 1H, 
Man_H5), 3.26 – 3.23 (m, 4H, OCH3 and GlcN_H5), 3.21 (ddd, 1H, J = 9.9, <2, <2 
Hz, GlcN_H5’), 2.78 (broad s, 1H, ManC2_OH). 13C NMR (CDCl3, 125 MHz): δC 
168.29 (Phth), 167.59 (Phth), 166.40 (Bz), 166.24 (Bz), 165.85 (Bz), 165.64 (Bz), 
165.51 (Bz), 165.50 (Bz), 165.45 (Bz), 138.82 (Ar), 138.54 (Ar), 138.51 (Ar), 138.35 
(Ar), 138.03 (Ar), 133.86 (Ar), 133.66 (Ar), 133.50 (Ar), 133.47 (Ar), 133.40 (Ar), 
133.37 (Ar), 133.24 (Ar), 133.16 (Ar), 133.04 (Ar), 131.97 (Ar), 131.66 (Ar), 130.21 
(Ar), 130.17 (Ar), 130.10 (Ar), 130.06 (Ar), 130.00 (Ar), 129.95 (Ar), 129.94 (Ar), 




(Ar), 128.82 (Ar), 128.78 (Ar), 128.74 (Ar), 128.69 (Ar), 128.59 (Ar), 128.56 (Ar), 
128.45 (Ar), 128.36 (Ar), 128.22 (Ar), 128.19 (Ar), 128.06 (Ar), 127.96 (Ar), 127.90 
(Ar), 127.75 (Ar), 127.61 (Ar), 127.45 (Ar), 126.98 (Ar), 123.64 (Ar), 123.28 (Ar), 
100.99 (1JC,H = 160 Hz, Man_C1), 99.83 (1JC,H = 171 Hz, Man_C1’3), 99.16 (1JC,H = 
165 Hz, GlcN_C1), 97.92 (1JC,H = 173 Hz, Man_C1’6), 97.11 (1JC,H = 169 Hz, 
GlcN_C1’), 85.95 (Man_C3), 79.85 (GlcN_C4’), 77.17 (GlcN_C3’), 77.03 
(GlcN_C3), 75.93 (GlcN_C4), 75.90 (PhCH2), 75.66 (Man_C5), 74.78 (PhCH2), 
74.76 (GlcN_C5), 74.59 (PhCH2), 74.40 (GlcN_C5’), 73.34 (PhCH2), 73.07 
(Man_C4), 72.88 (PhCH2), 71.26 (Man_C2), 70.96 (Man_C2’3), 70.88 (Man_C2’6), 
70.50 (Man_C3’3), 70.00 (Man_C3’6), 69.76 (Man_C5’3), 69.08 (Man_C5’6), 68.20 
(GlcN_C6), 68.07 (GlcN_C6’), 67.06 (Man_C4’6), 66.94 (Man_C4’3), 66.33 
(Man_C6), 63.24 (Man_C6’3), 62.97 (Man_C6’6), 56.78 (GlcN_C2’), 56.51 (OCH3), 






glucopyranoside (40). The starting material (39; 170 mg, 0.0713 mmol) and 
NH2NH2 H2O (87 µL, 1.8 mmol) in EtOH (1.5 mL) were heated at 70 °C for 24 
hours. Additional NH2NH2 H2O (17 µL, 0.35 mmol) was added and the solution left 
for another 16 hours, and then the reaction mixture was evaporated to dry. The crude 
material, NaHCO3 (237 mg, 2.82 mmol), and Ac2O (145 µL, 1.53 mmol) in dry 
MeOH (1.0 mL) were left mixing at ambient temperature for 1.5 hours. The reaction 
mixture was evaporated to dry and purified via MPLC on silica gel using 0→35% 
MeOH – CH2Cl2 to afford the pure product as a white solid (74 mg, 0.054 mmol, 76% 
yield over 2 steps). Rf = 0.59 (1:10:39 H2O : MeOH : CH2Cl2). [α]D20: +11° (c 1.0, 
MeOH). 1H NMR (MeOD, 500 MHz): δH 7.38 – 7.16 (m, 25H, Ar), 5.02 – 4.99 (m, 
3H, 2x PhCHaHb and Man_H1’3), 4.80 (d, 1H, J = 1.6 Hz, Man_H1’6), 4.79 (d, 1H, J 
= 11.1 Hz, PhCHaHb), 4.75 (d, 1H, J = 12.3 Hz, PhCHaHb), 4.64 – 4.55 (m, 6H, 
GlcNAc_H1’, PhCHaHb, 3x PhCHaHb, and Man_H1), 4.44 (d, 1H, J = 12.0 Hz, 
PhCHaHb), 4.41 (d, 1H, J = 12.0 Hz, PhCHaHb), 4.30 (d, 1H, J = 8.1 Hz, 
GlcNAc_H1), 4.12 (dd, 1H, J = 3.1, <1 Hz, Man_H2), 4.00 (dd, 1H, J = 9.2, 9.2 Hz, 




Man_H3’3, Man_H6a’3, and Man_H2’3), 3.85 (dd, 1H, J = 9.5, 8.3 Hz, GlcNAc_H2), 
3.83 – 3.69 (m, 9H, Man_H2’6, GlcNAc_H6a, GlcNAc_H6b, Man_H4, GlcNAc_H2’, 
Man_H6a, Man_H4’6, Man_H4’3, and Man_H6b’3), 3.68 – 3.54 (m, 10H, 
GlcNAc_H6a’, GlcNAc_H3’, Man_H5’3, Man_H5’6, Man_H6a’6, Man_H6b’6, 
Man_H6b, GlcNAc_H3, GlcNAc_H6b’, and Man_H3), 3.52 – 3.46 (m, 2H, Man_H3’6 
and GlcNAc_H5), 3.43 (s, 3H, OCH3), 3.25 (ddd, 1H, J = 9.5, 3.6, 2.1 Hz, 
GlcNAc_H5’), 3.19 (ddd, 1H, J = 9.8, 5.2, 1.8 Hz, Man_H5), 1.83 (s, 3H, Ac), 1.82 
(s, 3H, Ac). 13C NMR (MeOD, 125 MHz): δC 173.52 (Ac), 173.40 (Ac), 140.79 (Ar), 
140.67 (Ar), 139.91 (Ar), 139.86 (Ar), 139.76 (Ar), 129.69 (Ar), 129.59 (Ar), 129.59 
(Ar), 129.49 (Ar), 129.45 (Ar), 129.32 (Ar), 129.11 (Ar), 129.08 (Ar), 128.93 (Ar), 
128.88 (Ar), 128.83 (Ar), 128.66 (Ar), 128.35 (Ar), 104.16 (1JC,H = 169 Hz, 
Man_C1’3), 103.63 (1JC,H = 164 Hz, GlcNAc_C1), 101.79 (GlcNAc_C1’), 101.69 
(1JC,H = 169 Hz, Man_C1’6), 101.47 (1JC,H = 159 Hz, Man_C1), 84.24 (Man_C3), 
82.54 (GlcNAc_C3), 81.47 (GlcNAc_C3’), 78.43 (GlcNAc_C4’), 77.19 
(GlcNAc_C4), 76.59 (GlcNAc_C5), 76.27 (GlcNAc_C5’), 76.09 (Man_C5), 76.06 
(PhCH2), 75.57 (Man_C4), 75.41 (PhCH2), 75.30 (Man_C3’3), 75.29 (PhCH2), 74.58 
(Man_C3’6), 74.46 (PhCH2), 74.45 (PhCH2), 72.85, 72.73 (Man_C4’3 and 
Man_C4’6), 72.69 (Man_C2’3), 72.13 (Man_C2’6), 71.95 (Man_C2), 70.02 
(GlcNAc_C6), 69.81 (GlcNAc_C6’), 68.91 (Man_C5’3), 68.75 (Man_C5’6), 67.30 
(Man_C6), 63.19 (Man_C6’3), 62.81 (Man_C6’6), 57.30 (GlcNAc_C2’), 57.08 
(OCH3), 55.89 (GlcNAc_C2), 23.38 (Ac), 23.11 (Ac). ESI-MS m/z calc’d for 
C70H90N2O26 (M+Na)+: 1397.57; found: 1397.91. ESI-HRMS m/z calc’d for 




2-deoxy-b-D-glucopyranoside (9). The starting material (40; 64 mg, 0.047 mmol) 
and t-BuOH (1.0 mL) were added to condensed NH3 (40 mL) at –70 °C, and then 
Na(s) (0.68 g, 30 mmol) was added over 4 hours. The reaction was quenched via the 
slow addition of MeOH (10 mL), warmed back to ambient temperature, and the bulk 
NH3 left to evaporate overnight. The remaining mixture was co-evaporated with 
MeOH (2 x 10 mL), redissolved into H2O (15 mL), and then adjusted to pH 8 using 
dilute AcOH(aq) (25% v/v). The solution was dialyzed, concentrated, and then purified 




solid (28 mg, 0.030 mmol, 65% yield). [α]D20: -21° (c 1.0, H2O). 1H NMR (D2O, 500 
MHz): δH 5.13 (d, 1H, J = 1.4 Hz, Man_H1’3), 4.94 (d, 1H, J = 1.6 Hz, Man_H1’6), 
4.81 – 4.80 (m, 1H, Man_H1), 4.63 (d, 1H, J = 7.9 Hz, GlcNAc_H1’), 4.46 (d, 1H, J 
= 8.0 Hz, GlcNAc_H1), 4.28 (dd, 1H, J = 1.5, <1 Hz, Man_H2), 4.09 (dd, 1H, J = 
3.3, 1.7 Hz, Man_H2’3), 4.00 (dd, 1H, J = 3.4, 1.7 Hz, Man_H2’6), 3.97 – 3.88 (m, 
7H, Man_H6a, Man_H6a’6, Man_H6a’3, GlcNAc_H6a’, Man_H3’3, Man_H3’6, and 
GlcNAc_H6a), 3.85 – 3.62 (m, 19H, Man_H6b, GlcNAc_H2’, Man_H5’3, 
GlcNAc_H3’, Man_H3, Man_H4, Man_H6b’3, Man_H6b’6, GlcNAc_H6b’, 
GlcNAc_H4’, GlcNAc_H2, GlcNAc_H3, GlcNAc_H6b, Man_H5’6, Man_H5, 
Man_H4’3, Man_H4’6, GlcNAc_H4, and GlcNAc_H5’), 3.54 (ddd, 1H, J = 9.7, 5.4, 
2.0 Hz, GlcNAc_H5), 3.52 (m, 3H, OCH3), 2.11 (s, 3H, Ac), 2.06 (s, 3H, Ac). 13C 
NMR (D2O, 125 MHz): δC 175.34 (Ac), 175.32 (Ac), 103.16 (1JC,H = 171 Hz, 
Man_C1’3), 102.48 (1JC,H = 162 Hz, GlcNAc_C1), 102.00 (1JC,H = 162 Hz, 
GlcNAc_C1’), 101.01 (1JC,H = 162 Hz, Man_C1), 100.26 (1JC,H = 172 Hz, Man_C1’6), 
81.14 (Man_C3), 80.27 (GlcNAc_C4’), 79.97 (GlcNAc_C4), 75.16 (GlcNAc_C5), 
75.02 (GlcNAc_C5’), 74.82 (Man_C5), 74.08 (Man_C5’3), 73.32 (Man_C5’6), 73.18 
(GlcNAc_C3), 72.61 (GlcNAc_C3’), 71.05 (Man_C3’6), 70.97 (Man_C3’3), 70.79 
(Man_C2), 70.64 (Man_C2’3), 70.51 (Man_C2’6), 67.50 (Man_C4’3), 67.43 
(Man_C4’6), 66.48 (Man_C6), 66.46 (Man_C4), 61.78 (Man_C6’3), 61.60 
(Man_C6’6), 60.73 (GlcNAc_C6), 60.63 (GlcNAc_C6’), 57.75 (OCH3), 55.51 
(GlcNAc_C2 and GlcNAc_C2’), 22.83 (Ac), 22.79 (Ac). ESI-MS m/z calc’d for 
C35H60N2O26 (M+Na)+: 947.33; found: 947.52. ESI-HRMS m/z calc’d for 
C35H60N2O26 (M+Na)+: 947.3332; found: 947.3336. HPLC purity analysis: >99.5%, 
Rt 5.79 minutes, Eclipse XDB-C8 column. 
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Introduction
Urinary tract infections (UTI) caused by uropathogenic E. coli
(UPEC) are among the most common infections and account
for more than 70 % of the reported UTI cases.[1] Particularly
often affected are women, who have a 40–50 % risk of experi-
encing at least one symptomatic UTI episode during their
life.[2] Because of the high morbidity and the resulting associat-
ed costs, UTI pose a serious burden on healthcare systems.[3]
To date, patients with acute uncomplicated lower UTI are treat-
ed with antibiotics to relieve them from associated symptoms
and to prevent the infection from aggravating into life-threat-
ening pyelonephritis or urosepsis.[4] However, the repeated use
of antibiotics as a first-line treatment for UTI increasingly pro-
vokes antibiotic resistance,[5] highlighting the need for new
strategies for the prevention and treatment of UTI.[6]
The adhesin FimH, located on the tip of type 1 pili of UPEC,
is a bacterial virulence factor.[7] Its adherence to the highly
mannosylated glycoprotein uroplakin 1a on urothelial cells of
the host not only represents the initial step of the infection,
but also prevents clearance of UPEC by the urine bulk flow.[8]
FimH consists of two domains: an N-terminal lectin domain
(FimHLD), acting as a mannose-specific carbohydrate recogni-
tion domain (CRD), and a C-terminal pilin domain (FimHPD) an-
choring the adhesin FimH into the pilus core.[9] To successfully
colonize urothelial cells, bacteria only weakly interact with the
host cell surfaces, still allowing their exploration for optimal
nutrition supply. However, when shear forces arise, strong ad-
herence to host cells is necessary to avoid clearance from the
bladder. To fulfill these two opposing tasks, FimH relies on a
sophisticated allosteric mechanism, fine-tuning its mannose
binding affinity through conformational adaption. In the
medium-affinity state, a close interaction between FimHPD and
FimHLD allosterically attenuates the mannose binding capacity.
However, when shear forces induced by micturition provoke
the separation of the two domains, the CRD adopts the high-
affinity state. This conformational switch is by no means a one-
step mechanism. Intermediate states and a high variability of
the conformational ensemble have been described.[10, 11] Al-
though all conformational states of FimH play a relevant role
for the pathogenicity of UPEC, efforts for the development of
therapeutic FimH antagonists have almost exclusively been fo-
cused on the high-affinity state of the protein.[12]
Within the last three decades, a large number of monovalent
a-d-mannosides with lipophilic aglycones, such as alkyl,[13]
phenyl,[14] diarylamides,[15] dioxocyclo-butenylaminophenyl,[16]
umbelliferyl,[14] biphenyl,[17–20] indol(in)ylphenyl,[21] triazolyl,[22]
and thiazolylamino[23] have been synthesized. Moreover, a wide
range of multivalent ligands has also been explored.[24] Gener-
ally, FimH antagonists consist of a mannose moiety establish-
ing an extended hydrogen bond network within the CRD and
a lipophilic aglycone with a configuration that interacts with
Antimicrobial resistance has become a serious concern for the
treatment of urinary tract infections. In this context, an anti-ad-
hesive approach targeting FimH, a bacterial lectin enabling the
attachment of E. coli to host cells, has attracted considerable
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gated, despite the fact that a therapeutic antagonist should
bind predominantly to the low-affinity state. In this communi-
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the hydrophobic amino acids Tyr48, Ile52, and Tyr137 lining
the entrance to the CRD.[25]
To exploit electrostatic complementarity to the electron-rich
tyrosine side chain, a series of biphenyl aglycones were de-
signed with the goal of placing an electron-deficient terminal
phenyl moiety within interaction distance to Tyr48. Therefore,
we explored substitution with fluorine atoms having a van der
Waals radius similar to that of hydrogen to avoid unfavorable
steric clashes as a consequence of an altered docking mode.[26]
In case of hexafluorobenzene, the high electronegativity of flu-
orine causes an inductive polarization leading to a positive po-
tential above and below the ring plane, resulting in a quadru-
pole moment of 31.7 V 10@40 C m2. Because of the inverse elec-
tron density distribution, the quadrupole moment of benzene
exhibits the same magnitude but with opposite sign (@33.3 V
10@40 C m2).[27]
Such a complementary charge distribution results in a par-
ticularly strong electrostatic attraction as experimentally dem-
onstrated on the rotational barrier in 1,8-diarylnaphtha-
lenes.[28, 29] Fluorine substitution led to an increase of the
energy barrier of approximately 2.1 kJ mol@1 per fluorine
atom.[30] Finally, the influence of fluoroarenes on protein bind-
ing affinities was demonstrated for various targets, including
carbonic anhydrase II and the cysteine protease cathepsin L.[31]
Based on a series of biphenyl a-d-mannosides (1–3,
Figure 1), we aimed to improve the affinity for all relevant con-
formational states of FimH by introducing different fluorination
patterns on the terminal aromatic ring. In addition to perfluori-
nation, as in compounds 4 and 5, a cyano substituent was in-
troduced in the para position (!6). This modification is
marked by an increase in the Hammett constant,[32] which is an
indicator for the electrostatic properties of aromatic groups
and signifies a decrease in electron density, further increasing
the electrostatic attraction to the Tyr48 side chain. Finally,
the difluorinated compound 7 was designed to enable favora-
ble s–p interactions in a T-shape with the tyrosine gate resi-
dues.
Results and Discussion
For exploitation of p–p stacking interactions between the
outer aromatic ring of biphenyl a-d-mannopyranosides and
Tyr48, four representatives with different fluorination patterns
(!4–7) were synthesized.
Synthesis
The synthesis of test compounds 4 and 5 is depicted in
Scheme 1. The pentafluoro-substituted biphenyls 13 and 14
were obtained from the anisole derivatives 8 and 9 in a
copper-catalyzed arylation of arene 10 followed by demethyla-
tion using boron tribromide.[33] BF3·Et2O-promoted mannosyla-
tion (!16 & 17) followed by deprotection under Zempl8n
conditions afforded the mannosides 4 and 5.
For the synthesis of the tetrafluoro-substituted derivative 6
(Scheme 2), mannoside 18[21] was coupled in the presence of
CuI and 1,10-phenanthroline with commercially available
2,3,5,6-tetrafluorobenzonitrile (19) in a microwave-assisted ary-
lation reaction to yield intermediate 20. Because of the high
electrophilicity of the cyano group, cleavage of the acetyl
Figure 1. A) Electrostatic potential visualized on the interaction of the per-
fluorinated aglycone of mannoside 5 and Tyr48 of FimH. Regions of negative
potential (red) of the perfluorinated aglycone correspond with regions of
positive potential (blue) of the Tyr48 side chain and vice versa. B) The bi-
phenyl a-d-mannosides 4–7 exhibiting different fluorination patterns were
synthesized.
Scheme 1. a) CuI, 1,10-phenantroline, K3PO4, DMF/p-xylene, 130 8C, 2–10 h,
36 % for 11, 46 % for 12 ; b) BBr3, CH2Cl2, @78 8C!RT, 5–19 h, 88 % for 13,
90 % for 14 ; c) BF3·Et2O, CH2Cl2, 40 8C, 3–24 h, 40 % for 16, 42 % for 17;
d) MeONa/MeOH, RT, 2 h, 74 % for 4, 89 % for 5.
Scheme 2. a) CuI, 1,10-phenantroline, K3PO4, p-xylene, microwave, 150!
160 8C, 13 h, 66 %; b) 2.0 m aq. NH3, iPrOH, THF, RT, 24 h, 39 %; c) bis(pinacola-
to)diborone, PdCl2(dppf)·CH2Cl2, KOAc, DMF, microwave, 120 8C, 2 h, 61 %;
d) PdCl2(dppf)·CH2Cl2, K3PO4, DMF, 90 8C, 2.5 h, 58 %; e) 1.3 m aq. NH3, iPrOH,
THF, RT, 4.5 days, 73 %.
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groups under Zempl8n conditions (NaOMe, MeOH) almost ex-
clusively led to the formation of by-products. Although this
could not be completely avoided under milder deacetylation
conditions (aq. NH3 in isopropanol/THF), the test compound 6
could be isolated, however, only with moderate yield.
For the synthesis of the difluoro-substituted derivative 7
(Scheme 2), mannoside 18 was transformed into the boronic
acid pinacol ester 21 followed by Suzuki coupling (!23).[34] Fi-
nally, by deprotection with aq. NH3, by-product formation
could be avoided in this case, yielding test compound 7 in
73 % yield.
FimH constructs
Two different recombinant FimH constructs were used to de-
termine binding affinities. The isolated lectin domain of FimH
(FimHLD) locked in the high-affinity conformation was ex-
pressed as previously described.[17] The full-length FimH variant
(FimHFL), representing the low- and, after ligand binding, the
medium-affinity state, consists of the tethered lectin and pilin
(FimHPD) domain, the latter stabilized by a synthetic oligopep-
tide corresponding to residues 1–14 of the natural FimG donor
strand (Figure 2 A).[10]
Competitive fluorescence polarization assay (FP assay)
In this assay, the antagonist of interest displaces a fluorescently
labeled competitor from the binding site, thereby causing a
decrease in fluorescence polarization.[19] As a surrogate for the
high-affinity conformation of FimH, FimHLD was used in most
published studies for affinity determination. However, because
the low/medium-affinity conformation most likely represents
the relevant therapeutic state of the protein,[12, 35, 36] we also in-
vestigated affinities of FimHFL for selected compounds (!4–7)
with the FP assay (Figure 2 A).
Affinity to FimHFL
Relative to their non-fluorinated counterparts, all fluoro-substi-
tuted antagonists exhibited higher affinities to full-length FimH
(Table 1). While pentafluorination led to a roughly three-fold
improvement in affinity (1!5, KD 1100 nm vs. 346 nm), antago-
nist 4, exhibiting an additional o-chloro substituent on the
phenyl ring adjacent to the anomeric position, showed an
even 4.5-fold improvement (2!4, KD 458 nm vs. 103 nm).
Apart from the electron-withdrawing effect of fluorine, which
enhances p–p stacking interactions to Tyr48, the new antago-
nists can also benefit from a slightly increased surface area
leading to improved van der Waals contacts. Because the Ham-
mett constants (spara) revealed that the introduction of a cyano
group in the para position of the terminal phenyl ring impli-
Figure 2. A) Structural models of different FimH conformations. Except for
the first structure (low-affinity state), the ligand n-heptyl-a-d-mannoside is
bound to the active site. B) Ligand-induced conformational adjustments of
the mannose binding site of low- (PDB ID: 4XOD) to medium- (PDB ID:
4XOE) affinity FimH states.
Table 1. Affinity of FimH antagonists to FimHFL and FimHLD determined































[a] Dissociation constants were determined by FP assay using the lectin
receptors FimHFL, FimHLD, and the fluorescent reference compound 3’-
chloro-N-(2-(3-(3’,6’-dihydroxy-3-oxo-3H-spiro-[isobenzofuran-1,9’-xanth-
en]-5-yl)thioureido)ethyl)-4’-(a-d-mannopyranosyloxy)biphenyl-4-carboxa-
mide.[19] For all new compounds, 95 % confidence intervals from curve fit-
ting of data for three independent experiments are given as an estima-
tion of experimental error.
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cates a significantly higher electron-withdrawing potential
than a para-fluoro substituent (spara 0.660 vs. 0.062), the in-
crease in the binding affinity (4!6, KD 103 nm vs. 22 nm) is
not surprising. The cyano-difluoro derivative 7 was designed to
capitalize on s–p interactions resulting from T-shaped orienta-
tion to Tyr48, which has been shown to be energetically more
favorable than the face-to-face conformation in the benzene
homodimer.[29] However, the observed affinity is practically
identical to the cyano-tetrafluoro derivative 6, possibly because
the more beneficial s–p interaction is compensated by a
higher desolvation penalty, originating from the strong polari-
zation of the aromatic ring in 7 and the related larger dipole
moment.
Affinity to FimHLD (locked in the high-affinity state)
The fluorination of the terminal phenyl moiety in the biphenyl
aglycone resulted in an almost four-fold gain in affinity (1!5 ;
3!6). A similar effect was found for the difluoro-substituted
derivative 7. In contrast to earlier observations,[20] the addition-
al ortho-chloro substituent in mannoside 4 unexpectedly de-
creased binding affinity.
Ab initio calculation of p–p stacking interactions
As an estimate for the p–p stacking interaction energies of dif-
ferent aglycones and Tyr48, quantum mechanical calculations
were performed based on X-ray structural data. Analysis of the
interaction energies in Table 2 suggest that the p–p stacking is
strongest between Tyr48 and the tetrafluoro-cyano derivative
6 (DEgas =@42.9 kJ mol@1) and weakest for compounds 1 and 2
featuring unsubstituted terminal aromatic rings (DEgas =@19.8
and @19.6 kJ mol@1, respectively). Introduction of the o-chloro
substituent to the biphenyl derivatives 1 (!2) and 5 (!4)
does not influence the p–p stacking. Addition of a p-cyano
group or perfluorination of the terminal phenyl ring equally
improves the p–p stacking energies as observed for com-
pounds 3, 4 and 5 (DEgas between @34.3 and @35.2 kJ mol@1).
However, substitution of the p-fluoro with a p-cyano group (!
6) induces further polarization and accordingly a further en-
Table 2. Physicochemical and pharmacokinetic parameters (solubility, distribution coefficient, and permeability), and quantum mechanical calculation of
the p–p stacking energies of Tyr48 with different biphenyl derivatives in the gas phase.
Compd Solubility [mg mL@1] logD7.4
[c] PAMPA logPe [cm s
@1][d] DEgas [kJ mol
@1]
1[19] 21:1[a] 2.1:0.1 @4.7:0.1 @19.8
2[35] 5.5:0.2[a] 2.6:0.1 n.d. @19.6
3[19] 195:5[b] 2.1:0.0 @5.2:0.0 @34.3
4 47:7[b] 2.7:0.2 @4.7:0.2 @35.2
5 131:10[b] 2.3:0.1 @4.7:0.2 @34.4
6 111:7[b] 2.2:0.1 @4.8:0.1 @42.9
7 97:15[b] 2.2:0.1 @5.0:0.1 @39.8
[e]/
@30.7[f]
[a] Kinetic solubility was measured in a 96-well format using the mSOL Explorer solubility analyzer in triplicate. The experimental error for all experiments is
given as standard deviation from the mean. [b] Thermodynamic solubility was measured in 0.1 m Tris·HCl buffer pH 7.4 in duplicate. [c] Octanol/water distri-
bution coefficients (logD7.4) were determined at pH 7.4 by a miniaturized shake-flask procedure in sextuplicate. [d] Pe = effective permeability: diffusion
through an artificial membrane was determined by the parallel artificial membrane permeability assay (PAMPA) in quadruplicate at pH 7.4. [e] DEgas ob-
tained with fluorine atoms on the same side as the chlorine atom. [f] DEgas obtained with fluorine atoms on opposing side of the chlorine.
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hancement of the p–p stacking energy (DEgas =
@42.9 kJ mol@1). Interestingly, the difluoro-cyano derivative 7
exhibits similar interaction energy when the two fluorine
atoms are on the solvent-exposed, coinciding side with the
chlorine atom (DEgas =@39.8 kJ mol@1). See the Supporting In-
formation for experimental details.
X-ray crystallography
To get better insight into the effect of fluorination on the bind-
ing mode, antagonists 5 and 6 were co-crystallized with
FimHLD (Figure 3; see the Supporting Information for experi-
mental details). The structures were obtained at a resolution of
2.2 a and 2.1 a, respectively. The binding mode of the man-
nose moieties is identical to previously reported non-fluorinat-
ed analogues 1 (PDB ID: 4X50)[15] and 3 (PDB ID: 4CST).[19] In all
crystal structures, the biphenyl aglycones interact with Tyr48
and Tyr137. Although side chain orientation of Tyr137, which is
in contact with the inner aromatic ring, is not affected, sub-
stantial effects can be seen for the orientation of Tyr48. With
the non-fluorinated antagonist 1 (Figure 3 A), the Tyr48 side
chain adopts a slightly tilted orientation with a distance of
4.4 a between the ring centers, implicating a suboptimal ar-
rangement for p–p stacking interactions with the aglycone. Al-
though the introduction of the electron-withdrawing cyano
group (!3, Figure 3 B) is supposed to improve p–p stacking, a
face-to-face conformation with Tyr48 is not observed. Instead,
the Tyr48 side chain displays a certain degree of flexibility im-
plicated from the observation of two distinct rotamers (3.6 a
and 3.8 a distance between ring centers).[19]
By contrast, the cyano-tetrafluoro derivative 6 (Figure 3 D) is
in an optimal parallel alignment with Tyr48 (3.6 a distance),
most likely due to a markedly enhanced p–p stacking resulting
from the electron deficiency of the fluorinated ring. A similar
orientation is found for the pentafluorinated derivative 5 (3.7 a
distance, Figure 3 C). Because the binding sites are solvent ex-
posed, it should be mentioned that the aglycones of the co-
crystallized antagonists 5 and 6 are involved in crystal packing
contacts potentially influencing the binding modes.
NMR chemical shift perturbation (CSP)
The structural information obtained from X-ray crystallography
was complemented with data from NMR CSP experiments of
FimHLD in solution.
1H,15N-HSQC spectra of 15N-labeled
FimHLD
[15] were measured upon addition of the fluorinated
compounds 4, 5 and 6 as well as their non-fluorinated counter-
parts 1 and 3. Residues in the mannose binding pocket exhibit
nearly identical chemical shifts for all five antagonists (Fig-
ure 4 A) confirming a similar orientation and hydrogen bond
network of their mannosyl moieties as observed in the X-ray
structures shown in Figure 3. In contrast, chemical shift differ-
ences were observed for residues in the binding loop around
Tyr48. Previously, the residues Glu50 and Thr51 have been
identified as sensitive reporters for the conformation of the
Tyr48 residue.[15] The formation of a T-shaped NH–p interaction
of Thr51 HN and the Tyr48 ring in complex with the non-fluori-
nated biphenyl mannosides 1 and 3 leads to a strong upfield
shift of Thr51 HN while Glu50 is shifted downfield, correspond-
ing to shielding and deshielding effects by the aromatic ring
current from Tyr48, respectively (Figure 4 B). The 1H,15N-HSQC
spectra of FimHLD with the fluorinated counterparts 4, 5 and 6
revealed the presence of this Tyr48 conformation in agreement
with the X-ray structural data (Figures 3 C, D). It is tempting to
Figure 3. Comparison of the crystal structures of FimHLD co-crystallized with
fluorinated antagonists 5 and 6. A) Binding mode of non-fluorinated ana-
logue 1 (green sticks, PDB ID: 4X50). B) Binding mode of non-fluorinated an-
alogue 3 (cyan sticks, PDB ID: 4CST), Tyr48 exhibits two alternate conforma-
tions). C) Binding mode of 5 (yellow sticks, PDB ID: 6G2S). D) Binding mode
of 6 (magenta sticks, PDB ID: 6G2R).
Figure 4. 1H,15N-HSQC spectral regions of FimHLD with fluorinated com-
pounds 4, 5 and 6 as well as their non-fluorinated counterparts 1 and 3.
A) Signal shifts of four representative amino acids in the mannose binding
site. B) Signal shifts of Glu50 and Thr51.
ChemMedChem 2019, 14, 749 – 757 www.chemmedchem.org T 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim753
Full Papers
284
speculate that the observed conformation of the tyrosine gate
and the aglycone in the X-ray structures of these three com-
pounds represents the optimal stacking arrangement of Tyr48
and aglycone.
Physicochemical and in vitro pharmacokinetic characteriza-
tion
The introduction of fluorine in pharmacologically active mole-
cules can have a significant impact on their physicochemical
and pharmacokinetic characteristics.[37] In general, non-fluori-
nated FimH antagonists, such as 3, are known to exhibit ac-
ceptable pharmacokinetic properties.[19] To exclude disadvanta-
geous effects from fluorination, we determined the aqueous
solubility[38] and lipophilicity[39] and passive permeability in a
parallel artificial membrane permeation assay (PAMPA)[40] of the
new antagonists. The results are summarized in Table 2.
Whereas the introduction of an ortho-chloro substituent
(1!2 or 5!4) substantially decreased solubility, fluorination
of the terminal aromatic ring (1!5, 2!4) led to a six- to
eight-fold improvement. When the para-fluoro substituent was
replaced by a para-cyano group (5!6), solubility remained un-
changed. However, against expectations, tetrafluorination of
cyanide 3 (!6) decreased solubility two-fold. Interestingly, de-
spite a higher predicted polarization of the terminal phenyl
ring, the difluorinated analogue 7 had essentially the same sol-
ubility as 6. For the two sub-nanomolar antagonists 6 and 7,
solubility is above the 52 mg mL@1 threshold required for com-
plete absorption of a 1 mg kg@1 dose of moderately permeable
compounds.[41]
Non-fluorinated and fluorinated antagonists show similar lip-
ophilicity with logD7.4 between 2.2 and 2.7 and are expected to
be well absorbed by means of passive diffusion upon oral ad-
ministration.[42] Moreover, a high lipophilicity supports tubular
re-absorption from the glomerular filtrate favoring slower renal
clearance and thus a prolonged therapeutic effect in the blad-
der upon application of a single dose.[43] The logPe values de-
termined in the PAMPA for both non-fluorinated and fluorinat-
ed antagonists are also a clear indication of oral permeability,
as logPe values above @5.7 indicate a high potential for intesti-
nal absorption.[44]
In summary, fluorination of the aromatic aglycones showed
little effect on lipophilicity and passive permeability. Interest-
ingly, solubility is much more influenced by the presence of an
ortho-chloro substituent on the aromatic ring adjacent to the
anomeric center and by a para-cyano substituent on the termi-
nal aromatic ring. Based on the results of prior pharmacokinet-
ic evaluations[17, 19, 20, 35] and in vivo studies[17, 19] of biphenyl a-d-
mannosides, favorable in vivo profiles for the high-affinity
FimH antagonists 6 and 7 can be reasonably expected.
Conclusions
Over the years, the high-affinity conformation of FimH present
in its isolated lectin domain (FimHLD) was mainly used for the
development of anti-adhesives for prevention and therapy of
UTI, while the more relevant low-affinity state (FimHPD) dis-
played by the full-length FimH was neglected. In a recent
study, we addressed this issue, demonstrating an offset of ap-
proximately two orders of magnitude between the affinity of a
compound for FimHFL relative to FimHLD.
[35] We therefore de-
signed and synthesized a series of FimH antagonists with fluo-
rinated aglycones with the goal to increase affinity for both
states by enhancing the p–p stacking with the tyrosine gate.
Pentafluorination (Table 1, 1!5 or 2!6) gave a three- to four-
fold improvement of binding to FimHFL. When the para-fluoro
substituent was replaced by a para-cyano group (Table 1, 4!
6), a further increase in affinity to a KD of 22.1 nm was ob-
tained. To our knowledge, this represents the best reported af-
finity for a FimHFL antagonist to date. In the case of FimHLD, a
similar improvement was observed, with 6 and 7 reaching
even sub-nanomolar affinities. Structural models of the interac-
tion of FimHLD with fluorinated antagonists confirm strong p–p
stacking interactions. In summary, the fluorination of the termi-
nal phenyl rings of biphenyl aglycone results in improved p–p
stacking interactions leading to low nanomolar antagonists for
FimHFL and sub-nanomolar antagonists for FimHLD. In addition,
the two best antagonists 6 and 7 display physicochemical
properties supporting oral bioavailability.
Experimental Section
Synthesis : The synthesis of compounds 4–7, including compound
characterization data, can be found in the Supporting Information.
Protein production and purification : FimHLD and FimHFL were pro-
duced and purified as reported earlier.[10, 45]
Fluorescence polarization (FP) assay : FP assays were essentially
performed as previously described.[19] A detailed experimental pro-
tocol is given in the Supporting Information.
FimH crystallization and structure refinement : For crystallization,
FimHLD (residues 1–158) at a final concentration of 15 mg mL
@1 (ca.
0.9 mm) with a three-fold molar excess of ligand 5 (ligand dis-
solved in DMSO) in 20 mm HEPES pH 7.4, 2 % DMSO was used.
FimHLD/5 crystals were grown in sitting-drop vapor diffusion at
19 8C in 0.1 m BisTrisPropane, propionic acid, cacodylate (PCPT
buffer) pH 8.0 and 25 % PEG1500. Crystals appeared after two
months and grew to their final size within three months. They
were cryopreserved by the addition of 20 % ethylene glycol (v/v)
and flash-cooled with liquid nitrogen. FimHLD/6 was crystallized in
0.1 m NaOAc pH 5.0, 1.5 m (NH4)2SO4 at 19 8C and flash-cooled after
a quick soak in 2.5 m Li2SO4.
[46] Data were collected at the X06SA
beamline of the Swiss Light Source (Paul Scherrer Institute, Switzer-
land) and indexed, integrated, and scaled with XDS.[47] The struc-
tures were solved by molecular replacement with PHASER[48] using
the FimHLD/biphenyl a-d-mannopyranoside (1) complex (PDB ID:
4X50)[15] as search model. The structures were built using COOT
software[49] and periodically refined with PHENIX software.[50] Geo-
metric restraints for the ligands were generated with PRODRG.[51]
The final protein models were validated with Molprobity[52] and de-
posited in the Protein Data Bank with PDB IDs 6G2S and 6G2R.
NMR chemical shift perturbation (CSP): NMR samples for back-
bone CSP experiments contained 250 mm uniformly 15N-labeled
FimHLD and an excess (1.3–1.7 mm nominal due to solubility limita-
tions) of fluorinated compounds 4, 5 and 6, respectively, in 20 mm
sodium phosphate buffer pH 7.0 with 7 % D2O; 0.1 mm [D4]TSP (3-
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(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionic acid, Armar Chemi-
cals, Switzerland) was added as an internal reference. All spectra
were acquired on a 500 MHz Bruker Avance III NMR spectrometer
equipped with a 5 mm TXI RT probe head at a temperature of
298 K. All spectra were acquired and processed with Topspin 3.2
(Bruker BioSpin, Switzerland) and analyzed with CcpNmr Analysis
2.4[53] The backbone resonance assignment as well as CSP data
with the non-fluorinated reference compounds 1 and 3 were avail-
able from a previous study.[15] As all tested mannoside ligands
bound in the slow-exchange regime, peak assignment was per-
formed based on chemical shift proximity.
Physicochemical and in vitro pharmacokinetics studies
Materials : Tris·HCl, 1-octanol, NaOH, formic acid, and 1-propranolol
were purchased from Sigma–Aldrich Chemie GmbH (Steinheim,
Germany). PRISMA HT universal buffer, GIT-0 Lipid Solution, and Ac-
ceptor Sink Buffer were purchased from pIon (Billerica, USA). MeCN
and MeOH were ordered from Acros Organics (Geel, Belgium). Sol-
ubility, permeability, and lipophilicity of 3 was reported previous-
ly.[19]
LogD7.4 determination (shake-flask method): Equal amounts of
0.1 m Tris·HCl buffer pH 7.4 and 1-octanol were mixed and vigo-
rously shaken for 5 min to saturate the phases. The mixture was
left until complete separation of the phases occurred and the
buffer was retrieved. The test compound was diluted with buffer
to a concentration of 10 mm. The buffer was transferred to a 96-
well plate and saturated 1-octanol was added, resulting in a 3:180
and 4:180 1-octanol/water ratio, respectively. Each ratio was mea-
sured in triplicate, and simultaneous measurements were conduct-
ed with 1-propanolol as positive control. The plate was sealed with
aluminum foil, shaken (1350 rpm, 25 8C, 2 h) on a Heidolph Titra-
max 1000 plate shaker (Heidolph Instruments GmbH & Co. KG,
Schwabach, Germany), and centrifuged (2000 rpm, 25 8C, 5 min,
5804 R Eppendorf centrifuge, Hamburg, Germany). The aqueous
phase was transferred to a 96-well plate for analysis by liquid chro-
matography–mass spectrometry (LC–MS, see below).
The logD7.4 coefficients were calculated from the 1-octanol/buffer
ratio (o :b), the initial concentration of the analyte in buffer (10 mm),
and the concentration of the analyte in buffer (cb) with Equa-
tion (1).
Aqueous solubility : Lyophilized compound was added to 200 mL
0.1 m Tris·HCl buffer pH 7.4 in duplicate until a precipitate was
formed. The vials were put into a super-sonication bath (Branson
2510, Danbury, USA) for 30 min at 25 8C and then left at 25 8C for
24 h to equilibrate. The dispersion was filtered (0.2 mm), diluted in
Tris·HCl buffer, and analyzed by LC–MS (see below).
Parallel artificial membrane permeability assay (PAMPA): Effec-
tive permeability (logPe) was determined in a 96-well format with
PAMPA.[40, 44] For each compound, measurements were performed
at pH 7.4 in quadruplicate. Four wells of a deep-well plate were
filled with 650 mL of PRISMA HT universal buffer (pIon, Billerica,
USA) and adjusted to pH 7.4 by adding the requested amount of
NaOH (0.5 m). Samples (150 mL) were withdrawn from each well to
determine the blank spectra by UV/Vis spectroscopy (190 to
500 nm, SpectraMax 190, Molecular Devices, Silicon Valley, CA,
USA). Then, analyte dissolved in DMSO (10 mm) was added to the
remaining buffer to yield 50 mm solutions. Afterward, samples
(150 mL) were withdrawn to determine the reference spectra. Fur-
ther 200 mL was transferred to each well of the donor plate of the
PAMPA sandwich (pIon, P/N 110 163). The filter membranes at the
bottom of the acceptor plate were infused with 5 mL of GIT-0 Lipid
Solution and 200 mL of Acceptor Sink Buffer was filled into each ac-
ceptor well. The sandwich was assembled, placed in the GutBoxTM
(pION), and left undisturbed for 16 h. Thereafter, it was disassem-
bled and samples (150 mL) were transferred from each donor and
acceptor well to UV plates for determination of the UV/Vis spectra.
Effective permeability (logPe) was calculated from the compound
flux deduced from the spectra, the filter area, and the initial
sample concentration in the donor well with the aid of the PAMPA
Explorer Software (pIon, version 3.5).
Liquid chromatography–mass spectrometry measurements (LC–
MS): Analyses were performed using a 1100/1200 Series HPLC
System coupled to a 6410 Triple Quadrupole mass detector (Agi-
lent Technologies, Inc. , Santa Clara, CA, USA) equipped with elec-
trospray ionization. The system was controlled with the Agilent
MassHunter Workstation Data Acquisition software (version
B.03.01). The column used was an AtlantisS T3 C18 column (2.1 V
50 mm) with a 3 mm particle size (Waters Corp., Milford, MA, USA).
The mobile phase consisted of eluent A: H2O containing 0.1 %
formic acid; and eluent B: MeCN containing 0.1 % formic acid. The
flow rate was maintained at 0.6 mL min@1. The gradient was
ramped from 95 % A/5 % B to 5 % A/95 % B over 1 min, and then
held at 5 % A/95 % B for 0.1 min. Subsequently, the system was
brought back to 95 % A/5 % B, resulting in a total duration of
4 min. Fragmentor voltage and collision energy were optimized for
the analysis of compounds in multiple reaction monitoring mode
in positive mode. The concentrations of the analytes were quanti-
fied by the Agilent Mass Hunter Quantitative Analysis software
(version B.04.00).
Interference compounds : Tested compounds do not belong to
the known classes of assay interference compounds and are there-
fore not expected to interfere unselectively with the applied
assays.
PDB IDs
The crystal structures of FimHLD co-crystallized with the fluorinated
antagonists 5 (PDB ID: 6G2S) and 6 (PDB ID: 6G2R) are shown in
Figure 3. The authors will release the atomic coordinates and ex-
perimental data upon article publication.
Supporting Information
Experimental and analytical data for compound syntheses, experi-
mental details for affinity data from fluorescence polarization
measurements, data collection and refinement statistics from X-ray
diffraction experiments, method for ab initio calculations, and
HPLC as well as NMR spectra for the compounds can be found in
the Supporting Information.
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Enhancing the enthalpic contribution of hydrogen
bonds by solvent shielding†
Jonathan Cramer, a Xiaohua Jiang,a Wojciech Schönemann,a
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Roman Peter Jakob, b Said Rabbani,a Timm Maier b and Beat Ernst *a
In biological systems, polar interactions are heavily burdened by high desolvation penalties resulting
from strong solute–solvent interactions. As a consequence thereof, enthalpic contributions of hydrogen
bonds to the free energy of binding are severely diminished. However, this effect is strongly attenuated
for interactions within solvent-shielded areas of proteins. In microcalorimetric experiments, we show
that the bacterial lectin FimH utilizes conformational adaptions to effectively shield its binding site from
solvent. The transition into a lower dielectric environment results in an enthalpic benefit of approximately
13 kJ mol1 for mannoside binding. However, this effect can be abrogated, if the hydrogen bond
network within the binding site is disturbed by deoxygenation of the ligand. Conformational adaption
leading to reduced local dielectric constants could represent a general mechanism for proteins to enable
enthalpy-driven recognition of polar ligands.
Introduction
The energetics of hydrogen bonds in biomolecular recognition
are highly affected by severe desolvation penalties imposed by
strong interactions with the aqueous solvent in the unbound
state. A common conception is that strongly directional hydro-
gen bond interactions provide selectivity, but do not necessarily
augment the overall binding affinity of a ligand because
favorable contributions are often canceled out by significant
desolvation penalties.1–3 The free energy penalty for the trans-
fer of a hydroxyl group from aqueous solvent to the gas phase
was estimated as 26 kJ mol1, with an associated enthalpy
penalty of 36 kJ mol1 and the transfer of an alcohol function
from bulk solvent into a hydrophobic pocket was associated
with a free energy penalty of 18–21 kJ mol1.4,5 Furthermore, in
an aqueous system, the contribution of a single hydrogen bond
to the free energy of binding has been estimated to equally
amount to 18–21 kJ mol1.6–10 In summary, a hydrogen bond
hardly contributes to the binding process, unless additional
conditions are fulfilled. It has been proposed that hydrophobic
occlusion and solvent shielding are able to advance the strength
of hydrogen bonds in biological systems. Thus, enthalpies of
formation for solvent-exposed hydrogen bonds on protein surfaces
amount to 6 kJ mol1, whereas buried interactions contribute
with up to 25 kJ mol1.11,12 For the arabinose-binding protein,
removal of buried hydrogen bond interactions in deoxy D-galactose
derivatives was associated with an enthalpy-driven loss in binding
free energy of 30 kJ mol1.13 Similarly, hydrophobic solvent-
shielding has been shown to impact the activity of enzymes, as
well as the pKa of buried titratable groups.
14–18 The exclusion of
polar water molecules effectively creates a low dielectric environ-
ment that supports electrostatic interactions and accelerates
the reaction of charged intermediates. Thus, solvent shielding
of hydrophilic binding sites may contribute to enthalpy-driven
recognition of highly polar molecules such as carbohydrates. In
this study, we aim to demonstrate that proteins actively harness
the modulation of local dielectric properties by conformational
transitions and to quantify the thermodynamic consequences on
polar hydrogen bond interactions.
As a model system to study the impact of the dielectric
constant er on the thermodynamics of binding, we employed
FimH, a bacterial adhesin located on type I pili of uropathogenic
E. coli.19–21 The functional lectin domain of FimH features
a carbohydrate recognition site tailor-made to accommodate
mannose epitopes. The mannose binding affinity of the lectin
domain is allosterically controlled by the adjacent regulatory
pilin domain.22,23 When mechanical forces, such as shear
forces during micturition, cause the separation of lectin and
pilin domain,23,24 a switch from the low-affinity conformation
to the high-affinity conformation of FimH is induced and
mannoside ligands are bound with B100-fold stronger affinity
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compared to the domain-associated low affinity state. Here,
we compare the properties of the two affinity states by means of
two different recombinant FimH constructs.
Results and discussion
The isolated FimH lectin domain (FimHLD) is a common in vitro
model for the domain-separated, high-affinity conformation of
the protein.25 FimHLD features a rigid structure and a well-
defined carbohydrate binding site (Fig. 1). Mannoside ligands
engage in an impressive network of ten hydrogen bonds. In the
absence of a ligand, water molecules assume the positions of
mannose hydroxyl groups, pre-organizing the binding site for
carbohydrate recognition (RMSDapo-bound = 0.35 Å). The binding
event is a single-step mechanism that proceeds without
any major conformational adjustment of the residues in the
mannose binding site.26,27 On the other hand, the domain
associated full-length FimH construct (FimHFL) has been
shown to bind mannoside ligands by a more complex mecha-
nism caused by conformational distortions of the protein due
to the presence of the regulatory subunit.22,23 In the absence of
a ligand, the protein exists in an ensemble of conformational
states that are characterized by a shallow, solvent-exposed
binding site, a low affinity to carbohydrate ligands, and a high
degree of flexibility (FimHFL-open, Fig. 1).
23,28 In the presence of
Fig. 1 Molecular structure of the bacterial lectin FimH. The isolated lectin domain (FimHLD, PDB 4BUQ) is fairly rigid and pre-organized in the closed
conformation even in the absence of a ligand. The recombinant full-length FimH construct (FimHFL) undergoes a conformational transition from an open
(FimHFL-open, PDB 4XOD) to a closed (FimHFL-closed, PDB 4XOE) state when a ligand binds to the mannose binding site.
Fig. 2 Thermodynamic model of the interaction of FimH with mannoside ligands. FimH states and complexes are colored analogous to available X-ray
structures in Fig. 1. Desolvated states are indicated with an asterisk.
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a ligand, the conformational equilibrium is shifted toward a
closed state (FimHFL-closed), in which the clamp loop is accom-
modated close to the carbohydrate binding site and shields the
mannose moiety from the solvent. The atomistic features of
this mechanism, namely clamp loop mobility in the open and
solvent shielding of the binding site in the closed conforma-
tion, have been thoroughly characterized in MD simulations.29
Although the overall structure of this state differs from
the high-affinity conformation, the binding site regions are
virtually identical (RMSDlectin_domain = 2.0 Å, RMSDbinding_site =
0.2 Å). Fig. 2 depicts a thermodynamic model of ligand binding
to FimHLD and FimHFL. The experimentally observed free energy
of binding to FimHLD DGLD-obs
 






; and solvation of the assembled complex DGsolv
 
(Fig. 2, pathway A). For FimHFL, the conformational rearrange-
ment associated with ligand binding theoretically proceeds via a
conformational selection (Fig. 2, pathway B) or an induced-fit
(Fig. 2, pathway C) mechanism. In case of conformational
selection, the experimentally observed thermodynamics
DGFL-obs
 
contain contributions from a conformational transi-







; and solvation of the
assembled complex DGsolv
 
. In the induced-fit pathway C,







; induced-fit transition DGind-fit
 
;
and solvation of the assembled complex DGsolv
 
. Thus, the
difference in the thermodynamic profiles of ligand binding to
FimHFL and FimHLD DDGFL-LD
 
gives access to an experimental
approximation of clamp loop rearrangement and hydrophobic
occlusion of the polar mannose binding site. In the conforma-
tional selection model (Fig. 2, pathway B), DGconf-sel is a constant
term, and ligand binding affinity scales entirely with binding
affinity to the closed state. In the induced-fit model (Fig. 2,
pathway C), however, differences between ligands can scale with
the affinity of a low-affinity encounter complex DGbind-open
 
and
the effect of the conformational transition DGind-fit
 
.
As a result of an extensive network of hydrogen bonds
between the pre-organized binding site and the mannose moiety,
the interaction between mannosides 1–4 and FimHLD (high-
affinity state) is characterized by a strongly enthalpic contribu-
tion (Fig. 3A). The weak entropic penalty has been linked to the
rigidification of the tyrosine gate, an ensemble of hydrophobic
residues that control access to the mannose binding site and
interact with the aglycones of ligands 1–4.26,27 An improved p–p-
stacking and hydrophobic interaction between aglycone and
tyrosine gate further accentuates their thermodynamic profile,
as the electrostatic nature of the aglycones gives rise to progres-
sively tighter, enthalpy-driven binding from 4 - 3 - 2 - 1.
The thermodynamic profiles of mannoside interactions with
the FimHFL construct (low-affinity state) show similar charac-
teristics (Fig. 3B). The binding process is equally driven by
enthalpy, with a counteracting entropic penalty. However, the
magnitude of this enthalpy–entropy compensation is much more
substantial. Overall, the binding affinity of the mannosides 1–4 is
reduced roughly by 12 kJ mol1, approximately two orders of
magnitude in KD, compared with the same ligands binding to
FimHLD. This value represents the experimental approximation of
the thermodynamics related to the conformational rearrangement
from the open (FimHFL-open) to the closed (FimHFL-closed) state.
The difference in the thermodynamics (Fig. 3C) shows that
this fairly constant affinity reduction mainly originates from a
Fig. 3 Thermodynamic profiles (see Fig. S1–S4, ESI†) for the interaction of
mannosides 1–4 with FimHLD (A) and FimHFL (B). Data for the interactions
FimHLD-2/3/4 and FimHFL-2/4 have been published before.
24,30,31
(C) Difference in the thermodynamic profiles between ligand binding to
FimHFL and FimHLD. Error bars represent (propagated) 68% confidence
intervals. Numeric data and further information can be found in the ESI.†
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severe entropy penalty of roughly 26 kJ mol1, which can be
correlated to a shift of the conformational equilibrium of
FimHFL toward a closed state, in which the clamp loop is fixed
near the mannose moiety. The high mannose binding affinity
of FimHLD thus results from pre-organization of the mannose
binding site. This concept has been thoroughly characterized in
the study of enzyme catalysis.32,33 Less intuitively, the thermo-
dynamics are also characterized by a favorable enthalpic con-
tribution of approximately 13 kJ mol1. Since the mannose
hydrogen bond networks and any other electrostatic contacts
between protein and ligand are identical in the bound states of
FimHLD and FimHFL, this difference has to originate from
the conformational transition of the clamp loop region upon
ligand binding. While the local dielectric constant on protein
surfaces, as in the open form of FimHFL, is commonly esti-
mated to be 20, it is reduced to approximately 5 in the shielded
binding site of FimHFL-closed.
17 Based on these simplified
qualitative estimations,34,35 the shift between the open and
closed protein states is accompanied by hydrophobic shielding
of polar hydrogen bond interactions in the binding site. This
leads to reduced local permittivity er in FimHFL-closed, which is
associated with an enhanced enthalpic contribution to binding





In order to investigate the outcome of a perturbation of
the hydrogen bond network, several deoxygenated derivatives
of n-heptyl a-D-mannoside (4) were subjected to thermodynamic
and structural analyses. The X-ray crystal structures of 4–7 in
complex with FimHLD reveal very little variation (RMSDs E 0.2 Å)
upon sequential removal of mannose hydroxyl groups (Fig. 4A),
indicating that the loss of hydrogen bonds is not associated
with any major conformational adjustments. Next, NMR
chemical shift perturbations (CSP) of residues involved in
hydrogen bond interactions to mannose hydroxyl groups were
studied (Fig. 4B). Gly14, engaged in a water-mediated hydrogen
bond to 2-OH, shows a minor CSP upon ligand binding.
Variations between different mannosides are negligible, even
when the 2-OH group is removed (-5). This indicates that the
position of the interacting water molecule W1 is not affected.
The backbone amide NH of Asp47 forms a hydrogen bond with
6-OH, leading only to slight CSP upon binding to the ligands 4
and 5 (2-deoxy). In case of the 3-deoxy derivative 6, the CSP is
more pronounced, whereas the signal is superimposed to the
apo protein for 7 (4-deoxy). CSP of the amide side chain protons
of Gln133 report on hydrogen bond formation with 3-OH. For 4,
the signal of the amide proton (PDB nomenclature He22) is
shifted downfield by 0.8 ppm, indicating hydrogen bond for-
mation. A smaller downfield shift of 0.3–0.5 ppm signifies the
slightly weaker interaction for 5 and 7, whereas the absence of
the interaction for 3-deoxy derivative 6 is obvious from a strong
upfield shift of 1.6 ppm.
Similarly, CSP of the side chain signals of Asn135 indicate
the interaction with 4-OH. The signal is shifted downfield for
4, 5, and 6, whereas a relative upfield shift for the 4-deoxy
derivative 7 signifies the absence of the interaction. Importantly,
none of the observed residues show a marked shift in the
Fig. 4 Structural characterization of interactions between mannoside 4 and the deoxygenated compounds 5–7 and FimHLD. (A) X-ray crystal structures
of mannoside 4 (black, PDB 4BUQ), 2-deoxy-mannoside 5 (blue, PDB 5L4T), 3-deoxy-mannoside 6 (green, PDB 5L4V), and 4-deoxy-mannoside 7 (red,
PDB 5L4X). Hydrogen bond interactions of 4 are indicated as grey dashes. (B) 1H,15N-HSQC NMR experiments reveal chemical shift perturbations for
residues in the mannose binding site in the presence of ligands. Color coding according to panel A. Nomenclature of Asn and Gln d and e protons
according to PDB guidelines. Full spectrum is shown in Fig. S20 (ESI†).


































































































This journal is©The Royal Society of Chemistry 2020 RSC Chem. Biol., 2020, 1, 281--287 | 285
15N-dimension of the spectra, reporting on changes in dihedral
angles of protein backbone and side chains.
In summary, the structural information obtained by NMR
and X-ray is in good agreement, and the conformational
changes of protein and ligand are remarkably small upon the
loss of relevant interactions. In both experiments, low binding
affinity prevented a characterization of compound 8.
The thermodynamics of 5–7 binding to FimHLD (Fig. 5A)
illustrate that removal of the hydroxyl groups in the 2-, 3-, and
4-position of n-heptyl a-D-mannoside 4 coincide with a sizeable
reduction of the enthalpic contribution to binding.
In addition, the negative value forTDS1 indicates an increased
degree of disorder, probably as a consequence of the impaired
hydrogen bond network. This is in line with the reduced downfield
shifts in NMR experiments. The interaction of 5–7 with FimHFL
shows an equivalent trend in the thermodynamic profiles
(Fig. 5B). Yet, the magnitude of the enthalpy–entropy compen-
sation effect differs substantially. As a consequence, the fairly
constant trend we observed in the differential profiles for 1–4
(Fig. 3C) is lost for 5–7 (Fig. 5C). Here, the enthalpic contribu-
tion that was attributed to the modulation of binding site
permittivity er in FimHFL is considerably diminished and even
reversed for 6 and 7. Instead, a progressive shift toward
entropic binding is observed.
When the thermodynamic profiles of 5–7 are compared with
the parent compound 4, notable dissimilarities between the
two protein constructs, FimHLD (Fig. 6A) and FimHFL (Fig. 6B)
can be observed. For FimHLD, the enthalpic penalty for removal
of a hydroxyl group amounts to 26–32 kJ mol1. The same
modification in FimHFL, however, results in an enthalpic
penalty that ranges from 42 kJ mol1 up to 65 kJ mol1. The
discrepancy suggests that the loss of a hydrogen bond in the
interaction of 5–7 and FimHFL is superimposed by global
Fig. 5 Thermodynamic profiles (see Fig. S5–S8, ESI†) for the interaction
of deoxygenated n-heptyl a-D-mannoside derivatives 5–8 with FimHLD (A)
and FimHFL (B). Data for the interactions of FimHLD with compounds 5–7
have been published elsewhere.30 (C) Difference in the thermodynamic
profiles between ligand binding to FimHFL and FimHLD. Error bars represent
(propagated) 68% confidence intervals.
Fig. 6 Difference in thermodynamic profiles between 4 and deoxygenated
n-heptyl a-D-mannoside derivatives 5–7 with FimHLD (A) or FimHFL (B). Error
bars represent propagated 68% confidence intervals.
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effects resulting from a modulation of clamp loop dynamics
and the associated solvent shielding mechanism.
Thus, the observed thermodynamics are not indicative
of the protein–ligand interaction itself, but instead reflect a
shift in the conformational equilibrium of the protein. This
mechanism has been termed entropy–enthalpy transduction.36
The existence of distinctive enthalpy–entropy compensation
profiles for different ligands might also indicate that binding
does not proceed via selection of a preexisting FimHFL con-
formation (Fig. 2, pathway B), but through a ligand-induced fit
(Fig. 2, pathway C). The conformational equilibrium in a
conformational selection model is an inherent property of the
protein and does not depend on the nature of a ligand.
Thus, DGconf-sel must be a constant term, and differences in
ligand thermodynamics originate solely from interaction
with the binding-competent conformation DGbind-closed
 
: In
an induced-fit model, however, formation of an encounter
complex DGbind-copen
 
and contrasting consequences of the
conformational transition DGind-fit (e.g. loss of enthalpic benefit
from solvent shielding) can account for differences between
ligands. For ligands with an intact mannoside core (1–4),
the induced-fit transition reaches its full effect so that the
differential thermodynamic profiles (Fig. 3C) appear constant.
Intriguingly, X-ray and NMR experiments yielded no infor-
mation about the binding mode of 8 to FimHLD. ITC data
suggests that this compound actually binds with very low, but
similar affinity to the high- and low-affinity construct of the
protein (Fig. 5). These observations could signify a different
binding mode that does not proceed via a conformational
rearrangement in FimHFL.
Conclusions
In conclusion, we have investigated the binding thermo-
dynamics of two FimH constructs that share a similar binding
mode but explore a very different conformational landscape.
We could demonstrate that an observed enthalpic contribution
of roughly 13 kJ mol1 for mannoside ligands is a direct
consequence of solvent shielding enabled by the rearrange-
ment of the clamp loop in FimHFL and the associated modula-
tion of local dielectric properties. When the hydrogen bond
network in the binding site is disrupted, the enthalpic benefit is
completely abolished (Fig. 5C). In the case of FimHFL, the effect
of the solvent shielding mechanism is superimposed by an
entropic penalty for the arrest of the clamp loop dynamics.
A similar transition of the binding site into a lower dielectric
environment was observed for a number of other carbohydrate
binding proteins, such as arabinose-binding protein (ABP),
glucose/galactose-binding protein (GGBP) und sialic acid-
binding periplasmic protein (SiaP). Their conformational tran-
sition upon ligand binding involves a twist of rigid protein
domains around a fixed axis (‘‘hinge-bending’’ motions).37–40
These transitions do not alter the flexibility of individual
protein domains to an extent as observed in FimH and
can be considered entropically neutral. Thus, modulation of
binding site permittivity could represent a general mechanism
for carbohydrate binding proteins to enable enthalpy-driven
recognition of polar ligands in aqueous solution.
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M. Smiesko, N. Lüdin, J. Bezençon, O. Schwardt, T. Maier
and B. Ernst, J. Med. Chem., 2015, 58, 2221–2239.
32 J. Lameira, R. P. Bora, Z. T. Chu and A. Warshel, Proteins:
Struct., Funct., Bioinf., 2015, 83, 318–330.
33 G. Jindal and A. Warshel, Proteins: Struct., Funct., Bioinf.,
2017, 85, 2157–2161.
34 C. N. Schutz and A. Warshel, Proteins: Struct., Funct., Genet.,
2001, 44, 400–417.
35 A. Warshel, P. K. Sharma, M. Kato and W. W. Parson,
Biochim. Biophys. Acta, Proteins Proteomics, 2006, 1764,
1647–1676.
36 A. T. Fenley, H. S. Muddana and M. K. Gilson, Proc. Natl.
Acad. Sci. U. S. A., 2012, 109, 20006–20011.
37 M. J. Borrok, L. L. Kiessling and K. T. Forest, Protein Sci.,
2007, 16, 1032–1041.
38 L. Unione, G. Ortega, A. Mallagaray, F. Corzana, J. Pérez-
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TIRFM), thermal stability (DSF), enzyme activity assay 
 
Protein Purification  Chromatographic methods (FPLC: SEC, CEX, AEX, affinity), dialysis 
 
Nucleic acid analytics  Polymerase chain reaction (PCR, real-time PCR), electrophoretic methods 
(agarose gel electrophoresis), cDNA microarrays 
 
Molecular genetics:                                        Cloning, mRNA isolation, cDNA synthesis, quantitative real-time PCR, 
hybridization and evaluation of cDNA microarrays 
 
Cell- and tissue-based work:                   FACS, MACS, handling of mammalian cells and FFPE-tissue  
 





Operating systems Microsoft Windows (advanced) 
 
Software Microsoft Office (very good), Biacore T200 Software (very good),  
Empower Pro (advanced), Chromeleon (advanced), NITPIC (advanced), 





 German (native), English (fluent), French (basic) 
 
COURSES AND CONFERENCES 
 
 
• QA/GMP representative in the pharmaceutical industry (Concept Heidelberg)  
 
• Quality management in the pharmaceutical industry, lecture (University Basel)  
 
• Good Clinical Practice (GCP) Training for Investigators and Study Teams (Swiss TPH, Basel)  
 
• Career and Mentoring Program: Antelope@Novartis (Novartis, Basel) 
 
• Time Management; Project Management for Researches; Project Management II  
   (Graduate Center and Advanced Studies University of Basel)  
 
• Conflict Management (Graduate Center, University of Basel) 
 
• Leadership Practice (Advanced Studies, University of Basel) 
 
• Logic and argumentation (Institute for Argumentation Competence, Berlin)  
 
• Turning ideas into innovations - The role of intellectual property rights in life sciences  
   (Pharmazentrum, Basel) 
 
• Conference - Biophysics in Drug Discovery (NovAliX, Strasbourg) 
 
• Practical Course: Biophysical Methods (Biozentrum, Basel) 
 
• 11th Swiss Course on Medicinal Chemistry (Swiss Chemical Society, Leysin) 
 




   
2010 – 2014; since May 2017 Volunteer at the animal shelter Viernheim; animal protection beider Basel 
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